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Mouse mammary gland morphogenesis at puberty is a complex developmental 
process, regulated by systemic hormones, local growth factors and dependent on 
the epithelial/epithelial and epithelial/stromal interactions. TEBs which invade 
the fat pad are important in laying down the epithelial framework of the gland 
at  this  time  point.  The  objective  of  this  thesis  was  to  use  a  combination  of 
„pathway-„ and „candidate gene analysis‟ of the transcriptome of isolated TEBs 
and ducts and associated stroma, combined with detailed analyses of selected 
proteins, to further define the key proteins and processes involved at puberty. 
Using  GeneChip
®  Mouse  Exon  1.0  ST  Arrays  we  identified  the  epithelial-, 
epithelial-stromal- and stromal transcriptomes of TEBs and ducts and defined 
the  major  functional  pathways/biological  processes  in  each  compartment.  By 
ranking the transcripts according to their expression levels and known functions 
in  other  systems,  we  identified  genes  of  potential  importance  for  pubertal 
mammary morphogenesis. We focused our study on Upk3a and Fbln2 and their 
protein products. Upk3a could only be detected at mRNA level and thus further 
analysis was based on Fbln2. We demonstrated that Fbln2 V1 and Fbln2 protein 
are  predominantly  expressed  in  the  epithelium  and  stroma  of  TEBs.  Using 
hormone primed mice we demonstrated that Fbln2 expression and localisation in 
the mouse mammary gland is positively regulated by E2 and P. Furthermore, by 
a combination of further in silico analysis, in vitro functional assays, IHC and IF 
we identified Vcan, Lama1, Fbn1, ColVIαIII, ColIVαI, ColXVIIIαI, Eln, Per, Acan, 
Nid, Itgb3 and Itga5 as potential binding partners of Fbln2 in mammary gland. 
Finally, we reported lack of an obvious mammary phenotype in Fbln2 KO
-/- mice 
at  puberty  but  demonstrated  that  this  may  be  attributed  to  the  over-
compensation by Fbln1.         
This  thesis  demonstrates  the  benefit  of  DNA  microarray  analysis  in  studying 
pubertal  development  of  mouse  mammary  gland.  It  identifies  Fbln2  as  a 
potential  pubertal  mammary  regulator  which by  interacting  with  various  ECM 
proteins at  different sites  of  mammary  milieu  may contribute  to  an  array  of 
structural and migratory functions during mammary morphogenesis. These data 
substantially add to the understanding of the development of mammary gland at 
puberty and reveal many potential avenues for further investigations.  4 
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1  Introduction 
1.1 Overview of mouse mammary gland development 
The mammary gland is an epidermis derived organ that develops as a result of 
reciprocal  epithelial-mesenchymal  interactions  and  its  primary  function  is  to 
provide milk [1]. The mammary gland is exclusively present in mammals and it is 
the only organ where the majority of development occurs postnatally, with the 
onset at puberty. The mammary gland consists of an epithelial ductal tree which 
is surrounded by fat pad. The ductal tree forms a branched network of ducts 
that transport milk to the nipple to feed the new born. Mice have five pairs of 
mammary glands located to both thoracic (near forelimb) (3 pairs) and inguinal 
(next to hindlimb) (2 pairs) body regions. There is a gradient of differentiation 
between the murine glands, with the first being the least and fifth, the most 
differentiated  [2].  The  mammary  glands  initially  develop  in  both  female  and 
male embryos. Sexual dimorphism arises as a result of androgen production by 
the testis and becomes apparent from embryonic day 14 (E14) [3].  
During  embryogenesis  and  puberty  the  mammary  gland  undergoes  a  series  of 
complex and dynamic morphological changes that result in epithelial invasion of 
the surrounding fat pad and development of a ductal network. During pregnancy 
alveolar structures establish. During lactation milk is produced and released and 
after the pups are weaned a regression to the mature virgin-like state, by a 
process called involution, takes place.  Both the wide array of developmental 
stages and postnatal development make the mammary gland a valuable model to 
delineate  general  mechanisms  of  morphogenesis.  Processes  involved  in  the 
formation of embryonic mammary placodes are similar to these that orchestrate 
formation of other skin appendages, such as teeth and feathers [4]. Hallmarks of 
puberty include extensive elongation of ducts and secondary branching making 
the  mammary  gland  a  good  model  to  study  branching  morphogenesis  and 
cell/tissue  migration  or  invasion.  During  pregnancy,  on  the  other  hand,  the 
mammary gland can be used to study not only branching morphogenesis but also 
cellular  proliferation,  since  elevated  cell  proliferation  and  formation  of 
additional  tertiary  ductal  side  branches,  terminating  in  alveolar  buds  are 
characteristic  of  this  developmental  stage.  Involution  is  a  perfect  system  to 23 
 
 
study  cell  death  by  apoptosis  as  the  post-lactational  regression  is  the  most 
dramatic example of physiologically regulated apoptosis in adult tissue. Finally, 
an  understanding  of  the  biological  processes  implicated  in  mammary 
morphogenesis may assist our understanding of cancer as similar processes of 
proliferation, apoptosis and invasion occur in both.  
Female mouse mammary gland morphology during the embryonic and postnatal 
development  (pre-puberty,  puberty,  adulthood,  pregnancy,  lactation  and 
involution) and its main regulatory cues are discussed below. Detailed analysis of 
pubertal  mouse  mammary  development  and  its  regulation,  which  this  thesis 
focuses on, is presented in 1.2. 
1.1.1 Embryonic development of mouse mammary gland 
Mammary  gland  development  begins  at  E10  with  the  formation  of  the 
milk/mammary lines. Milk lines arise from ectoderm and stretch between the 
anterior  and  posterior  limb  buds,  on  the  ventral  side  of  the  embryo.  The 
columnar,  multilayered  cells  within  the  milk  line  are  delineated  by  the 
expression of Wnt pathway members including Wnt 10a and Wnt 6. At E11.5 the 
mammary  lines  resolve  into  mammary  placodes  –  lens-shaped  epidermal 
structures  consisting  of  several  layers  of  large  columnar  cells  which  are  not 
uniformly orientated and are likely to derive from epidermal cells that migrate 
along the milk lines [5]. There are five pairs of mammary placodes in the mouse 
embryo. The development of individual pairs is not simultaneous and occurs in a 
distinct order  [5] [6] [3]. Subsequently each mammary placode invaginates into 
the underlying mesenchyme to form a mammary bud [7]. From E12 to E14 the 
mammary  buds  submerge  beneath  the  skin  [5].  This  is  accompanied  by  two 
processes:  formation of an epidermal-like cell stalk connecting the mammary 
bud to the skin and formation of the condensed primary mammary mesenchyme 
and embryonic fat pad [7]. Primary mesenchyme consists of multiple layers of 
fibroblasts [8]. It surrounds the basal lamina (BL) (laminin and heparan sulphate 
proteoglycans) of the stalk and ball of a mammary bud [9]. The fat pad, on the 
other  hand,  forms  distally  to  the  mammary  bud  and  consists  of  loosely 
positioned preadipocytes [8]. At E16 mammary buds elongate to form mammary 
sprouts which invade primary mesenchyme and grow into the embryonic fat pad, 24 
 
 
where they  undergo branching  to create a  primary ductal tree  with  a  lumen 
which opens on the surface of the skin. The ductal opening is surrounded by a 
nipple sheath which is formed by epidermal invagination [3] [10]. By E18.5 the 
rudimentary mammary tree consists of one short primary duct and about 10-15 
initial branches. The rudimentary tree grows very slowly until puberty when the 
next  cycle  of extensive  branching and  elongation  occurs (reviewed  in  [3]).  It 
forms a scaffold on which further postnatal developmental changes will occur. 
An  overview  of  female  embryonic  mouse  mammary  gland  development  is 
demonstrated in Figure 1-1.      
Embryonic development of mouse mammary glands is fully dependent on the 
continuous  communication  between  the  ectoderm  and  mesenchyme  of  the 
developing mammary rudiment [11] [12], as shown by Sakakura et al. (1987), 
where mouse mammary epithelial explants fail to form buds when removed from 
its  mesenchymal  environment  [7].  If  recombined  with  mammary  epithelial 
mesenchyme,  epithelial  explants  from  elsewhere  in  the  embryo  develop  into 
mammary  epithelium.  The  importance  of  primary  mesenchyme  in  governing 
mammary cellular fate is also highlighted by the fact that the recombination 
experiments are only successful at E14-E17 – when the primary mesenchyme is 
formed  [13].  The  E17  mammary  epithelium  shows  different  morphological 
responses to the mammary mesenchyme and mammary fat pad. When grafted to 
an  E14-E17  fat  pad,  normal  ductal  development  can  be  seen,  but  when 
combined  with  E12-E17  mammary  mesenchyme,  ductal  hyperplasia, 
characterised by frequent branching and lack of ductal elongation occurs  [8]. 
Sustained epithelial-mesenchymal interactions direct and regulate expansion of 
placodes,  formation  of  mammary  buds  and  development  of  the  rudimentary 
ductal tree.  
The  canonical  pathways  which  signal  from  epithelium  to  mesenchyme  and 
orchestrate  different  stages  of  embryonic  mammary  morphogenesis  include 
wingless-related  (Wnt),  fibroblast  growth  factor  (Fgf),  T-lymphocyte 
differentiation  parathyroid  hormone-related  protein  signalling  (PTHrP)  and 
Insulin  growth  factor  1/Rho  GTPase  activating  protein  5  (IGF-1/p190-B) 
pathways.  Proteins  associated  with  Wnt  and  FGF  signalling  are  known  to  be 
essential for the milk line specification and placode formation. Deficiency of t-
box transcription factor 3 (Tbx3) which can be induced by Wnt signalling results25 
 
 
Figure 1-1 Overview of mouse mammary gland embryogenesis. 
The embryonic development of mouse mammary gland starts with the formation of a mammary 
placode  at  E11.5.  By  E12  a  mammary  bud  is  apparent  as  a  swelling  on  the  surface  of  the 
ectoderm. By E15 the mammary bud invaginates and mammary mesenchyme condenses to form 
primary mammary mesenchyme. The mammary bud elongates to form a mammary sprout which 
further elongates to invade the underlying fat pad (E16). Finally at E18.5 the mammary sprout has 
branched to form a rudimentary mammary tree. The newly formed mammary tree is composed of a 
primary duct with a lumen opening into the nipple and multiple branched secondary ducts.    26 
 
in  complete  loss  of  placodes  [14]  while  loss  of  lymphocyte  enhancer  factor 
factor-1 (Lef1), a Wnt target gene, leads to loss of two pairs of placodes and the 
underdevelopment  of  the  remaining  ones  [15].  In  addition  to  its  role  in 
mammary  line  and  placode  formation,  Wnt  signalling  also  contributes  to 
mammary bud formation. The decrease in mammary bud size is associated with 
the loss of Wnt modifier - pygopus 2 (Pygo2) or Wnt coreceptors low density 
lipoprotein receptor-related protein 5 (Lrp5) and Lrp6 expression [16] [17] [18]. 
Furthermore, loss of Lrp6 or Pygo2 expression also impairs the formation of the 
primary ductal system [17] [16]. Finally, blocking of Wnt signalling at E14.5 with 
its inhibitor dickkopf 1(Dkk1) results in suppression of mammary bud formation 
[19].  Fibroblast  growth  factor  10  (Fgf10)  is  expressed  at  E10.5-E11,  when  it 
localises directly underneath the forming mammary line suggesting a function in 
early mammary line specification. Fgf10 and fibroblast growth factor 2b receptor 
(Fgfr2b)  are  also  necessary  for  the  development  of  mammary  buds  as  their 
deficiency results in the failure of all but mammary bud number 4 to develop 
[20]. On the other hand, expression of transcription factor GATA binding protein 
3 (GATA3), which is implicated in regulation of T lymphocyte differentiation in 
response to parasitic infections, is essential for both placode and nipple sheath 
formation [21]. PTHrP signalling is essential for full differentiation of mammary 
mesenchyme (essential for determining of epithelial cell fate), formation of the 
nipple  sheath  and  further  ductal  morphogenesis  [10]  [22].  The  downstream 
target  of  PTHrP,  bone  morphogenic  protein  4  (BMP4)  also  plays  a  role  in 
regulation of embryonic mammary ductal morphogenesis [23]. Finally, disruption 
of the IGF-1/p190-B pathway by knock out (KO) of p190-B (inhibits Rho activity) 
or insulin receptor substrates 1 or 2 (IRS1 and 2) expression, results in formation 
of small mammary buds and disorganisation of the mammary mesenchyme [24]. 
Some of the other molecules which are critical for embryonic mammogenesis 
include: v-erb-a erythroblastic leukemia viral oncogene homolog 4 (ErbB4) ligand 
- neuregulin 3 (Nrg3)  [25],  homeobox msh-like 2 (Msx2)  and Msx1 the double    
KO
-/- of which results in the formation of small placodes which fail to transform 
into mammary buds [26].  27 
1.1.2 Postnatal development of mouse mammary gland 
The  majority  of  mammary  gland  morphogenesis  occurs  postnatally.  It  begins 
during  puberty  with  ductal  proliferation,  carries  on  through  adulthood  with 
oestrus  cycle  induced  early  alveolar  development  and  is  completed  with  the 
cycles  of  proliferation,  differentiation  and  cell  death  with  each  pregnancy, 
lactation  and involution.  The  summary  of the  subsequent  stages  of  postnatal 
mouse mammary gland development is shown in Figure 1-2.              
At  birth,  the  mammary  gland  consists  of  a  rudimentary  ductal  tree  which  is 
similar to that seen at the E18.5  (Figure 1-1). During the first few weeks of 
postnatal  life,  up  until  the  onset  of  puberty,  the  mammary  rudiment  grows 
allometrically.  At  the  onset  of  puberty  (~3-4  weeks)  increased  levels  of 
gonadotrophins and oestrogen in the serum trigger formation of terminal end 
buds (TEBs), which in turn drive ductal elongation. The ductal tree expands via 
ductal  elongation  and  branching  up  until  week  ~10-12  (adulthood)  when  the 
ductal system becomes fully developed. Detailed overview of pubertal mammary 
gland morphogenesis is discussed in Section 1.2.  
At ~10-12 weeks of age, depending on the mouse strain, the edges of the fat pad 
are reached, TEBs start regressing into terminal end ducts and ductal outgrowth 
ceases.  In  response  to  ovarian  hormones,  secreted  with  each  oestrus  cycle, 
mature  ductal  epithelium  further  undergoes  cycles  of  proliferation, 
differentiation and involution that results in formation of small ductal branches 
and lateral buds [27]. Lateral buds then turn either into lateral branches or form 
alveolar buds. Lateral branches are characterised by the presence of a cap cell 
layer at its growing tip (as seen in TEBs). Alveolar buds are comprised of a single 
epithelial cell layer  enclosing a hollow lumen  [28].  During pregnancy-induced 
growth,  alveolar  buds  progress  into  fully  differentiated  units  capable  of  milk 
secretion called alveoli. Although the secretion of milk occurs during lactation 
the expression of milk proteins can already be observed during the oestrus cycle 
in murine adult virgin mammary glands [29].  
Pregnancy  is  further  characterised  by  extended  epithelial  differentiation.  In 
mice gestation lasts for 19-21 days. Its onset is defined by two events: extensive 
proliferation and branching of the ductal epithelium and formation of alveolar      28 
 
 
Figure 1-2 Overview of the postnatal mouse mammary gland development. 
Figure shows the representative stages of mouse mammary gland morphogenesis. At pre-puberty, 
the mammary gland consists of a rudimentary tree that contains TEB-like structures and is similar 
to that seen at E18.5. Onset of puberty initiates TEBs formation and bifurcation, ductal elongation 
and branching, which collectively form a ductal tree. Upon reaching adulthood, most TEBs regress 
and ductal expansion ceases. Mature ductal epithelium undergoes estrus cycle dependent cycles 
of proliferation, differentiation and involution which gives rise to tertiary branching and development 
of lateral buds. With the onset of pregnancy, the rate of proliferation increases and lateral buds 
develop into alveoli. At parturition and during lactation, the whole gland is filled with alveoli that 
produce milk proteins and lipid which are secreted and transported through the ducts to feed the 
pups.  Upon  weaning,  the  alveoli  regress  and  the  gland  undergoes  remodelling  in  the  process 
called involution, which returns the gland to a morphological state similar, but not identical, to that 
seen in mature virgin mice (adulthood).     29 
 
buds, as seen in murine adult virgin mammary glands. Towards the middle part 
of pregnancy, alveolar buds cleave and further differentiate to form individual 
alveoli  (lobuloalveolar  phase  of  mammary  gland  morphogenesis).  Alveoli 
synthesise and secrete milk from late pregnancy and throughout lactation. As for 
epithelial ducts and virgin alveolar buds, the alveoli are formed by the luminal 
(innermost cells enclosing the lumen) and myoepithelial cells (outermost cells). 
Here,  however,  the  myoepithelial  cells  are  less  continuous.  This  enables  the 
direct  contact  of  luminal  cells  with  the  basement  membrane  (BM),  which  is 
critical for full differentiation and milk secretion  [30]. Alveoli are suggested to 
originate  from  the  lobule-limited  progenitor  cells  [31]  (reviewed  in  [32]).  By 
gestation day 18, the alveolar epithelial cells enlarge and produce milk proteins 
(whey  acidic  protein  (WAP)  and  α-lactalbumin,  ß-casein)  and  lipids  in 
preparation for lactation [33]. At the final stages of pregnancy, alveoli occupy 
the majority of the fat pad. Secretion of milk proteins and lipids to the alveolar 
lumen  starts  one  day  prior  to  parturition.  The  main  regulators  of  gestation 
include  progesterone  (P)  and  prolactin  (PRL).  Presence  of  progesterone 
receptors  (PRs)  is  critical  for  mediating  ductal  outgrowth  and  lobuloalveolar 
differentiation  (reviewed  in  [34]).    Furthermore,  P  suppresses  active  milk 
secretion.  The  absence  of  alveoli  is  also  associated  with  lack  of  prolactin 
receptor (PRLR) expression [35].  
At  parturition,  the  luminal  epithelium  becomes  flattened  due  to  the 
engorgement  of  alveoli  and  firstly  colostrum  and  then  milk  and  lipids  are 
secreted  to  the  lumen.  PRL  acts  on  luminal  epithelial  cells  to  sustain  milk 
secretion  [36].  In  response  to  oxytocin,  the  surrounding  myoepithelial  cells 
contract to force milk out of the alveoli into the ducts, towards the nipple. This 
process of milk secretion is referred to as lactation and can occur for up to 3 
weeks. It is stimulated by suckling pups which cause the release of oxytocin [28].  
After natural or forced weaning (pup removal) and in response to milk stasis, the 
mammary gland enters a phase of dramatic cell death and tissue remodelling, 
called  involution.  At  this  time  point,  the  expression  of  genes  encoding  milk 
proteins  decreases  to  basal  level.    The  expression  of  genes  associated  with 
processes  such  as  apoptosis  (e.g.  serum  gp70  production  2  (SGP-2),  signal 
transducer and activator of transcription 3 (STAT3)), regulation of proliferation 
and  differentiation  (e.g.  tumour  suppressor  p53  (p53),                   30 
 
myelocytomatosis oncogene (c-myc), transforming growth factor ß (TGF-ß)) [37] 
increases. Inflammation/acute phase response proteins also increase at this time 
(e.g. CD 14 antigen (CD14), lipopolysaccharide binding protein (LBP)) [38] [39] 
(reviewed in [40]). Initially, during the first 2-3 days the process is reversible 
and lactation can be reintroduced upon suckling [41].  
Apoptosis of the alveolar secretory luminal cells commences just within hours 
after weaning and by day 3 it becomes irreversible [42]. The alveoli collapse into 
clusters of epithelial cells and the fat pad is thought to become refilled with 
adipocytes.  The  collapsed  apoptotic  epithelium  is  cleared  mainly  by 
neighbouring  epithelial  cells  which  recognise  and  engulf  them  into  the 
specialised vesicles called the efferosomes [43] [44]. By day 4 of involution the 
clearance of apoptotic cells is completed and the epithelial, stromal and BM-
associated  rearrangements  occur  [44]  [37].  Involution  lasts  for  14-21  days 
approximately  and  at  its  conclusion,  the  mammary  gland  resembles  a  pre-
pregnant mature mammary gland. In comparison to the virgin gland, however, 
the involuted gland is more differentiated and contains the occasional remaining 
alveoli [28]. 
1.2 Mouse mammary gland morphogenesis at puberty 
The onset of puberty can be defined by three pubertal events: vaginal opening, 
first  vaginal  cornification  and  onset  of  cyclicity.  The  vaginal  opening,  first 
oestrus  and  the  following  increase  in  the  production  and  secretion  of 
gonadotrophins and oestrogen (E2) are the most frequently used measurements 
of puberty in mice. The timing of all three pubertal events depends on the strain 
of mice [45]. Generally, the onset of puberty arises at 3-4 weeks of age. In some 
mice, however, it can occur several weeks after vaginal cornification  [46]. In 
C57BL/6 mice the vaginal opening, first vaginal cornification and first oestrus 
occur at approximately 4, 6 and 8 weeks of age respectively [45]. The murine 
oestrus cycle lasts for 4-5 days and comprises of four phases: proestrus, oestrus 
(ovulation), metoestrus and dioestrus. Each of these stages are characterised by 
distinct  changes  in  vaginal  cytology  and  mammary  gland  morphology.  As 
described by Bronson et al. (1975), in virgin mice, proestrus is associated with 
appearance of small TEBs at the ducts located at the periphery of the gland     31 
 
(similar structures can be seen at pre-puberty) and large, blunt projections on 
the main ducts at the nipple region. At oestrus, the mammary ducts become 
dilated and TEBs elongate. Epithelial growth regresses during metoestrus when 
ducts decrease in width and their endings collapse giving rise to the very open 
network of narrow, thread-like ducts seen in dioestrus [47]. At each subsequent 
oestrus cycle, a slight burst of proliferation and growth of mammary epithelium 
can be noted [48].  
Morphologically,  the  pubertal  mouse  mammary  gland  consists  of  two 
compartments:  epithelial  and  stromal  (fat  pad).  In  addition  each  mammary 
gland  has  one  or  two  lymph  nodes  (LN),  blood  vessels  and  nerves  [49].  The 
epithelial compartment of the pubertal mouse mammary gland consists of TEBs 
and ducts. TEBs, which are situated at the ends of ducts, promote and direct the 
outgrowth of the ductal tree into the surrounding fat pad  [50]. TEBs migrate 
forward  and  bifurcate  while  ductal  epithelium  elongates  behind  them  thus 
producing secondary branches and a ductal network. Epithelial expansion peaks 
between ~ 4-7 weeks of age and takes place until the whole fat pad is filled 
(~10-12 weeks of age), when TEBs regress and the extensive mitotic activity, 
ductal  outgrowth  and  branching  cease,  with  only  minor  proliferative  activity 
noted in response to the oestrus cycle  [51]. The structure of pubertal mouse 
mammary gland is illustrated in Figure 1-3.  
1.2.1 The morphology and characteristics of pubertal mouse 
mammary gland 
1.2.1.1  Epithelium  
Although both TEBs and ducts are essential for pubertal outgrowth their role is 
very  different.  These  differences  are  reflected  in  their  morphology,  the 
character  of  their  surrounding  stroma,  the  mechanisms  underlying  branching 
morphogenesis, outgrowth and its regulation.    
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Figure 1-3 Morphology of pubertal mouse mammary gland. 
Carmine alumn stained wholemount of a pubertal C57BL/6 mouse mammary gland (6 week old). 
(A) The asterisk denotes the nipple region; double asterisk represents the Fat pad; the thin arrow 
shows  ducts;  thick  arrow  denotes  TEBs  while  arrowhead  the  LN.  Scale  bar  is  2.5  mm.  (B) 
Magnified image of two TEBs and a duct. Scale bar is 100 um.      33 
 
1.2.1.1.1  TEBs 
 
TEBs are bulbous epithelial structures which range in size from 0.1 to 0.5mm 
[52]. They are mainly present at puberty, when they drive directional outgrowth 
of  the  ductal  tree,  at  the  rate  of  approximately  0.5mm/day  [53].  Similar 
structures can be seen between late gestation and week 1 of pre-puberty where 
they  appear  in  response  to  maternal  hormones.  The  decrease  in  maternal 
hormones stops mitosis in the TEB-like structures, until the onset of cyclicity at 
puberty when cellular proliferation begins again  [7] [54]. TEBs consist of two 
types of epithelial cells: inner body cells and outer cap cells (Figure 1-4 B and 
C). Cap cells are enveloped by a BM that belongs to the extracellular matrix 
(ECM), and this will be discussed in 1.2.1.2.4  
Cap cells are exclusively present in TEBs [55] and TEB-like structures where they 
form either a single or double layered envelope all around the body of the TEB. 
The number of cap cells is proportional to the size of TEB [54]. At the apical 
side, they are adjacent to the BM while at the lateral side, although slightly 
separated, they flank the bulk of the TEB. Cap cells located at the tip of TEB are 
characterised by loose organisation, presence of multiple intercellular spaces, 
and a lack of specialised cell junctions for adhesion or communication. As shown 
by Williams and Daniel (1983) they can be easily detached from the underlying 
bulk of the TEB and overlaying BM when treated with testicular hyaluronidase 
[53]. The nuclei of cap cells are round or oval with diffuse chromatin while their 
cytoplasm  comprises  of  multiple  free  ribosomes,  a  moderate  number  of 
mitochondria,  some  rough  endoplasmic  reticulum  and  lipid  droplets.  Highly 
organised cytoskeletal elements are lacking. 
Cap cells exhibit poor apical-basal polarity evidenced by sporadic secretion of 
hyaluronate and laminin (Lama1) (BM molecules) to their interior surfaces [56]. 
At the tip of the TEB cap cells have a columnar shape. As the contour of TEB is 
followed to its lateral sides and neck, however, the columnar cells progressively 
transform into cuboidal (lateral) and spindle shaped (neck) cells. The spindle 
shaped cells exhibit the characteristics of myoepithelial cells (outer cell layer in 
ducts)  suggesting  that  the  myoepithelium  of  the  subtending  ducts  originates 
from cap cells. In addition, it is suggested that individual cap cells are able to      34 
 
 
Figure 1-4 Structure of TEB with duct and surrounding stroma. 
(A) (B) H&E stained section through (A) TEB and (B) duct. (C) Diagram representing structural 
characteristics of epithelial and stromal compartments of TEB and duct. TEB consists of a single 
layer of outer cap cells and multiple layered inner body cells. Cap cells give rise to myoepithelial 
cells of ducts, while body cells most likely differentiate into the ductal luminal cells. Both TEBs and 
ducts are surrounded by a BM. The stromal environment of TEBs and ducts consists of adipocytes, 
fibroblasts  and  mast  cells.  In  addition,  macrophages  and  eosinophils  can  be  also  seen  in  the 
stroma around TEB. The ECM provides a link between the epithelial and stromal cells. Scale bars 
are 50µm.     35 
 
break away and migrate to deeper regions of the body of TEB. Cap cells stained 
using their molecular markers: P-cadherin (Cdh3)) (adhesion molecule specific 
for cap cells) [57] and Lama1 (BM component synthesised in epithelium)  [58] 
translocated to the body cell layers, where they gradually lost the expression of 
cap cell markers in favour of acquiring a luminal identity. Similar observations 
were confirmed using phase-contrast time-lapse microcinematography of freshly 
isolated TEBs [53]. Together these events suggest that cap cells contribute to 
the body cells and therefore are likely to be progenitors of the luminal epithelial 
cells of ducts. Furthermore, due to their presence at the tips of migrating TEBs, 
but not ductal tips of mature adult epithelium [59] it is likely that cap cells play 
a pivotal role in directing and patterning of ductal outgrowth.                      
The  main  bulk  of  the  TEB,  however,  is  formed  by  tightly  compacted  and 
multilayered body cells (6-10 layers). Morphologically, body cells are similar to 
ductal luminal cells and they are proposed to be their progenitors. Body cells 
tend to be polarised and possess tight cell-cell junctions characterised by the 
expression of E-cadherins (Cdh1) [53] [57]. The outer layers, although, in some 
places separated by an intercellular space, are in contact with cap cells while 
the inner most layer of body cells surrounds the lumen of the TEB. Inner layers 
of body cells are characterised by a high apoptotic rate that can be detected by 
TUNEL assay and positive B-cell leukaemia 2 (Bcl-2), chemokine ligand 13 (Blc-x) 
and Bcl-2-associated X protein (Bax) expression (apoptotic checkpoint proteins) 
while the outermost body cells layers are more proliferative. Apoptosis is p53-
independent and most probably leads to lumen formation. Each TEB contains 
reciprocal zones of apoptotic and proliferative cells which, although dispersed 
throughout the TEB, tend to appear in close proximity to each other [60]. The 
observed rate of apoptosis (11.3 %) is higher than that calculated for any other 
stage  of  mouse  mammary  development  (apoptosis  detected  for  involution  is 
4.5%) or that detected during kidney morphogenesis (3%) [61].    
1.2.1.1.2  Ducts 
 
Ducts account for the majority of the mammary epithelium at puberty where 
they form a branched ductal tree that serves as a scaffold on which secretory 
alveoli  develop  during  pregnancy.  In  comparison  to  TEBs,  however,  ductal     36 
 
epithelium is relatively growth quiescent [62]. Ducts are composed of an inner 
luminal and outer myoepithelial layer. Myoepithelial cells are surrounded by BM 
(Figure  1-4  A  and  C).  Myoepithelial  cells  form  a  thin  monolayer  of  basally 
arranged  cuboidal  cells.  They  are  likely  to  play  a  part  in  signal  transition 
between the BM and the internally located luminal epithelium. Cytologically, 
myoepithelial  cells  are  characterised  by  desmosomes,  hemidesmosomes, 
myofilaments,  irregular  nuclei  with  marked  heterochromatin,  peripheral 
cytoplasmic caveoli and ragged basal borders. Luminal epithelial cells, on the 
other hand, exhibit short, blunt microvilli on their apical surface and display 
well-developed cell-cell junctions [63]. Generally they form a monolayer but in 
some regions 1-3 layer thick wall of ductal epithelium around the hollow lumen 
can be seen. The layer closest to the lumen exhibits a higher apoptosis rate than 
that  seen  in  the  more  outer  cell  layers  which  is  consistent  with  a  role  of 
apoptosis  in  lumen  formation  [61]  [60].  In  addition,  the  ductal  lumen  may 
originate from the lumen of the advancing TEBs. One of the markers of luminal 
epithelial cells is keratin 18 (Krt18) [64] while the smooth muscle α-actin (SMA) 
marks the myoepithelial cells [65].   
Both TEBs and ducts, i.e. the entire pubertal mammary epithelial tree contain 
stem  cells  which  further  persist  through  the  subsequent  stages  of  mammary 
morphogenesis  and  are  capable  of  reconstructing  a  complete  and  functional 
gland when transplanted into cleared mammary fat pad of recipient host [66] 
[67]  [68].  Mammary  stem  cells  are  defined  as  undifferentiated,  pluripotent, 
relatively quiescent and long lived cells. As shown by the experiments based on 
the serial transplantation of mammary epithelium from the MMTV infected mice 
to  the  fat  pads  of  recipient  host,  the  mammary  stem  cells  are  capable  of 
producing 5-8 transplant generations before senescing [68]. Furthermore, they 
exhibit the capacity to self maintain and proliferate – it is suggested that when 
transplanted, a stem cell initially divides symmetrically to repopulate the gland 
but  any  of  their  subsequent  divisions,  if  and  when  they  happen,  are  most 
probably asymmetric (with the template DNA strand being retained) (reviewed in 
[32]).  Moreover,  apart  from  the  „mother‟  stem  cells  that  act  as  initial 
progenitors  that  give  rise  to  cellular  make  up  of  mammary  gland,  as  firstly 
demonstrated  by  transplantation  studies  using  limiting  dilution  of  mammary 
epithelial cells, the following generations of the „daughter‟ mammary stem cells     37 
 
produce two distinct lineage-limited progenitor cells: duct-limited and lobule-
limited  (also  called  –  the  parity  induced  mammary  epithelial  cells-  PI-MEC) 
progenitors.  Duct-limited  progenitors  produce  oestrogen  receptor  (ER)
+/-  and 
PR
+/- luminal cells and cap cells but are unable to produce progeny capable of 
sustaining epithelial growth at pregnancy and during alveologenesis, while the 
lobule-limited  progenitors  give  rise  to  ER
+/-  and  PR
+/-  luminal  epithelial  and 
myoepithelial cells, but are incapable of generating cap cells and thus can not 
give rise to ductal tree [31]. Both progenitor cell types are therefore essential to 
create mouse mammary gland in its entirety.       
1.2.1.2  Fat pad  
Fat pad (stroma) is a crucial component of the mouse mammary gland. Not only 
does it provide the structural scaffold for the ductal epithelial tree but it also 
regulates its morphogenesis. Numerous studies in which pre-pubertal fat pads 
were cleared from their endogenous epithelium and engrafted with exogenous 
epithelium  demonstrated  its  magnificent  role  in  sustaining  and  directing 
epithelial cell fate and promoting growth [69] [66]. As demonstrated by Daniel 
et al. (1968), transplantation of a small fragment of ductal epithelium into the 
cleared  fat  pad  results  in  reconstitution  of  the  whole  ductal  tree.  In  this 
experiment epithelial growth is induced at puberty and the mature ductal tree is 
formed  within  10-12  weeks  after  transplantation  [59].  This  phenomenon  was 
further elucidated by Kordon et al. (1998) who suggested the capability of the 
cleared fat pad (mature) to allow growth of the whole mammary gland from a 
single pluripotent mammary stem cell [68] which in 2006 has been demonstrated 
to be true by Shackleton et al. [70]. Furthermore, it has also been shown that 
testicular  cells,  when  mixed  with  mammary  epithelial  cells  (MECs)  and 
transplanted into denuded fat pad, acquire an epithelial cell fate and contribute 
to ductal outgrowth [71]. Similar results were also obtained firstly with murine 
fetal and  adult  neural  stem  cells  combined  with  equal numbers  of  MECs and 
engrafted into the clear fat pad [72] and secondly with the MECs mixed with 
human  embryonic  carcinoma  cells  (NTERA2cl)  which,  when  inoculated  into 
denuded fat pad, reprogrammed to normal MECs and contributed progeny to the 
resulting functional mammary outgrowths [73]. It is worth noting, however, that 
no outgrowths could be seen if the exogenous implants were not mixed with 
MECs  upon  the  transplantation.  Recently,  it  was  also  shown  that  mammary     38 
 
morphogenesis can be induced and promoted by transplantation of mouse stem 
cells  which  are  undergoing  hematopoietic  differentiation  into  the  receptive 
cleared murine mammary fat pads [74].  This phenomenon of cell fate regulation 
by  the  stromal  environment  can  be  also  seen  in  reverse  experiments  where 
mammary embryonic epithelium cotransplanted into salivary gland mesenchyme 
and grafted under the renal capsule of a host mouse, formed structures that 
resembled salivary glands [75].  
This ability to impose and regulate cell fate is attributed to stem cell niche – a 
milieu, which based on current knowledge, includes the stromal environment, 
pluripotent cells, lineage-specific progenitors and fully differentiated cells which 
all  contribute  and  signal  together  to  support,  maintain  and  control  the  stem 
cell/progenitor fate (reviewed in [32]).  
Pubertal  mouse  mammary  stroma  is  very  heterogeneous  in  its  composition. 
Adipose  tissue  is  the  most  abundant  mesenchymal  cell  type  followed  by 
fibroblasts, ECM, immune cells, endothelial and neural cells (Figure 1-4 C) [76].  
1.2.1.2.1  Adipose tissue 
 
There  are  two  types  of  adipose  tissue:  brown  adipocytes  which  are  energy 
dissipating  cells  and  white  adipocytes  which  store  energy  [77].  Brown 
adipocytes,  as opposed to  white  ones,  are  highly  innervated and  functionally 
controlled by the sympathetic nervous system [78]. They contain numerous well 
developed  mitochondria  and  multilocular  lipid  inclusions  whereas  white 
adipocytes consist of a single, large inclusion and a low number of mitochondria 
[79].  Both  are  present  throughout  pubertal  mouse  mammary  development. 
Brown adipocytes are most prevalent during pre-puberty where they surround 
the  ductal  tree  (between  the  nipple  and  lymph  node)  but  their  structural 
contribution  to  mammary  stroma  decreases  as  the  mice  age  and  prior  to 
adulthood they are undetectable [80]. White adipocytes, on the other hand, are 
present throughout mammary development where they are known to secrete a 
range of hormones, cytokines and growth factors, such as leptin, adiponectin, 
hepatocyte growth factor (HGF), collagen type VI (ColVI), interleukin 6 (IL-6) and 
tumour necrosis factor alpha (TNFα) and metabolise androgen to E2 [81].      39 
 
1.2.1.2.2  Fibroblasts 
 
The  second  most  abundant  type  of  stromal  cells  present  in  pubertal  mouse 
mammary glands are fibroblasts - principal components of all connective tissues. 
Fibroblasts are spindle shaped. They are embedded within the ECM which they 
synthesise  and  maintain.  They  secrete  collagen  type  I  (ColI),  III  and  V, 
fibronectin (Fn) and matrix metalloproteases (MMPs) which are essential for ECM 
maintenance;  Lama1  and  ColIV  for  BM  formation.  They  are  also  involved  in 
wound  healing,  regulation  of  inflammation  and  epithelial  morphogenesis  via 
secretion of growth factors (reviewed in [82]).          
1.2.1.2.3  Migratory cells of the immune system 
 
Migratory cells of the immune and haemopoietic system such as macrophages, 
eosinophils  and  mast  cells  are  other  crucial  components  of  the  mammary 
stroma. Macrophages and eosinophils detected by the marker protein F4/80 are 
associated  with  morphogenesis  of  numerous  tissues.  Initially,  expression  of 
macrophages in the mouse mammary gland can be detected at 2.5 weeks of age 
where  they  gather  around  the  rudimental  ductal  tree.  At  puberty,  however, 
macrophages  cluster  at  the  neck  of  TEBs  where  they  support  epithelial 
development,  angiogenesis  and  matrix  remodelling.  The  macrophages  secrete 
trophic factors which are thought to play a role in ColI assembly and organisation 
into fibrillar bundles, which in turn are suggested as a part of the mechanism 
which directs the shape of TEBs and provides a framework for their outgrowth 
[83]. Furthermore, macrophages also intersperse among the adipocytes where 
they are involved in the phagocytosis of dying tissue [84]. Some macrophages 
also locate inside TEBs within the population of body cells that are proximal to 
the  lumen.  The  recruitment  of  macrophages  to  the  TEB  is  paralleled  by  the 
appearance of eosinophils which localise at the tips of TEBs. Initial recruitment 
of  macrophages  to  the  pre-pubertal  mammary  gland  is  regulated  by  colony 
stimulating factor 1 (CSF-1) [85]. It is expressed by the developing ducts and 
secreted  as  biologically  active  cell  surface  protein  while  the  CSF-1  receptor 
(CSF-1R)  is  exclusively  expressed  on  the  macrophages  [86]  [85].  Specialised 
recruitment of macrophages to the TEBs, on  the other hand, depends on the 
chemo-attractant action of chemokine C10 the expression of which depends on     40 
 
the eosinophil recruitment around TEBs [87]. The recruitment of eosinophils, in 
turn, is regulated by interleukin 5 (IL-5) and eotaxin. IL-5  mobilizes eosinophils 
and their progenitors from the bone marrow while eotaxin directs their homing 
around  TEBs  [88]  [87].  Similar  spatial  localisation  and  regulatory  dependency 
suggest that macrophages and eosinophils could act synergistically [87].  
Recently,  further  examination  of  immune  response  cells  in  pubertal  mouse 
mammary  gland  morphogenesis  identified  mast  cells  in  the  stromal 
microenvironment  [89].  Mast  cells  are  produced  in  the  bone  marrow  and 
released into the blood stream to be delivered into tissues, where they mature 
i.e.  acquire  a  granular  phenotype.  The  granules  consist  of  histamine, 
proteoglycans,  growth  factors,  proteases  and  many  other  factors  which  are 
secreted  into  the  surrounding  microenvironment  through  the  process  of 
degranulation.  Mast  cells  are  normally  present  around  blood  vessels,  nerves, 
epithelial cells and muscle cells [90]. In the mammary gland, a few (scattered 
around the stroma) mast cells can be detected during pre-puberty. Peak of their 
activity, however, occurs at puberty when most mast cells gather in the stroma 
surrounding the BM of TEBs and ducts, the stroma ahead of the advancing TEB 
and around blood vessels. Some mast cells can be also seen at the periphery of 
the LN [89].  
1.2.1.2.4  ECM 
 
Stromal cells surrounding mammary epithelium are embedded in cell-secreted 
interstitial  ECM.  ECM  can be  divided  into  two  compartments:  BM  and  fibrous 
connective tissue (reviewed in [91]). BM can be also referred to as basal lamina 
(BL).  The  two  names  are  often  used  interchangeably;  BM  refers  to  an  ECM 
structure visualised by light microscopy while BL is visualised only by electron 
microscopy. BM is a highly organised outermost component of TEB and ducts that 
lies directly outside cap cells and myoepithelial cells respectively. It consists of 
three  layers.  Namely,  lamina  lucida  interna,  formed  by  periodically  arranged 
stalks,  lamina densa and anionic globular lamina externa.  (reviewed in  [91]). 
Lamina lucida interna and -externa contain high levels of proteoglycans which 
facilitate the attachment of lamina densa to both epithelial cell surface and 
collagen fibres which are part of the ECM fibrous connective tissue. There are     41 
 
two types of proteoglycans: hyaluronate – present at the tip of the advancing 
bud and sulphate-rich glycosaminoglycans (S-GAGs) which are present towards 
the neck of the bud where ductal morphogenesis takes place [50]. S-GAGs are 
linear polysaccharides which consist of repeating hexuronic acid and hexosamine 
and are generally associated with cellular differentiation, tissue stabilisation and 
collagen fibrillogenesis [92]. The affinity of BM to ECM proteins also differs with 
the spatial location.  
As shown by Williams and Daniel (1983), when TEBs were teased away from the 
surrounding stroma the anterior part of BM was free of stromal adhesions while 
the neck region was still attached to ECM fibres and adipocytes. Furthermore, 
transmission electron microscopy carried out by the same research group, on the 
TEBs that were surgically removed from fat pad, demonstrated heterogeneity in 
the thickness of BM and the composition of its associated ECM depending on 
whether the tip or neck of TEBs was studied. BM at the anterior side was 104nm 
thick  and  its  associated  stromal  cells  appeared  undifferentiated  and 
mesenchyme derived. In contrast, at the neck of TEB, BM consisted of multiple 
folded  layers  (14  times  thicker)  and  its  associated    stromal  environment 
exhibited cytoplasmic specialisation [53]. In the ducts, BM was 130nm thick [53] 
and synthesised by myoepithelial cells while around TEBs, it was synthesised by 
cap cells and fibroblasts  [93] [50] [94].  Major constituents of BM are Lama1, 
ColIV, nidogens (Nid) and perlacan (Per) (reviewed in [91]).  
The  second  type  of  mammary  ECM,  the  fibrous  connective  tissue,  is 
characterised by the absence of epithelial cells and presence of fibroblasts and 
immune  cells.  It  is  rich  in  collagen  content.  Some  of  its  other  components 
include  Fn,  fibrillar  collagens,  tenascin-C  (Tn),  elastin  fibres  (Eln),  Small 
Leucine-Rich Proteoglycan (SLRP) such as decorin and biglycan type I  [95] and 
Secreted Protein Acidic and Rich in cysteine (SPARC) [95] (reviewed [91]). These 
proteins are then cross linked via covalent chemical bonds to organise, stabilise 
and regulate the tension of the ECM scaffold. The cross linking is catalysed by 
lysyl  oxidase  (LOX)  and  tissue  transglutaminase  2  (tTG2)  [96]  [97].  The 
composition of the fibrous connective ECM also varies depending on its spatial 
location in the growing mammary gland. It is denser at the neck region of TEBs 
or  around  the  ducts  and  looser  at  the  tips  of  TEBs.  ECM  interacts  with  the 
cytoskeleton of epithelial cells via integrins.      42 
 
ECM  not  only  anchors  the  epithelial  cells  and  provides  them  with  physical 
support,  but  is  also  essential  for  signal  transmission  between  stromal  and 
epithelial cells which is a prerequisite to normal mammary gland development. 
As demonstrated by Emerman et al. (1977), mammary epithelial cells collected 
from pregnant or lactating glands failed to synthesise milk proteins in response 
to lactogenic hormones when cultured on a plastic substrate, but did so when 
cultured on floating collagen membranes [98].  
Fibrous  connective  ECM  is  also  capable  of  cleaving,  binding  and  sequestering 
signalling molecules.  Some of these molecules that can bind to ECM include: 
Amphiregulin (Areg), IGF-like binding proteins, TGF-ß, Wnts and FGFs. Binding of 
TGF-ß  to  ECM  is  facilitated  by  transglutaminase  while  growth  factors  and 
cytokines bind to ECM through GAGs [99] [50]. GAGs are thought to act as “glue” 
that enables the attachment of secreted molecules to BM or fibrillar matrix [50]. 
Most  of  these  molecules  are  then  released  and  activated  as  a  result  of  ECM 
remodelling by enzymes, mostly MMPs (reviewed in [100] [91]). Some molecules, 
such  as  TGF-ß,  however,  can  be  also  released  from  ECM  by  altering  its 
mechanical tension [101].   
1.2.2 Motility in the mouse mammary gland at puberty 
1.2.2.1  TEBs 
TEBs serve as the driving force of ductal development during puberty. These 
highly motile structures pattern the open architecture of the mammary gland by 
driving  the  linear  forward  growth  and  undergoing  dichotomous  bifurcation, 
hence giving rise to the major branches of the ductal tree and preferentially 
directing  ductal  outgrowth  into  the  epithelium-free  fat  pad.  The  motile 
behaviour  of  TEBs  is  dynamic  and  highly  receptive  to  the  surrounding 
environment. As shown by Hinck and Silberstein (2005), introduction of a plastic 
obstacle into the fat pad that surrounds advancing ducts alters normal ductal 
architecture. Not only do the ducts change their migratory path in an attempt to 
avoid the obstacle, but they still manage to recreate the normal ductal spacing 
pattern similar to that seen in the unaffected part of the gland [102].      43 
 
1.2.2.1.1  Forward movement 
 
Motility of TEBs encompasses three behaviours: forward movement, bifurcation 
and turning. There are two different hypotheses for the mechanism of forward 
movement.  It  is  suggested  that  TEBs  either  pull  themselves  forward  or  push 
forward [102]. The first theory, however, is unlikely as no cellular extensions 
(filopodia) or actin protrusions (lamelliopodia) which are usually associated with 
the leading edge of single or groups of collectively migrating cells have been 
demonstrated on the TEB‟s surface to date. The second hypothesis, on the other 
hand,  is  supported  by  the  electron  microscopy  demonstration  of  adipocytes‟ 
imprints  on  the  BL  that  surrounds  the  tip  of  advancing  TEBs  [102].  It  is 
speculated that this forward movement of TEBs results from the increased cell 
mass, produced by intensive mitosis in both cap and body cells of TEBs  [102] 
[62]. The level of mitotic activity translates into the size of TEBs and depends on 
the  phase  of  oestrus  cycle.  The  highest  mitotic  activity  of  TEB  can  be  seen 
during  the  transition  from  proestrus  to  late  oestrus  when  TEBs  reach  their 
maximum size, acquire an elongated shape and the border between epithelium 
and  surrounding  stroma  becomes  indistinct  and  straddled  by  the  multiple 
replicating cells [103] and it is likely that forward outgrowth occurs at this time 
point. At metoestrus and dioestrus TEBs have a low mitotic index and small size. 
This shrinkage of TEBs could potentially be attributed to the migration of cells 
out of the bud to form a new segment of duct [103]. It is also likely that TEBs 
push forward using the pressure generated during reshaping of the TEB into the 
dimensions of a duct. This phenomenon takes place at the neck of the TEB and is 
characterised by the addition of new cells into the subtending ducts, extensive 
ECM remodelling and ColI deposition at the flanks and neck of the TEB which, 
taken together  create  a  girdle  to  contain  and direct  the  pressure and hence 
contribute to the elongation [53].    
The forward movement of TEBs may also result from the unusual composition of 
its BM. BM surrounding the tip of TEBs is rich in hyaluronan while that enclosing 
the  neck  region  is  associated  with  collagens  [50]  [53].  Both  the  documented 
association of hyaluronic acid with cell mobility during embryogenesis and the 
observation that during microdissection or enzymatic digestion the tip of TEB 
separates much easier from the surrounding stroma than its neck suggest that     44 
 
hyaluronan may facilitate forward movement by reducing friction and epithelial-
stromal adhesion during cellular migration  [104] [53].  
Recent  experiments  carried  out  using  3D  Matrigel  cultures  of  mammary 
epithelial  organoids  suggested  collective  cell  migration  and  cellular 
rearrangements as two possible mechanisms facilitating the forward movement 
of TEBs [105]. This type of cellular migration has been already described for 
neuronal precursors in the zebra fish lateral line, epithelial cells during dorsal 
closure and migrating border cells in Drosophila melanogaster [106] [107] [108]. 
Collective cell migration is characterised by coherent movement of a group of 
cells where cells at the front show cellular extensions or protrusions projected in 
the direction of movement.  In the cultured TEB-like organoids,  however,  the 
leading edge of cells, although lacking cellular protrusions, remained adherent 
as demonstrated by positive Cdh1 and Cdh3 staining and showed presence of 
dynamic  cellular  rearrangements  [105].  It  must,  however,  be  stressed  that 
organoids in vitro are not a good model of TEBs in vivo. Thus, it is crucial to 
develop appropriate in vitro models to aid the study of TEBs migration and the 
first step towards this goal would be to isolate and maintain pubertal mammary 
glands in vitro. During the course of the work for this thesis, pilot experiments 
were carried out to maintain TEB explants in culture (4.1.2.5).  
1.2.2.1.2  Bifurcation 
 
Bifurcation of TEBs is a defining morphogenetic event in the patterning of ductal 
branching during puberty  (Figure 1-5).  The appearance of a cleft creates an 
indent  in  the  epithelium  which  in  turn  marks  the  site  where  the  primary 
branching will occur and from which two new TEBs will elongate. Newly formed 
TEBs continue to invade stroma and give rise to two subtending primary ducts. 
The exact mechanism underlying TEB bifurcation,  however, has not yet been 
elucidated.     45 
 
 
Figure 1-5 Branching morphogenesis in pubertal mouse mammary gland. 
High-magnification carmine alum-stained wholemount (6 weeks) showing a fragment of duct with 
lateral branches forming (arrow and arrow head) and a bifurcating TEB (asterisk). Scale bar is 
200um.     46 
 
The few existing studies suggest the importance of the BM and ECM composition 
in driving the process [50] [109]. Silberstein (2001) proposed the formation of a 
cleft in the distal surface of the TEB to result from highly localised presence of 
S-GAG and ColI in this region. According to this model, the focal induction of S-
GAG in the BM of TEB, followed by the deposition of ColI in the surrounding ECM 
would retard the growth advancement at the induction point and, on the other 
hand, promote the directional elongation of newly bifurcated lobes [56].  
Further  insights  into  the  process  of  TEB  bifurcation  were  delivered  using  3D 
culture of EpH4. EpH4 cells derive from normal mammary epithelium of a mid-
pregnant mouse and when embedded in the cavities of ColI gel and cultured 
under  specified  conditions,  they  form  hollow  epithelial  tubes  of  defined 
geometry. Upon the addition of epidermal growth factor (EGF) or HGF, these 
tubules are able to undergo branching morphogenesis similar to that seen during 
TEB  bifurcation  or  ductal  branching  in  vivo.  Parts  of  these  tubules  are  also 
shown to express vimentin [110], one of the main markers used to identify a 
mesenchymal phenotype. In these experiments the sites of vimentin expression 
were  identified  by  real  time  imaging  of  the  expression  of  green  fluorescent 
protein  (GFP)  under  the  control  of  a  vimentin  promoter.  Cells  present  at 
subsequent  bifurcation/branching  sites  were  shown  to  acquire  an  invasive 
mesenchymal  phenotype,  suggesting  that  cells  are  instructed  to  branch 
depending on their spatial location and ability to attain the invasive phenotype. 
Furthermore, it was also demonstrated that an increase in tubule length resulted 
in increased magnitude of branching and curved tubules branched preferentially 
from the convex side of the curve, suggesting that the magnitude and position of 
bifurcation/branching  is  dependent  on  the  initial  geometry  of  the  tubule. 
Further  analysis  revealed  that  the  observed  bifurcation/branching  did  not 
coincide with increased epithelial proliferation or enhanced signalling by growth 
factor receptors. The bifurcation/branching position, however, was determined 
by the concentration gradient of stromal inhibitory morphogens, such as TGF-ß, 
as  their  concentration  was  shown  to  be  lowest  in  the  position  where 
bifurcation/branching was induced [110]. Taken together, these results suggest 
that an epithelial-to-mesenchymal (EMT)-like transition event is required at the 
branch points for bifurcation/branching to occur and TEB (or duct) geometry,     47 
 
length  and  stromal  composition  are  likely  to  control  the  position  of 
bifurcation/branching. 
EMT  can  be  identified  during  certain  other  events  that  require  epithelial 
remodelling  and  multilayering,  such  as  embryogenesis,  organ  development, 
tissue regeneration and cancer progression and metastasis. It is characterised by 
a  series  of  biochemical  changes  that  enable  polarised  epithelial  cells  which 
normally interact with BM to acquire a mesenchymal phenotype, consistent with 
enhanced  migratory  capacity,  invasiveness,  increased  resistance  to  apoptosis 
and elevated production of ECM components. The completion of EMT is marked 
by  ECM  degradation and the  detachment of  the  mesenchymal-like  cells  away 
from the epithelial cell layer [111]. 
Epithelial  bifurcation  is  also  essential  for  the  formation  of  lungs,  kidneys  or 
salivary glands [112].  
1.2.2.1.3  Turning 
 
Another area which has not yet been extensively researched is the mechanism 
underlying the coordinated, directional turning of TEBs and spatial patterning of 
ductal branches in response to other approaching epithelial branches. No clear 
explanation  for  this  phenomenon  has  been  proposed  to  date.  However,  the 
stromal environment surrounding the tips of TEBs may act as a source of chemo-
attractants or inhibitors which could govern the direction of the outgrowth. In 
fact, various guiding molecules such as cytokines (CSF-1 or eotaxin) or axonal 
guidance  proteins  (small  proline  rich  protein  1A  -  Sprr1A,  semaphorin  3B  - 
Sema3B or brain abundant membrane attached signal protein - BASP) have been 
reported in this region [87] [113]. Moreover, when EpH4 cells were cultured on 
ColI  matrices  to  form  epithelial  tubules  in  response  to  FGF  or  HGF  (See 
1.2.2.1.2), an increase in the local concentration of the inhibitor  - TGF-ß by 
decreasing  the  distance between tubules,  ceased  the  growth/branching  when 
the  distance  between  epithelial  tubules  was  ≤~75µm  [110].  Although  highly 
speculative, the asymmetric deposition and remodelling of S-GAG and ColI may 
control the turning of TEB as the extended synthesis and deposition of ColI on 
one side of the end bud might channel its extension in the opposite direction.     48 
 
Asymmetric  mitosis  has  also  been  considered  as  a  potential  effector  of 
directional outgrowth. No obvious correlation, however, was observed between 
mitosis and turning when mitotic patterns were examined [102].   
In conclusion, although numerous suggestions have been made to unravel the 
mechanism underlying the motility of TEBs,  in the absence of solid scientific 
evidence, all these questions still remain to be elucidated.          
1.2.2.2  Ducts 
Motile  behaviour  exhibited  by  ducts  at  puberty  is  limited  to  branching 
morphogenesis. There are two types of branch-point that form on the ductal 
scaffold  during  this  time  point  –  secondary  (lateral  branching)  and  tertiary 
branching. The former process is fundamental for epithelial tree formation and 
occurs throughout the whole of puberty until the entire fat pad is filled with an 
extensive  system  of  branched  ducts.  Tertiary  branching,  on  the  other  hand, 
takes place after the margins of mammary fat pad are met. It occurs in response 
to recurrent oestrus cycles and gives rise to a much less pronounced form of 
epithelial growth – short tertiary branches ending with initial alveolar buds.   
Secondary  branches  originate  from  primary  ducts.  The  formation  of  lateral 
branches can be seen in Figure 1-5. Secondary branches most probably bud out 
from the basal myoepithelial cell layer and while keeping the BM intact invade 
the surrounding stroma, but the exact mechanism underlying this phenomenon is 
still to be elucidated [114]. Newly formed secondary branches have end buds 
which, like TEBs on primary ducts, are characterised by cap cells and smooth-
surfaced BM. In this case, the cap cells may form by reverse differentiation of 
ductal basal myoepithelium, although the lack of scientific evidence means the 
involvement  of  other  underlying  epithelial  cells  in  this  process  can  not  be 
excluded.  
The branching mechanism has been shown to be fairly conserved between organs 
(salivary  gland,  lung,  kidney,  pancreas,  and  mammary  glands)  and  species 
(Drosophila Melanogaster) hence it is likely that, for example, cell migration, 
cell rearrangement and change of cell shape, as suggested for D. melanogaster 
[115]  [116],  could  be  the  underlying  events  of  ductal  branching  in  mouse     49 
 
mammary gland too [112]. It is likely therefore, that the research on branching 
morphogenesis in other systems may be the key facilitator for its understanding 
in mammary gland development. Finally, as previously discussed in 1.2.2.1.2 it 
is suggested that the EMT-like transition event is required at the branch points 
for  branching  to  occur  and  the  ductal  geometry,  ductal  length  and  stromal 
composition are likely to control the position of branching [110]. 
1.2.3 Regulation of ductal morphogenesis at puberty 
Normal  pubertal  morphogenesis  of  mouse  mammary  gland,  i.e.  ductal 
outgrowth, branching morphogenesis and patterning of the open architecture of 
the  ductal  tree  depends  fully  on  the  correct  regulation  of  TEB  motility, 
bifurcation  and  patterning  and  lateral  ductal  branching.  The  nature  of  these 
regulatory signals is very complex. For normal pubertal development to occur, 
both proper communication between the epithelial cells and cross-talk between 
epithelial  and  stromal  compartments  needs  to  be  maintained.  Epithelial-
epithelial  cross-talk  encompasses  cell-cell  interactions  within  the  TEB.  The 
communication  between  epithelium  and  stroma,  on  the  other  hand,  is 
multifactorial. It occurs through the ECM and encompasses hormonal and local 
growth factor signalling and other stroma-derived signalling.  
1.2.3.1  Epithelial-epithelial communication    
Maintenance  of  cellular  integrity  within  TEB  is  essential  for  normal  ductal 
outgrowth.  As  demonstrated  by  experiments  which  disrupt  cellular  adhesion 
protein function, e.g. cadherins (Cdh), Netrin-1 (Ntn1) or its receptor Neogenin 
(Neo1),  erythroblastic  leukemia  viral  oncogene  homolog  2  (ErbB2)  or 
erythroblastic  leukemia  viral  oncogene  homolog  3  (ErbB3),  deregulation  of 
cellular communication between epithelial cells compromises ductal elongation 
[57] [117] [118] [119].  
Cadherins 
Cadherins  are  an  integral  part  of  adherent  junctions  and  desmosomes  which 
contribute to joining cells together physically. There are at least two types of 
cadherins  expressed  in  the  TEB  –  E-cadherin  and  P-cadherin.  The  former  is     50 
 
expressed by the body cells while the latter is synthesised in the cap cells. As 
demonstrated  by  Daniel  et  al.  (1995),  using  slow-release  implants  containing 
function blocking antibody surgically inserted ahead of advancing ducts, lack of 
E-cadherin resulted in significantly disrupted adhesion between body cells. This 
was  followed  by  an  abrupt  decline  in  DNA  synthesis  and  disruption  of  ductal 
elongation.  The  observed  phenotype  was  reversible  upon  withdrawal  of  the 
function  blocking  antibodies.  Similar  experiments,  designed  to  ablate  the 
expression of P-cadherin in cap cells resulted in much less disruption of cellular 
morphology  and  a  much  smaller  decline  in  DNA  synthesis  than  following  E-
cadherin  depletion.  No  aberrant  phenotype  could  be  seen,  suggesting  that 
although  tissue  integrity  is  essential  for  ductal  outgrowth  either  the  modest 
perturbation  in  TEB  structure  can  be  accommodated  or  other  molecules 
compensate for the loss of cadherin expression [57].  
Netrin 1 and Neogenin 1 
Disorganisation of TEB structure and retarded ductal elongation was caused by a 
homozygous  loss-of-function  mutation  in  either  Ntn1  or  its  receptor,  Neo1. 
Although, initially identified as guidance cues for developing neurons, this family 
of proteins has recently been identified in TEBs at puberty [120] [117]. Ntn1 was 
expressed by body cells and secreted to its cell membranes and ECM while Neo1 
was expressed in a complementary pattern by the overlaying cap cells. In TEBs, 
loss  of  function  of  either  gene  resulted  in  significantly  disrupted  adhesion 
between  the  cap  and  body  cell  layers,  followed  by  the  appearance  of  large 
spaces below the cap cell region which were filled with dissociated cap cells. 
Breaks  in  BM  were  also  seen.  However,  the  rate  of  DNA  synthesis  stayed 
constant.  These  observations  highlight  the  crucial  role  of  Ntn1  and  Neo1 
signalling in mediating cellular contact between cap and body cells which in turn 
is essential for maintenance of TEB integrity, but has no obvious effect on the 
outgrowth of the ductal tree, as suggested by the normal ductal elongation seen 
in either Neo1 or Ntn1 KO
-/- mice [117].  
Erythroblastic leukemia viral oncogene homolog 2 and 3 
Similar  loss  of  adhesion  between  the  cap  and  body  cells  of  TEB  was  also 
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mutations in either ErbB2 or ErbB3 - orphan receptors which form heterodimers 
with epidermal growth factor receptor (EGFR), ErbB3 and ErbB4 allowing them 
to respond to EGF- and Nrg1 - like growth factors. In both mice, TEBs were small 
and  disorganised,  with  exaggerated  spaces  between  the  two  cellular 
compartments and ductal elongation was significantly reduced [118] [119]. The 
ErbB3 KO
-/- mice, however, showed an additional increase in the number of TEBs 
and lateral branches [119]. Thus, suggesting presence of divergent roles of ErbB2 
or ErbB3 in controlling ductal morphogenesis.  
1.2.3.2  Epithelial-stromal interactions 
The second prerequisite for normal ductal morphogenesis during puberty is an 
uninterrupted cross-talk between epithelial-stromal compartments. This ability 
of stromal cells to communicate and signal to the outgrowing epithelium is an 
underlying  mechanism  for  the  morphogenic  effect  which  hormonal  and  local 
growth  factor  signalling  and  other  stroma-derived  signals  exert  on  the 
epithelium. 
1.2.3.2.1  Hormonal control of pubertal mouse mammary gland 
morphogenesis 
 
Oestrogen and Progesterone 
The two main sex hormones at puberty are oestrogen (E) and progesterone (P). E 
is produced from androgens during the process of aromatization catalysed by an 
enzyme  called  aromatase.  Aromatase  can  be  found  in  many  tissues  including 
gonads, brain, adipose tissue, placenta, endometrium skin or bone. There are 
three major members of the E family: estradiol (E2), estrone and estriol. E2 is 
the most potent one and is responsible for most E mediated signalling in women 
[121]. Most of the circulating E2 is produced by the ovaries. Other tissue such as 
the adrenal cortex, however, can also serve as a minor source. P is the major 
naturally occurring member of the progesterone family, and like E2, is mainly 
produced by the ovaries and secondly by the adrenal cortex. During pregnancy 
the placenta synthesises P. Since both hormones are mainly synthesised in the 
ovaries the hallmark for their production is the onset of puberty – the time when     52 
 
the  ovaries  develop.  At  puberty,  increased  production  of  gonadotrophin-
releasing  hormone  (GnRH)  by  the  hypothalamus  stimulates  the  production  of 
gonadotrophins- luteinising hormone (LH) and follicle stimulating hormone (FSH) 
in the pituitary gland. The gonadotrophins stimulate pubertal development of 
ovaries  which  in  turn  produce  E2  and  P.  From  then  onwards  levels  of  both 
hormones fluctuate depending on the levels of FSH and LH, i.e. the phase of 
oestrus  cycle,  causing  changes  in  reproductive  organs  (vagina,  uterus,  and 
mammary glands). The normal oestrus cycle of the laboratory mouse lasts for 4-6 
days and it can be divided into four stages (proestrus, oestrus, metoestrus and 
dioestrus).  Together,  proestrus  and  oestrus  contribute  to  the  follicular  phase 
while metoestrus and dioestrus constitute the luteal phase. The follicular phase 
is characterised by an increase in FSH levels which in turn stimulate aromatase 
production and thus E2 synthesis. Increased E2 suppresses further release of FSH 
while promoting LH synthesis and hence ovulation. Increased LH stimulates the 
synthesis of P and luteotrophic hormone (LTH)  and initiates the onset of the 
luteal phase [47]. In return, P decreases the expression of aromatase and thus 
negatively regulates E2 levels [122]. If mating takes place at this time point, the 
rising  level  of  LTH  activates  the  corpus  luteum  which  in  conjunction  with  P 
prepares the uterus to receive the fertilised egg. In the absence of pregnancy, 
titers of gonadal hormones decrease terminating the luteal phase and allowing 
reabsorbtion of the endometrium and succession of a new cycle [47]. Mammary 
glands, like the uterus and vagina, undergo a series of anabolic and catabolic 
changes during the oestrus cycle (See 1.2).  
Since the E2 and P driven onset of puberty parallels TEB formation and ductal 
morphogenesis  of  mouse  mammary  gland,  E2  was  suggested  as  the  main 
regulator of this process. The role of E2 in mouse mammary gland development 
has been studied since 1900 when it was demonstrated that ovariectomy causes 
cessation of mouse mammary gland development and exogenous E2 can restore 
it  (reviewed  in  [123]).  Classical  endocrine  ablation-replacement  experiments 
carried  out  by  Lyons  (1958)  and  Nandi  (1958)  showed  that  mouse  mammary 
glands underdeveloped due to simultaneous ovariectomy, hypophysectomy and 
adrenalectomy  respond  to  combined  treatment  with  E2  and  growth  hormone 
(GH) by restoring normal ductal morphogenesis. GH on its own induced only mild 
stimulation and pure E2 none at all [124] [125]. Taken together, these results     53 
 
established the endocrine basis for ductal outgrowth that stands today. Since 
then, it has been shown that E2 triggers the development of TEBs, stimulates 
DNA synthesis in the mammary epithelium (mostly in TEBs) and proliferation of 
stromal cells  [126] [127] [128]. It has also been demonstrated that E2 signals 
through oestrogen receptor alpha (ERα) and its ablation results in formation of 
underdeveloped mammary glands comprising a truncated ductal rudiment which 
lacked  TEBs  [129].  The  rudimentary  ductal  structure  was  comparable to  that 
seen  in  wild  type  newborn  mice.  Further  autoradiographic  experiments, 
demonstrated that murine mammary ERα localises to mammary epithelium of 
TEBs and ducts (except for cap cells) and stroma surrounding TEBs. However, co-
transplantation  of  ERα  KO
-/-  embryonic  mammary  epithelium  with  wild  type 
stroma showed that stromal not epithelial, ERα is essential for normal ductal 
elongation as only wild type stroma supported epithelial outgrowth [130] [131] 
[132].  In  contrast,  other  experiments  based  on  tissue  grafts  collected  from 
hormone stimulated adult mice indicated that both stromal and epithelial ERs 
were essential for normal pubertal outgrowth. Most recently, however, a newly 
engineered  ERα  KO
-/-  mouse  model  showed  that  ERα  expression  was  not 
completely ablated in the early ERα KO
-/- mouse models and in fact, it is the 
epithelial rather than stromal ERα that is essential for ductal outgrowth during 
puberty  [133].  Moreover,  despite  its  role  in  mediating  cellular  proliferation, 
most  of  the  proliferating  cells  lacked  ERα  expression  suggesting  a  paracrine 
manner  of  E2  signalling  in  which  E2  promotes  ductal  outgrowth  by  signalling 
through epithelial ERα to promote proliferation in adjacent cells. EGF and Areg 
which are a locally produced growth factor are likely to act as the downstream 
effector  of  E2  in  inducing  cellular  proliferation,  whereas  TGF-ß  could  be 
responsible  for  the  proliferative  quiescence  of  ERα  expressing  cells 
(See1.2.3.2.2) [134]. In 1996, a second oestrogen receptor, ERß was identified. 
Although to a much lesser extent, ERß was also expressed in the pubertal mouse 
mammary. Its ablation (ERß KO
-/- mice), however, did not alter normal pubertal 
outgrowth, suggesting that it is dispensable for pubertal mouse mammary gland 
development. Double KO, ERα/ß KO
-/- mice showed a mammary phenotype which 
was similar to that seen for ERα mice [131].  
In  contrast  to  E2,  P  is  mainly  declared  as  non  essential  for  pubertal  mouse 
mammary  development.  More  recent  evidence  showed  that  P  orchestrates     54 
 
morphological changes associated with both pre-pregnancy where it is involved 
in  preparation  of  the  uterus  for  egg  implantation  after  fertilization,  and 
pregnancy  when  it  is  essential  for  maintaining the  placenta  and  inhibition of 
uterine contractility [47]. In the mammary gland, the action of P is mediated 
through PR. There are two isoforms of PR in mammary gland: PR-A and PR-B. PRs 
localise to both epithelium and stroma. Selective PR-A KO
-/-, PR-B KO
-/- mice and 
general PR KO
-/- mice show that the exclusive interaction of P with stromally 
localised PR-B regulates tertiary side branching in virgin mice and lobuloalveolar 
development in pregnant mice [135] [136] [137] [138]. Evidence for a role of P in 
proliferation,  however,  is  not  straightforward.  Administration  of  P  to 
ovariectomised mice increases DNA synthesis in epithelial cells of TEBs and ducts 
which  suggests  P  may  play  an  intermediate  role  in  regulating  pubertal 
morphogenesis, possibly by mediating DNA synthesis  [139]. However, since E2 
promotes the expression of PR-A, the regulation of this mitogenic effect would 
have to be PR independent [140]. Furthermore, when administered with IGF-1 to 
ovariectomised IGF-1 KO
-/- mice, P enhances the action of IGF-1 and promotes 
ductal  outgrowth  during  puberty  by  producing  duct  extension  and  branching 
equivalent  to  that  seen  with  IGF-1  plus  E2,  but  without  an  increase  in  the 
number of TEBs (See 1.2.3.2.2). No such effect on the ductal epithelium can be 
noted with P or IGF-1 acting independently [141]. This finding may explain the 
very  rapid  epithelial  outgrowth  during  puberty  when  oestrus  cycle  P  and  E2 
acting together with IGF-1 could stimulate this outgrowth.   
Glucocorticoid 
Other systemic hormones such as glucocorticoids (G), GH or parathyroid hormone 
(PTH)  have  also  been  implicated  in  pubertal  mouse  mammary  development. 
Glucocorticoids are adrenal hormones which were initially described as essential 
for inducing the expression of milk proteins during lactation [142]. They function 
by  binding  to  glucocorticoid  receptors  (GRs)  and  stimulate  target  gene 
transcription either by direct binding to DNA or by protein-protein interactions. 
GR  KO
-/-  results  in  postnatal  lethality  as  mice  die  shortly  after  birth  due  to 
respiratory failure [143]. Further experiments, demonstrated that the GR KO
-/- 
anlagen can be rescued from these mice when transplanted into the cleared fat 
pad  of  wild  type  mice  where  it  produces  abnormal  mouse  mammary  glands, 
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ducts, increased periductal stroma and a much higher rate of ductal outgrowth 
than  that  seen  in  the  wild  type  epithelium.  Furthermore,  mice  which  were 
genetically engineered to express a mutated form of GR that lacked the ability 
to bind DNA but maintained the receptor-protein binding function, also exhibited 
reduced side branching and the presence of some TEBs in the adult gland [144]. 
Together  these  results  provide  strong  evidence  for  the  role  of  G  signalling, 
through  GR,  in  regulating  normal  mouse  mammary  gland  morphogenesis  at 
puberty [145]. 
Growth hormone 
GH  is  a  pituitary  hormone  which  binds  to  growth  hormone  receptors  (GHRs) 
expressed  in  both  epithelial  and  stromal  compartments  of  virgin  mouse 
mammary glands [146]. Research devoted to understanding the role of GH in 
pubertal mammary morphogenesis dates back to the early 1990s. In 1993 it was 
demonstrated  that  the  implantation  of  GH  release  pellets  into  pubertal 
mammary  glands  of  E2  treated  hypophysectomised,  ovariectomised  rats 
stimulated an increase in TEB number [147]. Since the exogenous E2 alone failed 
to  rescue  this  pubertal  phenotype  it  was  hypothesised  that  the  GH  driven 
phenotype arose independently of E2 signalling [148]. The importance of GH for 
normal  pubertal  mouse  mammary  gland  development  was  further  elucidated 
using  GHR  KO
-/-  mice.  Loss  of  GHR  produces  severe  retardation  of  ductal 
outgrowth  and  side  branching  impairment.  Furthermore,  tissue recombination 
experiments,  in  which  GHR  KO
-/-  epithelium  was  grafted into the cleared  fat 
pads of wild type mice revealed that epithelial GHR is dispensable for normal 
pubertal  morphogenesis  [149].  These  findings  suggest  that  GH  in  conjunction 
with stromal GHR acts independently or synergistically with E2 and is necessary 
for the regulation of normal pubertal mouse mammary gland morphogenesis. In 
fact,  GH  is  now  considered  as  the  second  most  important  driver  of  pubertal 
morphogenesis after E2. 
Parathyroid hormone 
Although initially associated with mammary gland embryogenesis both PTH and 
PTHrP are implicated in pubertal mouse mammary gland development. PTH is 
secreted by the parathyroid gland while PTHrP is produced by numerous adult     56 
 
and  embryonic  tissues  including  mammary  glands  where  PTHrP  expression  is 
concentrated  in  the  cap  cells  of  TEBs  and  myoepithelial  cells.  The  cognate 
receptors  are  located  in  the  surrounding  stroma  which  suggests  paracrine 
signalling is important. In 1995 mice over-expressing either PTH or PTHrP under 
the control of a Krt14 promoter showed severe impairment of ductal elongation 
and branching at puberty [150]. More recently mice engineered to over-express 
PTHrP under the control of a Krt14 promoter in a tetracycline-regulated manner 
showed that this phenotype depended on the timing of PTHrP over-expression. 
When  transiently  over-expressed  in  prenatal  mice,  PTHrP  impaired  branching 
whereas  the  decreased  rate  of  ductal  elongation  was  seen  exclusively  in 
response to PTHrP over-expression at puberty. In addition, the defect in ductal 
elongation was associated with a failure to decrease apoptosis of epithelial cells 
in  TEB  and  increase  the  proliferation  in  response  to  E2  and  P  [151]. 
Unfortunately the PTHrP KO
-/- mouse model failed to provide further insights into 
the impact of PTHrP on pubertal morphogenesis due to its embryonic lethality 
[22].   
Vitamin D 
Although, endocrine glands determine the hormonal milieu for pubertal mouse 
mammary gland development additional systemic factors such as vitamin D3 are 
also  involved  in  the  orchestration  of  this  process.  Vitamin  D3  can  be  either 
produced in skin of vertebrates after the exposure to ultraviolet B (UVB) light 
from the sun or artificial sources or occurs naturally in a small range of food 
(fatty  fish,  eggs,  meat).  Upon  ingestion,  vitamin  D3  gets  converted  to  its 
hormonally  active  form  –  1,25-  dihydroxyvitamin  D3  (calciol)  which  interacts 
with the vitamin D3 receptor (VDR). VDR is a nuclear steroid hormone receptor 
which localises to pubertal stroma and epithelium of TEBs and subtending ducts. 
The  expression  of  VDR  in  TEBs  is  much  higher  in  mitotically  quiescent  than 
proliferating cells. VDR KO
-/- mice display enhanced development of mammary 
glands  during  puberty  after  supplementation  with  dietary  Ca
2+  to  regulate 
fertility,  serum  E2  and  neonatal  growth.  This  pubertal  phenotype  is 
characterised by extensive ductal elongation and branching and an increase in 
the number of TEBs. Further growth enhancement is seen on exposure of VDR 
KO
-/- mice to ovarian hormones in vivo or during whole mammary gland organ 
culture [152]. Collectively, these results suggest that vitamin D3 signals through     57 
 
VDR to oppose E2 driven proliferation and to maintain cellular differentiation, 
hence  participating  in  negative  regulation  of  pubertal  outgrowth  of  mouse 
mammary gland [153].      
1.2.3.2.2  Local growth control of pubertal mouse mammary gland 
development 
 
Although  systemic  hormones  play  a  central  role  in  pubertal  mouse  mammary 
gland  morphogenesis  (See  1.2.3.2.1)  this  observation  was  challenged  by  the 
discovery that proliferating cells in TEBs and ducts are in fact those that lack 
expression of steroid hormone receptors and that the receptor-expressing cells 
are often those adjacent to these cells. This suggested that systemic hormones 
regulate cellular proliferation in a paracrine manner using local mediators. Since 
some of the locally produced growth factors were able to mediate the effect of 
some of the hormones, they were thought to play the role of local mediators of 
hormone signalling. Further evidence for this was that the expression of these 
growth factors could rescue several of the mammary phenotypes seen in the 
steroid mouse models while their ablation produced mammary phenotypes that 
were similar to these seen in steroid mouse models. Since then, mammary gland 
growth factors that signal via their receptors have been demonstrated to play a 
pivotal role in pubertal mouse mammary gland morphogenesis by acting both as 
a part of and independently of systemic hormone signalling. 
There are four main families of growth factors and their receptors that regulate 
pubertal  mouse  mammary  gland  development.    These  include:  FGFs  and  FGF 
receptors (FGFRs); HGF and its receptor – met proto-oncogene (c-Met); IGFs and 
IGF receptors (IGFRs) and EGF-related proteins and their EGFRs (also called ErbB 
family  of  proteins  and  ErbB  receptors).  All  of  these  receptors  belong  to  the 
receptor tyrosine kinase superfamily (reviewed in [154]). 
Fibroblast growth factors 
The FGF ligand family consists of 18 members. These can be further subdivided 
in to six subfamilies called FGF1, FGF4, FGF7, FGF8, FGF9 and FGF19. Each FGF 
ligand binds to a specific FGFR. The receptors are encoded by four different     58 
 
genes which are alternatively spliced to produce at least seven FGFRs (reviewed 
in [154]). Initially, FGFs and FGFRs were established as critical during mouse 
mammary  gland  embryogenesis  (See  1.1.1).  Subsequent  research,  however, 
revealed that FGF1, FGF2, FGF4, FGF7 and FGF10 as well as receptors FGFR1 
and  FGFR2  were  also  expressed  in  mouse  mammary  gland  during  puberty 
(reviewed in [155]). Conditional over-expression of FGF3 in the mouse mammary 
epithelium  during  puberty  resulted  in  cessation  of  ductal  elongation.  Ductal 
epithelium  was  expanded,  multilayered  and  full  of  cysts  (severe  epithelial 
hyperplasia). The phenotype was proposed to arise from the imbalance between 
mitogenic  and  apoptotic  signals  [156].  The  pubertal  phenotype  of  mammary 
glands lacking FGF3 (FGF3 KO
-/- mice), however, has not yet been elucidated due 
to the severe lethality of these mice [157].  
Other members of the family have also been shown, mainly through genetically 
engineered  mice,  to  have  impact  on  mammary  development.  Mice  over-
expressing FGF4 under the control of the WAP promoter which initiates WAP-
FGF4 expression at the onset of puberty (~ 4 weeks) showed decreased apoptosis 
within TEBs which in turn led to the inhibition of ductal elongation after a week 
of  FGF4  expression.  TEBs  were  present  in  normal  numbers  but  exhibited 
impaired  morphology.  The  decrease  in  apoptotic index  was  attributed  to  the 
increase in Bcl2 which serves as an anti-apoptotic factor [158]. More recently, 
Parsa  et  al.  (2008)  demonstrated  high  expression  of  FGF10  and  its  receptor 
FGFR2IIIb  in  the  stroma  and  epithelium  of  pubertal  mouse  mammary  gland 
respectively.  Induced,  by  using  a  transactivator/tetracycline  promoter  (mice 
homozygous  for  FGFR  null  allele  die  at  midgestation),  reduction  of  pubertal 
FGFR2IIIb triggered a 40% reduction in ductal outgrowth compared to wild type 
controls and complete loss of TEBs. The phenotype was reversible upon removal 
of doxycycline [159]. A related study, based on the novel mosaic mouse model 
for  FGFR2IIIb  expression,  confirmed  expression  of  FGFR2IIIb  in  TEB  and  duct 
epithelium and was first to identify the advancing tip of TEB as a main site of 
epithelial  FGFR2IIIb  expression  whilst  demonstrating  its  lack  of  function  in 
mature  ducts.  In  TEBs,  the  FGFR2IIIb  null  cells  were  at  a  competitive 
disadvantage  to  their  heterozygous  counterparts  showing  decreased  cellular 
proliferation followed by growth retardation, whereas null cells present in the 
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FGF  ligands  and  their  receptors  regulate  tracheal  branching  in  Drosophila 
melanogaster and lung sac development in mice. As seen in Drosophila mutants 
breathless (encodes FGFR homologue) and branchless (encodes FGF homologue), 
alteration  of  either  of  these  genes  results  in  complete  ablation  of  tracheal 
branching. Similarly, the ablation of FGF10 in mice (FGF10 KO
-/- mice) strikingly 
inhibits  branching  in  the  lung,  demonstrating  the  critical  role  of  this  growth 
factor in the bifurcation of buds during lung morphogenesis [161]. The signalling 
mechanism of bifurcation in the mammary gland has not been yet elucidated, 
however,  since  primary  branching  shows  evolutionary  conservation  between 
species it is likely that FGF ligands and receptors take part in TEB bifurcation.  
Hepatocyte growth factor 
HGF (also known as scatter factor) and its receptor c-Met are also expressed and 
regulated  during  pubertal  morphogenesis  of  mouse  mammary  gland.  HGF  is 
expressed  by  mesenchymal  cells  while  c-Met  is  produced  by  the  epithelium 
[162]. KO of either HGF or c-Met have not been studied due to their prenatal 
lethality resulting from liver and placental defects. Insight into the role of HGF 
in  pubertal  morphogenesis,  however,  has  been  gained  using  mammary  gland 
organ culture, cell culture and transplantation experiments. In organ culture, 
branching  morphogenesis  of  ductal  epithelium  was  promoted  on  addition  of 
exogenous  HGF,  but  abolished  when  antisense  nucleotides  which  blocked 
endogenous HGF expression were used [162]. In transplant experiments where 
retrovirally infected epithelial cells were transplanted into clear fat pads, the 
over-expression of HGF in the mammary gland epithelium resulted in an increase 
in the size of TEBs and the number of ductal branch points compared to controls 
[163].  Furthermore,  HGF  was  also  able  to  promote  proliferation  of  epithelial 
cells  and  production  of  tubular/ductal  morphology  when  epithelial  cells,  co-
cultured with mammary fibroblasts or supplemented with fibroblast conditioned 
medium were grown in collagen gels using a minimally supplemented serum-free 
medium.  Treatment  of  epithelial  cultures  with  HGF  neutralizing  antibody 
reversed this morphogenic effect. Treatment of mammary fibroblasts with E2 
increased the production of HGF [164] and more recently, it was demonstrated 
that together HGF and EGF act synergistically to enhance proliferation, scatter 
and  invasion  of  HC11  cells  (non-tumourigenic  mammary  epithelial  cells)  in 
culture  [165].  Thus  HGF  is  capable  of  regulating  pubertal  mammary  gland     60 
 
development by acting downstream from E2 and potentially cooperating with 
EGF to mediate cellular proliferation.    
Insulin like growth factor 1 
IGF-1 is a local mediator of GH signalling. GH increased IGF-1 mRNA levels within 
the mammary glands of hypophysectomised rats [166] and this effect was further 
enhanced by the presence of E2 [167]. Given the pivotal role of GH in pubertal 
mouse  mammary  gland  morphogenesis,  it  was  not  surprising  that  IGF-1  also 
emerged  as  an  important  player  in  pubertal  development.  In  fact,  IGF-1 
signalling was demonstrated to be potent enough to substitute for GH and mimic 
GH-induced mammogenesis [167].  
Early studies of IGF-1 function, carried out using hypophysectomised, castrated, 
sexually  immature  male  rats,  demonstrated  that  when  administered  with  E2, 
IGF-1 induced development of TEBs [168]. On its own, IGF-1 exhibited a smaller 
although  still  significant  effect  on  pubertal  mouse  mammary  gland 
morphogenesis.  With  E2,  however,  the  morphogenic  effect  of  IGF-1  was 
significantly  enhanced  and  similar  to  that  seen  when  E2  and  GH  were 
administered  [167].  More  recently,  IGF-1  was  shown  to  be  expressed  in  the 
epithelium and stroma of the pubertal mouse mammary gland [169]. Loss of IGF-
1 expression (IGF-1 KO
-/- mice) was associated with impaired TEB development 
and limited ductal outgrowth with fewer branches than wild type controls. This 
phenotype was reversible upon administration of exogenous IGF-1 or IGF-1 with 
E2. No stimulatory effect was seen, however, when a combination of GH and E2 
was administered to mice, indicating that the morphogenic effect of GH is fully 
mediated  by  IGF-1  [170].  Similarly,  embryonic  mammary  buds  rescued  from 
prenatally lethal IGF-1R KO
-/- mice and grafted into cleared fat pads of wild type 
hosts,  showed  limited  ductal  branching  and  decreased  size,  number  and 
proliferative index of TEBs [171]. IGF-1 also permits the morphogenic action of P 
in  the  mammary  gland  (See  1.2.3.2.1).  In  addition,  the  reduction  in  ductal 
branching, but not elongation seen in IGF-1R KO
-/- mice means it is likely IGF-1 
may play a role in governing TEB bifurcation. This hypothesis, however, is still to 
be proven. Collectively, these studies suggest that IGF-1 in conjunction with IGF-
1R acts downstream of GH and when administered with E2 is responsible for TEB 
formation  and  ductal  morphogenesis  during  pubertal  mouse  mammary  gland     61 
 
development.  Furthermore,  IGF-1  acting  independently  of  E2  can  promote 
pubertal morphogenesis to some extent, but as for GH, E2 is required for a full 
effect.  
EGF-related ligands and receptors  
There are four types of EGF receptors: EGFR, ErbB2, ErbB3 and ErbB4. Peptides 
in  the  EGF  family  are  produced  as  transmembrane  precursors  that,  upon 
cleavage,  bind  and  activate  EGF  receptors.  Some  of  the  proteases  that  are 
known  to  facilitate  this  cleavage  include  A  Disintegrin  and  Metalloprotease 
(ADAM) and MMP families [172] [173]. EGF-like ligands are characterised by the 
presence of  a  six-cysteine  residue  motif,  the EGF  domain,  and  depending  on 
their  receptor  specificity  can  be  divided  into  three  groups.  Group  one  binds 
EGFR and consists of: EGF, Areg, TGF-α and epigen (EPG); group two binds either 
EGFR or ErbB4 and consists of betacellulin (BTC), heparin-binding EGF (HB-EGF) 
and epiregulin (EPR) while the third group binds ErbB3 or ErbB4 – Nrg-1 and Nrg-
2 or just ErbB4 – Nrg-3 and Nrg-4 [174]. Some of these EGF-family ligands (EGF 
and  Areg)  and  ErbB  receptors  –  (EGFR  and  ErbB2)  are  expressed  in  and  are 
essential for normal pubertal mouse mammary development.       
The EGFR is strongly expressed in the epithelium and adjacent stroma of TEBs. 
Some  expression  is  also  noted  in  ductal  myoepithelium  and  its  surrounding 
stroma  [175].  As  demonstrated  in  waved-2  mutant  mice  which  express  a 
truncated form of EGFR (lacks the functional tyrosine kinase domain) under the 
control  of  a  mammary  gland  specific  promoter  (the  mouse  mammary  tumour 
virus (MMTV) promoter), impairment of EFGR leads to a significant inhibition of 
ductal  morphogenesis  with  reduced  outgrowth  and  branching  [176].  A  similar 
phenotype was also seen with complete EGFR loss. Since EGFR KO
-/- mice are not 
viable, their mammary glands have to be transplanted into a wild type host to 
study  epithelial  morphogenesis.  EGFR  null  mammary  glands  show  severe 
cessation of ductal outgrowth but when transplanted into the wild type stroma, 
the pubertal phenotype of EGFR KO epithelium can be rescued. However, this is 
not  true  for  reciprocal  experiments.  Thus,  it  was  suggested  that  signalling 
through stromal EGFR is critical for normal pubertal ductal morphogenesis while 
the epithelial EGFR is not essential for this process [177].      62 
 
The importance of EGFR signalling was further highlighted when EGF-like ligands 
(EGF  and  Areg)  were  shown  to  be capable  of  promoting  ductal  outgrowth  at 
puberty and to act as a downstream effector of E2 signalling. Coleman  et al. 
(1988)  showed  that  the  administration  of  EGF  rescued  the  mammary  gland 
phenotype seen in ovariectomised mice. The delivery of EGF via slow-release 
pellets stimulated formation of new TEBs, restored normal TEB histomorphology 
and the reappearance of cap cells, reinitiated DNA synthesis in epithelial cells 
and  led  to  an  increase  in  ductal  diameter  [175].  In  contrast,  a  neutralising 
antibody to EGF inhibited the stimulatory effect of E2 on TEBs [178] suggesting 
mitogenic and morphogenic properties of EGF, an ability to substitute for E2 and 
serve as a downstream effector of E2 signalling in mouse mammary gland.  
The most profound defect in pubertal ductal morphogenesis has been seen in 
Areg KO
-/- mouse mammary glands.  Targeted loss of Areg resulted in stunted 
ductal outgrowth, but the formation, shape and morphology of TEBs in Areg KO
-/- 
glands remained unaffected. In contrast, implantation of Areg-secreting pellets, 
promoted ductal outgrowth in the pubertal mouse mammary gland [179]. When 
compared  with  other  EGF-like  ligands,  Areg  exhibited  the  highest  pubertal 
expression. In the mammary gland, Areg expression is mainly associated with the 
epithelium of advancing TEBs but lower expression, can be also demonstrated in 
the ductal epithelium and its surrounding stroma [180]. In ovariectomised mice, 
Areg expression becomes strongly up-regulated after E2 treatment. The lack of 
Areg expression in ERα KO
-/- mammary glands demonstrated that the induction 
of  Areg  occurred  through  the  ERα.  Furthermore,  as  Areg  KO
-/-  epithelium 
engrafted into the cleared fat pad of the wild type host failed to rescue ductal 
outgrowth it was concluded that epithelial Areg expression is required to induce 
proliferation  of  mammary  epithelium.  Further  research  on  mice  containing 
mammary  epithelium  that  was  mosaic  for  wild  type  and  Areg  KO
-/-  cells, 
revealed that when in close vicinity to wild type cells, Areg KO
-/- cells were able 
to  proliferate  and  contribute  to  ductal  outgrowth,  suggesting  a  paracrine 
mechanism of Areg signalling [181]. Areg, like other EGF-like ligands is expressed 
as  an  inactive  precursor  which  must  be  shed  from  the  cell  surface.  In  vitro 
cleavage of Areg by ADAM17 has been previously demonstrated [182]. In vivo, 
unprocessed Areg was found in the mammary glands obtained from ADAM17 KO
-/- 
mice, showing ADAM17 also mediates the cleavage of Areg in mammary glands     63 
 
and its absence leads to a pubertal phenotype which is similar to that seen in 
Areg KO
-/- mice [183]. Collectively these data suggest that Areg acts downstream 
of E2 in the epithelial compartment, where it is released by ADAM17 to act in a 
paracrine manner on stromal EGFR to promote normal ductal morphogenesis at 
puberty.        
The role of ErbB2 in pubertal mouse mammary gland development has already 
been  mentioned  since  a  loss-of-function  mutation  in  ErbB2  affects  cell-cell 
adhesion  causing  severe  alteration  in  TEB  morphology  and  a  delay  in  ductal 
outgrowth (See 1.2.3.1) [118]. Similarly, mammary-specific ablation of ErbB2 
through  MMTV-Cre-mediated  recombination  resulted  in  a  defect  in  ductal 
elongation and reduced branching [184]. In order to respond to growth factors, 
ErbB2 has to form a heterodimer with EGFR, ErbB3 or ErbB4. The pivotal role of 
EGFR in pubertal morphogenesis has already been described. Furthermore, ErbB3 
has also been demonstrated to be crucial for ductal outgrowth during puberty. 
When transplanted to the fat pads of wild type hosts, embryonic mammary buds 
of ErbB3 KO
-/- mice showed increased impaired ductal elongation and increase in 
the number TEB and lateral branches [119]. ErbB4, on the other hand, exerts 
pro-differentiation and anti-proliferative effects on mammary epithelium [185]. 
Its expression is lowest during periods of epithelial outgrowth, such as puberty 
(reviewed  in  [186])  and  its  loss  (ErbB4  KO
-/-  mice)  does  not  impact  ductal 
morphogenesis at puberty [187].  
1.2.3.2.3  Transcriptional control of pubertal mouse mammary gland 
development 
 
Correct  transcriptional  regulation  of  gene  expression  is  a  very  important 
prerequisite  of  normal  organ,  tissue  or  cell  morphogenesis.  Since  systemic 
hormones  are  pivotal  in  regulating  pubertal  mouse  mammary  gland 
morphogenesis the main group of associated transcription factors are nuclear 
hormone receptors, such as ER, PR, GR and VDR. Each of these receptors utilises 
a common mechanism of action. Classically, upon activation by the hormonal 
ligand, nuclear hormone receptors undergo a conformational change and working 
in  synergy  with  specific  co-activators  and  co-repressors  bind  to  the  hormone 
response element of a gene and so regulate its transcription.  In some cases,     64 
 
however,  other  non-genomic  mechanisms  of  action  can  be  used.  Specific  co-
activators can exert their function on particular downstream target genes of the 
individual receptor to determine a specific response to the hormone [188].  
Steroid receptor co-activator family 
SRC-1 and SRC-3 belong to the steroid-receptor co-activator (SRC) family and 
illustrate  how  these unique  tissue  specific  responses  to  hormones  occur.  SRC 
proteins function as co-factors for steroid hormone receptors such as P, E2 and 
thyroid hormone receptor. SRC-1 KO
-/- mice exhibited reduced ductal branching 
and ductal outgrowth at puberty. Their ability to respond to E2 or P treatment 
was  also  impaired  compared  to  their  wild  type  counterparts  [189].  Similar 
cessation  of  ductal  outgrowth  was  also  seen  in  SRC-3  deficient  (SRC-3  KO
-/-) 
mouse  mammary  glands.  In  this  case,  however,  the  observed  mammary 
phenotype was secondary to other associated defects, such as dwarfism, delayed 
puberty  and  reduced  female  reproductive  function,  since  the  E2  treatment 
rescued the mammary phenotype but not the other observed defects [190]. More 
recently, bigenic PRAI-SRC-1 KO
-/- and PRAI-SRC-3 KO
-/- mice were generated to 
compare the role of SRC family members on PR activity in the mammary gland 
and uterus by crossing PR activity indicator (PRAI) mice with SRC-1 KO
-/- or SRC-3 
KO
-/- mice. PRAI was linked to GFP to monitor its activity. Loss of SRC-1 impaired 
the E2- and P-induced activation of PR in the uterus but not in mammary glands. 
In contrast ablation of SRC-3 impaired the activation of PR by E2 and P in the 
mammary gland but not in the uterus. Together, these results reveal SRC-3 as a 
primary  co-activator  of  PR  in  the  mammary  gland  and  show  SRC-1  to  be  its 
primary  co-activator  in  uterus  [191].  The  absence  of  a  pubertal  mammary 
phenotype in SRC-3 KO
-/- mice can be explained by the minimal role that PR 
plays  in  pubertal  mouse  mammary  gland  development.  The  distinct  pubertal 
mammary phenotype in SRC-1 mice, on the other hand, is probably due to the 
requirement  for  SRC-1  in  ER  activation  and  function.  Furthermore,  SRC-2 
appears to be an indispensable co-regulator of both uterine and mammary gland 
responses to P as demonstrated by a mouse model in which SRC-2 function is 
abrogated only in PR expressing cells. The absence of SRC-2 in uterus impaired 
embryo implantation while lack of SRC-2 in mammary gland resulted in defective 
branching morphogenesis [192].      65 
 
Cbp/p300 –interacting transactivator with Glu/Asp-rich carboxy-terminal domain 
1 
Another co-activator of ER that is crucial for pubertal mouse mammary gland 
development  is  the  Cbp/p300  –  interacting  transactivator  with  Glu/Asp-rich 
carboxy-terminal  domain  1  (CITED1).  Loss  of  CITED1  (CITED1  KO
-/-  mice)  in 
mammary  glands  caused  reduced  ductal  outgrowth  and  aberrant  ductal 
patterning.  Ducts  appeared  dilated  and  spatial  patterning  of  subtending 
branches  was  lost  [193].  This  phenotype  probably  arose  due  to  altered 
transcription  of  some  ER  target  genes,  such  as  Areg,  EGFR/ErbB2  or 
stanniocalcin 2 (Stc2). Synergistic interaction between these two proteins during 
pubertal mouse mammary gland morphogenesis is supported by the observation 
that both CITED1 and ERα localise to the same mammary epithelial cells [194].  
The activator protein 1 
The activator protein 1 (AP-1) is also involved in E2 signalling at puberty either 
acting as a co-regulator for ER or as a downstream target. AP-1 is a transcription 
factor composed of dimers of the oncogenes Jun (cJun), FBJ osteosarcoma (Fos) 
or  other  factors  such  as  activating  transcription  factor  (ATF)  proteins.  Early 
experiments  targeting  cJun  in  AP-1  KO
-/-  mice  resulted  in  their  embryonic 
lethality so mammary gland development was not examined in these mice. More 
recently,  a  bi-transgenic  mouse  model,  has  been  generated,  expressing  an 
inducible AP-1 inhibitor (Tam67) under the control of the MMTV promoter such 
that AP-1 could be inhibited in a controlled manner. If inhibited at puberty, AP-1 
deficiency  resulted  in  reduced  size  of  the  ductal  tree  by  decreasing  cellular 
proliferation  but  increasing  apoptosis  which  reflected  onto  pubertal 
morphogenesis  by  suppressing  primary  ductal  branching  and  decreasing  TEB 
formation.  Inhibition  of  AP-1  also  suppressed  the  expression  of  both  AP-1 
dependent genes, such as vimentin, fibronectin or TIMP-1 and AP-1 dependent 
growth regulatory genes (cyclin D1 and c-myc) and reduced the ability of the 
mammary gland to respond to E2 and P treatment [195].      
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Mediator complex subunit 1 
Mediator complex subunit 1 (MED1) is another co-activator of nuclear hormone 
receptors. It may act as a main bridge for direct communication between the 
transcriptional  activator  and  general  transcription  machinery  (especially  RNA 
Polymerase II) and facilitate nuclear receptor-mediated gene transcription [196]. 
The interaction between receptor and MED1 is mediated through the LxxLL motif 
that is present in MED1. In MED1 LxxLL motif mutant knockin mice, disruption of 
the LxxLL motif resulted in severe defects in pubertal mouse mammary gland 
development manifested by decreased ductal outgrowth and side branching and 
decreased  cellular  proliferation.  Furthermore,  aberration  of  normal  LxxLL 
function down-regulated the expression of ERα-regulated genes (cyclin D1, PR) 
and, as seen in AP-1 KO
-/- mice, reduced the ability of the mammary gland to 
respond  to  E2  stimulation  and  diminished  E2-regulated  ductal  outgrowth. 
Together,  these  results  show  that  MED1  is  important  for  pubertal  mouse 
mammary  gland  morphogenesis.  Loss  of  its  function  decreased  cellular 
proliferation and down-regulated E2 signalling, both of which resulted in delayed 
development of the mammary tree at puberty [197].     
Metastasis-associated protein 1 
Metastasis-associated  protein  1  (MTA1)  is  an  ER  co-modulator  which  causes 
inappropriate  mammary  gland  development  if  deregulated  during  puberty. 
Transgenic mice over-expressing MTA1 under the control of the MMTV promoter 
displayed increased proliferation of ductal epithelium leading to extensive side 
branching  and  precocious  differentiation  of  mammary  glands.  The  mammary 
glands of these pubertal transgenic mice strongly resembled those in wild type 
mid-pregnant mice. A similar phenotype could also be seen in mammary glands 
collected from ovariectomised female mice, suggesting that an E2-independent 
mechanism might cause these morphological changes. MTA1 over-expression also 
deregulated pubertal ß-casein,  ß-catenin and cyclin D1 expression,  decreased 
PR-B expression and increased PR-A expression [198]. 
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CCAAT-enhancer binding proteins 
CCAAT-enhancer binding proteins (C/EBPs) belong to the family of leucine zipper 
DNA  binding  transcription  factors.  There  are  six  members,  called  C/EBPα  to 
C/EBPζ which promote the expression of certain genes by interaction with the 
CCAAT  box  motif  on  their  promoter.  C/EBPα,  C/EBPß  and  C/EBPδ  are 
differentially expressed in mouse mammary gland (reviewed in [199]) but only 
C/EBPß,  to date,  is  important  for  pubertal  mammary  morphogenesis.  C/EBPß   
KO
-/-  mice  showed  disrupted  ductal  morphogenesis  that  was  characterised  by 
reduced  outgrowth  and  branching  [200].  This  disruption  persisted  until 
adulthood, when enlarged ducts and a reduced number of side branches could 
be  noted  [201].  In  tissue  transplantation  experiments,  a  pubertal  phenotype 
arose  mostly  due  to  the  absence  of  C/EBPß  in  the  mammary  epithelium, 
although partly induced by an ovarian defect. When wild type epithelium was 
grafted into the empty fat pad of C/EBPß KO
-/- mice normal mammary epithelial 
outgrowth was seen. In contrast, C/EBPß KO
-/- epithelium grafted into the empty 
fat pad of a wild type host failed to develop. The mechanism by which C/EBPß 
regulates  pubertal  ductal  morphogenesis  has  yet  to  be  elucidated.  However, 
since E2 partially rescues the pubertal phenotype, C/EBPß may act downstream 
of hormone signalling cascades and compromised E2 signalling may be partially 
responsible for the observed pubertal phenotype [200].   
GATA binding protein 3 
GATA-3 is one of the six highly conserved transcription factors that belong to the 
GATA family. In mammary gland morphogenesis, GATA-3 expression marks the 
formation of the embryonic placode, which makes it the earliest transcription 
factor  that  is  expressed.  Its  expression  persists  throughout  the  whole  of 
mammary  development.  At  puberty,  GATA-3  is  the  most  highly  expressed 
transcription factor in the mammary epithelium, where it localises to the ductal 
luminal  cells  and  the  body  cells  of  TEBs.  Conditional  deletion  of  GATA-3 
impaired TEB formation and hence severely compromised ductal morphogenesis. 
Furthermore, its prolonged loss led to large numbers of undifferentiated luminal 
cells and compromised cellular attachment to the BM which in the long term led 
to caspase-activated cell death [202]. GATA-3 is therefore important for normal     68 
 
mouse mammary gland development by maintaining differentiation of luminal 
epithelial cells.  
Activating enhancer binding protein 2 gamma 
Another  transcription  factor  pivotal  for  normal  mouse  mammary  gland 
development at puberty is the activating enhancer binding protein 2 gamma (AP-
2γ).  AP-2γ  regulates  gene  expression  during  embryogenesis.  In  the  mammary 
gland, AP-2γ localises to cap and body cells of TEB. Mice lacking AP-2γ (AP-2γ 
KO
-/- mice)  displayed reduced proliferation within the cells of TEB leading to 
impaired ductal branching and elongation. Although these mice expressed ER, 
normal mammary development could not be restored by adding of exogenous E2, 
suggesting  AP-2γ  may  regulate  ductal  outgrowth  by  acting  downstream  of 
ovarian hormones [203].      
1.2.3.2.4  Immune response cells and cytokines in the regulation of 
pubertal mammary gland development 
 
Although, it has been comprehensively documented that the combined activities 
of  stroma/epithelium  expressed  systemic  hormones  and  locally  acting  growth 
factors are pivotal for normal mammary epithelial morphogenesis at puberty, a 
number  of  mouse  models  with  uncompromised  hormonal  signalling  have  still 
demonstrated  abnormalities  in  pubertal  mammary  morphology.  This  suggests 
that  other  molecular  players  may  be  involved  in  normal  mammary  gland 
morphogenesis.  
Both  positive  and  negative  signalling  is  crucial  for  regulating  epithelial 
outgrowth  and  maintenance  of  ductal  tree  open  architecture.  The  growth-
promoting signalling factors within pubertal mouse mammary gland development 
have  been  well  researched  and  the  key  players  have  been  described  in  this 
section. In contrast, the mechanisms by which mammary epithelial outgrowth 
ceases, as a response to ductal patterning or reaching the end of the fat pad, 
are much less clear. To date, the best candidate for an inhibitory factor that 
regulates epithelial outgrowth at puberty and consequently ductal patterning is 
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Transforming growth factor beta family 
TGF-ß proteins belong to the superfamily of multifunctional secreted cytokines 
that compromises TGF-ß (TGF-ß1, TGF-ß2 and TGF-ß3), BMPs, activins, inhibins, 
nodals,  myostatin and others  [204].  Members of the TGF-ß superfamily signal 
through their heteromeric type I and type II serine/threonine kinase receptors. 
TGF-ß  binding  to  the  type  II  receptor  results  in  the  recruitment  of  a  type  I 
receptor to the complex. The receptor type II further facilitates phosphorylation 
of the receptor type I on the serine and threonine residues which results in its 
activation and hence initiation of signalling to the downstream components of 
the pathway, mainly Sma/Mad-related (Smad) proteins. Several copies of Smads 
aggregate to form complexes which translocate to the nucleus to regulate gene 
transcription  [205].  TGF-ß  mediated  cellular  processes  are  very  diverse  and 
include:  cell  division,  differentiation,  proliferation,  migration,  adhesion, 
morphogenesis and programmed cell death. Five of the TGF-ß family members: 
TGF-ß  transcripts,  inhibins,  activins,  nodal  and  BMPs  are  expressed  in  the 
mammary gland.  
Transforming growth factor beta  
TGF-ß  transcripts  show  overlapping  expression  within  epithelium  of  TEBs  and 
ducts. TGF-ß1 and TGF-ß3 mostly localise to body cells of TEBs and luminal and 
myoepithelial  cells  of  ducts  with  higher  TGF-ß  levels  in  the  former  than  the 
latter.  Some  TGF-ß3  expression  further  associates  with  cap  cells  and 
myoepithelial  cells  while  the  additional  expression  of  TGF-ß1  can  be  also 
denoted in stroma that surrounds epithelium, where it forms a complex with 
ECM around ducts that are rather growth quiescent at puberty (in contrast to 
TEBs). TGF-ß2 expression although weak is detectable over both the epithelial 
and stromal compartments of pubertal mammary gland. In contrast, no TGF-ß 
peptides could be seen in the stroma at the front of advancing TEBs [206]. In 
fact, TEBs were shown to regress upon the administration of TGF-ß1, TGF-ß2 or 
TGF-ß3  releasing  pellets.  The  growth  inhibited  mammary  epithelium  was 
histologically normal and the inhibitory effect was fully reversible [206] [207]. 
The  administration  of  exogenous  TGF-ß1,  however,  had  an  impact  on  the 
morphology  of  stroma  surrounding  the  tip  of  TEBs.  As  demonstrated  by 
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tissue  cap,  that  consisted  of  S-GAGs,  ColI  and  chondroitin  sulfate  which  was 
indistinguishable from that seen on the flanks of TEBs and ducts was identified in 
front of the manipulated TEBs [208].  
A marked suppression of TEB outgrowth and lateral branching resulting in the 
impairment  of  normal  ductal  patterning  and  duct  hypoplasia  has  also  been 
demonstrated in mouse models engineered to over-express TGF-ß1, using simian 
TGF-ß1 mutated to produce a constitutively active product under the control of 
the MMTV promoter/enhancer [209]. The inhibitory effect of TGF-ß on mammary 
epithelium was further confirmed when endogenous TGF-ß levels in mammary 
gland  were  manipulated.  Mice  carrying  a  function-ablating  dominant-negative 
mutation  in  TGF-ß  receptor  type  II,  expressed  under  the  control  of  a 
metallothionein-derived  promoter,  showed  a  dramatic  increase  in  lateral 
branching  of  ductal  epithelium  that  overrode  normal  ductal  spacing. 
Furthermore, TGF-ß receptor type II localised to stroma, suggesting a paracrine 
manner of TGF-ß signalling [210]. In contrast, a decrease of TGF-ß1 expression, 
in TGF-ß1 KO
+/- mice, which expressed only 10-30 % of TGF-ß1 protein levels, 
caused  accelerated  ductal  development  and  cellular  proliferation  at  puberty. 
Tissue transplantation experiments showed this TGF-ß1-deficient phenotype was 
intrinsic  to  the  epithelium.  Further  analysis,  based  on  the  use  of  antibodies 
raised  against  the  latent  (active)  form  of  TGF-ß1  revealed  that  TGF-ß1 
expression in these mice was modulated by the oestrus cycle. Together with the 
increased  epithelial  proliferation  seen  on  administration  of  E2  and  P  to 
ovariectomised TGF-ß1 KO
+/- mice, this suggested a role for ovarian hormones in 
the expression of TGF-ß1 which in turn regulates the proliferative response to 
hormones [211]. 
Investigation  of  the  effect  of  complete  loss  of  TGF-ß1 on pubertal  mammary 
gland morphogenesis has been difficult due to the early lethality of TGF-ß1 KO
-/- 
mice which die from a gross inflammatory response before reaching 3 weeks of 
age [212]. Recently, however, this pathological phenotype has been rescued by 
immunocompromising the mice. TGF-ß1 KO
-/- mice exhibited fairly normal ductal 
outgrowth at puberty. When transplanted to wild type recipients, however, TGF-
ß1 KO
-/- epithelium exhibited a much higher rate of outgrowth than that seen for 
TGF-ß1  epithelium.  Thus,  two  opposing  roles  of  TGF-ß1  in  pubertal  mouse 
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outgrowth and endocrine/paracrine stimulation of ductal morphogenesis [213]. 
The autocrine nature of TGF-ß1 signalling is confirmed by co-localisation of TGF-
ß1 and phosphorylated Smad 2/3 (downstream target of activated TGF-ß) to the 
same cells. Since, nuclear Smad co-localised with ERα, and ERα positive cells do 
not  proliferate,  it  was  further  investigated  whether  TGF-ß1  could  inhibit  the 
proliferative capacity of these cells. In fact, the number of proliferating, ERα 
positive cells increased in mature ducts of TGF-ß1 KO
-/- glands (especially during 
oestrus) and was significantly reduced in mouse models over-expressing active 
TGF-ß1. At puberty, however, no evidence for TGF-ß1-regulated proliferation of 
ERα positive cells was denoted [214]. Thus, although TGF-ß1 appears to act in an 
autocrine manner to inhibit the proliferative index of ERα expressing cells, in 
mature  mammary  glands,  at  puberty  this  regulatory  effect  appears  to  be 
independent of TGF-ß1 expression. TGF-ß1 has been recently shown to regulate 
spacing of ductal branching. Using an  in vitro 3D assay to reconstruct ductal 
structures characteristic of mammary epithelium, local, low gradients of TGF-ß1 
were demonstrated to control the positional milieu of  ductal lateral branching 
[110].  Collectively,  these  results  provide  evidence  for  the  role  of  TGF-ß  in 
regulating  TEB  outgrowth  and  lateral  ductal  branching.  TGF-ß  seems  to  act 
through its type II receptor in both an autocrine and paracrine manner and as 
recently suggested, HGF is likely to play a role in TGF-ß paracrine signalling. 
HGF  stimulates  ductal  branching  morphogenesis  in  vitro  and  its  expression  is 
significantly increased in mutant TGF-ß receptor transgenic mice  [215] [210]. 
Thus inhibition of epithelial outgrowth may be a result of HGF inhibition by TGF-
ß.     
Inhibins and Activins 
Inhibins  and  activins  also  regulate  mouse  mammary  gland  development  at 
puberty. Activins function as dimers of two subunits: ßA and ßB. There are three 
types of activins that have been identified to date, namely activin A (ßA ßA), 
activin B (ßB ßB) and activin AB (ßA ßB). The inhibin family, on the other hand, 
consists of two members who share a common α subunit: inhibin A (α ßA) and 
inhibin B  (α  ßB). Inactivation  of  the activin/inhibin  gene  ßB and  thus  loss  of 
activin  B,  activin  AB,  inhibin  B  or  a  combination  of  the  three  affects  ductal 
architecture during puberty. Ductal elongation was incomplete and TEBs showed 
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persisting  up  until  postpartum.  This  mammary  phenotype,  however, could  be 
rescued by transplantation of ßB-deficient epithelium into the cleared fat pads 
of  wild  type  hosts,  suggesting  stromal  regulation  of  ßB-dependent  epithelial 
morphogenesis at puberty [216].  
Nodal 
Nodal is a potent embryonic regulator which is also crucial for normal mouse 
mammary gland morphogenesis. It is expressed in ductal epithelium at puberty 
and  transgenic  mice,  carrying  lacZ  floxed  nodal  alleles  that  display  25% 
decreased expression of Nodal, exhibited impaired ductal branching at puberty. 
Furthermore, when administered into the mammary gland in the form of slow-
release  pellets,  nodal  influenced  both  the  direction  and  development  of 
branching [217].  
Bone morphogenic proteins 
BMP2  and  BMP4  are  also  expressed  during  pubertal  mouse  mammary  gland 
morphogenesis  [218].  BMP-4  potentiated  the  mitogenic  activity  exerted  by 
several  growth  factors  on  mammary  epithelium.  When  added  in  combination 
with  suboptimal  concentrations  of  FGF2,  FGF7,  FGF10,  EGF  or  HGF,  growth 
factor induced proliferation of epithelial cells in low density in vitro culture was 
significantly  enhanced  confirming  its  potential  role  in  ductal  morphogenesis 
[219].  
Macrophages and Eosinophils 
The formation and outgrowth of TEBs during puberty is closely paralleled by the 
homing  of  macrophages  and  eosinophils  to  the  mammary  gland  where  they 
localise to the extracellular regions of TEBs (See 1.2.1.2.3). Because of their 
spatial location and timing of expression, many research groups have focused on 
their role in puberty and demonstrated that both macrophages and eosinophils 
are essential for the normal outgrowth of the ductal tree. As demonstrated by 
Gouon-Evans et al. (2002), mice depleted of a hematopoietic system, by gamma 
irradiation,  showed  significant  curtailment  of  pubertal  morphogenesis  with 
complete  absence  of  TEBs  and  therefore  an  arrest  of  ductal  outgrowth.  This     73 
 
phenotype,  however,  could  be  rescued  by  bone  marrow  transplantation  that 
replaced the population of leukocytes [85].  
The  critical  role  of  macrophages  during  puberty  was  further  highlighted  by 
analysis of CSF-1 null mice (osteopetrotic mice which are deficient in CSF-1 due 
to  a  naturally  occurring  inactivating  mutation).  These  mice  showed  impaired 
formation and outgrowth of TEBs and defective ductal branching [220] [85]. This 
TEB-associated phenotype has, more recently, been suggested to result from the 
impaired ColI fibrillogenesis which is at least partly promoted by macrophages 
(and  thus  reduced  in  CSF-1  null  mice)  and  provides  a  framework  for  TEBs 
elongation [83].  
Macrophages contribute to ECM remodelling during wound healing and produce 
ECM  components,  such  as  Fn  or  thrombospondin  1  as  well  as  ECM  degrading 
proteases such as MMP-7 which degrades collagen. Given the importance of ECM 
remodelling during ductal outgrowth, the association of macrophages with ColI 
fibrillogenesis  and  the  dramatic  phenotype  of  CSF-1  null  or  hematopoietic 
system depleted mice it is very likely that the ECM remodelling is the way that 
macrophages take part in regulation of mouse mammary ductal morphogenesis 
at puberty.  
Mammary  gland  branching  and  TEB  formation  are  also  reduced  in  mice 
homozygous for a null mutation in eotaxin, i.e. deficient in eosinophils [85]. 
Mast cells 
Another immune system response element that has been recently discovered to 
localise to TEB stroma during puberty are mast cells [89]. Previously, mast cells 
were  thought  only  to  contribute  to  allergy,  inflammatory  disease  or  cancer 
development. However, using two transgenic mice models - Kit 
+/W-sh and Kit 
W-
sh/W-sh , Lilla et al. (2009) showed that mast cells are also required for normal 
mammary development [89]. Complete or partial ubiquitous deficiency of mast 
cells was seen in transgenic mice which were either heterozygous or homozygous 
for a spontaneous inversion mutation in the regulatory region of the c-kit proto-
oncogene,  which  is  located  at  the  white  spotting  (W)  locus  and  encodes  a 
putative tyrosine kinase receptor [221] [222]. Wholemount analysis showed no     74 
 
abnormal  phenotype  in  pre-pubertal  mouse  mammary  glands.  At  puberty  (5 
weeks), however, the mammary glands collected from mast cell deficient mice 
(Kit 
W-sh/W-sh) showed a significantly reduced number of TEBs and ducts than their 
wild type counterparts while Kit 
+/W-sh mice showed an intermediate phenotype. 
These phenotypes persisted until adulthood, where the reduced ductal length 
and number of duct ends were still present. The observed growth impairment 
was independent of macrophage or eosinophil recruitment (mast cells serve as 
key recruiters of leukocytes) as no differences in the amount of these cells could 
be seen in the Kit 
W-sh mutant mice. These phenotypes most likely resulted from 
decreased cellular proliferation noted in TEBs and ducts in these mice [85] [89].  
In addition, treatment of 3 week old female CD1 outbred mice with cromolyn 
sodium for 2 weeks revealed that degranulation is critical for mast cells to affect 
ductal  mouse  mammary  gland  morphogenesis,  because  of  essential  mediators 
(such as serine protease) of TEB outgrowth within the mast cells‟ granules.  As 
demonstrated by the wholemounts, TEB formation and ductal outgrowth were 
significantly inhibited in response to the treatment [89].  
1.2.3.2.5  The role of other stromal components in regulation of 
pubertal mammary morphogenesis 
 
Further  insight  into  the  mechanisms  regulating  pubertal  morphogenesis  was 
gained  when  the  growth-promoting  potential  of  the  TEB  stroma  and  its 
associated cells was researched in more detail. Not only immune response cells, 
but all types of stromal cells found in close proximity to outgrowing mammary 
epithelium,  namely  adipocytes,  fibroblasts  and  ECM,  play  a  dynamic  and 
essential role in promoting and regulation this outgrowth. 
Adipocytes 
Experiments  based  on  FAT-ATTAC  mice,  designed  to  facilitate  inducible  and 
reversible loss of adipocytes (induced by dimerisation of caspase 8 fusion protein 
and thus apoptosis), showed that the absence of adipocytes resulted in failure of 
TEBs  to  redevelop  at  puberty  and  impaired  ductal  elongation  and  branching 
[223]. In this mouse model, in which adipocytes can be reversibly ablated at any 
point during the mouse‟s life span a significant reduction in ductal branching,     75 
 
number of TEBs and changes in proliferation and apoptosis associated with TEB 
epithelium were seen when adipocytes were ablated (both white and brown) in 2 
week old mice [224]. The dynamic and growth promoting character of mammary 
fat pad, however, is not only due to the morphogenic activity of its resident 
cells, but also depends on extensive DNA synthesis. As shown by Berger et al. 
(1983),  extensive  DNA  synthesis  was  detected  in  the  stroma  surrounding  the 
invading  TEB  while  far  less  DNA  synthesis  was  detectable  around  growth-
terminated ducts in the adult gland [225].    
ECM 
BM  and  the  fibrous  connective  tissue  of  ECM  are  also  essential  for  TEB 
maintenance, pubertal outgrowth in vivo and epithelial mammary tubulogenesis 
in vitro. ECM and its components provide a scaffold for epithelial cells, play an 
active  role  in  regulating  cellular  shape,  proliferation  and  polarity  and  are 
essential  in  mediating  the  cross-talk  between  epithelial  and  stromal 
compartments.  ECM  remodelling  is  believed  to  be  pivotal  in  enabling  the 
epithelial invasion of the fat pad during pubertal mammary morphogenesis.  
ECM signalling 
There are many studies that show uninterrupted ECM signalling and normal ECM 
composition  to  be  important  in  normal  pubertal  development.  Both  Streuli 
(1998) and Klinowska (1999) used antibody mediated ablation of ß-integrin, the 
main  mechanotransducer  that  relays  ECM  cues,  to  demonstrate  reversibly 
inhibited  TEB  development  in  vivo  and  blocked  tubulogenesis  in  vitro  [226] 
[227].  Mammary  epithelial  cells  cultured  on  Lama1-ColI  based  ECM  showed 
increased cell growth, inhibition of lumen formation and loss of cellular polarity 
when the structural characteristics of ECM, such as its stiffness, were altered 
[228]. Disruption of ColI/Lama1 signalling in pubertal mouse mammary glands of 
mice lacking their exclusive receptor (α2 integrin subunit KO
-/- mice) resulted in 
reduced  branching  of  the  epithelial  tree  [229].  In  contrast,  mouse  mammary 
gland explants formed branched “spikes” when minced, 3D cultured in ColI gels 
and stimulated with any of the growth factors [230]. Moreover, the impairment 
in ColI fibrillogenesis has been shown to delay the outgrowth of TEB [83] in vivo.     76 
 
Taken  together,  these  results  indicate  that  ColI  is  an  important  regulator  of 
epithelial outgrowth and branching during puberty.  
Compromised branching morphogenesis has also been noted with Fn deficiency 
in the salivary gland. Ex vivo down-regulation of Fn expression using siRNA, anti-
Fn  antibody  or  anti-ß1  integrin  subunit  antibody  (α5ß1  integrin  serves  as  Fn 
receptor) blocked cleft formation and branching in the salivary gland [231]. The 
similarity between salivary gland and mammary gland branching morphogenesis 
suggests that Fn may also be involved in the latter. In fact, recent experiments 
based on conditional KO of Fn in mammary epithelium (Cre-loxP-mediated gene 
KO technology) showed Fn deletion to cause a moderate retardation of pubertal 
mammary  morphogenesis  manifested  by  delayed  ductal  outgrowth  and 
decreased  branching  [232].  Disruption  of  Tn-C  in  mice  did  not  produce  any 
visible abnormalities [233], while the functions of the remaining mammary gland 
ECM-associated molecules, Lama1, Per, Nid, SLRP, SPARC, Eln and other fibrillar 
collagens  are  yet  to  be  elucidated  in  pubertal  mouse  mammary  gland 
development. 
ECM remodelling 
ECM remodelling is essential for normal development of the mouse mammary 
gland.  Degradation  and  remodelling  of  ECM  at  puberty  provide  a  permissive 
environment for ductal elongation and branching facilitated by proteases. There 
are  two  main  types  of  matrix  degrading  proteases  that  are  activated  during 
mammary  gland  remodelling.  These  are  MMPs  and  a  serine  protease  called 
plasmin. MMPs are synthesised as zymogens and their activity is regulated mostly 
by  transcription  and  the  action  of  their  endogenous  inhibitors,  the  tissue 
inhibitors  of  metalloproteases  (TIMPs).  Plasmin  is  also  activated  from  its 
precursor, plasminogen and is involved in the degradation of fibrin and laminin 
and activation of pro-MMP3, -MMP9 and -MMP13 precursors (reviewed in [234]). 
Mouse mammary glands treated with the broad spectrum MMP inhibitor, GM6001 
displayed arrested ductal outgrowth and impaired branching  [235]. Five MMPs 
can be identified in the normal mouse mammary gland at puberty: MMP2, MMP3, 
MMP9, MMP11 and MMP14.      77 
 
Mice  lacking  MMP2  (MMP2  KO
-/-  mice)  were  characterised  by  delayed  ductal 
outgrowth, increased number of apoptotic cells in TEB but an elevated number 
of secondary branches. The phenotype, however, does not persist for long, as by 
late puberty, normal ductal morphogenesis is restored.  
The mammary glands of MMP3 deficient mice (MMP3 KO
-/-), on the other hand, 
displayed a ductal tree that is thinner and characterised by a lower number of 
side branches than that seen in the wild type control. The rate of ductal invasion 
as well as the number and size of TEBs in these mice, however, were normal 
[235]. The opposite phenotype, ducts with supernumerary side branches, could 
be seen in transgenic mice expressing an autoactivated form of MMP3 controlled 
by  the  WAP  promoter  [236].  Similarly,  an  increased  number  of  epithelial 
branching  compared  to  wild  type  littermates  could  also  be  detected  in  mice 
expressing activated MMP3 under the regulation of a MMTV promoter [237]. It 
should be noted, however, that the normal MMP3 expression is associated with 
the stromal compartment of the pubertal mouse mammary gland while these 
two studies were designed to express MMP3 in epithelium using MMTV or WAP 
promoters [235]. None-the-less, it appears that MMP2 stimulates TEB migration 
whilst  also  inhibiting  lateral  branch  formation  and  MMP3  directs  spatial 
localisation of branch points.  
In addition, MMP9 may also stimulate epithelial branching in vitro. Using a 3D 
primary culture model of rat mammary epithelial organoids that were grown on 
reconstituted BM, it was shown that TNF-stimulated secretion of activated MMP9 
coincided with increased proliferation and branching morphogenesis of epithelial 
cells. This effect was blocked by adding MMP9 neutralizing antibody [238]. The 
effect of MMP9 on epithelial branching morphogenesis in vivo, however, is yet to 
be elucidated. Using a similar culture system Simian et al. (2001) showed that 
the addition of plasmin or plasminogen to primary mammary organoid cultures 
mediated branching morphogenesis whereas the MMP inhibitor, galardin blocked 
this  morphogenic  effect.  Thus,  plasmin  stimulated  epithelial  branching 
morphogenesis  in  culture  by  MMP  activation  rather  than  by  direct  ECM 
degradation [230].  
The  endogenous  expression  of  TIMPs  during  pubertal  mouse  mammary  gland 
development is differentially regulated. At pre-puberty, TIMP1 and TIMP2 are     78 
 
minimally expressed but show significantly high expression at both puberty and 
adulthood  while  TIMP3  and  TIMP4  are  highly  expressed  at  pre-puberty  and 
remain abundant at puberty. All TIMPs are produced by mammary epithelial cells 
and fibroblasts except for TIMP2 which is exclusively synthesised by epithelial 
cells. Implanting TIMP1 releasing pellets into the outgrowing mouse mammary 
gland led to decreased proliferation in TEBs which then resulted in attenuated 
ductal expansion. In contrast, transgenic mice generated to reduce TIMP1 levels 
by  using  TIMP1  antisense  RNA  expression  under  the  control  of  the  MMTV 
promoter displayed augmented mammary ductal expansion and an increase in 
the number of ducts as well as disruption of BM integrity [239]. Moreover, the 
complete loss of TIMP1 in TIMP1 KO
-/- mice produced morphologically altered 
TEBs that were bigger than those seen in wild type controls [235].  
In  addition,  the  enzymatic  degradation  of  hyaluronate  in  situ  disrupted  the 
cellular  organisation  of  TEBs  [52]  [50],  whilst  S-GAG-degrading  enzymes,  ß-
glucuronidase and N-acetylglucosaminidase, strongly localised to cap cells of TEB 
and  myoepithelial  ductal  cells  [102].  This  suggests  that  correct  regulation  of 
polysaccharides turnover in BM and within the fibrous ECM (some ECM molecules 
possess  the  ability  to  bind  S-GAGs)  is  also  important  for  normal  ductal 
morphogenesis. Collectively, these results demonstrate that proteases and their 
inhibitors  are  critical  in  regulating  ductal  elongation  and  branching  during 
normal  pubertal  mouse  mammary  gland  morphogenesis,  at  least  in  part,  by 
regulating BM integrity.           
Finally, ECM mediated regulation of pubertal outgrowth can also be executed by 
regulating the morphogenic activity of growth factors and cytokines which are 
known to commonly bind to ECM (reviewed in [100] [91]).  
1.2.3.2.6  Axonal guidance proteins  
 
Microarray experiments have shown that axonal guidance proteins, expressed in 
neural  growth  cones  and  previously  thought  to  function  only  in  neuronal 
guidance,  can  also  play  a  key  role  in  regulating  mouse  mammary  gland 
development at puberty.      79 
 
Netrin 1 and Neogenin 1 
As previously discussed in 1.2.3.1, Ntn-1 and Neo-1 appear to play important 
roles  other  than  just  guiding  neurons  and  axons  during  nervous  system 
development, although, their role in pubertal mammary gland morphogenesis is 
most likely to be associated with adhesion rather than guidance.  
Ephrin family of receptor tyrosine kinases and their ligands 
Another group of axonal guidance proteins involved in embryonic development 
and  morphogenesis  of  many  adult  organs  including  pubertal  mouse  mammary 
gland development is the ephrin (Eph) family of receptor tyrosine kinases and 
their ligands  [240].  Both the Eph receptor B4 (EPHB4) and its cognate ligand 
ephrin  B2  (EFNB2)  are  expressed  in  the  ductal  epithelium  of  pubertal  mouse 
mammary gland. EPHB4 localises predominantly to the myoepithelial cells while 
the  expression  of  EFNB2  is  associated  with  luminal  epithelial  cells.  Their 
expression  commences  with  the  onset  of  ductal  elongation  at  puberty  and 
appears  to  be  further  differentially  regulated  during  the  oestrus  cycle. 
Furthermore, mammary gland associated expression of both the receptor and 
ligand  is  abolished  in  ovariectomised  mice  but  can  be  restored  with  E2 
treatment [241]. Over-expression of the EPHB4 receptor under the control of the 
MMTV-LTR  promoter  resulted  in  delayed  epithelial  morphogenesis  at  puberty 
manifested  by delayed ductal outgrowth and reduced secondary and tertiary 
branching when compared to the wild type controls [242]. Thus, EFNB2 signalling 
via EPHB4 is regulated in an oestrogen dependent manner and this interaction is 
important for normal epithelial outgrowth and ductal patterning at puberty.  
Brain acid-soluble protein 1, Small proline rich protein 1A and Semaphorins 
Further insights into the role of axonal guidance proteins during pubertal mouse 
mammary gland morphogenesis were gained from the microarray study by Morris 
et al. (2006) who demonstrated high expression of BASP1 and Sppr1A, Sema(s): 
Sema3B,  3C,  4A,  4F  and  their  receptors-  plexins  and  neuropilins  in  the 
epithelium  of  TEBs  [113].  However,  the  effect  that  these  proteins  exert  on 
mouse mammary gland development has yet to be elucidated in vivo.       80 
 
1.2.3.2.7  Other regulators of pubertal mouse mammary gland 
morphogenesis 
 
Other proteins which have been shown through KO models to regulate mouse 
mammary gland development include actin binding protein - gelsolin (Gsn) [243]; 
pro-apoptotic factor – Bcl2-like 11 (Bim) [244]; secreted milk fat globule - EGF 
factor 8 (MFGE8) [245] and Crk splice variant II [246].  
Gelsolin 
Mice with a targeted deletion of Gsn (Gsn KO
-/- mice) displayed inhibited ductal 
elongation. The ductal tree resembled a rudimentary structure up until week 9 
when TEBs become evident and ductal outgrowth begun. Cellular proliferation in 
TEBs  was  also  diminished  when  compared  to  their  age-matched  wild  type 
controls. Transplantation of Gsn null epithelium into the fat pad of wild type 
mice,  however,  resulted  in  the  restoration  of  normal  ductal  morphogenesis, 
suggesting  that  stromal  Gsn  is  required  for  pubertal  mouse  mammary 
development [243].  
Pro-apoptotic  factor-Bim,  Crk  splice  variant  II,  Secreted  milk  fat  globule-EGF 
factor 8 
Delayed ductal outgrowth paralleled by the increased deposition of ColI at the 
front of TEBs was also shown in Crk II over-expressing mice [246]. Deficiency of 
Bim,  on  the  other  hand,  prevented  induction  of  apoptosis  and  proper  lumen 
formation in TEB and ducts at puberty [244] while loss of MFGE8 led to a severe 
reduction in ductal branching and formation of thin and poorly developed TEBs 
[245].    
1.2.4 Summary 
Pubertal  mouse  mammary  gland  morphogenesis  is  a  complex  process  that 
involves ductal elongation, TEB bifurcation and ductal branching and epithelial 
patterning.  Its  regulation  is  facilitated  by  a  wide  range  of  factors  that  are 
expressed in the epithelium and stroma, including hormones and growth factors; 
ECM  molecules  and  proteases  with  their  inhibitors;  immune  cells  and  other     81 
 
stromal  cells.  The  cross  talk  between  epithelial  and  epithelial-stromal  cells 
provides global and directional cues for this development. A summarised list of 
pubertal regulators of mouse mammary gland and the effect they exert on TEB 
motility or ductal branching can be seen in Table 1-1. 
1.3 Microarray analysis of gene expression to study 
pubertal mouse mammary gland development 
In  order  to  fully  understand  regulatory  mechanisms  that  control  organ 
development an understanding of the genome, the products it encodes and the 
way  they  interact  to  produce  the  complex  living  organism  is  crucial.  Since 
protein  based  research  is  often  less  sensitive,  more  difficult  and  time 
consuming, gene expression profiling emerged as an effective way of studying 
genetic make-up of cells. Gene expression analysis can be performed either on 
an  individual  gene  basis,  using  techniques  such  as  northern  blot  or  reverse 
transcription polymerase chain reaction (RT-PCR), or more efficiently, on the 
whole genome level using DNA microarrays. Both northern blotting and RT-PCR 
require the design of primers and probes for each individual gene, making the 
process of analysis of multiple genes timely and rather expensive. Thus, since 
the completion of the human genome project and sequencing projects in other 
species  that  identified  many  genes  of  unknown  function,  DNA microarray  has 
become  a  very  popular  tool  for  transcriptome  analysis.  In  fact  it  has 
revolutionised the whole area of genomic research. 
The  DNA  microarray  technique  is  based  on  one  of  the  most  fundamental 
biological  laws  which  is  a  high  hybridisation  affinity  between  two 
complementary  strands  of  nucleic  acids.  In  microarray  technology,  single 
stranded  DNA  sequences,  in  the  form  of  either  cDNA  fragments  (~  100 
nucleotides)  or  synthesised  oligonucleotides  (most  commonly  25  nucleotides) 
that  represent  specific  genomic  coding  sequences,  called  probes,  are 
immobilised (spotted) or directly synthesised onto the solid surface of an array 
[247].  The  surfaces  most  commonly  used  to  produce  microarrays  are 
nitrocellulose  or  charged  nylon  membranes  or  coated  glass  slides.  Once 
extracted  from  the  biological  material,  purified  RNA  is  converted  into  single 











PTH [150], PTHR [150], 
FGF3 [156], FGF4 [158], 
TIMP-1 [239], EPBHB4 
[242], TGF-ß [209] [206] 
E-cadh [57], ErbB2 [118], ErbB3 [119], 
ERα [129], GHR [149], FGFR2IIIb [159], 
Areg [179], IGF-1 [170], EGFR [176], 
ADAM17 [183], SRC-1 [189], SRC-3 [190], 
MED-1 [197], CITED-1 [194], C/EBPß 
[201], AP-2γ [203], Fn [232], MMP-2 
[235], TIMP-1 [239], Gsn [243], Activin B 
[216], Activin AB [216], Inhibin B [216], 
Macrophages [85], Eosinophils [85], 
Adipocytes [223], Fibroblasts [248], 
CrkII [246]                 
Increased ductal 
elongation 
IGF-1 with P [141], Areg 
[179] 





FGF4 [158]  ErbB2 [118], ErbB3 [119], MFGE8 [249], 
Ntn1 [117], Neo1 [117], IGF-1 [170], 
Inhibin B [216], Activin AB [216], Activin 
A [216] 
Decrease in TEB 
formation 
TGF-ß [206] [209], EGF 
[175], Itgb [226] 
GATA-3 [202], CSF-1 [85] [220], Eotaxin 
[85], Mast cells [89], AP-1 [195], IGF-1R 
[171], VDR [152] 
Absence of TEBs    ERα [129], FGFR2IIIb [159], Adipocytes 
[223], Macrophages [85], Eosinophils 
[85] 
Decrease in TEB 
size 
  ErbB2 [118], ErbB3 [119], IGF-1R [171] 
Increase in TEB 
size 
HGF [163]  TIMP-1 [235] 
Aberrant ductal 
patterning 
TGF-ß [209], Nodal [217]  CITED-1 [194] 
Reduced 
branching 
PTH [150], PTHrP [150], 
TGF-ß [209], EPHB4 
[242] 
GR [144], GHR [144], IGF-1 [170], IGF-
1R [171], EGFR [176], SRC-1 [189], SRC-
3 [190], SRC-2 [192], AP-1 [195], MED-1 
[197], C/EBPß [201], AP-2γ [203], Nodal 
[217], CSF-1 [220] [85], Eotaxin [85], 
Adipocytes [223], α 2 integrin subunit 




IGF-1 with P [141], MMP-
3 [236] [237], HGF [162] 
[163], MMP-9 [238], 
MTA-1 [198], Nodal [217] 
ErbB2 [118], ErbB3 [119], VDR [152], 
TGF-ß [210], MMP-2 [235] 
Table 1-1 List of pubertal regulators of mouse mammary gland and the effect they exert on 
TEB motility or ductal branching.     83 
 
radioactive isotope and hybridised to the array chip  [250]. Upon hybridisation 
the array is scanned to detect the location of hybridisation sites to determine 
which gene is expressed in the sample of interest. The intensity of the signal 
detected  at  each  hybridisation  site  further  translates  into  the  level  of  gene 
expression, enabling the researcher to determine whether the gene is expressed 
and at what magnitude. Fluorescence data can then be normalised, verified and 
analysed by a variety of methods.  
Currently there are 5 main types of DNA microarray platforms that differ in the 
type  of  solid  surface,  the  length  of  probe  and  the  method  of  manufacture, 
namely:  printed  arrays,  in  situ  synthesised  arrays,  high  density  bead  arrays, 
electronic arrays and liquid bead suspension arrays (reviewed in [251]). Printed 
arrays are the first microarrays that were used in research laboratories. They are 
made  of  glass  slides  printed  with  DNA  probes  (cDNA  or  25-80  nt  long 
oligonucleotides) [252]. For in situ synthesised arrays, the oligonucleotides are 
directly synthesised on the quartz surface using photochemistry. Multiple probe 
sets  are  used  per  individual  gene  to  improve  sensitivity,  specificity  and 
statistical accuracy [253]. The length of probes depends on the manufacturer; 
Affymetrix  GeneChips  contain  25  nt  long  probes,  Agilent  ~  60  nt  probes  and 
Roche NimbleGen 60-100 nt long probes (reviewed in [251]). Furthermore, the 
recently developed Affymetrix GeneChip Exon arrays allow the analysis of gene 
expression at the exon as well as the whole transcript level. High density bead 
array technology, on the other hand, is based on the sequence tagged beads 
randomly  assorted  on  silicon  slides  [254].  In  electronic  microarrays,  the 
hybridisation and immobilisation of the DNA onto the array surface is facilitated 
by an electric field and streptavidin-biotin bonds respectively. The NanoChip 400 
is one of the platforms that operate using this system [255]. Finally, the most 
advanced microarray technology, the liquid-bead suspension arrays are 3D arrays 
that utilise microspheres as a solid support for the application of probes and 
flow cytometry for bead and target detection (reviewed in  [251]). Affymetrix 
GeneChip Exon arrays are the arrays of choice in this study. They accommodate 
oligonucleotide sequences that translate into 17500 well-annotated transcripts 
and  every  exon  of  each  transcript  is  represented  by  four  probe-sets  (each 
consisting of 3-4 25  nt long probes)  (For further details on the platform and 
microarray data generation workflow see 3.2.1.3 and 2.2.5.3 respectively).         84 
 
The  main  advantage  of  microarray  technology  is  the  quick  and  reproducible 
analysis of literally thousands of genes in one experiment. This increases the 
efficiency  with  which  potential  trends  in  cellular  functions,  regulatory 
mechanisms and pathways can be identified. The high sensitivity of microarrays 
minimises  the  amount  of  starting  material  that  is  required  to  carry  out  the 
analysis, while the high-throughput nature of the data provides an overview of 
the transcriptome  which is  useful  for  selection  of  potentially  important  gene 
targets. As with every technique, microarray analysis also has limitations and 
they include: i) quality of RNA – degraded mRNA can produce false microarray 
data, and ii) occurrence of discrepancies between mRNA and protein expression 
levels.  
Microarray  based  gene  expression  profiling  has  been  used  to  study  mouse 
mammary gland development in the past. To date, most of these studies are 
time course microarray experiments that utilise whole mammary glands obtained 
from various stages of development, ranging from pre-puberty up to involution. 
There are only six published microarray studies, however, that address pubertal 
mouse mammary gland development. Four of these: Morris et al. (2006) [113], 
Kouros-Mehr et al. (2006) [256], McBryan et al. (2007) [194] and Deroo et al. 
(2009) [257] focus directly on puberty. The two former ones use isolated TEB and 
ducts and compare gene expression in TEBs with the gene expression elsewhere 
in the gland whereas the latter two compare gene expression in whole mouse 
mammary glands collected at different pubertal time points. The two remaining 
microarray studies by Master et al. (2002) [258] and Howlin et al. (2006) [193] 
present  gene  expression  analysis  across  the  whole  development  of  mouse 
mammary gland, including puberty. 
The  study  by  Morris  et  al.  (2006)  was  carried  out  to  identify  new  genes 
associated with migration of TEBs and ductal differentiation at puberty [113]. It 
used  a  novel  digestion-based  technique  to  isolate  TEBs  and  ducts  from  their 
surrounding  stroma  [259].  After  digestion  with  type  II  collagenase  isolated 
epithelial structures were collected under a dissecting microscope and when the 
sufficient amount of isolates was obtained, RNA extraction was performed.  The 
gene expression profile of isolated TEBs and ducts was then compared using in 
situ  synthesised,  oligonucleotide  microarrays  (Affymetrix).  To  confirm  the 
results and ensure that the removal of epithelium from its natural environment     85 
 
did not alter gene expression, the RNA expression was additionally compared 
between whole mammary gland strips. Pairs of mammary glands were collected 
from 5-6 week old mice. One of the mammary glands was wholemounted and 
stained with carmine alumn to assess the position of the TEB advancement front. 
Based on this morphology,  the contralateral gland from the same mouse was 
then  cut  transversely  into  four  tissue  strips:  Pre-LN  (ductal  epithelium  and 
stroma), LN (epithelium and stroma of ducts and LN), Post-LN (TEB and ducts 
epithelium and stroma) and Fat pad (epithelium free stroma). 91 genes were 
shown  to  be  expressed  more  highly  in  TEB  than  duct  epithelium.  Functional 
analysis of this gene set revealed that the majority of these genes (57%) were 
associated  with  DNA  replication,  cell  division  or  cell  cycle  regulation.  More 
interestingly, however, this was the first study that highlighted expression of 
axonal guidance proteins in TEBs at puberty. Three genes in particular: BASP-1, 
Sprr1A  and  Sema3B  were  associated  with  TEB  epithelium.  However,  TEB 
associated expression of a number of other semaphorins (Sema3C, 4A, 4F and 4d) 
along with their receptors, Plexins A2, A3, B2 and D1 and Neuropilins 1 and 2 
were  also  detectable  [113].  This  was  consistent  with  the  findings  of  the 
proteomic study that was previously published by the same research group [259] 
which  led  to  the  conclusion  that  axonal  growth  cone  associated  proteins  are 
likely to regulate the migration of TEBs at puberty. 
Kouros-Mehr and Werb, on the other hand, used ß-actin-GFP reporter mice (5 
week  old)  to  surgically  microdissect  TEB,  mature  ducts  and  epithelium-free 
stromal compartments [256]. These mice show ubiquitous expression of GFP in 
their mammary glands which enables their visualisation and facilitates precise 
dissection  of  TEB  or  duct  microenvironments  (epithelium  and  its  proximal 
stroma)  and  epithelium  free  stroma.  RNA  was  extracted  from  the  different 
microenvironments  and  the  transcriptomes  of  TEB  and  mature  duct 
microenvironments were compared with epithelium free stroma to identify novel 
genes involved in the regulation of mouse mammary branching morphogenesis. 
This microarray study was performed using long-oligonucleotide (80 nt long) in 
situ  synthesised  arrays  (Operon)  and  it  identified  1074  genes  exclusively 
expressed  in  the  TEB  microenvironment  and  222  genes  in  the  mature  duct 
microenvironment. A further 385 genes were up-regulated in both the TEB and 
duct microenvironments when compared to empty Fat pad. Some of the main     86 
 
gene families identified within these gene sets and further verified using in situ 
hybridisation included: Wnt (Wnt-2, 5a, 7b, Dsh-3, Frizzled-1 and Frizzeld-2) and 
hedgehog (Dhh), ephrin (Ephrin-B1 and A2) family members and EMT molecules 
(Twist-1, Twist-2 and Snail) [256]. This suggested that the Wnt family members 
which have also shown a similar expression pattern in the developing lung [260] 
[261]; Dhh, which is likely to act as an activator of hedgehog signalling which is 
important  for  mammary  gland  development  [262];  ephrins,  which  belong  to 
axonal guidance proteins [263], and Twist and Snail transcription factors, which 
are the markers of mesenchymal phenotype [264], all may play a potential key 
role in the orchestration of mouse mammary gland morphogenesis. 
McBryan et al. (2007) carried out an expression microarray time course analysis 
on  the  whole  mouse  mammary  glands  to  assess  gene  expression  changes 
associated  with  the  onset  of  puberty.  Five  representative  stages  of  pubertal 
development were chosen (V3, V4, V5, V6 and V7). As shown by wholemount 
analysis, TEBs were absent from the 3 week old mammary glands, present at 4, 5 
and 6 weeks and had regressed by the week 7. Gene expression analysis was 
carried out using Affymetrix MOE430A arrays and a pubertal gene set consisting 
of 930 unique transcripts was identified. Further analysis showed Wnt-, TGF-ß 
and  oestrogen  signalling  pathways  members  to  be  enriched  at  puberty  and 
highlighted biological functions such as growth factor activity, cell growth, fatty 
acid  metabolism,  proteolysis  and  peptidolysis  as  over-represented  in  mouse 
mammary gland transcriptome at puberty. Moreover, the pubertal gene set was 
further analysed to identify genes that were expressed or repressed specifically 
upon the presence or absence of TEBs, i.e. „TEB profile‟ genes. As a result, 15 
expressed and 9 repressed „TEB profile‟ genes were found and the „apoptosis‟ 
and  „cell  cycle  regulation‟  were  identified  as  the  main  biological  functions 
associated with TEB associated genes [194].   
The  latest  microarray  analysis  carried  out  using  biological  material  obtained 
from pubertal mouse mammary glands was published by Deroo B. J. et al. (2009) 
[257]. The main focus of this study was the identification of an E2-responsive 
pubertal gene set. Thus, mice were ovariectomised at pre-puberty and treated 
with 17-ß estradiol hormone pellets from 2 to 28 days. RNA was extracted from 
whole mammary glands collected at 2, 5, 7, 14 and 28 days after implantation 
and  global  gene  expression  was  analysed  using  in  situ  synthesised     87 
 
oligonucleotide  microarrays  (Agilent).  This  showed  that  the  observed  gene 
expression changes mimicked those that appear at puberty in normal mice. Both 
overlapping and distinct gene profiles were identified at different time points, 
i.e.  at  varying  extents  of  ductal  elongation.  The  most  common  functional 
categories  associated  with  the  E2  regulated  genes  that  were  over-expressed 
included: cell proliferation, immune response and metabolism/catabolism while 
the carbohydrate-metabolism associated genes were down-regulated in response 
to E2. Collectively, this analysis confirmed that E2 has a crucial role in ductal 
outgrowth  of  the  mouse  mammary  gland  at  puberty  and  identified  pubertal 
genes whose expression is regulated by E2 signalling [257].        
Some further insights into the pubertal transcriptome of mouse mammary gland 
were  also  provided  by  the  two  time  course  experiments:  the  early  study  of 
Master et al. (2002) [258] and more recent microarray analysis carried out by 
Howlin  et  al.  (2006)  [193].  Although  the  former  study  performed  microarray 
analysis on 12 time points that were chosen across the whole mouse mammary 
development it focused mainly on pre-puberty. The most important finding was 
that brown adipose tissue is a component of pre-pubertal stroma and that the 
mammary gland functions in adaptive thermogenesis [258]. The study carried out 
by  Howlin  et  al.  (2006)  consisted  of  two  separate  microarray  analyses.  The 
initial study compared gene expression across the whole development of mouse 
mammary gland and the main finding was the role of CITED1 in mouse mammary 
gland  development  at  puberty.  The  importance  of  CITED1  in  pubertal 
morphogenesis has previously been discussed in 1.2.3.2.3.  
A summary of the microarray studies carried out to examine the transcriptome 
of pubertal mouse mammary gland and their main characteristics is shown in 
Table 1-2.   
At the beginning of the work for this thesis,  in November 2006,  it had been 
demonstrated in our laboratory that it was possible to isolate TEBs and ducts 
that could be rapidly processed to generate high quality RNA. The Morris et al. 
(2006)  paper  had  limitations  in  terms  of  the  restricted  transcriptome 
represented  on  these  early  microarray  chips  and  the  methods  available  for 
analysis [113]. It was therefore decided that one objective of this thesis would 
be  to  use  novel  exon  in  situ  synthesised,  oligonucleotide  microarrays,  which     88 
 
provide a much wider gene range and also enable the differential examination of 
gene expression at the exon level, use wild type mice to collect isolated TEB and 
duct  epithelium  and  GFP  mice  to  accurately  microdissect  TEBs  and  ducts 
contained within the stroma and to carry out their in depth analysis. In addition 
to  elucidating  the  signalling  pathways  and  biological  processes  that  were 
differentially over-represented in the TEB and duct epithelium and surrounding 
stroma it was also hypothesised that this approach would identify new genes of 
interest  that  could  be  followed  up  at  a  functional  level.  As  a  result,  we 
identified  new  genes  expressed  in  both  epithelial  compartments  of  TEBs  and 
ducts  and  the  main  biological  functions  and  processes  that  these  genes  are 
involved in. Furthermore, with our study we also added to the understanding of 
pubertal mouse mammary morphogenesis by carrying out, a completely novel 
identification  of  the  gene  expression  signature  of  TEB  and  duct  associated 
stroma (See Chapter 3).                   89 
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free stroma 
Association of Wnt, hedgehog, 
ephrin family members and EMT 
markers with branching 




Whole mouse mammary glands 
collected at 5 pubertal time 
points (V3, V4, V5, V6 and V7) 
Association of Wnt, TGF-ß and 
oestrogen signalling pathway 
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from CITED1 null heterozygous 
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development, 
Involvement of CITED1 in the 




Table 1-2 Summary of the microarray studies carried out on the pubertal mouse mammary 
glands, to date, and their main characteristics.     90 
 
2  Materials and methods 
2.1 Materials 




Beekay Rat and Mouse diet No 1  B & K Universal Ltd., Hull, UK 
M3 cages  North Kent Plastic Cages Ltd., Kent, UK 




Collagenase type II   Sigma Aldrich Company Ltd., Dorset, UK 
Fetal Bovine Serum (FBS) (0.1%)  Sigma Aldrich Company Ltd., Dorset, UK 
Gridded contact dish   Nalge Nunc International, Hereford, UK 
Histobond
®+ glass slides   Paul Marienfeld GmbH & Co. KG; Landa-
Königshofen, Germany 
Leibovitz L15 medium   Invitrogen Ltd.; Paisley, UK 
Neutral buffered formalin (10%)  Genta Medical; York, UK 
RNaseZap   Applied Biosystems/Ambion; Austin, USA   
Scalpel blades  Swann-Morton, Ltd.; Sheffield, England 
Surgical instruments  John Weiss International; Milton Keynes, 
UK 
Trizol
® Reagent   Invitrogen Ltd., Paisley, UK 
 
Cell culture and Explant Culture  
 
75 cm
2 tissue culture filter flasks  Corning Incorporated, Corning, USA 
Dulbecco‟s Modified Eagle medium 
(DMEM)  
Invitrogen Ltd., Paisley UK 
Dulbecco‟s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) 
Invitrogen Ltd., Paisley UK 
Epidermal growth factor (EGF)   PeproTech EC Ltd., London, UK 
FBS (10%)  Sigma Aldrich Company Ltd., Dorset, UK 
Fibronectin  Sigma Aldrich Company Ltd., Dorset, UK 
Haemocytometer  Superior, Marienfield, Germany 
Insulin   Sigma Aldrich Company Ltd., Dorset, UK 
Lab-Tek-II Chamber Slide™ System   Nalge Nunc International Corp., 
Naperville, USA 
Leukaemia Inhibitory factor (LIF)  Donated by Dr. J. Mounthford 
L-glutamine   Invitrogen Ltd., Paisley UK 
Phosphate Buffered Saline (dPBS)  Invitrogen Ltd., Paisley UK 
Roswell park memorial institute 1640 
(RPMI-1640) medium 
Invitrogen Ltd., Paisley UK     91 
 




Ampicillin  Sigma Aldrich Company Ltd., Dorset, UK 
Bacterial culture dishes  Sterilin Ltd. UK, Aberbargoet, UK 
Competent DH5α E. coli cells  Invitrogen Ltd., Paisley, UK 
Ethylenediaminetetraacetic acid 
(EDTA) (2mM) 
Sigma Aldrich Company Ltd., Dorset, UK 
HiSpeed
® Plasmid Maxi kit  Qiagen Ltd., Crawley, UK 
Luria Bertani (LB) Broth  Sigma Aldrich Company Ltd., Dorset, UK 
Microbiological spreader  Microspec, Elesmere Port, UK 
NaCl  VWR International Ltd., Dublin, Ireland 
pcDNA3  Invitrogen Ltd., Paisley UK 
pEGFP   Clontech-Takara Bio Europe, Saint-
Garmain-en-Laye, France 
pRc/CMV-Fbln2  Donated by Dr. Mon-Li Chu, Thomas 
Jefferson University, Philadelphia, USA 
QIAprep Miniprep kit  Qiagen Ltd., Crawley, UK 
S.O.C. medium   Invitrogen Ltd., Paisley UK 
Tryptone  ForMedium™, Norfolk, UK 
Yeast extract  Sigma Aldrich Company Ltd., Dorset, UK 
 
Cell transfections and Adhesion assays 
 
10 cm cell culture plate   Corning Incorporated, Corning, USA 
12 well tissue culture plate   Corning Incorporated, Corning, USA 
25 cm
2 tissue flask  Corning Incorporated, Corning, USA 
DharmaFECT
® Duo Transfection 
Reagent  
Thermo Fisher Scientific Inc., Surrey, UK 
Extracellular Matrix (ECM) Cell 
Adhesion Array Kit  
Millipore Ltd, Livingstone, UK 
Lipofectamine
™ 2000 Transfection 
Reagent 
Invitrogen Ltd., Paisley UK 
Opti-MEM




Amersham ECL Western blotting 
detection reagents and analysis 
system  
GE Healthcare UK Limited, Little 
Chalfont, UK 
Anti-Actin (C-20) antibody  Santa Cruz Biotechnology Inc., Santa 
Cruz, USA 




Donated by Dr. Mon Li Chu (Thomas 
Jefferson University, Philadelphia, USA) 
Anti-goat (HRP-labelled) rabbit 
polyclonal antibody 
Dako UK Ltd., Eli, UK 
Anti-mouse (HRP-labelled) rabbit 
polyclonal antibody 
Dako UK Ltd., Eli, UK     92 
 
Anti-N-terminus of Fbln2 antibody  Santa Cruz Biotechnology Inc., Santa 
Cruz, USA 
Anti-rabbit (HRP-labelled) donkey 
polyclonal antibody  
GE Healthcare UK Limited, Little 
Chalfont, UK 
Anti-Upk3a (AU1) antibody 
 
Donated by Dr. T. Sun (New York 
University Medical School, New York, USA) 
BCA™ Protein Assay Kit  Thermo Fisher Scientific Inc., Surrey, UK 
Bis-Tris-HCl buffered (pH 6.4) (4-
12%) gel 
Invitrogen Ltd., Paisley UK 
Bovine Serum Albumin (BSA)    Thermo Fisher Scientific Inc., Surrey, UK 
Cell lifters   Corning Incorporated, Corning, USA 
Dithiothreitol (DTT)  Sigma Aldrich Company Ltd., Dorset, UK 
Glycine  Sigma Aldrich Company Ltd., Dorset, UK 
Marvel Original dried skimmed milk  Premier International Foods Ltd., Susson, 
UK 
Methanol  Thermo Fisher Scientific Inc., Surrey, UK 
Microcon
® Centrifugal Filter Device 
equipped in the Ultracel YM-3 
membrane  
Millipore Ltd, Livingstone, UK 
Novex NuPage™ Electrophoresis 
system  
Invitrogen Ltd., Paisley UK 
Novex XCell II™ Blot module   Invitrogen Ltd., Paisley UK 
Novex
® Sharp Pre-stained Protein 
Standards  
Invitrogen Ltd., Paisley UK 
NP-40  Sigma Aldrich Company Ltd., Dorset, UK 
NuPage LDS sample buffer (4x)  Invitrogen Ltd., Paisley UK 
NuPage MES SDS running buffer (20X)  Invitrogen Ltd., Paisley UK 
NuPage transfer buffer (20X)  Invitrogen Ltd., Paisley UK 
Phosphatase inhibitor cocktail 2  Sigma Aldrich Company Ltd., Dorset, UK 
Ponceau S stain  Sigma Aldrich Company Ltd., Dorset, UK 
Protease inhibitor cocktail tablets  Roche Diagnostics Ltd., Burgess Hill, UK 
Sodium deoxycholate  Sigma Aldrich Company Ltd., Dorset, UK 
Sodium dodecyl sulfate (SDS)  Sigma Aldrich Company Ltd., Dorset, UK 
TRIS (TRIZMA base)  Thermo Fisher Scientific Inc., Surrey, UK 
NuPage Tris-Acetate polyacrylamide 
gel (3-8%) 
Invitrogen Ltd., Paisley UK 
NuPage Tris-Acetate SDS Running 
Buffer (20X) 
Invitrogen Ltd., Paisley UK 
Tween-20  Sigma Aldrich Company Ltd., Dorset, UK 




Transfer Membrane (0.2 µm) 
Sigma Aldrich Company Ltd., Dorset, UK 
 
 
RNA and DNA 
 
0.5 ml microcentrifuge tube  Thermo Fisher Scientific Inc., Surrey, UK 
Acetylated BSA (10µg/µl)  Promega Corporation, Madison, USA 
Agilent RNA 6000 Nano Kit  Agilent Technologies. Inc. UK, UK 
Dimethyl sulfoxide (DMSO)  Sigma Aldrich Company Ltd., UK 
DNA-free
™ Kit  Applied Biosystems/Ambion; Austin, USA       93 
 
dNTPs mix (10mM)  Invitrogen Ltd., Paisley UK 
Electrophoresis grade agarose  Invitrogen Ltd., Paisley UK 
Ethidium bromide (10mg/ml)  Sigma Aldrich Company Ltd., Dorset, UK 
GoTag
® DNA Polymerase (5U/µl)  Promega Corporation, Madison, USA 
Green GoTag
® Flexi Buffer (5X)  Promega Corporation, Madison, USA 
J Buffer (1X)  Promega Corporation, Madison, USA 
LightCycler
® 480 96 Well Plates  Roche Applied Science, Mannheim, 
Germany 
LightCycler
® 480 Probes Master (2X)  Roche Applied Science, Mannheim, 
Germany 
LightCycler
® 480 Sealing Foil  Roche Applied Science, Mannheim, 
Germany 
MgCl2 (25mM)  Promega Corporation, Madison, USA 
Oligo dT primer (0.5 µg/µl)  Invitrogen Ltd., Paisley UK 
Random primer (1 µg/µl or 100 
ng/µl) 
Invitrogen Ltd., Paisley UK 
Reaction Buffer (cDNA synthesis)  Roche Diagnostics Ltd., Burgess Hill, UK 
RNase OUT (40U/µl)  Invitrogen Ltd., Paisley UK 
RNase-free 1.5 microcentrifuge tube  Applied Biosystems/Ambion; Austin, USA   
RNase-free H2O  Applied Biosystems/Ambion; Austin, USA   
RNeasy
® Micro Kit  Qiagen Ltd., Crawley, UK 
RNeasy
® Mini Kit  Qiagen Ltd., Crawley, UK 
Sma I enzyme (10U/µl)  Promega Corporation, Madison, USA 
Transcriptor Reverse Transcriptase 
(20 U/µl) 
Roche Diagnostics Ltd., Burgess Hill, UK 
 
Microarray analysis of pubertal gene expression 
 
Biotinylated  LNA  RiboMinus  probes 
(100 pmol/µL) 
Invitrogen Ltd., Paisley, UK 
GeneChip
®  Hybridisation,  Wash  and 
Stain Kit 
Affymetrix UK Ltd., High Wycombe, UK 
GeneChip
® IVT cRNA Cleanup Kit  Affymetrix UK Ltd., High Wycombe, UK 
GeneChip
® Mouse Exon 1.0 ST Array  Affymetrix UK Ltd., High Wycombe, UK 
GeneChip
® Whole Transcript (WTr) 
Sense 1 µg Total RNA Target 
Labelling Assay 
Affymetrix UK Ltd., High Wycombe, UK 
GeneChip
® WTr cDNA Synthesis Kit  Affymetrix UK Ltd., High Wycombe, UK 
GeneChip
®  WTr  Terminal  Labelling 
Kit 
Affymetrix UK Ltd., High Wycombe, UK 
RiboMinus Human/Mouse 
Transcriptome Isolation Kit  
Affymetrix UK Ltd., High Wycombe, UK 
Streptavidin coated RiboMinus 
Magnetic Beads 
Invitrogen Ltd., Paisley, UK 
T7 RNA Polymerase GeneChip
® WTr 
cDNA Amplification Kit 
Affymetrix UK Ltd., High Wycombe, UK 
 
Tissue processing and staining 
 
3.3-Diaminobenzidine 
tetrahydrochloride (DAB) + 
Dako UK Ltd., Eli, UK     94 
 
Chromogen 
Acetic Acid (analytical grade)  VWR International Ltd., Dublin, Ireland 
Acid Alcohol (1%)  Sigma Aldrich Company Ltd., UK 
Alexa Fluor 488 dye  Invitrogen Ltd., Paisley, UK 
Alexa Fluor 594 dye  Invitrogen Ltd., Paisley, UK 
Anhydrous MgSO4  Thermo Fisher Scientific Inc., Surrey, UK 
Antibody Diluent  Dako UK Ltd., Eli, UK 
Anti-Fbln1 antibody 
 
Donated by Dr. Mon-Li Chu, Thomas 
Jefferson University, Philadelphia, USA 
Anti-Fibronectin (ab2413) antibody  Abcam Inc; Cambridge, USA 
BD Microlance™ 3 needle  Becton Dickinson UK Ltd., Oxford, UK 
Carmine  Sigma Aldrich Company Ltd., UK 
Chloroform (analytical grade)  Thermo Fisher Scientific Inc., Surrey, UK 
Coplin Jar  Raymond A. Lamb Ltd., Eastbourne, UK 
Elastica van Gieson (EVG) kit  Merck KGaA; Darmstadt, Germany 
Eosin (1%)  CellPath Ltd.; Newtown, UK 
Ethanol (analytical grade)  Hayman Ltd., Witham, UK 
Haematoxylin Z  CellPath Ltd.; Newtown, UK 
Horse Serum (2.5%)  Vector Laboratories Ltd.; Peterborough, 
UK 
Image-iT ™ FX Signal Enhancer  Invitrogen Ltd., Paisley, UK 
KAI(SO4)2  Sigma Aldrich Company Ltd., UK 
NaHCO3  Sigma Aldrich Company Ltd., UK 
Pertex  CellPath Ltd., Newtown, UK 
ProLong
® Gold antifade reagent with 
4,6-diamidino-2-phenylindole 
dihydrochloride (DAPI)  
Invitrogen Ltd., Paisley, UK 
Superfrost
® Plus slides  Thermo Fisher Scientific Inc., Surrey, UK 
Thymol  Sigma Aldrich Company Ltd., UK 
Twin Frost Microscope Slide  Raymond A. Lamb Ltd., Easbourne, UK 
Weigert‟s solution A  Merck KGaA; Darmstadt, Germany 
Weigert‟s solution B  Merck KGaA; Darmstadt, Germany 
Xylene  Genta Environmental Ltd., York, UK 
 
In vivo hormonal treatment of mouse mammary glands 
 
21 day release oestrogen (E2) 
(0.72mg/pellet) pellet 
Innovative Research of America, Sarasota, 
Florida, USA 
21 day release oestrogen-
progesterone (E2+P) (0.1mg/pellet, 
10 mg/pellet) pellet 
Innovative Research of America, Sarasota, 
Florida, USA 
21 day release placebo (10.01 
mg/pellet) pellet 
Innovative Research of America, Sarasota, 
Florida, USA 
Biogel
®P Suretech surgical gloves  Marigold Industrial Ltd., Broxbourne, UK 
Polyamide 6 blue monofilament non-
absorbable suture 5-0 Ethicon 
Johnson & Johnson; Langhorne, PA, USA 
Table 2-1 List of reagents and materials. 
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2.1.2 Solutions and Buffers 








LB-Agar (1.5%)  10g of Tryptone, 5g of yeast extract and 
10g NaCl and 15g of Agar in 1L of dH2O, 




2.5% BSA blocking solution  2.5% BSA in 1X TBS Tween-20 wash buffer 
3% milk blocking solution 
 
3% Marvel Original dried skimmed milk in 
1X TBS Tween-20 wash buffer 
EDTA buffer  10mM EDTA, protease inhibitor and 
phosphatase inhibitor cocktail in TBS 
NP-40 buffer  50mM TRIS pH 7.5, 150mM NaCl, 5mM 
EDTA, 1% NP-40, protease inhibitor and 
phosphatase inhibitor cocktail in dH2O 
RIPA buffer  25mM TRIS pH 8, 150mM NaCl, 1% NP-40, 
1% sodium deoxycholate, 0.1% SDS, 
protease inhibitor and phosphatase 
inhibitor cocktail in dH2O 
Stripping buffer pH 2.2   5M Glycine, 0.1% SDS, 1% (v/v) Tween-20, 
pH 2.2 in dH2O   
Tris Buffered Saline (TBS) buffer 
(10X) 
50mM Tris-HCl, 150mM NaCl, pH 7.4 in 
dH2O 
TBS Tween-20 wash buffer (1X)  1X TBS, 0.1% (v/v) Tween-20 in dH2O 
Transfer buffer (western blotting) 
(1X) 
1X NuPage transfer buffer, 10% methanol 
in dH20 
Urea buffer  6M Urea, protease inhibitor and 
phosphatase inhibitor cocktail in TBS 
 
Tissue processing and staining 
 
1 mM EDTA buffer (pH 8)  1mM EDTA disodium salt, 4.5mM TRIS, pH 
8 in dH2O  
Carmine dye  2mM Carmine, 5mM KAI(SO4)2 in dH2O, boil 
for 20 min, filter and add crystal of 
Thymol (preservative) 
Carnoy‟s fixative  6 parts of 100 % (v/v) ethanol, 3 parts of 
chloroform and 1 part of acetic acid 
Scott‟s tap water  81.14mM anhydrous MgSO4, 41.66mM 
NaHCO3 in dH2O 
TBS buffer pH 7.6 (10X)  50mM Tris-HCl, 150mM NaCl, pH 7.6 in 
dH2O     96 
 
TBS Tween-20 buffer pH 7.6 (1X)  1X TBS, 0.1% (v/v) Tween-20 detergent in 
dH2O 
Weigert‟s A&B solution  Weigert‟s solution A (Alcoholic 
Haematoxylin Solution) and Weigert‟s 
solution B (Hydrochloric Acid Iron(III) 
Nitrate Solution) mixed 1:1 
Table 2-2 List of solutions and buffers. 
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2.1.3 Electric equipment 
Agilent 2100 bioanalyser   Agilent Technologies. Inc. UK, South 
Queensferry, UK 
Biometra T 3000 Thermocycler  Thistle Scientific Ltd., Glasgow, UK 
C-28 centrifuge   Boeckel and Co; Hamburg, Germany 
CKX41 microscope  Olympus UK Ltd., Surrey, UK 
Dissecting microscope   Olympus UK Ltd., Surrey, UK 
Dynatech MR7000 Plate Reader   Primera Scientific LLC, Princeton, NJ, 
USA 
Electrisaver E30 Thermostat heated 
chamber 
RS Components Ltd., Corby, UK 
Fluosorber vaporiser   The Harvard Apparatus, Kent, UK 
Fujifilm Fla-5000   Raytek Scientific Ltd., Sheffield, UK 
Galaxy S tissue culture incubator   New Brunswick Scientific, Cambridge, 
UK 
Intelligent Dark Box LAS-3000   Fujifilm UK Ltd., Manchester, UK 
Labophot-2 light microscope   Nikon UK Ltd.; Kingston upon Thymes, 
UK 
Leica ASP300 tissue processor   Leica Microsystems Ltd.; Milton 
Keynes, UK 
Leica DMD108 Digital Microimaging 
Network  
Leica Microsystems Ltd.; UK 
Leica EG1150C cold plate   Leica Microsystems Ltd.; Milton 
Keynes, UK 
Leica EG1150H  heated paraffin 
dispensing module  
Leica Microsystems Ltd.; Milton 
Keynes, UK 
Leica TCS SP2 confocal microscope   Leica Microsystems Ltd.; UK 
Leitz 1512 microtome   Leica Microsystems Ltd.; Milton 
Keynes, UK 
LightCycler
® 480 Instrument  Roche Applied Science, Germany 
Mikro-Dismembrator   B. Braun Biotech International GmbH, 
Melsungen, Germany 
NanoDrop ND 1000 Spectrophotometer  NanoDrop Technologies, USA 
NanoZoomer Digital Pathology scanner   Hamamatsu; Bridgewater, USA 
ND-1000 Spectrophotometer   NanoDrop Technologies, USA 
IX51 inverted microscope  Olympus UK Ltd., Southend-on-Sea, UK 
Shaking incubator Certomat
 BS-1  B. Braun Biotech International, 
Allentown, USA 
Stemi SV6 fluorescent dissecting 
microscope  
Carl Zeiss Ltd., Welwyn Garden City, UK 
Water bath   Thermo Fisher Scientific Inc., Surrey, 
UK 
Table 2-3 List of electric equipment. 
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2.2 Methodology 
2.2.1 Sample Collection 
2.2.1.1  Mouse husbandry 
Wild type C57BL/6 (WT), transgenic EGFP expressing C57/BL6 (TG) and Fibulin 2-
null C57BL/6 (Fbln2 KO
-/-) mice were used for the purpose of this research. The 
WT mice were supplied by Harlan UK Limited Breeding Laboratories while the TG 
colony was derived from a breeding pair kindly donated by Prof. Cathrin Brisken 
(EPFL/ISREC, Lausanne, Switzerland). TG animals were of C57BL/6 background 
and  constitutively  expressed  the  EGFP  transgene  under  the  control  of  a  CAG 
promoter (combination of  -actin promoter and hCMV  enhancer)  [265].  Males 
heterozygous for EGFP expression were mated with WT female mice in order to 
establish our own colony of transgenic mice. WT and EGFP heterozygous female 
littermates were used for further experiments. The male offspring were culled 
before  weaning  unless  needed  for  breeding  purposes.  The  mice  were 
accommodated  and  bred  at  the  Biological  Services  Central  Facilities  at 
Gilmorehill Campus and the Veterinary Research Facility on the Garscube Estate, 
Glasgow.  
Animals were kept in conventional M3 cages bedded with wood chips and paper 
nesting material. Each of the cages was equipped ad lib with food; Beekay Rat 
and Mouse diet No 1 and ad lib tap water containers. Mice were housed in a 
temperature-controlled environment at 21 1ºC with humidity of 45% to 55% on a 
12-hour (h) light, 12-h dark exposure cycle. All WT mice were allowed a 7 day 
acclimatisation  period  after  their  arrival  on  site  prior  to  being  used  for 
experiments. The transgenic founder breeders were screened for the presence 
of pathogens upon their arrival.    
Fbln2  KO
-/-  mice  were  initially  generated  by  Dr.  Chu  (Thomas  Jefferson 
University,  Philadelphia,  USA)  [266]  but  bred  and  kindly  made  available  for 
mammary gland collection by Dr. Tsuda (Nemours/Alfred I. DuPont Hospital for 
Children,  Wilmington,  USA).  Tissue collection  for  wholemounting  and  paraffin     99 
 
embedding was carried out in Nemours/Alfred I. DuPont Hospital for Children in 
Wilmington in USA by Mrs. Joyce. 
2.2.1.2  Dissection of mouse mammary glands 
The  weight  and  age  of  the  animals  was  recorded  prior  to  culling.  Surgical 
instruments were sterilized by autoclaving prior to performing the dissections. 
Mammary tissue was obtained from both left and right fourth inguinal glands of 
WT  and  TG  females.  Tissue  was  collected  at  the  following  stages  of 
development: virgin (between 2 and 12 weeks old), pregnancy (day 3, 8.5, 12.5, 
14.5 17.5), lactation (day 1 and 7) and forced involution (day 1, 2, 3, 4, 10 and 
20). The first day of pregnancy was denoted by the appearance of a vaginal plug 
(counted  as  day  0.5).  The  collection  of  mammary  glands  from  pregnant, 
lactating and involuting mice was performed by Marie-Anne Pringle. Mice were 
euthanized by a schedule 1 method of killing, either cervical dislocation or rising 
concentration of carbon dioxide. Death was confirmed by checking for absence 
of  heart  beat,  respiration  and  paw  withdrawal  due  to  pinching  the  toe.  The 
cadaver was placed on a corkboard in dorsal recumbent position and secured to 
the board using metal pins. 70% ethanol (v/v) was applied to the body and a 
midline inverted Y incision into the skin was performed using blunt scissors. The 
incision  began  halfway  between  the  fourth  and  fifth  nipples  and  continued 
rostrally to the thorax and laterally to each thigh. The skin flaps with mammary 
glands attached were then pulled away from the peritoneum and secured to the 
corkboard  (Figure  2-1).  Mammary  tissue  was  gently  excised  using  dissecting 
scissors and forceps. Glands to be used for isolation of epithelium were chilled 
on ice in Leibovitz L15 medium. Glands to be used for microarray studies and 
protein or RNA extraction had their lymph nodes removed prior to being snap 
frozen in liquid nitrogen. Glands to be used for immunohistochemistry (IHC) or 
immunoflurescence (IF) were transferred to 10% Neutral Buffered Formalin upon 
removal. Glands to be used for tissue imaging, tissue strips collection or organ 
culture were gently dissected out and immediately used for further applications. 
Glands to be used for carmine alum stained wholemount analysis were spread 
out on microscope slides and placed in Carnoy‟s fixative.     100 
 
 
Figure 2-1 Dissection of the 4-th (inguinal) mouse mammary gland. 
(A) The image illustrates a mouse carcass secured to the corkboard in the recumbent position, 
ventral side up. (B) Image demonstrates carcass with 4-th mammary gland exposed by incision. 
Insert shows a higher magnification of the left mammary gland.  
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2.2.1.3  Dissection of other mouse organs and tissues 
All tissues and organs used in this research were excised from adult WT or TG 
mice at the Veterinary Research Facility, Garscube Estate, Glasgow, UK. Surgical 
instruments were sterilised by autoclaving prior to performing the dissection. 
Animals were weighed and euthanized by cervical dislocation. Collected organs 
of interest were either fixed in 10% Neutral Buffered Formalin or snap frozen in 
liquid nitrogen depending on their further application.    
2.2.1.4  Collection of mouse mammary gland tissue strips 
Pre-pubertal  and  pubertal  mouse  mammary  gland  can  be  divided  into  the 
following  sections:  pre  lymph  node  (Pre-LN),  post  lymph  node  (Post-LN)  and 
empty fat pad (Fat pad). The Pre-LN tissue strip contains ductal epithelium and 
stroma,  the  Post-LN  tissue  strip  consists  of  TEBs,  duct  epithelium  and 
surrounding stroma while Fat pad consists of epithelium-free stroma (Figure 2-2 
A). Mammary gland tissue strips were collected from 7 week old TG mice. Mice 
were transferred to the Beatson Animal Facility (Beatson Institute for Cancer 
Research, Glasgow, UK) immediately before commencing the experiments where 
they were culled by cervical dislocation. Glands were excised as described above 
in the designated area of Dr. Tomoko Iwata‟s laboratory (Beatson  Institute of 
Cancer  Research,  Glasgow,  UK).  The  4-th  mammary  gland  was  gently  spread 
onto a HistoBond
®+ glass slide, visualised using Stemi V6 fluorescent dissecting 
microscope  and  imaged  (Figure  2-2  B).  Tissue  strips  were  cut  using  sterile 
scalpel blades  under the fluorescent dissecting microscope  (See  2.2.8.1) and 
snap frozen in liquid nitrogen. Collected tissue was used for microarray analysis 
or RNA and protein extraction. All work surfaces and instruments used in the 
collection of tissue strips for use in RNA extraction were cleaned using RNaseZap 
prior to commencing work.  
2.2.1.5  Collection of isolated epithelium 
Two  types  of  epithelial  structures,  TEBs  and  ducts,  were extracted  from  the 
mammary tissue dissected from WT mice, aged between 6-8 weeks as described 
above. 20 glands were removed for each experiment and chilled in Leibovitz L-
15 medium. Collected tissue was coarsely minced using surgical non-sterile     102 
 
 
Figure 2-2 7 weeks old 4-th mouse mammary glands. 
(A) Mouse mammary gland wholemount stained with Carmine stain, collected from WT mice (B) 
Mammary gland collected from TG mice imaged with a fluorescent dissecting microscope.     103 
 
scalpel blades and subjected to 1mg/ml (w/v) collagenase type II digestion in 
Leibovitz L-15 medium. The enzymatic reaction was carried out at 37ºC for 35 
min using a shaking incubator Certomat
 BS-1 at max speed. The tissue soup was 
then shaken by hand to encourage the release of the epithelial structures from 
the tissue. The obtained suspension was split between two universals, diluted in 
fresh, ice-cold Leibovitz L-15 medium supplemented with 0.1% FBS to inhibit the 
collagenase  activity  and  centrifuged  for  5  min  at  room  temperature  (RT)  at 
250rcf  using  a  C-28  centrifuge.  The  resulting  supernatants  were  then  gently 
aspirated and pellets gently resuspended in 1 ml of Leibovitz L-15 medium and 
combined prior to being transferred into a gridded contact dish. The released 
TEBs  and  ducts  were  visualised  by  means  of  a  dissecting  microscope  and 
manually  collected  using  a  10µl  Gilson  pipette.  Isolated  epithelial  structures 
were stored in 50-100µl volume of TRIzol
® Reagent at –80C prior to extraction of 
RNA or fixed in 10% Neutral Buffered Formalin to be used in IHC or IF. 
2.2.2 Cell culture 
2.2.2.1  Cell lines and Cell maintenance 
Cell lines used in this study comprised three mouse non-tumourigenic cell lines: 
EpH4 and HC11, derived from mouse mammary epithelium, and NIH3T3 derived 
from mouse embryonic fibroblasts. NIH3T3 were kindly supplied by Dr. Iglesias 
while  EpH4  and  HC11  cells  were  kindly  supplied  by  Prof.  Birchmeier  (Max-
Delbrück-Centrum  für  Molekulare  Medizin,  Berlin,  Germany)  and  Dr.  Allan 
(formerly Hannah Research Institute, Glasgow, UK) respectively. 
Unless stated otherwise, all cells were routinely grown in 75cm
2 tissue culture 
filter  flasks  in  a  Galaxy  S  tissue  culture  incubator  at  37°C  in  a  humidified 
atmosphere with 5% CO2. Growth conditions applied to each cell line were as 
follows: EpH4 cells - DMEM, 10% FBS, 2mM L-glutamine; HC11 cells - RPMI-1640, 
10%  FBS,  2mM  L-glutamine,  5µl/ml  insulin,  10ng/ml  EGF  and  NIH3T3  cells  - 
DMEM,  10%  FBS,  2mM  L-glutamine.  All  cell  culture  maintenance  and  in  vitro 
experiments were performed under sterile conditions.  
For  maintenance  purposes,  all  cells  were  grown  until  nearly  confluent.  They 
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flask via enzymatic proteolysis facilitated by incubation with 0.25% Trypsin-EDTA 
Solution for 2 min at 37°C and passaged into the fresh tissue culture flask by 
splitting 1:7 for NIH3T3, 1:12 for EpH4 and 1:5 for HC11 cells. 
2.2.2.2  Cell Counting 
Cells  were  then  counted  using  a  haemocytometer  as  follows:  10µl  of  cell 
suspension  was  applied  to  the  upper  and  lower  chambers  of  the 
haemocytometer,  the  number  of  cells  per  1mm
2  square  was  counted  in  3 
different areas and the mean number of cells was calculated. The number of 
cells in 1ml of medium was calculated by multiplying mean number of cells with 
10
4.  
2.2.2.3  Plasmid information and plasmid DNA purification 
Plasmid Information 
The eukaryotic expression vectors used in this study were pEGFP, pcDNA3 and 
pRc/CMV-Fbln2  (Appendix  1).  pEGFP  encoded  Enhanced  Green  Fluorescent 
Protein  (EGFP)  under  the  control  of  a  cytomegalovirus  (CMV)  promoter  while 
pcDNA3  is  an  empty  vector  and  hence  was  used  as  a  negative  transfection 
control.  pRc/CMV-Fbln2  contains  variant  1  (V1)  of  the  mouse  Fbln2  gene 
(NM_007992) under the control of a CMV promoter. 
Preparation of LB Agar plates 
1.5% LB-Agar was prepared (See Solutions and Buffers) and autoclaved. The mix 
was then preheated in the microwave, left to cool down and then supplemented 
with 100µg/ml of Ampicillin. Finally it was poured onto bacterial culture dishes, 
allowed to solidify and stored upside down at 4°C.   
Purification of plasmid DNA 
PRc/CMV-Fbln2 was obtained as DNA blotted onto filter paper. DNA was eluted 
from the filter paper by placing the area of filter paper containing the plasmid 
in a 1.5ml Eppendorf tube and incubating in 50µl of dH2O for 30 min at RT,     105 
 
followed by centrifugation for 3 min at 13,000rcf. 1µl of eluted plasmid DNA was 
then transformed into 50µl of competent DH5α E. coli cells. Transformation was 
performed by incubating the cells with the DNA on ice for 20 min, heat shocking 
for 90 sec at 42°C to facilitate plasmid entry and returning to ice for a further 2 
min. Transformed cells were then incubated with 250µl of S.O.C. medium for 45 
min at 37°C with agitation at 220rpm using a Certomat
® BS-1 shaking incubator 
to assist cell recovery. Finally, 50µl of the transformation mix was transferred 
onto prepared LB-Agar (1.5%) plates containing 100µg/ml of Ampicillin, spread 
using a sterile disposable microbiological spreader and incubated upside down 
overnight at 37°C. After the incubation period the plate was investigated for the 
presence of single bacterial colonies. Four colonies were picked and each one 
was transferred to 10ml of LB medium supplemented with 100µl/ml of Ampicillin 
and cultured overnight at 37°C with agitation at 220rpm using Certomat
® BS-1 
shaking incubator. 100µl of each culture were kept at 4°C. Obtained bacterial 
cultures were then centrifuged at 5,000rcf at 4°C for 15 min. Supernatant was 
removed and plasmid DNA was retrieved from the bacteria and purified using 
QIAprep Miniprep kit as per manufacturer‟s instructions. Briefly, bacteria were 
lysed under alkaline conditions. The lysate was neutralised and adjusted to high 
salt  binding  conditions  and  cleared  from  the  cell  debris  by  centrifugation. 
Plasmid DNA was then selectively bound to a QIAprep silica-based membrane, 
washed to remove endonucleases and salts and eluted in RNase-free H2O (low 
salt conditions).  
The  DNA  was  quantified  using  a  NanoDrop  ND-1000  Spectrophotometer  (See 
2.2.4.4). 
Each  plasmid  preparation  was  checked  using  restriction  digestion  (See 
2.2.4.11).  
Once the correct clone was identified by restriction digestion, 25µg of plasmid 
DNA  was  sent  for  sequencing  to  confirm  the  sequence  of  the  insert  (See 
2.2.4.10). Six primers were designed (See 2.2.4.7) (Table 2-5) to amplify the 
full sequence of Fbln2 V1 publicly available at the Nucleotide Database of the 
National  Centre  for  Biotechnology  Information  (NCBI) 
(http://www.ncbi.nlm.nih.gov/)  (NM_007992).  Sequencing  results  were 
visualised  and  examined  using  Chromas  Lite  2.01  (Technelysium  Pty  Ltd)  and     106 
 
compared  to  the  publicly  available  Fbln2  V1  GeneBank  nucleotide  sequence 
using  Basic  Local  Alignment  Search  Tool  (BLAST),  blastn  algorithm 
(http://blast.ncbi.nlm.nih.gov/) to assess the degree of similarity.      
Once the correct clone was identified, the aliquot of bacteria set aside before 
DNA  purification,  was  transferred  to  a  flask  containing  150ml  of  LB  medium 
supplemented with 100µg/ml of Ampicillin and grown  overnight at 37°C  with 
agitation at 220rpm. Bacterial cultures were then centrifuged at 5,000rcf at 4°C 
for 15 min. Supernatant was removed and plasmid DNA was extracted from the 
bacteria  and  purified  using  HiSpeed
®  Plasmid  Maxi  kit  as  per  manufacturer‟s 
instructions. Briefly, bacteria were lysed under alkaline conditions and the DNA, 
proteins and cell debris were precipitated from the lysate. Lysate was filtered 
through  the  Anion  Exchange  Resin  under  the  appropriate  low  salt  and  pH 
conditions  to  facilitate  DNA  binding  to  the  Resin.  Resin  was  then  washed  to 
remove  the  remains  of  RNA,  proteins  and  low  molecular  weight  impurities. 
Plasmid  DNA  was  eluted  in  high  salt  buffer,  concentrated  and  desalted  via 
isopropanol precipitation and finally eluted in RNase-free H2O.  
Purified DNA from the pEGFP and pcDNA3 was kindly supplied by Dr. Camille 
Huser. 
2.2.2.4  Transfections 
Transfections were performed on HC11 cells using 3 different plasmids: pEGFP, 
pcDNA3 and pRc/CMV-Fbln2 and a liposomal transfection reagent. 
2.2.2.4.1  Optimisation of transfections 
 
The  optimisation  of  transfection  efficiency  and  toxicity  was  performed  for 
DharmaFECT
®  Duo  Transfection  Reagent  and  Lipofectamine
™  2000  in  order  to 
find optimal transfection conditions for HC11 cells. All optimisation experiments 
were performed using the pEGFP. HC11 cells were plated in growth medium in 6 
well  tissue  culture  plates  at  the  same  density  per  well  24-48h  before 
transfection. Cells at the time of transfection were 60-80% confluent. 
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Optimisation of Transfections using Lipofectamine
™ Transfection Reagent 
Optimisation of the transfection protocol for Lipofectamine
™ was performed as 
follows: 4µg of DNA of pEGFP and varying volumes of Lipofectamine
™ transfection 
reagent  (2µl,  4µl,  6µl,  10µl  and  12µl)  were  diluted  in  250µl  of  Opti-MEM
®  I 
Reduced Serum Medium by gentle mixing. All mixes were incubated at RT for 5 
min.  Diluted  pEGFP  DNA  samples  were  then  added  to  each  of  the  diluted 
transfection reagent mixes and incubated at RT for a further 20 min in order to 
facilitate  generation  of  the  DNA-liposomes  complexes.  Finally  500µl  of 
complexes  were  added  directly  to  each  well  containing  HC11  cells  and  fresh 
standard cell culture medium. Cells were then returned to incubator. After 5h 
the culture medium was changed. Cells were then further incubated to be tested 
for the transgene expression by fluorescence microscopy (See 2.2.8.1). 
Optimisation of Transfections using DharmaFECT
® Duo Transfection Reagent 
Optimisation  of  the  transfection  protocol  for  DharmaFECT
®  Duo  Transfection 
Reagent was performed as follows: 100µl of 20µg/ml of pEGFP was mixed with 
100µl of serum free culture medium. Increasing volumes of DharmaFECT
® Duo 
Transfection Reagent (2µl, 4µl and 6µl) were each diluted in 200µl of serum free 
culture medium and incubated at RT for 5 min. The DNA dilutions were then 
added to the transfection reagent mixes and incubated at RT for an additional 
20 min. Finally, 1.6ml of fresh standard cell culture medium was added to each 
mix and the diluted complexes were added to each well containing HC11 cells. 
Cells were then tested for transgene expression after 48h of incubation.  
The efficiency of transfections, i.e. estimation of the EGFP transgene expression 
levels was performed using an inverted fluorescent microscope. Each well was 
visualised and imaged at x400 magnification (See 2.2.8.1). The number of EGFP 
expressing cells was counted at 3 chosen random fields within the well and the 
mean number of cells and standard errors of the mean (S.E.M.) were calculated.  
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2.2.2.4.2  Fbln2 over-expression in HC11 cells 
 
Fbln2 was over-expressed by transfecting HC11 cells with pRc/CMV-Fbln2 using 
Lipofectamine
™ transfection reagent for 48h. The plasmid DNA to transfection 
reagent ratio was 1:1 and it was adjusted for the size of each tissue culture 
plate or dish. PcDNA3 DNA was used as a negative control in all experiments.  
The  experimental  procedure  was  carried  out  as  described  above  (See 
2.2.2.4.1). Transfected HC11 cells were then incubated for 48h prior to being 
collected in RIPA buffer (See Solutions and Buffers) for protein extraction or 
used for further applications. Transgene expression was determined by Western 
blotting. 
2.2.2.5  Wound Healing Assay 
HC11 cells were plated in 6 well cell culture plates at equal density per well and 
transfected  in  triplicates  with  either  pRc/CMV-Fbln2  or  pcDNA3  using 
Lipofectamine
™  transfection  reagent  as  described  above  (See  2.2.2.4.1).  48h 
after the transfections, when cells had become confluent, a double cross was 
marked on the surface of each well using a sterile 200µl pipette tip. As Fbln2 is 
an ECM molecule, the culture medium was collected from each well, spun down 
at RT for 5 min at 1,100rcf to discard floating cells, mixed with fresh culture 
medium and placed back on the cells. Two areas around the double cross were 
selected for each well to be imaged over time. Images were acquired straight 
after performing the scratch, i.e. at 0 h and after 4, 7, 11, 24 and 36h. The 
width  of  the  gap  was  measured  in  triplicate  for  each  selected  area  at  x400 
magnification (See 2.2.8.3). The experiment was repeated 3 times. Mean values 
and S.E.M. were calculated for each well, and the percentage of gap closure 
over time in each well was plotted. Upon completion of the assay, cells were 
collected  in  RIPA  buffer  for  protein  extraction  to  determine  transgene 
expression by Western blotting.       109 
 
2.2.2.6  Adhesion Assays 
2.2.2.6.1  Adhesion of pRc/CMV-Fbln2 transfected HC11 cells to 
plastic surface 
 
HC11 were plated in 75cm
2 tissue culture flasks prior to being transfected with 
either  pRc/CMV-Fbln2  or  pcDNA3  with  Lipofectamine
™  transfection  reagent  as 
described above (See 2.2.2.4.1). 48h after transfection, the cells were washed 
twice  with  sterile  dPBS  (1x),  detached  from  the  tissue  culture  flask  by 
incubation with filtered 2mM EDTA-PBS buffer (See Solutions and Buffers) for 10 
min at RT, resuspended, centrifuged at 150rcf for 3 min at RT, washed twice in 
filtered 2mM EDTA-PBS buffer and resuspended in 2ml of DMEM. Cells were then 
counted (See 2.2.2.2) and plated at a final concentration of 1.5x10
6 cells/ml in 
96-well tissue culture plate in quintuplicates at 100µl/well and incubated for 2h. 
Adherent cells were then washed, stained and quantified using the methodology 
and  reagents  from  the  ECM  Cell  Adhesion  Array  Kit  as  described  below  (See 
2.2.2.6.2). 
2.2.2.6.2  Adhesion of pRc/CMV-Fbln2 transfected HC11 cells to ECM 
proteins 
 
Influence of Fbln2 over-expression on the adhesiveness of HC11 cells to human 
ECM proteins, such as ColI, ColII, ColIV, Fn, Lama1, Tnc and vitronectin (Vtn) 
was studied using ECM Cell Adhesion Array Kit. The ECM Cell Adhesion Array Kit 
utilises colorimetric detection of the amount of experimental cells adherent to 
wells coated with seven human ECM proteins in a 96-well cell culture plate. BSA-
coated wells are used as a negative control. The main experimental steps of the 
assay  include:  plating  of  the  cells  at  a  given  constant  density  per  well,  cell 
attachment, washing, staining and determination of the relative cell attachment 
via absorbance reading.  
Determination of the  optimal cell  density  was  performed  using  untransfected 




6 cells/ml) and the relative cell attachment was determined according 
to  the  manufacturer‟s  instructions.  Briefly,  HC11  cells  were  plated  in  75cm
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tissue culture flasks and cultured until confluent. Cells were then detached from 
the  flask  using  filtered  2mM  EDTA-PBS  buffer  (See  2.2.2.6.1),  counted  (See 
2.2.2.2)  and  plated  at  the  final  concentration  in  the  supplied  strips  in 
100µl/well and incubated for 2h. Each strip was rehydrated with 200µl of dPBS 
for  10  min  prior  to  being  used  for  the  experiment.  After  incubation,  culture 
medium was aspirated from the wells and cells were washed three times with 
200µl/well of supplied Assay Buffer to remove unattached cells. The remaining 
attached cells were then stained for 5 min with 100µl/well of the supplied Cell 
Stain Solution, washed three times with deionised H2O to remove excess staining 
solution and allowed to air dry. Finally, the stain was released from the cells and 
solubilized by the addition of 100µl of supplied Extraction Buffer to each well 
and incubating the plate at RT for 15 min while shaking. The amount of released 
stain  was  directly  proportional  to  the  amount  of  attached  cells  and  it  was 
determined using absorbance readings at 560nm.   
The  amount  of  Fbln2  over-expressing  HC11  cells  adherent  to  different  ECM 
proteins was determined as follows: HC11 cells were plated in 75cm
2 cell culture 
flasks  prior  to  being  transfected  with  either  pRc/CMV-Fbln2  or  pcDNA3  as 
described  above  (See  2.2.2.4).  48h  after  transfection,  both  cell  lines  were 
washed twice with sterile dPBS (1x), detached from the flask using filtered 2mM 
EDTA-PBS, washed, resuspended in DMEM and counted as described above. Both 
cell lines were then resuspended in DMEM to a final concentration of 1.5x10
6 
cells/ml,  plated  in  triplicates,  incubated,  washed,  stained  and  analysed 
following the experimental steps described above. The mean amount of cells 
and S.E.M. for each condition were calculated and plotted.  
2.2.3 Protein work 
2.2.3.1  Protein extraction from the cell lines 
Protein  extracts  were  collected  from  untransfected  cell  lines  grown  to  sub-
confluency in either 6 well plates or 10cm cell culture dishes. Protein extraction 
from transfected cells was performed upon completion of transfections or wound 
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Cells were washed twice with dPBS and incubated on ice with either 0.25ml/per 
well (6 well tissue culture plate) or 0.5ml/plate (10cm tissue culture) of ice cold 
RIPA lysis buffer until the cells were lysed, i.e. the buffer became viscous due to 
the nucleic acid release and the cell membranes appeared digested when viewed 
under an Olympus CKX41 microscope at x400 magnification. The cell lysates 
were then scraped off from the tissue culture dishes or plates using cell lifters, 
transferred to 1.5 Eppendorf tubes and incubated on ice for a further 15 min 
with occasional mixing. The cell lysate was finally centrifuged at 4°C for 20 min 
25,000rcf to separate the fraction of extracted proteins (supernatant) from cell 
debris (pellet). The supernatant, i.e. protein lysate was then quantified (See 
2.2.3.3), concentrated, used for Western Blotting or stored at -80°C. 
 
2.2.3.2  Protein extraction from the frozen tissues 
Frozen  tissues  were  pooled  or  individually  crushed  in  liquid  nitrogen  using  a 
mortar and pestle cooled on dry ice. The obtained tissue powder was transferred 
to a Down‟s Homogeniser chilled on dry ice and resuspended in 0.5ml of ice cold 
NP-40,  RIPA,  EDTA  or  Urea  lysis  buffers  (See  Solutions  and  Buffers). 
Homogenised  samples  were  transferred  to  ice  chilled  1.5ml  microcentrifuge 
tubes and placed on dry ice. The obtained tissue lysates were then defrosted, 
incubated on ice for 30 min to facilitate further cell lysis and centrifuged at 
25,000rcf at 4ºC for 20 min to separate out the fraction of extracted proteins 
from  the  cell  debris.  The  resulting  supernatant  was  retained,  quantified, 
concentrated, used in Western blotting or stored at -80ºC.   
2.2.3.3  Protein Quantification 
The concentration of proteins was determined with the BCA™ Protein Assay Kit 
that utilises the ability of proteins in alkaline medium to facilitate Cu
2+ to Cu
1+ 
reduction (Biuret reaction). Briefly, 10µl of each sample (diluted 1:5) was plated 
in the 96 well tissue culture plate along with equal volumes of eight BSA protein 
standards (0, 25, 125, 250, 500, 750, 1000 and 1500µg/ml). Each sample and 
protein standard was plated in duplicate and triplicate respectively and mixed 
with 200µl of BCA reagent (prepared by mixing Reagent A and Reagent B in a 
50:1 ratio). The plate was then incubated at RT for 30-40 min. The absorbance 
of  each  well  was  read  at  570nm  using  a  Dynatech  MR7000  Plate  Reader  and     112 
 
Revelation  Version  3.04  software  (Revelation  UK,  London,  UK).  Finally,  the 
absorbance readings of BSA standards were used to plot a standard curve and 
calculation of sample protein concentration was based on a linear line of best fit 
using Microsoft Excel
®.  
2.2.3.4  Concentration of Protein Extracts 
Cellular  protein  extracts  of  a  concentration  too  low  to  be  used  for  further 
applications were concentrated using a Microcon
® Centrifugal Filter Device with 
Ultracel  YM-3  membrane  according  to  the  manufacturer‟s  instructions.  The 
Ultracel YM-3 membrane has a cut off of 3kDa. Briefly, a maximal volume of 
0.5ml of protein extract was transferred into the sample reservoir assembled 
with the collection vial and sealed with the attached cap. The column was then 
centrifuged  at  14,000rcf  for  40  min  at  RT  with  the  cap  strap  aligned  to  the 
centre of the rotor. The reservoir was then removed from the column, placed 
upside down in the new collection vial and spun at 1,000rcf for 3 min to retain 
the  concentrate.  The  concentration  of  the  resulting  extract  was  once  more 
determined by the BCA™ Protein Assay Kit.                
2.2.3.5  Electrophoresis and Western blotting 
One  dimensional  electrophoresis  under  denaturing  conditions  and  in  the 
presence  of  0.1%  SDS  was  performed  to  enable  separation  of  the  proteins 
according to their molecular weight.  The separation and blotting of proteins 
was carried out using the Novex NuPage™ Electrophoresis system.  
Sample preparation 
Prior to SDS polyacrylamide gel electrophoresis (PAGE), 25-50µg of each protein 
extract was mixed with 0.33 volumes of 4xNuPage LDS sample buffer and 0.1 
volume  of  1M  DTT.  The  mix  was  incubated  at  70ºC  for  10  min  to  facilitate 
protein denaturation.  
 
     113 
 
SDS polyacrylamide gel electrophoresis 
The  prepared  protein  samples  were  resolved  on  either  4-12%  Bis-Tris-HCl 
buffered (pH6.4) gels in the presence of 1xNuPage MES SDS running buffer or 3-
8%  Tris-Acetate  polyacrylamide  gels  in  the  presence  of  1X  Tris-Acetate  SDS 
Running  Buffer.  Molecular  weight  markers,  Novex
®  Sharp  Pre-stained  Protein 
Standards, were separated alongside the samples. The choice of polyacrylamide 
gel type was dependent on the molecular weight of the protein of interest and 
the level of resolution required.  500µl of NuPage Antioxidant was added to the 
inner chamber of the gel apparatus. 4-12% Bis-Tris gels were electrophoresed at 
a constant voltage of 200V for approximately 45 min, while the 3-8% Tris-Acetate 
polyacrylamide gels were run for 60 min at a constant voltage of 150V.  
Protein Transfer 
Upon  completion  of  electrophoresis,  proteins  were  transferred  from  the  SDS 
polyacrylamide gel onto Whatman
® Protran
® Nitrocellulose Transfer Membrane 
(0.2µm)  using  a  Novex  XCell  II™  Blot  module,  protein  transfer  buffer  (See 
Solutions  and  Buffers),  sponges  and  filter  papers.  Filter  papers,  transfer 
membrane and sponges were pre-soaked in protein transfer buffer and protein 
transfer was carried out at a constant voltage of 30V for 60 min.  
Membrane Blocking and Incubation with Antibodies 
After  protein  transfer  the  nitrocellulose  membrane  was  removed  from  the 
module and briefly stained with Ponceau S stain (0.1% Ponceau S (w/v) in 5% 
acetic acid (v/v)) to determine the efficiency of the transfer. 1xTBS Tween-20 
wash buffer (See Solutions and Buffers) was used to remove the stain. The blot 
was  incubated  for  40  min  at  RT  in  3%  Marvel  Original  dried  skimmed  milk 
blocking solution (See Solutions and Buffers) or 2.5% BSA blocking solutions (See 
Solutions and Buffers). It was then incubated for 2h at RT or overnight at 4ºC 
with primary antibody, washed three times with 1xTBS Tween-20 wash buffer for 
10  min,  incubated  for  1h  at  RT  with  horseradish  peroxidase  (HRP)-labelled 
secondary antibody and finally washed three more times with 1xTBS Tween-20 
wash buffer for 10 min. All of the above incubations and washes were performed 
using horizontal or oscillating shakers. Both primary and secondary antibodies     114 
 
were diluted in 1xTBS Tween-20 wash buffer to the final working concentrations 
shown in (Table 2-4). 
Signal Detection 
The  HRP  activity  of  the  secondary  antibodies  allow  antigen  detection  to  be 
carried  out  using  chemiluminescence,  i.e.  emission  of  light  resulting  from 
dissipation of energy from the product of chemical reaction. In this system, HRP 
catalyses oxidation of luminol in the presence of phenol (chemical enhancer) in 
alkaline conditions.  
Signal  detection  was  performed  using  the  Amersham  ECL  Western  blotting 
detection reagents and analysis system as per manufacture‟s instructions. The 
membrane  was  incubated  with  the  prepared  detection  mix  (equal  volume  of 
detection solution 1 and 2) for 1 min at RT. Excess solution was removed from 
the  membrane  prior  to  and  after  the  incubation.  The  membrane  was  then 
wrapped in Saran wrap and the chemiluminescence signal was detected using an 
Intelligent Dark Box LAS-3000 equipped with a cooled to -30°C charge coupled 
device,  camera  and  FO.85  Fujinon  Lens.  Images  were  acquired  and  analysed 
using LAS-3000 v.2.2 software (Fujifilm UK Ltd., UK) after 4-20 min of exposure 
under standard sensitivity. Densitometry was performed using MacBiophotonics 
ImageJ (http://rsb.info.nih.gov/ij/). 
Stripping for re-probing of membranes  
In order to be re-used, the membranes were transferred into 1xTBS Tween-20 
wash buffer immediately after performing the signal detection step of Western 
blotting and stored at 4°C for up to 48h. When needed, membranes were briefly 
rinsed twice in 1xTBS Tween-20 wash buffer, washed for 5 min in 1xTBS Tween-
20 wash buffer and stripped of attached primary and secondary antibodies by 
two separate 10 min incubations in stripping buffer (pH2.2) (See Solutions and 
Buffers), rinsing in-between. Membranes were then finally washed using 1xTBS 
Tween-20 wash buffer three times for 5 min to fully remove detached antibodies 
and eliminate the remains of stripping buffer. All washes and incubations were 
performed at RT, using an oscillating shaker. Stripped membranes were then      115 
 





Mouse monoclonal, donated by Dr. T. Sun (New York 
University Medical School, New York, US) 
2.5% BSA  1: 1000 
Anti-Fbln2 
Rabbit polyclonal, donated by Dr. Mon Li Chu (Thomas 
Jefferson University, Philadelphia, US) 
3% milk  1:5000 
Anti-Actin (C-20) 
Goat polyclonal, Santa Cruz Biotechnology Inc., Santa Cruz, 
USA  
3% milk  1:1000 
Anti-N-terminus of Fbln2 
Rabbit polyclonal, Santa Cruz Biotechnology Inc., USA 
3% milk  1:400 
Anti-C-terminus of Fbln2 
Goat polyclonal, Santa Cruz Biotechnology Inc., USA 
3% milk  1:200 





Rabbit polyclonal, Dako UK Ltd., Eli, UK  
3% milk  1:3000 
Anti-rabbit (HRP-labelled) 
Donkey polyclonal, GE Healthcare UK Ltd., UK 
3% milk  1:5000 
Anti-Mouse (HRP-labelled) 
Rabbit polyclonal, Dako UK Ltd 
3% milk  1:3000 
Table 2-4 Primary and secondary antibodies used for Western Blotting.     116 
 
blocked  and  re-probed  with  primary  and  secondary  antibodies  and  used  to 
detect other proteins of interest as described above.   
2.2.4 RNA and DNA  
2.2.4.1  Preparation of total RNA  
To prevent contamination by environmental RNAses, all instruments and working 
surfaces were cleaned using RNaseZap and RNase-free 1.5 microcentrifuge tubes 
were used as standard throughout the experimental procedure. 
2.2.4.1.1  Preparation of collected frozen tissue for RNA extraction 
 
Frozen  tissues  were  pooled  or  individually  crushed  in  liquid  nitrogen  using  a 
pestle and mortar previously cooled on dry ice. The obtained tissue powder was 
transferred  to  a  liquid  nitrogen  chilled  polytetrafluoroethylene  capsule  and 
further  homogenised  using  a  Mikro-Dismembrator  for  20  sec  at  15,000rpm. 
According to the amount of starting material, the homogenate was resuspended 
in 1-3ml of TRIzol
® reagent transferred to 1.5ml tubes and stored at -80ºC until 
all samples were ready for further processing.  
Once all samples were collected, they were thawed on ice, mixed by vortexing 
and incubated at RT for 5 min in order to facilitate the complete dissociation of 
nucleoprotein complexes. 
2.2.4.1.2  Preparation of isolated mammary gland epithelium for 
RNA extraction 
 
Isolated TEBs and ducts  (See 2.2.1.5) previously collected in  TRIzol
® reagent 
and stored at -80°C were thawed on ice and mixed by vortexing. All TEBs were 
pooled together in a final volume of 1ml of  TRIzol
® reagent. The ducts were 
pooled in the same way. Samples were then incubated at RT for 5 min.     117 
 
2.2.4.1.3  Extraction of RNA from frozen tissue and isolated 
epithelium 
 
Extraction of RNA was performed as follows: 0.2ml of chloroform was added per 
1ml of TRIzol
® reagent to each sample. Tubes were manually shaken for 15 sec, 
incubated for 2-3 min at RT and centrifuged at 12,000rcf for 15 min at 4ºC in 
order to separate the mixture into the three phases: a lower red phase that 
contained phenol-chloroform, intermediate phase containing DNA and proteins 
and an upper aqueous transparent phase containing RNA. The latter colourless 
phase was transferred to a new tube and the RNA was precipitated by mixing 
with 0.5ml of isopropanol and incubated for 10 min at RT. The precipitated RNA 
was then sedimented by centrifugation at 12,000rcf for 10 min at 4ºC. The RNA 
pellet  was  washed  by  adding  1ml  of  75%  (v/v)  ethanol  (RT)  and  vortexing. 
Finally, the RNA pellet was retained by centrifugation at 7,500rcf for 5 min at 
4ºC, careful removal of the supernatant and air drying. The RNA obtained from 
frozen  tissue  was  then  resuspended  in  10-40µl  of  RNase-free  H2O.  The  RNA 
extracted from isolated mammary gland epithelium was resuspended in 10µl of 
RNase-free H2O. All RNA extracted from TEBs was then combined and all RNA 
obtained  from  the  ducts  was  combined.    Extracted  RNA  was  quantified  (See 
2.2.4.4) and quality assessed (See 2.2.4.5), snap frozen and stored at – 80°C 
until used for further applications.  
2.2.4.1.4  Extraction of RNA from cell lines 
 
RNA extraction from cell lines was performed using an RNeasy
® Mini Kit as per 
manufacturer‟s instructions. Briefly, once grown close to confluency the cells 
were  washed  twice  with  dPBS  (1x)  and  lysed  using  0.6ml  RLT  Buffer.  The 
obtained cell lysates were transferred in 1.5ml Eppendorf tubes, homogenised by 
pipetting,  mixed  with  1  volume  of  70%  of  ethanol  (aids  RNA  binding  to  the 
membrane) and transferred onto RNeasy spin column. Membrane bound RNA was 
washed and residual ethanol was removed. RNA was then eluted in 20-30µl of 
RNA-free H2O. Eluted RNA was quantified, subjected to DNase I digestion (See 
2.2.4.2), snap-frozen, and stored at – 80°C until used for further applications.        118 
 
2.2.4.2  DNase I treatment 
All  RNA  to  be  used  for  cDNA  production  (RT-PCR)  was  subjected  to  DNase  I 
treatment using a DNA-free
™ Kit as per manufacturer‟s instructions to eliminate 
DNA contamination. Briefly, 0.1 volume of 10xDNase I Buffer and 1µl of DNase I 
(2U/µl) were incubated with the RNA for 20 min at 37°C. 0.1 volume of DNase 
Inactivation Reagent was then incubated with the reaction mix for 2 min at RT. 
The purified RNA was then retained by centrifugation at 9,300rcf for 1.5 min, 
snap frozen and stored at – 80°C until used for further applications.  
2.2.4.3  RNA purification, concentration and on column DNase I digestion  
All RNA extracted for use in microarray experiments was purified, DNase I on 
column  digested  and  concentrated  using  an  RNeasy
®  Micro  Kit,  as  per 
manufacturer‟s  instructions.  The  RNeasy
®  Micro  Kit  is  used  to  purify  small 
amounts  of  RNA  and  remove  genomic  contaminants  as  well  as  RNAs  <  200 
nucleotides, including 5.8S rRNA, 5S RNA and tRNA. Briefly, RNA was bound to an 
RNeasy  silica-based  membrane  using  the  appropriate  binding  conditions  of  a 
high-salt  buffer  supplemented  with  ethanol.  Membrane  bound  RNA  was  then 
DNase I digested with RNase-Free DNase, washed on the column and eluted in 
13µl of RNA-free H2O. The eluted, purified and concentrated RNA was quantified 
(See 2.2.4.4) and its quality assessed (See 2.2.4.5) prior to snap freezing and 
storing at – 80°C until used for further applications.    
2.2.4.4  Quantification of the nucleic acid (RNA or DNA) 
Both concentration as well as purity of the extracted nucleic acid was estimated 
using  a  NanoDrop  ND-1000  Spectrophotometer.  Based  on  the  absorbance  at 
260/280 nm the concentration of 1l of extraction product was calculated using 
ND-1000 U3.3.0 software (NanoDrop Technologies, USA). RNase-free water was 
used as a blank control. The ratio of the readings at 260nm and 280nm was used 
to estimate the purity of nucleic acid.      119 
 
2.2.4.5  Quality assessment of RNA 
The quality and integrity of RNA was assessed using an Agilent 2100 bioanalyser 
and Agilent RNA 6000 Nano Kit, as per manufacturer‟s instructions. The Agilent 
RNA kit consists of RNA chips containing a set of interconnected micro channels 
that are used to electrophoretically separate RNA fragments according to their 
size. The assessment of total RNA quality is based on the calculation of 28S rRNA 
to 18S rRNA ratio and the estimation of integrity of the total RNA sample, i.e. 
RNA integrity number (RIN). RIN is estimated taking into consideration the entire 
electrophoretic trace of the RNA sample.  
2.2.4.6  cDNA Synthesis - Reverse transcription polymerase chain reaction 
(RT-PCR) 
The  process  of  RT-PCR  is  catalysed  by  reverse  transcriptase and  involves  the 
synthesis of single stranded cDNA from RNA template. Obtained cDNAs can then 
be used in further applications that require the direct comparison of samples as 
the amounts of cDNA produced are linear.   
Briefly,  1µg/µl  or  100ng/µl  of  isolated,  DNase  I  treated  RNA  of  interest  was 
transferred to 0.5ml microcentrifuge tubes, mixed with 1µl of either oligo dT 
primers (0.5µg/µl) (used to produce full length cDNA to be send for sequencing) 
or  random  primers  (used  to  produce  fragments  of  cDNA  to  be  used  for 
Quantitative  Real  Time  Polymerase  Chain  Reaction  (Q  RT  PCR))  and 
supplemented with dH2O to a final volume of 13µl. To denature the RNA, the 
reaction mix was incubated at 65ºC for 5 min and chilled on ice. Each sample 
was then supplemented with 7.6µl of the reaction master mix, containing the 
following (final concentrations are shown): 1xReaction Buffer, 1mM dNTPs mix 
(10mM),  1U/µl  of  RNase  OUT  (40U/µl),  0.03%  of  DMSO  and  0.5U/µl  of 
Transcriptor Reverse Transcriptase (20U/µl). The resulting mix was incubated at 
25ºC for 10 min, followed by 50ºC for 30 min, to allow primer annealing, and 
85ºC for 5 min to inactivate Transcriptor Reverse Transcriptase. In each reaction 
run,  a  negative  control  that  lacked  reverse  transcriptase  (-RT)  was  prepared 
along  with  the  samples  of  interest  to  measure  the  presence  of  any  DNA 
contamination.     120 
 
2.2.4.7  Standard PCR 
Primer Design 
Design of the primers was performed either using Primer3 software developed at 
the  Whitehead  Institute  for  Biomedical  Research  (http://frodo.wi.mit.edu/) 
(Rozen  S.,  Skaletsky  H.  J.,  2000)  or  manually  using  either  Ensemble  Genome 
Browser  (http://www.ensembl.org/index.html)  or  the  Gene  database  at  the 
National  Centre  for  Biotechnology  Information  (NCBI)  (National  Library  of 
Medicine, Bethesda, USA) available at: http://www.ncbi.nlm.nih.gov/ to view 
the  gene  sequence  and  BLAST  algorithm 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi)  to  ensure  that  the  designed  primers 
were  sequence  specific.  The  characteristics  of  the  designed  primers,  such  as 
melting temperature (Tm), likely presence of secondary structure or probability 
to form primer-dimer complexes were examined either by Primer 3 software or 
using  the  DNA  calculator  application  available  from  Sigma-Aldrich
® 
(http://www.sigma-genosys.com/calc/DNACalc.asp). A list of primers used for 
PCR is shown in Table 2-5.   
PCR conditions 
All the reactions were prepared in a final volume of 50µl in 0.5ml PCR tubes. 
Each reaction contained the following: 2µl of cDNA template, 1xGreen GoTag
® 
Flexi Buffer (5x), 1mM MgCl2 (25mM), 0.2mM dNTPs mix, 1µM of forward (10µM) 
and  1µM  of  reverse  primers  (10µM)  (Table  2-5),  0.025U/µl  GoTag
®  DNA 
Polymerase (5U/µl) and dH2O. For each PCR run, a control reaction that lacked 
template cDNA was prepared to ensure that no contamination was present. The 
cycling  was  performed  using  a  Biometra  T  3000  Thermocycler  under  the 
following conditions: initial denaturation at 95ºC for 2 min followed by multiple 
cycles of 95ºC for 15 sec (denaturation), 60ºC for 30 sec (annealing), 72ºC for 
1min/1kb of amplicon (extension) and a final step of extension at 72ºC for 10 
min. The number of cycles employed in each PCR varied from 28 to 30 depending 
on the abundance of transcript.      121 
 
2.2.4.8  DNA Agarose Gel Electrophoresis 
PCR products were separated by size using agarose gel electrophoresis with 1% 
or  1.5%  agarose  gels  and  0.5xTAE  running  buffer  (Tris-acetate-EDTA,  pH8.5). 
Agarose gels were prepared by diluting electrophoresis grade agarose  in 0.5X 
TAE buffer and adding 1-2µl of intercalating dye ethidium bromide (10mg/ml) to 
the gel to facilitate visualisation of amplicons. 10-20µl of each PCR product was 
then mixed with 0.4 volumes of 5xGreen GoTag
® Flexi Buffer and loaded into 
each well of the gel and electrophoresis was carried out at 90-110V. Gels were 
examined  using  Fujifilm  Fla-5000  and  FLA5000  Image  Reader  software  v.  2.0 
(Fujifilm  UK  Ltd.,  Sheffield,  UK).  Images  were  manipulated  using  Advanced 
Image Data Analyser v. 4.13 (Aida) (Fujifilm UK Ltd., UK) or Adobe Photoshop 
CS2 (Adobe Photoshop Systems Inc., Mountain View, US). Either a 100bp or 1kb 
DNA ladder was used as a size marker. 
2.2.4.9  Q RT PCR 
Real time PCR is a quantitative method used to determine transcript expression 
levels using cDNA synthesised from the sample of interest as template for gene 
amplification via PCR. For the purposes of this project a hydrolysis probe-based 
system  was  chosen  for  the  detection  and  quantification  of  amplicons.  Each 
hydrolysis probe is sequence specific, with labelled probes, designed to anneal 
to template cDNA flanked by the two primer sites. Hydrolysis probes contain a 
fluorescent reporter dye at their 5‟ end and a quencher label at their 3‟ end. 
The 3‟ end of each probe is phosphorylated, hence it can not be extended during 
the PCR. When the probe is not annealed, fluorescence is suppressed by the 
close  proximity  of  the  quencher  and  is  undetectable.  During  the  annealing 
process of the PCR the probe hybridises to the template before the primers due 
to its lower Tm. FastStart Taq DNA Polymerase cleaves the probe due to its 5‟-3‟ 
exonuclease  activity,  while  extending  the  primer,  hence  releasing  the  dye, 
whose  fluorescent  emission  can  then  be  measured.  The  fluorescent  signal 










Upk3a  mouse  tctgtgcatgtttgatagctca  gaagcttgctggagaacacc  710  63,63 
Fbln2 V1  mouse  cctgcaaagacaatggaccc  tcgtccacgtctgtgcattc  394  66,67 
Fbln2 V2  mouse  cctgcaaagacaatggaccc  tcgtccacgtctgtgcattc  256  66,67 
Table 2-5 Primers used in Standard PCR. 
Tm stands for melting temperature. 
Transcript 
name 





Fbln2 V1  M.m.  tgttgttggggacacagcta  ccatcaaacactcgtcttggt  ctgcttcc  2202-2296 
Fbln2   M.m.  tctgtccccagaggtgatct  ctgcacaacaggtctcgattag  ctccacca  1402-1462 
Fbln2 V1  H.s.  caggtggcctctaacaccat  ttgcagggtccattgtcttt  tgccactg  2124-2193 
Fbln2  H.s.  Agctgcaccacggagagt  cctctgtgcccagtgaca  tggtgatg  4732-4803 
Ect2  M.m.  cgacatgtagccaacaccat  tttgtatttacttcaaaggattct  tgtggctg  2371-2456 
Upk3a  M.m.  Ttcctgctcgtgggtttc  catttccccatcagaactgc  tcctcagc  740-811 
Upk3a  H.s.  ccctgcccttctttctacttg  atcagaactccccatgtcca  cctcagcc  656-729 
Fbn2  M.m.  gcctgtcctgtcagaggttc  cacccatcggaagaccat  ctgtgcct  1331-1394 
Emb  M.m.  tgggtaatgaaaccgcaca  gtggcacgacaccagtagg  ggagga  804-945 
Dlg7  M.m.  gttgcgacattgttgtggat  aaaccgactggcaaaacg  ggatgctg  264-330 
Itih2  M.m.  aagagcaaagggcaagacg  tcacctctgtgttgaagttctcc  aggagcag  553-626 
ß actin  M.m.  aaggccaaccgtgaaaagat  gtggtacgaccagaggcatac  tgctgtcc  416-525 
ß actin  H.s.  Attggcaatgagcggttc  tgaaggtagtttcgtggatgc  cttccagc  832-922 
Krt18  M.m.  agatgacaccaacatcacaag  cttccagaccttggacttcct  agctggag  600-709 
Krt18  H.s.  tgatgacaccaatatcacacga  ggcttgtaggccttttacttcc  agctggag  682-793 
Ltf  M.m  Gggcaagtgcggtttagtt  ccattgcttttggaggattt  tggcagag  1294-1353 
Sema3B  M.m.  Ttcttcttccgcgagtcc  gccacccaggtcattcct  ggaagcag  939-1034 
Sprr1A  M.m  cctgaagacctgatcaccaga  aggcaatgggactcataagc  ggctgctg  504-566 
Table 2-6 Probes and primers used in Q RT PCR. 
For species, M.m. stands for Mus musculus while H.s. stands for Homo sapiens. Amplicon position 
refers  to  the  position  of  amplicon  on  mRNA  with  regards  to  the  5’  end  of  the  genes  which 
corresponds to transcription start site on DNA. 
Name of the 
primer 




Fbln2 V1 684  gtaacttctcggatgctgagg  684  64 
Fbln2 V1 1607  caaggagggtgagacctgtg  1607  65 
Fbln2 V1 2060  atagaggtgccccacaagttg  2060  64 
Fbln2 V1 3192  gcatacctgcacagacatcg  3192  64 
Fbln2 V1 3488  tcacggaatgtcaaacctca  3488  64 
T7 promoter   taatacgactcactataggg    51 
Upk3a  gaagcttgctggagaacacc  714  63 
Table 2-7 Primers used in sequencing. 
For Fbln2 and Upk3a based primers the start of primer annealing site refers to the position on 
cDNA.  Primer  annealing  site  on  T7  promoter  refers  to  the  position  on  the  plasmid  (pRc/CMV-
Fbln2). Tm stands for melting temperature.     123 
 
Probe and primers design for Q RT PCR 
The selection of hydrolysis probes and the design of the primers were performed 
using  ProbeFinder  software  (Roche  Applied  Science,  Germany)  (www.roche-
applied-science.com).  ProbeFinder  software  uses  transcript  information 
deposited in NCBI Reference Sequence Database to find the optimal set of probe 
and  primers  for  each  transcript  of  interest.  Primers  were  selected  to  be  on 
either side of exon-exon splice junctions to eliminate false positive signals from 
DNA contamination. A list of the primers and probes used is shown in Table 2-6. 
All primer sequences were designed to have a melting temperature (Tm) of 60°C 
and  flank  probe  hybridisation  sites.  All  primers  were  purchased  from  Sigma 
Aldrich Company Ltd., Dorset, UK.     
Q RT PCR Conditions 
Q RT PCR for each sample was performed as follows: 1µl of template cDNA was 
added in triplicate to the wells of LightCycler
® 480 96 Well Plates. A negative 
control  that  lacked  reverse  transcriptase  (-RT)  during  cDNA  preparation  was 
included on each plate to measure the presence of any residual, contaminating 
DNA  and  estimate  the  level  of  background  noise.  Each  well  was  then 
supplemented with the following reaction mix: 0.1µM of probe (2µM), 0.36µM of 
the forward (7.2µM) and 0.36µM of the reverse (7.2µM) primers (See Table 2-6), 
1xLightCycler
® 480 Probes Master (2x) and H2O to a final reaction volume of 20µl. 
The  stock  2xLightCycler
®  480  Probes  Master  contained  dNTPs  (10mM),  6.4mM 
MgCl2 and FastStart Taq DNA Polymerase which is a thermostable polymerase 
only activated at high temperatures.  
The Prepared 96-well plate was then sealed using LightCycler
® 480 Sealing Foil 
and centrifuged at RT at 850rcf for  2 min.  The PCR was carried out using a 
LightCycler
® 480 Instrument as follows: 1 cycle at 95°C for 10 min to activate the 
FastStart Taq DNA Polymerase, 40-50 cycles at 95°C for 15 sec followed by 60°C 
for 30 sec to perform primer and probe annealing and cDNA amplification and 1 
cycle at 40°C for 30 sec to cool down.      124 
 
The cDNA of each sample was amplified using probes and primers designed to 
amplify the gene of interest and house keeping genes:  ß-actin or Krt18. The raw 
data for each sample was then analysed using LightCycler
® 480 software v.1.5 
(Roche Applied Science, Germany), measuring the level of detected fluorescence 
over each PCR cycle and plotting an amplification curve for each sample. Every 
reaction  profile  consisted  of  three  phases:  lag  phase  (background  phase), 
exponential log phase and plateau phase (Figure 2-3 A). The fluorescence values 
of the log phase only were retained for analysis.  
Relative Gene Expression Analysis 
The fluorescence signal was analysed as follows: PCR cycles from the beginning 
up  to  5  cycles  before  the  beginning  of  the  log  phase,  showing  irregular 
fluorescence were excluded (Figure 2-3 A); the noise band was set to eliminate 
background noise  (Figure  2-3 B);  6  fit  points  were  selected  to  calculate  the 
fitted log-line of the exponential portion of each amplification curve and the 
threshold line was manually fitted in the middle of the calculated log-line and 
the crossing point (Cp) values (cycle number at which given sample crosses given 
fluorescence threshold) were calculated for each sample along with the standard 
deviation (SD) (Figure 2-3 C). 
Cp  values  obtained  for  individual  samples  amplified,  using  both  primers  of 
interest  and  house  keeping  primers,  were  used  to  calculate  the  relative 
concentration of transcripts. Calculations were performed with Microsoft Excel
® 
using  the  2
-ΔΔCp  method  as  follows:  the  difference  in  Cp  (ΔCp)  between  the 
transcript of interest and a house keeping gene was calculated for each sample. 
The difference in ΔCp (ΔΔCp) between compared samples was then calculated 
and  the  relative  gene  expression  (expression  fold  change)  was  calculated 
between the compared samples by setting ΔΔCp of the reference sample to 0 
and following 2
-ΔΔCp equation. 
2.2.4.10  DNA Sequencing 
Sequencing of linear DNA or plasmid DNA was performed via the GATC Biotech 
sequencing service (http://www.gatc-biotech.com/en/home.html) using      125 
 
  
Figure 2-3 Histograms showing comparison analysis of amplification curves of Q RT PCR 
product amplified from two distinct samples. 
Y axis shows level of detected fluorescence. X axis shows number of PCR cycles (A) Amplification 
curves showing lag, log and plateau phases. Setting of the cut off band for exclusion of signal 
generated during initial PCR cycles (B) Setting of the background noise band cut off (C) Selection 
of fit points and calculation of Cp values. Cp value for each sample corresponds to number of PCR 
cycles calculated at the crossing point of amplification curve with purple horizontal line. Figures 
were exported from LightCycler® 480 software v.1.5. 
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30ng/µl  subjected  DNA  and  10pmol/µl  of  forward  primer.  Obtained 
chromatograms  were  visualised  using  Chromas  Lite  v.2.01  software 
(Technelysium  Pty  Ltd.,  Tewantin,  Australia).  A  list  of  primers  used  in 
sequencing is shown in Table 2-7. 
2.2.4.11  Restriction Digestion   
Restriction digestion was performed using Sma I enzyme to identify the correct 
clones of pRc/CMV-Fbln2 DNA (See 2.2.2.3). 1µg/µl of plasmid DNA, 1xJ Buffer 
(10mM  Tris-HCl,  7mM  MgCl2,  50mM  KCl,  1mM  DTT,  pH7.5),  0.1µg/µl  of 
acetylated BSA (10µg/µl) and 0.25U/µl of Sma I enzyme (10U/µl) were mixed 
with dH2O to a final volume of 20µl. The reaction mix was then incubated at 
25°C for 4h. The differently sized restriction digestion products were resolved 
and visualised via electrophoresis, using 1% agarose gel (See 2.2.4.8).  
2.2.5 Microarray analysis of pubertal gene expression 
Gene expression profiling was performed on the isolated pubertal epithelium of 
TEBs and ducts, pubertal mammary gland tissue strips (Pre-LN, Post-LN and Fat 
pad)  and  whole  adult  mouse  mammary  glands  (negative  control  for  pubertal 
gene  expression)  collected  from  female  mice.  Biological  material  was  then 
processed to extract good quality RNA. RNA was converted to single strand (ss) 
cDNA  which  was  then  hybridised  to  microarray  chips.  Obtained  data  was 
normalised, assessed in terms of its quality and analysed.      
2.2.5.1  Collection of the experimental material 
All experimental material was obtained from both left and right 4th mammary 
glands  collected  from  pubertal  or  adult  virgin  WT  or  TG  female  mice.  The 
excision  of  mammary  glands  from  WT  and  TG  mice  was  performed  at  the 
Biological Services Central Facilities at Gilmorehill Campus, Glasgow and at the 
Beatson  Institute  for  Cancer  Research  in  Glasgow  respectively,  following  the 
methodology described before (See 2.2.1.2). 
WT  females  were  used  for  isolation  and  collection  of  the  mammary  gland 
epithelial  structures,  i.e.  TEBs  and  ducts  (See  2.2.1.5)  and  whole  mammary     127 
 
glands (See 2.2.1.2). Epithelium was collected into 100µl of TRIzol
® reagent and 
stored at –80C until subjected to RNA extraction. Whole mammary glands were 
subjected to central LN removal upon dissection, snap freezing in liquid nitrogen 
and storing at -80°C  until RNA extraction. TG mice were used to collect the 
tissue  strips  (See  2.2.1.4)  which  were  snap  frozen  in  liquid  nitrogen  upon 
collection and stored at -80°C until RNA extraction. 
2.2.5.2  Extraction, purification, concentration, quantification and quality 
assessment of RNA 
RNA was extracted from isolated epithelium stored in TRIzol
® reagent, mammary 
gland  tissue  strips  and  whole  mammary  glands  stored  at  -80°C,  as  described 
previously (See 2.2.4.1.1-2.2.4.1.3). Extracted RNA was quantified using the 
NanoDrop ND-1000 Spectrophotometer (See 2.2.4.4), purified, subjected to on-
column DNase I treatment, combined and concentrated using an RNeasy
® Mikro 
Kit (See 2.2.4.3). The RNA was then re-quantified as described above and its 
quality assessed using the Agilent 2100 bioanalyser (See 2.2.4.5).     
2.2.5.3  Microarray data generation workflow 
Samples of extracted and purified RNA were used as a matrix to generate single 
strand, sense, biotin labelled cDNAs that were hybridised to GeneChip
® Mouse 
Exon 1.0 ST Arrays, following GeneChip
® Whole Transcript (WTr) Sense 1µg Total 
RNA  Target  Labelling  Assay  Manual  (Affymetrix  UK  Ltd.,  High  Wycombe,  UK) 
(Figure  2-4)  and  using  appropriate  Affymetrix  kits.  All  of  the  experimental 
procedures  described  in  sections  2.2.5.3.1-2.2.5.3.8  were  performed  at  the 
Henry Wellcome Functional Genomics Facility by Mrs. Wang.     
Briefly, 1.5µg of each total RNA resuspended in a maximum volume of 3.2µl of 
RNase-free  H2O  was  mixed  with  2µl  of  supplied,  freshly  diluted  Poly-A  RNA 
controls (4 different transcripts) mix.  
2.2.5.3.1  Reduction of ribosomal RNA (rRNA) 
 
Total RNA/Poly-A RNA controls mix was then subjected to reduction of 28S and 




® WTr Sense 1µg Total RNA Target Labelling Assay Manual – Schematic 
representation of the experimental steps.       129 
 
Transcriptome Isolation Kit which facilitates hybridisation of four biotinylated 
LNA RiboMinus probes (100pmol/µL) to abundant 18S and 28S rRNA species in the 
total  RNA  of  interest,  in  the  presence  of  betaine  to  increase  hybridisation 
stringency. Probe bound rRNAs were then removed from the hybridisation mix 
using streptavidin coated RiboMinus Magnetic Beads and supernatant containing 
rRNA-Reduced  Total  RNA/Poly-A  RNA  Controls  Mix  was  concentrated  using 
GeneChip
® IVT cRNA Cleanup Kit. The quality of recovered RNA was analysed 
with the Agilent 2100 bioanalyser (See 2.2.4.5). 
2.2.5.3.2  Synthesis of double stranded cDNA (ds cDNA) 
 
rRNA-reduced total RNA/Poly-A RNA Controls Mix was then used as a template 
for the synthesis of the ds cDNA using GeneChip
® WTr cDNA Synthesis Kit. First-
strand  cDNA  synthesis  was  performed  using  random  primers  tagged  with 
T7promoter  sequence  (500ng/µl),  SuperScript  II  reverse  transcriptase,  dNTPs 
(10mM), DTT (0.1M) and 5x1
st Strand Buffer. Second-strand cDNA synthesis was 
carried  out  using  MgCl2  (17.5mM),  dNTPs  (10mM)  and  DNA  Polymerase  I  to 
facilitate the synthesis and RNase H to degrade the mRNA hybridised to the first-
strand DNA.  
2.2.5.3.3  Synthesis of cRNA 
 
Obtained  ds  cDNA  was  subsequently  used  as  a  template  for  antisense  cRNA 
production.  cRNA  synthesis  was  facilitated  by  T7  RNA  Polymerase  using  a 
GeneChip
® WTr cDNA Amplification Kit. cRNA was then purified by means of a 
GeneChip
®  Sample  Cleanup  Module  and  quantified  using  a  NanoDrop  ND-1000 
Spectrophotometer (See 2.2.4.4). 
2.2.5.3.4  Synthesis of ss cDNA 
 
Purified  cRNA  was  reverse  transcribed  by  means  of  a  GeneChip
®  WTr  cDNA 
Synthesis Kit using random primers (3µg/µl), SuperScript II reverse transcriptase, 
DTT  (0.1M),  dNTP+dUTP  (10mM)  and  5x1
st  Strand  Buffer.  ss  cDNA  containing 
incorporated  dUTP  was  then  hydrolyzed  from  cRNA-cDNA  hetero-duplexes  by     130 
 
means of RNase H, purified using the GeneChip
® WTr cDNA Synthesis Kit and the 
GeneChip
®  Sample  Cleanup  Module  as  per  manufacturer‟s  instructions  and 
quantified using a NanoDrop ND-1000 Spectrophotometer (See 2.2.4.4). 
2.2.5.3.5  Fragmentation and terminal labelling of ss cDNA 
 
The  ss  cDNA  was  then  subjected  to  fragmentation  and  labelling  using  a 
GeneChip
®  WT  Terminal  Labelling  Kit.  Fragmentation  was  facilitated  by  the 
combination of uracil DNA glycosidase (UDG) (10U/µl) and apurinic/apyrimidinic 
endonuclease 1 (APE 1) (1000U/µl) which recognise exogenous dUTP residues. 
The  efficiency  of  fragmentation,  i.e.  the  size  range  of  obtained  ss  cDNA 
fragments, was profiled using an Agilent 2100 bioanalyser (See 2.2.4.5). 
The labelling of DNA was performed by terminal deoxynucleotidyl transferase 
using an Affymetrix
® DNA labelling reagent covalently linked to biotin.   
2.2.5.3.6  Hybridisation of ss cDNA to microarray chips  
 
Fragmented and biotin labelled ss cDNA was hybridised to GeneChip
® Mouse Exon 
1.0  ST  chips  using  a  GeneChip
®  Hybridisation,  Wash  and  Stain  Kit.  Internal 
hybridisation quality controls such as bioB, bioC, bioD, cre and oligonucleotide 
B2 were hybridised to the chips alongside the target cDNA in the presence of 7% 
DMSO  and  2xHybridisation  Mix.  Biotinylated  oligonucleotide  B2  hybridises  to 
features around the edge, inside and in the corners of the chip and the signal 
that it emits is used to align the grid of the array (See 2.2.5.3.8). BioB, bioC, 
bioD  and  cre  are  probe  sets  for  prokaryotic  genes.  Pre-prepared  at  varied 
concentrations,  ss  cDNAs  of  BioB,  bioC,  bioD  and  cre  serve  as  internal 
hybridisation controls (See 2.2.5.8). Array hybridisation was performed by 16h 
long incubation in 45°C in a hybridisation oven with agitation at 60rpm. 
2.2.5.3.7  Washing, staining and scanning of the arrays 
 
Hybridised  arrays  were  washed,  stained  and  scanned  using  a  GeneChip
® 
Hybridisation, Wash and Stain Kit. Staining of the arrays was performed by using     131 
 
Streptavidin Phycoerythrin (SAPE) that binds to biotin on hybridised cDNA. SAPE 
signal was amplified by using anti-streptavidin biotinylated antibody and anti-
biotin SAPE conjugated antibody. The amplified signal intensity emitted by SAPE 
was detected and measured during scanning of the arrays. All above procedures 
were  performed  with  a  GeneChip
®  Fluidics  Station  450/250  and  GeneChip
® 
Scanner 3000 7G, operated by GeneChip
® Operating Software (GCOS) (Affymetrix 
UK Ltd., UK). All samples were washed, stained and scanned together to reduce 
technical variability.     
2.2.5.3.8  Signal detection and calculation of the cell intensity data 
(.CEL file)  
 
Signal  intensity  emitted  by  SAPE  bound  to  each  probe  was  detected  by  the 
scanner and imaged using GCOS which displays a picture of each scanned array 
(.DAT file) and superimposes the grid on the image. The main grid and sub-grids 
are generated using an Alignment Algorithm which uses check board images of 
oligonucleotide B2 positive hybridisation controls located at the corners of the 
array to superimpose the grid on the scanned image and align it so that each 
square in the grid delineates a probe cell.   
A Cell Intensity Algorithm was then used to compute a single intensity value for 
each probe cell using fluorescence intensity values from each pixel on the array 
to calculate the cell intensity data (.CEL file).   
2.2.5.4  Background correction, normalisation and probe set summarisation 
The  .CEL  file  was  further  analysed  using  a  Robust  Multichip  Analysis  (RMA) 
algorithm,  a  multi-chip  approach  that  consists  of  three  steps:  background 
correction, normalisation and data summarisation.  
The RMA algorithm was computated using either Expression Console™ software 
v.1.0 (Affymetrix UK Ltd., UK), Partek
® Genomics™ Suite (Partek Incorporated, 
St Louis, US) or XRAY Excel
® Array Analysis v.2.5 (Biotique Systems Inc. Reno, 
USA).  All  analyses  were  performed  at  the  core  level,  i.e.  only  taking  into     132 
 
consideration probe sets mapped to BLAST alignments of mRNA with annotated 
full length gene coding sequences.  
Background correction of intensities of perfect match (PM) probes was used to 
remove systematic effects that could not be explained by biological variation 
within each individual chip. It uses only information contained on the given chip 
and it is based on the model O = S+N, where O stands for overall intensity; S 
stands for signal and is assumed to be exponentially distributed (α); N means 
background noise which is assumed to be normally distributed (µ σ
2) [267] 
Normalisation  was  used  to  remove  the non-biological  variation throughout  all 
microarray chips used for the experiment. In this experiment non parametric 
quantile normalisation was used, which is based on the assumption that there is 
a  common  pattern  of  distribution  of  intensities  across  the  microarray  chips 
[268]. For each input array, for each probe expression value the „i
th‟ percentile 
probe expression value is replaced by the average of all „i
th‟ percentile points 
across  all  of  the  arrays.  When  all  the  probe  scores  are  sorted,  a  master 
distribution  of  intensity  is  created  and  the  distribution  of  intensity  for  each 
probe is mathematically fitted to the master distribution of intensity.   
Summarisation of the probe intensity levels across each microarray chip obtained 
summarised expression values (.CHP files) for each transcript ID or exon cluster 
ID. This was performed using Median Polish which takes into consideration probe 
and  chip  effects,  predicting  transcript  ID  or  exon  cluster  ID  expression  and 
combining the information across the chips. Median Polish is an algorithm that 
takes log2 of the probes‟ signal intensity and fits a robust linear model. 
In summary, the process of computing the expression data using RMA provides 
final signal intensity data which can be interpreted as                                           
           E = S(N(B(X)))  
Where E is the final intensity data of either the transcript ID or exon cluster ID, S 
is  Median  Polish  summarization,  N  is  quantile  normalisation,  B  is  the  RMA 
background correction process and X is the raw intensity of probes across the 
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2.2.5.5  Gene expression analysis at the gene level - The identification of ‘up- 
regulated gene sets’ 
This  section and  the following  section  2.2.5.6  should  be  read in  conjunction 
with Figure 3-1 (p.151). 
Gene expression analysis at the gene level was performed using transcript IDs. 
The „up-regulated gene sets‟ - list of genes are up-regulated above the set level 
in  one environment when  compared  to the  other environment.  „Up-regulated 
gene sets‟ were identified for the epithelial transcriptomes of TEBs and ducts 
(See  2.2.5.5.1),  epithelial-stromal  transcriptomes  of  TEBs  and  ducts  (See 
2.2.5.5.2) and the epithelium-free Fat pad (See 2.2.5.5.3). 
2.2.5.5.1  TEB and duct epithelium ‘up-regulated gene sets’ 
 
Transcripts whose expression was higher in the epithelium of TEBs than in ducts 
or  higher  in  ducts  than  in  TEBs  were  identified  using  signal  intensity  data 
obtained from isolated epithelium of TEBs and ducts. Differentially expressed 
transcripts were identified using a 5% Limit Fold Change (5% LFC) Model [269] 
and  the  transcript  ID  expression  data  obtained  using  the  RMA  algorithm 
(Expression Console™ software v.1.0). 
The 5% LFC Model was calculated as follows: First, signal intensity data for all 
transcripts obtained from duplicate TEB samples (T1 and T2) and duplicate duct 
samples (D1 and D2) were evaluated to exclude transcripts characterised by too 
low  an  expression  intensity  (background  expression),  i.e.  average  difference 
intensity (ADI). As recommended, to reduce background noise the ADI threshold 
was set to 20 and transcript IDs with ADIs equal to or lower than 20 were set to 
20 across all experiments (T1, T2, D1, D2) and therefore eliminated [269]. ADIs 
of  each  transcript  were  then  compared  between  the  replicates  of  individual 
samples  (T1  vs  T2  and  T2  vs  T1)  and  (D1  vs  D2  and  D2  vs  D1)  to  exclude 
transcripts of expression level variation between replicates greater or equal to 
2. ADIs of the remaining transcripts were then used to calculate the mean ADI 
for  TEBs  and  mean  ADI  for  ducts.  The  mean  ADI  for  each  transcript  over-
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and T2 or D1 and D2 respectively. Non-annotated internal Affymetrix controls, as 
enlisted by Affymetrix UK Ltd were subtracted from the 2 transcript IDs lists. 
The  mean  ADI  values  for  the  TEB  and  duct  associated  transcripts  were  then 
utilised to calculate the highest fold change (HFC), i.e. a maximum change in 
gene expression between the compared samples. The HFC for the TEB associated 
transcripts was obtained by calculating the ratio of the mean ADI in TEBs to 
mean  ADI  in  ducts  for  each  transcript.  The  HFC  for  each  ducts-associated 
transcript was obtained by calculating the ratio of the mean duct ADI to mean 
TEB ADI for the given transcript. The remaining transcripts in each data set (TEB 
or duct) were then sorted according to their mean ADI, divided into 200 gene 
rich bins and sorted within each bin, descending according to HFC. The top 5% of 
transcripts  within  each  bin  were  considered  as  significantly  over-expressed. 
Finally gene rank was assigned to each transcript. Gene rank was calculated by 
multiplying  HFC  by  ADI  therefore  incorporating  both  the  magnitude  of  fold 
change (FC) and expression value. 
All of the above calculations were performed using Microsoft Excel. Transcript 
IDs  were  annotated  using  the  NetAffx  Analysis  Centre  tool  developed  by 
Affymetrix.  
2.2.5.5.2  TEB and duct epithelial-stromal ‘up-regulated gene sets’ 
 
To compare transcripts of epithelial genes within a stromal environment rather 
than in isolation, mammary gland tissue strips were analysed using transcript ID 
signal  intensity  data.  Expression  levels  of  each  transcript  were  compared 
between  Pre-LN  and  Post-LN  of  mammary  gland  tissue  strips  and  transcripts 
whose  expression  was  differentially  expressed  between  TEBs  and  duct 
environments  were  identified.  The  RMA  algorithm,  statistical  analysis  and 
identification of significantly differentially expressed transcripts were performed 
using  Partek
®  Genomics™  Suite.  Bioinformatic  analysis  of  the  data  sets  was 
performed  at  the  core  level,  using  2-Way  Alternative  Splice  Paired  ANOVA. 
Transcripts of at least 1.5 fold change in expression and with p-value<0.05 were 
considered as significantly differentially expressed.    
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2.2.5.5.3  Epithelium-free Fat pad ‘up-regulated gene set’ 
 
To identify genes differentially expressed in the epithelium-free Fat pad of the 
pubertal mouse mammary gland the expression levels (signal intensity data) of 
each transcript ID were compared between the Fat pad and Post-LN tissue strips 
data  sets.  Gene  expression  analysis  was  performed  using  Partek
®  Genomics™ 
Suite as described above (2.2.5.5.4). Transcripts of at least 1.5 fold change in 
expression and with p-value<0.05 were considered as significantly differentially 
expressed.     
2.2.5.6  Gene expression analysis on the gene level – The identification of 
‘expressed gene sets’  
The  „expressed  gene sets‟  are  defined  as  lists  of  genes  expressed  ≥  1.1  fold 
change cut off in one environment when compared to the other environment 
2.2.5.6.1  TEB- and duct-only epithelium ‘expressed gene sets’ 
 
Genes expressed in the epithelium of TEB and ducts were identified using signal 
intensity data obtained from the microarrays performed on the epithelium of 
isolated TEBs and ducts. Signal intensity data was obtained using RMA performed 
by Expression Console™ software v 1.0. All transcript IDs corresponding to non-
annotated  internal  Affymetrix  controls  were  excluded  from  the  data  sets  as 
described above. ADIs lower than 20 were set to 20. The signal intensity levels of 
each transcript ID were compared in multiple ways between replicates in the 
TEB  and  duct  data  sets  (T1  vs  D1)  (T1  vs  D2)  (T2  vs  D1)  and  (T2  vs  D2)  to 
calculate the minimum change in gene expression between the compared data 
sets, i.e. MFC. All transcript IDs with a FC equal to 1 across all four comparisons 
were excluded from the analysis. The remaining transcript IDs were divided into 
genes expressed only in either TEBs or ducts. All transcripts with a MFC increase 
of 1.1 in the TEBs compared to ducts were considered to be only expressed in 
TEBs, while the ones with a MFC decrease in expression of 1.1 were considered 
as only expressed in the ducts.      136 
 
All of the above calculations were performed using Microsoft Excel. Transcripts 
IDs  were  annotated  using  the  NetAffx  Analysis  Centre  tool  developed  by 
Affymetrix.  
2.2.5.6.2  TEB- and duct-only stroma ‘expressed gene sets’ 
 
Transcripts  expressed  in  the  stroma  surrounding  TEBs  and  the  stroma  around 
ducts were identified using signal intensity data obtained from the mammary 
gland tissue strips and isolated epithelium. For the purpose of this analysis RMA 
was performed using Expression Console™ software v 1.0 and the obtained signal 
intensity data sets were used to identify TEB-only stroma- or duct-only stroma-
associated transcripts.  
Transcript ID expression levels obtained from the Post-LN, isolated epithelium of 
TEBs  and ducts  data sets  were compared and  used  to  identify stromal  genes 
around TEBs and ducts in the Post-LN strip. Stroma expressed transcripts were 
identified by subtracting all transcript IDs whose expression was associated with 
epithelium of TEBs or ducts from the list of Post-LN transcript IDs, as follows. 
Transcript IDs corresponding to non-annotated internal Affymetrix controls were 
excluded from the data sets, as described above. ADIs lower than 20 were set to 
20 and any transcripts with an ADI value of 20 across all replicate data sets 
within each experimental condition (Post-LN 1, Post-LN 2, Post-LN 3) (T1, T2) 
(D1, D2) were eliminated to reduce background noise. Expression levels of each 
transcript ID were compared in multiple ways between replicates for Post-LN 
and TEB data sets (Post-LN 1 vs T1, Post-LN 2 vs T1, Post-LN 3 vs T1, Post-LN 1 vs 
T2, Post-LN 2 vs T2, Post-LN 3 vs T2) and Post-LN and duct data sets (Post-LN 1 
vs D1, Post-LN 2 vs D1, Post-LN 3 vs D1, Post-LN 1 vs D2, Post-LN 2 vs D2, Post-LN 
3 vs D2) to calculate the minimum change in gene expression between compared 
data sets, i.e. MFC. Expression ratios of each transcript ID between Post-LN and 
TEB  data  sets  and  Post-LN  and  duct  data  sets  were  examined  and  used  to 
exclude the transcript IDs expressed in epithelium from the Post-LN data set. All 
transcripts  with  a  minimum  of  1.1  FC  increase  in  the  Post-LN  data  set  in 
comparison to their expression in TEBs or ducts were considered as stromal. The 
epithelial expression marker, cytokeratin 14 (CK14) expression level was used to 
identify the FC cut off between epithelial and stromal genes. CK14 expression     137 
 
was 2.6 and 2.7 times lower in the Post-LN data set than in TEB and duct data 
sets respectively and thus a FC cut off of 1.1 ought to minimise the number of 
the epithelial genes falsely identified as stromal. 
Transcript  ID  expression  levels  obtained  from  the  Pre-LN,  isolated  duct 
epithelium and TEB epithelium data sets were compared and used to identify the 
stromal genes expressed around ducts and occasional TEBs in the Pre-LN strips. 
Stroma expressed transcript IDs were identified by subtracting all transcript IDs 
whose expression was shown to be associated with the epithelium of ducts or 
TEBs from the list of Pre-LN transcript IDs, as described above.  
Finally the lists of transcript IDs expressed in the Post-LN strip stroma and Pre-
LN  strip  stroma  were  compared  using  GeneVenn  List  Diagram  (University  of 
Southern Mississippi, http://mcbc.usm.edu/genevenn/genevenn.htm) to exclude 
the common transcript IDs and identify those associated with only the stroma 
around either TEBs in Post-LN tissue strips or ducts in Pre-LN tissue strips.  
All of the above calculations were performed using Microsoft Excel. Transcript 
IDs  were  annotated  using  the  NetAffx  Analysis  Centre  tool  developed  by 
Affymetrix.  
 
2.2.5.7  Expression Analysis at the exon level 
Gene expression analysis at the exon level was performed for isolated TEBs and 
ducts using exon cluster ID signal intensity data. Gene expression analysis at the 
exon  level  was  performed  to  analyse  alternative  splicing  and  differential 
expression of each exon within a gene throughout the data sets. 
After  converting  probe  cell  signal  intensity  data  into  exon  cluster  ID  signal 
intensity data using the RMA algorithm, expression analysis was performed by 
comparing  Pre-LN,  Post-LN  and  mammary  fat  pad  tissue  strip  data  sets  with 
isolated TEB and isolated duct data sets, to identify transcript IDs which had 
alternative  splice  variants  differentially  expressed  in  TEB  and  duct 
environments.  The  RMA  algorithm,  statistical  analysis  and  identification  of 
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splice variants were performed using XRAY Excel
® Array Analysis v.2.5 Microsoft
® 
Excel
® add-in. Bioinformatic analysis of the data sets was performed at the core 
level, using a Nested Mix Model ANOVA and the Benjamini and Hochberg False 
Discovery  Rate  (FDR)  Multiple  Test  Correction.  Probe  sets  not  significantly 
expressed above background, i.e. of a p-value≥0.05 derived using the Fisher Test 
were  excluded  from  the  analysis.  Whole  transcripts  and  splice  variants  of  at 
least  2  fold  change  in  expression  and  p-value<0.05  were  considered  to  be 
significantly differentially expressed.    
2.2.5.8  Microarray data quality assessment 
Quality  and  reliability  of  the  data  generated  during  microarray  analysis  was 
assessed using six different quality assessment metrics: 
  Visual assessment of microarray chips. 
  Quality  of  hybridisation  was  estimated  by  investigating  the  probe  set 
signal  intensity  values  for  prokaryotic  internal  hybridisation  controls 
(bioB, bioC, bioD, cre) throughout the arrays. The signal intensities were 
graphed using Expression Console™ software v 1.0.  
  The degree of similarity between the replicates of each biological sample 
and the variation between different biological samples was investigated 
and graphed using PCA (Principal Component Analysis). PCA is a method 
designed  to  capture  the  variation  in  the  datasets  by  reducing  the 
dimensionality of the data to capture the most important features. PCA 
analysis was performed using Partek
® Genomics™ Suite.  
  Reliability  of  the  generated  gene  lists  was  verified by  screening  these 
lists  for  the  presence  of  previously  published  genes  known  to  be 
associated with epithelium of TEBs, epithelium of ducts, stroma of TEBs 
and stroma of ducts.  
  The accuracy of the generated data was assessed by comparing lists of 
genes found to be over-expressed in TEB epithelium, duct epithelium and 
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TEB and duct were also present in Post-LN strip but no ductal genes were 
present  in  TEB  and  vice  versa.  The  comparison  was  computated  using 
GeneVenn  List  Diagram  (University  of  Southern  Mississippi, 
http://mcbc.usm.edu/genevenn/genevenn.htm). 
  Finally,  the  observed  over-expression  of  chosen  genes  in  given 
compartments was verified using Q RT PCR.  
2.2.5.9  ‘Functional’ analysis of identified genes  
Further  analysis  of  identified  gene  lists  was  performed  to  gather  more 
information about the biological functions and characteristics of the data sets of 
interest as well as individually selected genes. 
2.2.5.9.1  Ingenuity Pathway Analysis (IPA) 
 
The groups of genes whose expression was characteristic of either epithelial or 
stromal  environment  of  TEBs  or  ducts  were  analysed  to  identify  the  over-
represented  molecular,  cellular  functions  and  processes.  The  analysis  was 
performed using IPA v 8.0 (Ingenuity Systems Inc., Redwood, US). IPA uses its 
own  data  repository,  Ingenuity  Knowledge  Base  (IKB),  to  assess  biological 
functions that are most significantly represented in the analysed data. Data sets 
are  screened  for  the  presence  of  mapped  (identified  within  IKB), 
function/pathway eligible molecules, i.e. genes that have at least one functional 
annotation in IKB and the over-represented functions are identified and ranked 
according to the p-values. P-values are calculated with a right-tailed Fisher‟s 
Exact  Test  and  Benjamini-Hochberg  False  Discovery  Rate  multiple  testing 
correction.  This  takes  into  account  the  following  parameters:  the  number  of 
function  eligible  genes  that  are  known  in  IKB  to  comply  with  a  particular 
functional category, the total number of molecules in the IKB with potential to 
be  associated  with  the  functional  category  of  interest,  the  total  number  of 
molecules in IKB database and the total number of function eligible molecules in 
IKB data set.  
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2.2.5.9.2  EMT signature 
 
Gene sets shown to be differentially  expressed in  the  TEB environment were 
further screened for the presence of EMT signature genes. The EMT signature, 
used in this study, consists of the EMT core signature genes identified by Taube 
et al. (2010) (87 and 159 genes up- and down-regulated respectively in breast 
cancer cells when manipulated to undergo EMT) [270] and 10 other mesenchymal 
markers which were absent from this signature but previously shown by other 
research groups as associated with EMT (9 genes up- and 1 down-regulated in 
response to EMT). The EMT signature genes are listed in Table 2-8. 
2.2.5.9.3  Literature Search 
 
Genes were also studied on an individual basis using a literature search approach 
to  identify  those  not  previously  associated  with  mammary  gland  biology  but 
exhibiting related biological functions. The main search engines used to gather 
information comprised of: PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and 
AceView  (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html) 
applications  developed  by  NCBI,  GeneCards
® 
(http://www.genecards.org/index.shtml)  (Crown  Human  Genomics  Centre, 
Bioinformatics Unit of the Weizmann Institute of Science in Rehovot, Israel) and 
Google Scholar (http://scholar.google.co.uk/). 
2.2.5.9.4  Oestrogen responsive genes  
 
Oestrogen responsive genes were identified using the Estrogen Responsive Gene 
Database v.2 (ERGDB), an integrated knowledge database which includes genes 
whose  expression  levels  have  experimentally  been  proven  to  be  either  up-
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Fbln5, Grem1, Col3a1, Col1a2, Dcn, Cdh2, Enpp2, Postn, Rgs4, 
C5orf13, Prrx1, Fbn1, Srgn, Spock1, Prr16, Dlc1, Bin1, Rgl1, 
Igfbp4, Pvrl3, Cdh11, Olfml3, Mmp2, Myl9, Col5a2, Ctgf, Plekhc1, 
Zeb1, Ror1, Ptger2, Chn1, Pmp22, Tram2, Tagln, Tnfaip6, 
Creb3l1, Ugdh, Has2, Dnajb4, Cdkn2c, Ccdc92, Wnt5a, Igfbp3, 
Ppm1d, Filip1l, Pdgfc, Tbx3, Xylt1, Fap, Dpt, Stc1, Krt81, Mmp1, 
Hs3st2, Lmcd1, N-Pac, Sept6, Nr2f1, Sccpdh, Mlph, Ltbp2, Tpm1, 
Ankrd25, Ddr2, Sema5a, Tgfb1i1, Pcolce, Stard13, Nid1, Sync1, 
Enox1, Fstl1, Vim, Mme, C10orf56, Ltbp1, Nrp1, Thy1, Nebl, Tns3, 
Ecm1, Fbln1, Tuba1a, Copz2, Cybrd1, Ppap2b, Ptx3, Fads2, Bgn, 
Tshz1, Zbtb38 
[270] 
Twist  [272] 
Snail3  [273] 
Slug  [274] 
ZEB2  [275] 
Gsc  [276] 
FOXC1  [277] 
TCF3, Ctnnb1  [278] 





C20orf19, Snx10, Tp73l, Kcnk1, Bdkrb2, Anxa8, Anxa8l1, 
Loc728113, Rhbdf2, Loc653562, Slc6a10p, Slc6a8, Krt18, Cds1, 
Thbd, Nefm, Rps6ka1, Smpdl3b, Abca12, Rhod, Krt14, Prkch, 
Zbed2, C10orf10, Lrrc1, Stap2, Jup, Il4r, Perp, Fgfbp1, Myo1d, 
Fat2, Wwc1, Fzd3, Znf165, Snca, Kiaa1815, Prss8, Sh2d3a, Gnal, 
Bik, Cdh3, Kiaa0888, Krt5, Gjb3, Kiaa0040, Celsr2, F11r, Nup62cl, 
Serpinb1, Spint2, Polr3g, Elmo3, Il1rn, Tspan1, Ifi30, Pls1, 
Loc729884, Tmprss11e, C1orf116, Alox15b, Col17a1, Rtel1, 
Tnfrsf6b, Lad1, Ptpn3, Mst1r, Epha1, E2f5, Krt6b, Stac, Itgb4, 
C6orf105, Gls2, Anxa3, Dst, Arhgap25, Dsc2, Slc6a8, Lsr, Cldn1, 
Flj20366, Cyp4f11, Ccnd2, Fgfr2, Ablim1, Xdh, Camk2b, Dsg3, 
Naip, Ocln, Krt17, Saa1, Saa2, Prrg4, Ank3, C10orf116, Tmprss4, 
Cst6, Ndrg1, S100a8, Coro1a, Klk5, Exph5, Irx4, Irf6, Hook1, Artn, 
Flj12684, Slc2a9, Klk8, Tmem40, Trim29, Hbegf, Aldh1a3, 
Rbm35b, Myo5c, Cyp27b1, Il1b, Nmu, Krt16, Cdh1, Jag2, Vsnl1, 
Rln2, Ctsl2, Syk, Saa1, Epb41l4b, Rnf128, St14, Leprel1, Pi3, 
Ap1m2, Ckmt1a, Ckmt1b, Grhl2, Arhgap8, Loc553158, Igfbp2, Il18, 
Ca9, S100a14, Ca2, Krt15, Eva1, Tmem30b, S100a7, Klk7, Lgals7, 
Fst, Cxadr, Slpi, Rbm35a, Rab25, Uchl1, Klk10, Tacstd1, Serpinb2, 
Sprr1a, Fgfr3, Sprr1b 
[270] 
E-cad  [280] 
Table 2-8 EMT signature genes. 
The EMT signature consists of the EMT core signature genes identified by Taube et al. (2010) (87 
and 159 genes up- and down-regulated respectively in breast cancer cells when manipulated to 
undergo EMT) [270] and 10 other mesenchymal markers which were absent from this signature but 
previously shown by other research groups as associated with EMT (9 genes up- and 1 down-
regulated in response to EMT). 
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2.2.6 Tissue processing and staining 
2.2.6.1  Preparation of mouse mammary gland wholemounts stained with 
carmine 
Immediately after dissecting from WT or Fbln2 KO
-/- mice, the fourth inguinal 
mammary glands were placed individually on a Twin Frost Microscope Slide. The 
tissue  was  spread  out  using  metal  BD  Microlance™  3  needles,  the  slide  was 
placed into a Coplin Jar containing Carnoy‟s fixative (See Solutions and Buffers) 
and fixed for 3h on an orbital shaker at RT. The gland was then hydrated through 
decreasing concentrations of ethanol [40 min in 70% (v/v), 50% (v/v), 30% (v/v) 
ethanol], followed by distilled water, and stained overnight with Carmine dye 
(See Solutions and Buffers). The gland was then de-hydrated by serially placing 
the  tissue  for  40  min  in  dH2O  and  increasing  concentrations  of  ethanol  [30% 
(v/v),  50%  (v/v),  70%  (v/v)  and  100%  (v/v)]  to  remove  excess  H2O.  The 
wholemount was finally placed in xylene for at least 12h to remove all traces of 
alcohol. The tissue was mounted using Pertex mounting medium, cover slipped 
and stored.   
2.2.6.2  Tissue fixation, paraffin wax embedding and sectioning 
Excised glands were fixed in 10% Neutral Buffered Formalin for 4-24h prior to 
being transferred into a plastic cassette, processed and paraffin wax embedded 
using a Leica ASP300 tissue processor as follows: tissue was de-hydrated through 
a graded concentration of ethanol (50 min in 50% (v/v), 50 min in 80% (v/v) 
ethanol and 1h in 100% ethanol (v/v)) and placed in xylene for 2h at 37°C, under 
vacuum  conditions,  transferred  into  paraffin  wax  for  4h  and  stored  at  -60°C 
overnight.  
Paraffin wax embedded tissue was then placed at the bottom of chilled metal 
grids and additional wax was used to embed it into paraffin wax blocks using a 
Leica EG1150H heated paraffin dispensing module. Paraffin tissue blocks were 
left  to  solidify  for  30  min  on  Leica  EG1150C  cold  plate,  chilled  to  -5°C  and 
stored at RT until required.      143 
 
Sectioning of paraffin wax blocks was performed using a Leitz 1512 microtome. 
3-4µm  sections  were  routinely  cut  but  10µm  were  used  for  3D  structure 
reconstruction experiments 
Paraffin sections were cut and placed on the surface of a 40°C water bath, a 
metal blade was used to separate them and Superfrost
® Plus electrostatically 
charged slides were used to pick the sections up from the water bath. Slides 
with paraffin embedded tissue sections were left to dry for 1h at 62°C.    
2.2.6.3  Preparation of paraffin embedded tissue sections for IHC and IF 
Paraffin  embedded  tissue  sections  were  deparaffinized,  rehydrated  and 
subjected to antigen retrieval prior to being used in IHC or IF staining.  
Slides  were  deparaffinized  by  submerging  in  xylene  3  times  for  5  min,  and 
rehydrated in decreasing concentrations of ethanol (100% (v/v) twice for 3 min, 
70% (v/v) for 3 min) and running tap water for at least 2 min. Tissue sections 
were then pre-treated with 3% (v/v) hydrogen peroxide for 10 min to quench 
endogenous peroxidases, rinsed in running tap water and subjected to antigen 
retrieval to unmask epitopes that can be masked during the fixation process due 
to the cross linkage by formalin.  Antigen retrieval was performed using 1mM 
EDTA  buffer  (pH8)  (See  Solutions  and  Buffers)  as  follows:  1L  of  1mM  EDTA 
buffer (pH8) was brought to boiling in a microwave pressure cooker, slides were 
added to the boiling EDTA buffer and heated in the microwave at full pressure 
for a further 7 min, of which 4 min were precisely timed for slides to be held at 
the retrieval pressure. Slides were placed in running tap water for 10 min to cool 
down prior to being used for IHC or IF staining.            
2.2.6.4  IHC on paraffin embedded tissue sections 
All incubations were performed at RT using a humidity chamber as follows: after 
antigen retrieval, slides were incubated in TBS-Tween 20 pH7.6 (See Solutions 
and Buffers) for 5 min. Excess wash buffer was drained off and tissue sections 
were  blocked  with  pre-diluted  2.5%  Horse  Serum  for  20  min  to  prevent  non-
specific binding. Tissue sections were then incubated with the primary antibody 
of interest (Table 2-9) for 30 min and rinsed again with TBS-Tween 20 three     144 
 
times for 5 min. Primary antibodies were diluted to their final concentrations 
(Table 2-9) using Antibody Diluent. Washed tissue sections were then incubated 
for 30 min with the appropriate secondary antibody diluted 1:500 in Antibody 
Diluent,  washed  using  TBS-Tween  20  three  times  for  5  min  and  incubated  in 
diluted  (1  drop  in  1ml  of  Antibody  Diluent)  DAB  +  Chromogen  for  4  min. 
Secondary antibodies were conjugated with HRP that catalyzes oxidation of DAB. 
The oxidation product can be seen in the form of a brown stain. Stained tissue 
sections  were  then  washed  under  running  tap  water  for  at  least  5  min, 
counterstained with haematoxylin (See 2.2.6.6), de-hydrated through increasing 
concentrations of ethanol (1 min in 30 % (v/v), 50 % (v/v), 70 % (v/v) ethanol), 
dipped in xylene for 40 sec and mounted using Pertex mounting medium and 
cover slips. Stained tissue sections were visualised and imaged (See 2.2.8.3) and 
stored at RT.  
Negative control (lacking primary antibody) and positive control (tissue known to 
express protein of interest) were used in each staining run.  
2.2.6.5  IF on paraffin embedded tissue sections 
All incubations were performed at RT using a humidity chamber as follows: after 
antigen retrieval, tissue sections were rinsed in TBS-Tween 20 pH7.6. Excess TBS 
was drained off and tissue sections were incubated with Image-iT ™ FX Signal 
Enhancer for 30 min to block the unspecific background staining that can result 
from tissue autofluorescence. Sections were then washed with TBS-Tween 20 to 
remove the remaining Image-iT ™ FX Signal Enhancer, blocked with pre-diluted 
2.5% Horse Serum for 15 min, rinsed with TBS-Tween 20 and incubated with the 
primary antibody of interest for 30 min  (Table 2-9). Primary antibodies were 
diluted to their final concentrations (Table 2-9) using Antibody Diluent. After 
the incubation, tissue sections were washed twice for 5 min with TBS-Tween 20 
and  incubated  for  20  min  in  darkness  with  fluorescent  secondary  antibody 
diluted  1:1000  in  Antibody  Diluent.  Secondary  antibodies  were  conjugated  to 
either  Alexa  Fluor  488  dye  (green)  or  Alexa  Fluor  594  dye  (red)  to  allow 
visualisation.  Tissue  sections  were  finally  washed  twice  for  5  min  with  TBS-
Tween 20 and mounted using ProLong
® Gold antifade reagent with DAPI to stain 
the nuclei. A cover slip was applied onto each slide and sealed with nail varnish      145 
 





Mouse monoclonal, donated by Dr. T. Sun 
1:100   
Anti-Fbln2 
Rabbit polyclonal, donated by Dr. Mon Li Chu  
1:10 000  1:15 000 
Anti-Fbln1 
Rabbit polyclonal, donated by Dr. Mon Li Chu 
1:1 000   
Fibronectin (ab2413) 
Rabbit polyclonal, Abcam Inc; Cambridge, 
USA 
  1:1 000 
Table 2-9 Primary antibodies used for staining of paraffin embedded tissue sections using 
IHC and IF methods.      146 
 
after 24h. Tissue sections were visualised, imaged (See 2.2.8.2) and stored at 
4°C in darkness. 
Negative control (lacking primary antibody) and positive control (tissue known to 
express protein of interest) were used in each staining run.  
2.2.6.6  Haematoxylin and Eosin (H&Eo) staining 
Every fifth section cut from paraffin embedded tissue blocks was stained with 
haematoxylin Z which stains negatively charged organelles such as nuclei (blue) 
and  1%  eosin  which  stains  positively  charged  cell  compartments  such  as 
cytoplasm (pink) to study the morphology of the specimen. Staining of tissue 
sections with H&E was performed as follows: slides were immersed in xylene 3 
times for 5 min and 99% ethanol 3 times for 20 sec and rinsed in water. After 
incubation  in  haematoxylin  for  2  min  slides  were  washed  under  running  tap 
water, dipped in 1% Acid Alcohol (HCl), rinsed again in running tap water, dipped 
in Scott‟s Tap Water (See Solutions and Buffers) for 30 sec and rinsed before 
examining  under  a  light  microscope  to  assess  the  intensity  of  haematoxylin 
staining. If the staining intensity was optimal, slides were transferred to eosin 
for 2 min and rinsed thoroughly using running tap water. Stained tissue sections 
were then de-hydrated through increasing concentrations of ethanol (1 min in 
30%    (v/v),  50%  (v/v),  70%  (v/v)  ethanol),  immersed  in  xylene  for  40  sec, 
mounted  using  Pertex  mounting  medium,  cover  slipped,  examined  under  a 
microscope (See 2.2.8.3) and stored.  
2.2.6.7  Elastica van Gieson (EVG) staining 
EVG  staining  was  performed  using  the  EVG  kit  as  per  manufacturer‟s 
instructions. Briefly, tissue section were immersed in xylene 3 times for 5 min, 
re-hydrated by dipping in 99% ethanol 3 times for 20 sec and rinsed with water. 
Tissue  sections  were  then  placed  in  Elastin  according  to  Weigert‟s  resorcin-
fuchsin  solution  for  10  min,  rinsed  under  running  tap  water,  immersed  in 
Weigert‟s A&B solution (See Solutions and Buffers) for 5 min, rinsed again and 
placed in Picrofuchsin solution according to van Gieson for 2 min and 70% (v/v) 
ethanol for 1 min. Stained sections were then de-hydrated through increasing 
concentrations of ethanol (1 min in 30% (v/v), 50% (v/v), 70% (v/v) ethanol),     147 
 
immersed in xylene for 40 sec, mounted using Pertex mounting medium, cover 
slipped, examined under a microscope (See 2.2.8.3) and stored.  
2.2.7 In vivo hormonal treatment of mouse mammary glands 
Hormonal treatment (priming) was performed using female TG and WT mice to 
study the regulation of Fbln2 by systemic hormones (E2 and P) in pubertal mouse 
mammary gland in vivo.  
2.2.7.1  Priming of mice with hormone pellets 
Hormones were administered to animals in the form of subcutaneous pellets to 
deliver standardized, continuous release of the active ingredient in the animal 
over  a  given  period  of  time.  For  the  purpose  of  this  study,  21  day  release 
oestrogen  (E2)  (0.72mg/pellet),  oestrogen-progesterone  (E2+P)  (0.1mg/pellet, 
10mg/pellet)  or placebo (10.01mg/pellet)  hormone pellets were implanted in 
3.5 week old pubertal TG mice. 
Pellet  implantation  was  performed  on  a  single  mouse  at  a  time.  After  being 
weighed,  the  animal  was  anesthetised  in  an  induction  chamber  via  ISoFlo
® 
isoflurane  (Abbot  Laboratories  Ltd.,  Kent,  UK)  inhalation,  marked  by  ear 
punching and shaved at the back of the neck. The animal was then transferred 
to the surgical table, covered with a sterile cloth and anaesthesia maintained 
using  a  slow  gas  rate  delivered  through  a  mask  placed  over  its  nose.  The 
anaesthesia was monitored by pinching the toe of the animal and checking for 
lack of paw withdrawal. The exposed skin at the back of the neck was sterilized 
with 70% ethanol and an incision through the skin was made using sharp sterile 
scissors.  The skin at the top part of the incision was then lifted with sterile 
forceps  and,  using the  tip of a  second  pair  of blunt-ended  sterile  forceps  to 
separate the skin from the body wall, a pocket was created for the pellet. The 
hormone pellet was then gently placed in the created pocket and the skin on 
either site of the incision was sutured using Polyamide 6 blue monofilament non-
absorbable  suture  5-0  Ethicon.  The  implanted  mouse  was  transferred  to  an 
Electrisaver E30 thermostat heated chamber to recover from anaesthesia and 
then placed back into the breeding cage (See 2.2.1.1). Animal vital signs were 
closely  monitored  throughout  the  surgical  procedure,  recovery  process  and     148 
 
thereafter. All animal work was carried out under personal licence PIL 60/11179 
and project licence PPL 60/3712. 
All  of  the  surgical  instruments  used  for  mice  priming  were  sterilized  by 
autoclaving prior to performing the surgery. Surgical procedures were carried 
out in surgical gowns using Biogel
®P Suretech surgical gloves at the Biological 
Services at Veterinary Research Facility in Garscube Estate in Glasgow under the 
supervision of a named veterinary surgeon residing at the facility or the facility 
manager. Isoflurane was administered in contained conditions at all times, using 
a  calibrated  thermostatically  controlled  Veterinary  Fluosorber  vaporiser, 
induction chamber, suitable circuit and scavenging system. 
Implanted mice were primed with hormones for 7 days prior to being culled to 
collect the mammary glands and use them for further applications. 
2.2.7.2  Mammary gland morphology assessment and tissue processing  
The excision of mammary glands (See 2.2.1.2) was performed at the Beatson 
Institute  for  Cancer  Research,  Glasgow,  UK.  Mice  were  culled  by  cervical 
dislocation  to  ensure  minimal  tissue  deterioration.  Both  left  and  right  4th 
inguinal  mammary  glands  were  collected.  Upon  dissection,  mammary  glands 
were  spread  onto  HistoBond
®+  glass  slides,  visualised  using  a  fluorescent 
dissecting microscope  and imaged at x80 magnification  (See 2.2.8.1). Glands 
were then either snap frozen in liquid nitrogen or fixed in 10% Neutral Buffered 
Formalin to be used in further applications.  
2.2.8 Visualisation and imaging 
2.2.8.1  Fluorescence microscopy 
Mammary  glands  excised  from  TG  mice  were  visualised  using  a  Stemi  SV6 
fluorescent  dissecting  microscope  and  imaged  with  Axio  Vision  release  4.6.3 
software (Carl Zeiss Ltd., UK) 
To monitor the efficiency of transfections, an Olympus IX51 inverted microscope 
equipped  with  U-MNIBA3  filter  for  the  detection  of  470-495nm  wave  length     149 
 
(green narrow) was used for visualisation while image acquisition was carried out 
using  F-view  Soft  Imaging  System  (Olympus  UK  Ltd.,  UK)  and  Cell
P  Imaging 
software (Olympus UK Ltd., UK).  
2.2.8.2  Confocal microscopy 
Tissue sections stained using IF methods were examined using a Leica TCS SP2 
confocal  microscope  with  x63  oil  immersion  lens  and  imaged  using  Leica 
Confocal Software (Leica Microsystems Ltd.; UK). Multiple images were captured 
for  each  tissue  section  using  360nm  (DAPI)  and  488nm  filters  (green 
fluorescence).  
3D  tissue  structure  reconstruction  was  performed  using  Volocity®  3D  Imaging 
Software  (PerkinElmer;  Massachusetts,  USA)  using  Z-stag  data  obtained  via 
confocal  microscopy.  Z-stags  were  captured  every  0.7-0.8µm.  Confocal 
microscopy  and  3D  structure  reconstruction  was  performed  at  the  Beatson 
Institute for Cancer Research.   
2.2.8.3  Light microscopy 
Wound  healing  experiments  were  monitored  using  an  Olympus  IX51  inverted 
microscope. F-view Soft Imaging System and Cell
P Imaging software were used to 
acquire images and calculate the percentage of wound closure. 
Most  of  the  tissue  sections  stained  using  IHC  and  the  wholemounts  were 
examined using a Labophot-2 light microscope and imaged and scanned using a 
NanoZoomer  Digital  Pathology  scanner  at  x200  magnification.  The  obtained 
images were then manipulated and analysed using Digital Image Hub (SlidePath; 
Dublin, Ireland). Remaining tissue sections stained using IHC, EVG stain or H&E 
were examined and imaged using Leica DMD108 Digital Microimaging Network.  
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3  Pubertal transcriptome of mouse mammary 
gland - Microarray analysis 
3.1 Introduction 
One of the aims of this project was to study the pubertal transcriptome of the 
mouse  mammary  gland  and  to  identify  individual  genes  and  biological 
functions/pathways that may be associated with TEB motility. Mouse mammary 
gland development during puberty, i.e. from 4 to 10 weeks of age, is a complex 
process of epithelial expansion into the surrounding stroma and differentiation. 
During this time TEBs provide the driving force for the invasion of the ductal tree 
into the empty fat pad. The whole process is tightly regulated by a multitude of 
cues,  including  systemic  hormones  and  interactions  between  epithelial  and 
stromal cells.     
3.2 Results 
This  chapter  should  be  read  in  conjunction  with  Figure  3-1  (p.151)  which 
provides a paradigm of microarray data analysis carried out in this project.  
To  study  pubertal  mouse  mammary  gland  development  different  types  of 
biological material were collected (isolated epithelium, mammary gland tissue 
strips  and  whole  mouse  mammary  glands)  (See  3.2.1)  and  the  microarray 
analysis of TEB and duct epithelial and stromal transcriptomes was performed. 
And since TEBs are the driving force of ductal morphogenesis, this study focused 
on:  
  Identification  of  genes  associated  with  TEBs  and  ducts  transcriptomes 
(See 3.2.6.1 and 3.2.6.2). 
  Identification and classification of new, potential regulators of pubertal 
mouse mammary gland morphogenesis – (Candidate gene approach) (See 
3.2.6.3).     151 
 
 
Figure 3-1 Microarray data analysis paradigm. 
Gene  expression analysis  was performed on RNA  obtained from isolated TEBs (T), ducts (D), 
mammary  gland  tissue  strips  (Pre-LN,  Post-LN  and  Fat  pad).  Gene  expression  analysis  was 
performed using 5% LFC Model to identify TEB and duct epithelium ‘up-regulated gene sets’ (See 
2.2.5.5.1) and these were then used for ‘candidate gene approach analysis’ and ‘pathway analysis’. 
Gene expression analysis was performed using Partek
® Genomic™ Suite to identify TEB and duct 
stromal-epithelial  ‘up-regulated  genes  sets’  (See  2.2.5.5.2)  and  these  were  then  used  for 
‘candidate gene approach analysis’. Finally Expression Console and manual analysis was used to 
compare  gene  expression  in  Post-LN,  Pre-LN,  isolated  TEB-  and  isolated  duct  epithelium  to 
identify TEB-only and duct-only stroma ‘expressed gene sets’ (See 2.2.5.6.2). Isolated TEB- and 
isolated  duct  epithelium  gene  expression  was  also  compared  to  identify  TEB-  and  duct-only 
epithelium  ‘expressed  gene  sets’  (See  2.2.5.6.1).  TEB-  and  duct-only  epithelium  and  stroma 
‘expressed gene sets’ were then used in ‘pathway analysis’. The ‘expressed gene set’ is defined as 
list of genes expressed ≥ 1.1 fold change cut off in one environment when compared to other 
environment. The ‘up-regulated gene set’ is defined as a list of genes up-regulated above the set 
level,  in  one  environment  when  compared  to  other  environment.  TEB  and  duct  epithelium  ‘up-
regulated gene sets’ and ‘expressed gene sets’ were used to study the epithelial transcriptome of 
TEBs and ducts. TEB and duct epithelial-stromal ‘up-regulated gene sets’ were used to study the 
epithelial-stromal transcriptomes of TEBs and ducts. TEB- and duct-only stroma ‘expressed gene 
sets’ were used to study the stromal transcriptomes of TEBs and ducts.     152 
 
  Identification  and  comparison  of  functional  characteristics  of  the 
epithelial  and  stromal  transcriptomes  of  TEBs  and  ducts  –  (Pathway 
analysis) (See 3.2.6.4 - 3.2.6.7). 
As a result, the different types of transcriptomes, the epithelial-, stromal- and 
epithelial-stromal transcriptomes, were identified in this project to study gene 
expression in TEBs and ducts. This allowed us to gain further insights into the 
function of epithelium and stroma in ductal morphogenesis and to study stromal-
epithelial interactions during epithelial outgrowth at puberty. In addition, the 
Fat pad transcriptome was identified to study the gene expression in the distal, 
epithelium-free Fat pad at puberty.   
Each of these transcriptomes was represented using either of the two different 
types of gene sets, the „up-regulated gene sets‟ or „expressed gene sets‟.  
The „up-regulated gene sets‟, defined as lists of genes up-regulated above the 
set level in one environment when compared to the other environment, were 
identified to study epithelial and epithelial-stromal transcriptomes of TEBs and 
ducts and the epithelium free Fat pad (See 2.2.5.5).  
The „expressed gene sets‟, defined as lists of genes expressed ≥ 1.1 fold change 
cut  off  in  one  environment  when  compared  to  the  other  environment,  were 
identified  to  study  stromal  transcriptomes  of  TEBs  and  ducts  and  epithelial 
transcriptomes  of  TEBs  and  ducts  as  the  analysis  used  to  select  the  stroma 
associated genes (manual screening of the raw gene expression data from the 
isolated epithelium and tissue strips) did not allow calculation of FCs but only 
enabled  presence  or  absence  of  gene  expression  to  be  determined  (See 
2.2.5.6).  
The TEB epithelium „up-regulated gene set‟ (TEBs vs ducts) and Post-LN „up-
regulated  gene  set‟  (Post-LN  vs  Pre-LN  strips)  were  used  for  candidate  gene 
approach. 
The degree of potential hormonal regulation of gene expression during puberty, 
based  on  the  number  of  oestrogen  responsive  genes,  as  defined  by  ERGDB, 
within the generated gene list, was also established.     153 
 
The TEB- and duct epithelium „up-regulated gene sets‟ (TEBs vs ducts) (ducts vs 
TEBs),  TEB-  and  duct-only  epithelium  „expressed  gene  sets‟  (TEBs  vs  ducts) 
(ducts vs TEBs) and TEB- and duct-only stroma „expressed gene sets‟ (TEBs vs 
ducts) (ducts vs TEBs) were used in pathway analysis.  
3.2.1 Collection of biological material 
Gene expression profiling of ductal outgrowth in pubertal mouse mammary gland 
was performed using the following biological material:  
  Isolated epithelium of TEBs and ducts (Figure 3-2 A, 3-2B and 3-2C),  
  Mammary  gland  tissue  strips  containing  either  ductal  epithelium  and 
surrounding stroma (Pre-LN); ducts and TEBs‟ epithelium and surrounding 
stroma (Post-LN) or epithelium free stroma (Fat pad) (Figure 3-3 A)  
  Whole adult virgin mammary glands (Figure 3-3 B).  
TEBs, ducts and whole adult glands were isolated from WT mice. Mammary gland 
tissue strips were collected from TG mice. 
In  WT  mice  visualisation  of  mammary  gland  epithelium  is  only  possible  with 
whole  mounts  fixed  and  stained  for  example  with  carmine  alum.  However, 
fixation  of  the  tissue  prior  to  imaging  makes  it  unsuitable  for use  in  further 
molecular applications. In TG mice, the mammary ductal tree is easily visible 
under UV light and so the stage of development, presence and size of TEBs can 
be easily assessed allowing increased precision in setting boundaries between 
the Pre-LN, Post-LN and Fat pad tissue strips. 
Microarray analysis of isolated TEBs and ducts was performed to characterise the 
specific epithelial transcriptomes. Microarray analysis of mammary gland tissue 
strips  further  permitted  the  study  of  epithelial-stromal  interactions  in  the 
pubertal mammary gland. Gene expression analysis of both epithelial structures 
and  tissue  strips  was  used  for  the  identification  and  characterisation  of  the 
stromal  transcriptome  around  TEBs  and  ducts  during  puberty.  Adult  glands 
served as negative controls.      154 
 
 
Figure 3-2 Isolated pubertal epithelium. 
Phase contrast microscopic images showing (A) (B) TEBs and (C) a duct isolated from pubertal 
mouse mammary gland following collagenase II treatment. Mammary glands were collected from 6-
7 week old WT female mice. Photographs were taken using an Olympus IX51 microscope. Scale 
bars are 50µm.     155 
 
 
Figure 3-3 Whole mouse mammary glands. 
Fluorescent microscopic images showing (A) Mouse mammary gland tissue strips collected from a 
7 week TG. The ductal epithelium and the central LN are clearly visible and the vertical black lines 
(black arrows) illustrate where cuts were made to divide the gland into tissue strips. White arrow 
denotes  TEB.  (B) Whole  adult  mouse  mammary  gland  obtained  from  12  week  old  TG  female 
mouse. Both photographs were taken using Stemi SV6 fluorescence dissecting microscope. Scale 
bars are 1mm. 
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3.2.2 Characterisation of pubertal development stages in WT and 
TG mice  
Prior to the collection of biological material, mammary glands obtained from 29 
WT and 23 TG mice were used to study the time course of the morphological 
changes  during  puberty  in  each  mouse  strain  to  ensure  their  comparability. 
Mammary glands were collected from 4, 5, 6, 7, 9 and 12 week old TG mice and 
visualised using a fluorescence dissecting microscope (Figure 3-4 A). Mammary 
glands from 5, 6 and 7 week old WT mice were wholemounted and stained with 
carmine alum (Figure 3-4 B). All mice were weighed at gland collection. 
The  length  of  the  ductal  tree  as  well  as  the  size  and  number  of  TEBs  were 
compared between collected glands. Mammary glands obtained from 4 week old 
mice were characterised by an undeveloped, rudimentary ductal tree. Numerous 
TEBs and significant outgrowth of the ductal tree was noticeable at 5-8 weeks of 
age, with the most prominent TEBs observed at 6-7 weeks of age. Upon reaching 
9 weeks of age most of the mammary fat pad was filled with ductal epithelium 
and very few small TEBs were visible. At 12 weeks of age, the whole mouse 
mammary gland fat pad was filled with a ductal tree and hardly any TEBs were 
present. Furthermore, mammary glands collected from mice that weighed 16-18 
g had the largest and most numerous TEBs. The extent of ductal outgrowth at 
given  developmental  stages  was  comparable  between  WT  and  TG  mouse 
mammary glands.    
Based on the above conclusions, mammary glands were collected from TG mice 
weighing 16-18g and aged 7 weeks to obtain tissue strips or WT mice aged 6-7 
weeks to collect isolated TEBs and ducts. Adult mammary glands, collected at 12 
weeks of age, which do not contain TEBs, were used as negative controls. 
3.2.3 Experimental set up for microarray analysis 
1145 TEBs and 1111 ducts were isolated from mammary glands collected from 
300 WT mice. 12 Pre-LN, 12-Post-LN and 12 Fat pad mammary gland strips were 
collected from 6 TG mice and 6 whole mammary glands were obtained from 3 
WT adult mice.     157 
 
 
Figure  3-4  Wholemounts  of  different  stages  of  pubertal  mouse  mammary  gland 
development. 
(A) Wholemounts collected from TG mice. (B) Carmine stained wholemounts obtained from WT 
mice. Scale bars are 1mm. 
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The  collected  biological  material  was  pooled  as  shown  in  Table  3-1  and  16 
samples  of  RNA  were  extracted,  purified  and  hybridised  to  GeneChip
®  Mouse 
Exon 1.0 ST arrays (Figure 2-4) (p. 106).  
Isolated TEBs and isolated ducts were pooled prior to extracting RNA to ensure 
that a sufficient amount of RNA, 1.5 µg per microarray chip, was obtained. This 
experimental design also allowed the production of RNA samples representative 
of a 300 mice population, not biased by mouse to mouse biological variation. For 
both  TEBs  and  ducts  the  amount  of  extracted  RNA  was  only  sufficient  to  be 
divided into 2 samples, generating technical duplicates. Prior to RNA extraction, 
mammary  gland  tissue  strips  were  paired  to  enable  a  more  comprehensive 
comparison  of  data  between  tissue  strips  and  to  ensure  sufficient  yield  of 
extracted RNA and to minimise biological variation.  
Animal breeding, excision and handling of biological material and experimental 
conditions  for  preparation  of  RNA  samples  were  maintained  as  similarly  as 
possible  to  minimize  data  discrepancy  that  could  occur  due  to  technical 
variation. This included extraction of RNA from mammary gland tissue strips at 
the same time and within a very short time from the RNA extraction from pooled 
TEBs and ducts and adult mammary glands, using the same batches of reagents 
and equipment.  
The  GeneChip
®  Mouse  Exon  1.0  ST  microarray  platform  was  chosen  for  this 
project as it allows the investigation of the level of transcription at both whole 
transcript and exon levels. Each GeneChip
® Mouse Exon 1.0 ST array contains 
only PM probes and accommodates oligonucleotide sequences that translate into 
17,500  well-annotated  transcript  IDs  based  on  publicly  available,  empirically 
obtained  annotations  of  the  mouse  genome  sequence  built  in  2004.  A  single 
array  consists  of  over  4.5  million  probes  (25  oligonucleotide  long  sequences 
complementary to each corresponding sequence from the genome)  which are 
synthesised  in  situ.  A  set  of  four  distinctive,  perfect  match  probes  makes  a 
probe set and usually four probe sets make up an exon cluster, i.e. a number of 
probes of nucleotide sequences unique for each exon. Multiple exon clusters can 
be  grouped  into  over  80,000  transcript  clusters,  i.e.  groups  of  putative 
alternatively spliced gene isoforms and each gene is annotated by a transcript 





RNA sample source 
(See collection of 
experimental material) 
Characteristics   Replicate 
type 
1, 2  Isolated TEBs  RNA extracted from pooled TEBs was 
divided into 2 samples 
Technical 
duplicate 
3, 4  Isolated ducts  RNA extracted from pooled ducts was 
divided into 2 samples 
Technical 
duplicate 
5, 6, 7  Pre-LN mammary gland 
strips 
Each RNA sample (replicate) 
contained RNA extracted from a pair 
of mice. The same pair of mice was 
used for replicates 5,8,11, second pair 












14, 15, 16  Whole mammary glands  Each RNA sample (replicate) was 




Table  3-1  Description  of  RNA  samples  used  for  microarray  analysis  of  pubertal  gene 
expression. Isolated epithelium of TEBs and ducts was collected from 6-7 week old WT mice. 
Mammary gland tissue strips were collected from 7 week old TG mice. Whole mammary glands 
were collected from 12 week old WT mice.      160 
 
3.2.4 RNA hybridisation to GeneChip
® Mouse Exon 1.0 ST Arrays  
All  RNA samples were subjected to quality and integrity assessment using an 
Agilent 2100 bioanalyser  (See 2.2.4.5).  Quality assessment was based on the 
calculation  of  28S  rRNA  to  18S  rRNA  ratio  which  ideally  should  be  2:1.  RNA 
integrity  number  (RIN)  was  estimated  taking  into  consideration  the  entire 
electrophoretic trace of the RNA sample. RINs were within the acceptable range 
for all of the RNA samples, i.e. between 6-10 as recommended by Qiagen Ltd.: 
for RNA samples obtained from TEBs and ducts they were 6.2; for RNA samples 
obtained from mammary gland tissue strips they varied between 7.7 and 9.0; 
and  for  RNA  of  adult  glands  they  were  between  8.4-8.8.  Thus,  all  16  RNA 
samples were able to be hybridised to the GeneChip
® Mouse Exon 1.0 ST Arrays 
using appropriate Affymetrix kits (See 2.2.5.3). Efficiency and performance was 
monitored throughout the procedure by performing quality assessment after 28S 
and  18S  rRNA  reduction  (See  2.2.5.3.1)  and  before  and  after  ss  cDNA 
fragmentation (See 2.2.5.3.5). Representative electrophoretograms, shown in 
Figure 3-5, illustrate that high quality of all samples was maintained throughout 
the experimental steps. The trace for total RNA showed low background noise 
between  the  clear  28S  and  18S  peaks  and  minimal  low  molecular  weight 
contamination (Figure 3-5 A). The trace obtained after rRNA reduction, which 
was performed to minimise the background, increase specificity and sensitivity 
of  the  array  and  increase  efficiency  of  cDNA  synthesis,  showed  successful 
reduction  of  28S  and  18S  peaks  from  20  and  27  fluorescence  units  (FU) 
respectively to 2 and 3 FU respectively (Figure 3-5 B). Electrophoretograms of ss 
cDNA  before  and  after  fragmentation  demonstrated  successful  elimination  of 
large ss cDNA fragments in favour of accumulation of smaller size range of ss 
cDNA fragments (Figure 3-5 C and D). Successfully fragmented ss cDNAs were 
hybridised to the microarray chips. Arrays were washed, stained and scanned 
and the obtained .CEL files normalised, background corrected and summarised 
(See 2.2.5.4). Technical variability was minimised by processing all the samples 
together.     161 
 
 
Figure 3-5 Assessment of hybridisation efficiency. 
Representative electrophoretograms showing RNA quality (A) after RNA extraction, (B) after rRNA 
reduction and cDNA quality (C) before cDNA fragmentation and (D) after cDNA fragmentation. (A) 
(B) Show good quality of the total and rRNA reduced RNA. The three visible peaks stand for the 
molecular weight marker, 18S rRNA and 28S rRNA. (C) (D) Demonstrate successful reduction in 
size of cDNA fragments. The two visible peaks stand for the molecular weight marker and a pool of 
cDNA fragments. (A) (B) Agarose  gel separation of the total RNA and  (C) (D) total cDNA are 
shown on the right hand side of each electrophoretogram.    
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3.2.5 Microarray data quality control 
A  number  of  quality  control  measures  were  performed  throughout  the 
experimental  stages  of  the  microarray  analysis  to  monitor  and  ensure  good 
quality of the generated data (See 2.2.5.8). Visual inspection of the scanned 
arrays did not show any irregularities. Furthermore, the quality check of RNA 
hybridisation, performed by investigating the signal intensity of a probe set for 
prokaryotic internal hybridisation controls (bioB, bioC, bioD and cre) showed the 
cre control, which was hybridised to the array at the highest concentration, to 
be characterised by highest signal intensity, followed by bioD, bioC and bioB 
(Figure 3-6 A), thus, showing the expected rank order of spikes. Comparison of 
sample  replicates  at  the  whole  genome  level,  performed  after  data 
normalisation, background correction and summarisation using PCA, showed all 
replicates of each biological sample to cluster together apart from the replicates 
of  the  isolated  ducts,  which  showed  higher  variability.  Although  the  two 
replicates failed to cluster precisely, the discrepancy was deemed slight enough 
that  neither  of  them  was  considered  an  outlier.  The  variability  between  the 
replicates  of  each  biological  sample  was  therefore  concluded  to  be  minimal. 
Replicates of different biological samples, on the other hand, clustered away 
from each other. This was mostly apparent when comparing the clustering of 
replicates of isolated epithelium (TEBs and ducts) with replicates of tissue strips 
and whole virgin glands. Samples of TEBs and ducts were shown to cluster in the 
same area of the plot indicating similar pattern of gene expression. Samples of 
tissue strips and whole adult virgin glands were also shown to cluster together 
but  at  a  distance  from  the  TEBs  and  ducts  clusters  indicating,  as  expected, 
dissimilarity in gene expression between the two groups of samples and possibly 
reflected  differences  in  sample  preparation.  Together  this  confirmed  a 
reproducibility and reliability of the generated data (Figure 3-6 B and C). 
Final  data  quality  control  that  was  carried  out  after  the  analysis  of  the 
microarray data, using a list of genes previously published as associated with 
either epithelial or stromal compartments of TEBs or ducts, revealed presence of 
these  genes  within  the  appropriate  gene  lists  generated  in  this  study  thus 
ensuring the reliability of our data. The list of reference genes screened for in      163 
 
 
Figure 3-6 Microarray data quality controls. 
(A) Quality check of RNA hybridisation. Figure illustrates the intensity of the hybridisation signal (Y 
axis) of Cre, bioD, bio C and bioB internal hybridisation controls across all the microarray chips (X 
axis).  (B)  (C)  PCA  based  comparisons  of  clustering  patterns  of  samples  replicates.  (B)  Image 
shows TEBs (yellow) and ducts (red) replicates clustering together but away from Post-LN (green), 
Pre-LN (violet), Fat pad (blue) mammary gland tissue strips and  whole adult gland (light blue) 
replicates. (C) Image illustrates close clustering of replicates of each tissue strip. Each tissue strip 
is represented as follows: Pre-LN (green), Post-LN (blue) and Fat pad (red). (D) Venn diagram 
comparison of lists of genes found to be differentially expressed in isolated TEB vs duct and Post-
LN vs Pre-LN tissue strips. Red, yellow and green circles illustrate genes associated with Post-LN 
(right)  or  Pre-LN  (left)  strips,  isolated  ducts  and  isolated  TEBs  respectively.  Common  parts 
between the circles represent genes that are commonly over- expressed in the compared gene 
lists.              164 
 
each compartment, their calculated FC and rank numbers are shown in Table 3-
2.    
Furthermore,  Venn  diagram  comparisons  of  lists  of  genes  found  to  be 
differentially expressed in TEB epithelium vs duct epithelium and Post-LN vs Pre-
LN  tissue  strips  identified  20  genes  commonly  up-regulated  in  both  Post-LN 
(Post-LN vs Pre-LN) and duct epithelium (Ducts vs TEBs) gene lists and 65 genes 
commonly up-regulated in both Post-LN (Post-LN vs Pre-LN) and TEB epithelium 
(TEBs  vs  Ducts).  This  was  expected  as  Post-LN  strips  contain  TEB  as  well  as 
ductal epithelium. Furthermore, 41 and 2 of the over-expressed genes in ducts 
(Ducts vs TEBs) and TEBs (TEBs vs Ducts) respectively were shown to be also up-
regulated in Pre-LN when compared to Post-LN (Figure 3-6 D). This was also 
expected as although the Pre-LN strip contains mostly ductal epithelium it may 
contain a very low number of TEBs. 
Finally, to confirm the reproducibility of the microarray data,  the expression 
levels of a selected set of genes was confirmed using QRT PCR analysis. Genes 
that were chosen for validation included some that had never been associated 
with mammary gland development previously, such as embigin (Emb) and Disk 
large homolog 7 (Dlg7), and others that had: Sema3B [113] and lactotransferrin 
(Ltf)  [113].  Expression  of  the  genes  was  validated  using  RNA  extracted  from 
Post-LN  and  Pre-LN  strips  collected  from three  animals,  different  from  those 
used for the microarray study. Tissue strips were used to avoid using valuable 
RNA  obtained  from  TEBs  and  ducts.  Gene  expression  levels  were  normalised 
against  the  expression  levels  of  the  epithelial  marker  Ktr18  to  measure  the 
abundance of gene expression in relation to the amount of epithelium present. 
As seen in Figure 3-7 A expression of Emb, Dlg7 and Sema3B was higher in the 
Post-LN strip than Pre-LN strip while expression of Ltf was up-regulated in Pre-
LN  strip  compared  to  Post-LN.  Those  findings  reflect  the  microarray  analysis 
results which showed over-expression of Emb, Dlg7 and Sema3B in isolated TEB 
epithelium and Post-LN strip and up-regulation of Ltf in isolated duct epithelium 
and Pre-LN strip (Figure 3-7 B). The up-regulation of all genes but  Dlg7 was 
identified as statistically significant.  
Together,  all  quality  control  measures  that  were  carried  out  were  deemed 
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analysis 
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TEB stroma  Plexin C1  2.44  70  [113] 
Table 3-2 List of reference genes known to be associated with TEB and duct environments 
and the level of their up-regulation in the generated in this study gene lists. 
FC and Rank number for epithelium and stroma expressed genes were calculated using 5% LFC 
Model (See 3.2.6.1.1) and Partek
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Figure 3-7 Validation of microarray gene expression profiling by RT PCR analysis. 
(A) RT PCR. The graph illustrates mean expression levels of Sema3B, Ltf, Emb and Dlg7 in Post-
LN strip relative to Pre-LN strip. Krt18 expression was used as an internal control for normalisation. 
Error bars are S.E.M. (*) denotes statistical significance, (*) p≤0.05 (**) p≤0.01 (***) p≤0.001, n=3 
(B) Microarray analysis. The table shows the levels of Sema3B, Emb and Dlg7 up-regulation in the 
isolated TEBs (TEBs vs ducts) and Post-LN strip (Post-LN vs Pre-LN) and Ltf up-regulation level in 
the isolated ducts (ducts vs TEBs) and Pre-LN strip (Pre-LN vs Post-LN). All FCs are statistically 
significant.     167 
 
3.2.6 Bioinformatic analysis of the pubertal mouse mammary 
gland transcriptome 
The bioinformatic analysis carried out in this project included three areas that 
are  listed  below  and  should  be  read  in  conjunction  with  Figure  3-1  (p.151) 
which provides an overview of the paradigm for data analysis adopted in this 
study. 
  Identification  of  genes  associated  with  TEBs  and  ducts  transcriptomes 
(See 3.2.6.1 and 3.2.6.2). 
  Identification and classification of new, potential regulators of pubertal 
mouse mammary gland morphogenesis – (Candidate gene approach) (See 
3.2.6.3). 
  Identification  and  comparison  of  functional  characteristics  of  the 
epithelial  and  stromal  transcriptomes  of  TEBs  and  ducts  –  (Pathway 
analysis) (See 3.2.6.4 - 3.2.6.7). 
3.2.6.1  Gene expression analysis – Identification of the ‘up-
regulated gene sets’  
Briefly, the „up-regulated gene sets‟ are defined as lists of genes up-regulated 
above  the  set  level,  in  one  environment  when  compared  to  the  other 
environment. 
3.2.6.1.1  TEB and duct epithelium ‘up-regulated gene sets’ 
 
Due to the low yield of RNA, obtained from isolated TEBs and ducts, microarray 
analysis had to be performed in duplicate rather than triplicate which caused 
analysis limitations. Given that statistical tests can not be applied in analyses 
consisting of fewer than three samples, we employed the 5% LFC Model which is 
used  for  data  analyses  in  the  absence  of  large  numbers  of  experimental 
replicates  [269].  The  5%  LFC  Model  aids  identification  of  the  significantly 
expressed  genes  by  calculating  the  rank  number  (RN)  based  on  the  absolute     168 
 
expression levels of transcripts across the compared conditions, „binning‟ them 
across  their  absolute  expression  levels  and  selecting  the  first  5%  of  the 
transcripts in each bin with the highest FC (HFC). Selected genes are ranked 
according  to  both  FC  and  expression  level  and  the  most  significantly  over-
expressed genes are identified (See 2.2.5.5.1). The 5% benchmark is based on 
the  finding  brought  by  the  survey  of  numerous  publications  on  microarray 
analysis  that  shows  that  regardless  of  the  gene  selection  method  used,  in 
general less than 5% of the total gene number show differential expression [269]. 
Initially 23,239 transcript IDs, i.e. genes, were employed in the analysis from 
which 3,038 were excluded after Average Difference Intensity (ADI) adjustment. 
A high level of variation in expression levels between the replicates resulted in 
further elimination of 1,425 transcript IDs in order to minimise false positive 
results. The remaining 18,777 genes (92.2%) were divided into transcripts up- 
regulated  in  TEBs  or  ducts.  11,738  and  7,039  genes  were  shown  to  be  over-
expressed in TEBs and ducts respectively. All non-annotated, internal Affymetrix 
controls, as defined by Affymetrix UK Ltd, were subtracted from the lists. To 
identify the top 5% of TEB and duct up-regulated genes, the transcripts over-
expressed in TEBs were „binned‟ into 58 bins that contained 200 genes and one 
that consisted of 137 genes while the transcripts over-expressed in ducts were 
divided into 39 bins that were 200 genes rich and one that consisted of 37 genes 
(See 2.2.5.5.1). The gene expression analysis aided identification  of 425 and 
186 genes over-expressed in isolated TEBs and ducts respectively (Table 3-3). 
The ranked top 20 genes from each gene list and their FC are shown in Table 3-
4. Full gene lists are shown in Appendix 2.  
3.2.6.1.2  TEB and duct epithelium-stroma ‘up-regulated gene sets’ 
 
The combined stromal-epithelial transcriptome of TEBs and ducts was identified 
using RNA extracted from Pre-LN and Post-LN mammary gland tissue strips. The 
yield of RNA obtained in each RNA extraction was sufficient to perform gene 
expression  analysis  in  triplicate  using  Partek
®  Genomics™  Suite  software  (See 
2.2.5.5.2).  Comparison  of  Post-LN  vs  Pre-LN  gene  expression  aided  the 
identification of 565 and 361 genes over-expressed in Post-LN strip (epithelial-




Data comparison type 
TEBs - ducts  Post-LN – Pre-LN  Post-LN - Fat pad 
Isolated TEBs  425     
Isolated ducts  186     
Post-LN strip    565  670 
Pre-LN strip    361   
Fat pad strip      688 
Table 3-3 Number of genes up-regulated in each transcriptome. 
Transcriptomes  of  the  isolated  epithelium  were  identified  by  comparing  gene  expression  levels 
across TEB and duct data sets. Genes up-regulated in Post-LN, Pre-LN and Fat pad mammary 
gland tissue strips were identified by comparing gene expression levels across Post-LN, Pre-LN 
and Fat pad data sets. Up-regulation of all identified genes was statistically significant, i.e. p≤0.05 
for genes over-expressed in Pre-LN and Post-LN and within the 5% LFC Model for genes over- 
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Table 3-4 Top 20 genes over-expressed in isolated TEBs, ducts, Post-LN and Pre-LN strips. 
FC(s)  of  gene  expression  were  calculated  from  TEBs  vs  ducts  and  Post-LN  vs  Pre-LN  gene 
expression  comparisons.  All  FC(s)  were  statistically  significant,  i.e.  p≤0.05  for  genes  over-
expressed in Pre-LN and Post-LN and within the 5% LFC Model for genes over-expressed in TEBs 
and ducts isolated epithelium.   
Gene 
symbol 
FC  Gene name  Gene bank 
symbol 















































Uroplakin 3a   
Fibrinogen 
RIKEN cDNA 2810417H13 gene,  
Histone cluster 1, H1b 
Cyclin A2 
Histone cluster 1, H2ab 
Serine (or cysteine) peptidase inhibitor, clade B, 
member 11 
Polo-like kinase 1 
Metallothionein 
Ribonucleotide reductase M1 
Cyclin B2 
Cysteine-rich secretory protein LCCL domain 
containing 
Ubiquitin-like, containing PHD and RING finger 
domains 1 
RAC GTPase-activating protein 1 
Topoisomerase (DNA) II alpha 
Cyclin D1 
Tubulin beta 5 
Pleiotropic regulator 1 
Glutathione S-transferase alpha 4 

































































cDNA sequence AY036118 
Deubiquitinating enzyme 2a 
Lactotransferrin 
Indoleamine-pyrrole 2,3 dioxygenase 
Deleted in malignant brain tumours 1 
Cystatin C 
Solute carrier family, member 2 
Chloride channel calcium activated 1 
Tryptophan hydroxylase 1 
CD79A antigen 
Solute carrier family 5 
Polycomb group ring finger 1 
Lymphocyte antigen 6 complex, locus D 
Ceruloplasmin 
Angiotensin II receptor, type 1a 
Amiloride binding protein 1 
Transferrin 
ATPase H+ transporting lysosomal V1 subunit B1 







































RIKEN cDNA 2810417H13 gene 
Chemokine (C-X-C motif) ligand 13 
Interferon-induced protein with 
tetratricopeptide repeats 
Complement component 6 
Predicted gene 11428 
Interleukin 1 receptor type II 













































Toll-like receptor 8 
CD86 antigen 
Macrophage galactose N-acetyl-galactosamine 
specific lectin 
Ficolin A 
Toll-like receptor 7 
Angiotensinogen 
Aldo-keto reductase family 1, member C14 
CD163 antigen 
H19 fetal liver mRNA 
Membrane-spanning 4-domains, subfamily A, 
member 6B 
Integrin alpha M 
Pleckstrin 
EGF-like module containing, mucin-like, 


































































Fatty acid binding protein 3 
Solute carrier family 27 
Otopetrin 1 
Lactotransferrin 
RIKEN cDNA 5439419D17 gene 
Carnitine palmitoyltransferese 1b 
Chitinase 3-like 1 
Acyl-CoA thioesterase 11 
Cell-death-inducing DNA fragmentation factor, 
alpha subunit-like effector 
Deiodinase, iodothyronine, type II 
Elongation of very long chain fatty acids 
(FEN1/Elo2, SUR4/elo3, yeast)-like 3 
Solute carrier family 5 
Indoleamine-pyrrole 2,3 dioxygenase 
Mucin 13 
Secretogranin III 
Secretory leukocyte peptidase inhibitor 
Tertraspanin 8 
Leucine rich repeat containing G protein coupled 
receptor 5 
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transcriptome) respectively (See Table 3-3). All of the above gene lists were 
created using FC≥1.5 and p≤0.05 cut off. The top 20 genes up-regulated in TEB 
and ductal stromal-epithelial signatures along with their FC are shown in Table 
3-4. Full lists of the above identified genes are shown in Appendix 3.  
3.2.6.1.3  Epithelium-free Fat pad ‘up-regulated gene set’ 
 
The Fat pad transcriptome was identified using RNA obtained from Fat pad, Pre-
LN and Post-LN mammary gland tissue strips. The yield of RNA obtained in each 
RNA extraction was sufficient to perform gene expression analysis in triplicate 
using Partek
® Genomics™ Suite software (See 2.2.5.5.3). Gene expression was 
compared  between  Fat  pad  and  Post-LN  and  688  genes  were  found  as  over-
expressed  in  Fat  pad  compared  to  Post-LN  strip  (Table  3-3).  Gene  list  was 
created using FC≥1.5 and p≤0.05 cut off. Full lists of the above identified genes 
are shown in Appendix 4. 
3.2.6.2  Gene expression analysis – Identification of the ‘expressed 
gene sets’  
Briefly, the „expressed gene sets‟ are defined as lists of genes expressed ≥ 1.1 
fold  change  cut  off  in  one  environment  when  compared  to  the  other 
environment. 
3.2.6.2.1  TEB- and duct epithelium-only ‘expressed gene sets’ 
 
6,577 non-annotated internal Affymetrix controls were excluded from both data 
sets that initially consisted of 23,239 genes. The remaining 16,661 genes were 
further reduced by 11,020 genes that were considered to be expressed to the 
same  level  in  the  TEBs  and  ducts.  A  TEB-only  expressed  transcriptome  was 
identified after subtraction of genes expressed in the ducts from the TEB data 
set.  Genes  only  expressed  in  the  ducts  were  identified  by  removing  the  TEB 
expressed genes from the ductal data set (See 2.2.5.6.1). This resulted in a set 
of 5,641 genes, which included 1,646 TEB associated genes (FC≥1.1) and 3,982 
duct associated genes (FC≤0.9). The full list of genes identified to be expressed 
specifically either in the epithelium of TEBs or ducts is shown in Appendix 5.     173 
 
3.2.6.2.2  TEB- and duct stroma-only ‘expressed gene sets’ 
 
Stromal  genes  expressed  around  the  epithelium  of  TEBs  and  ducts  were 
identified by comparing Post-LN and Pre-LN expressed genes with the gene sets 
of isolated TEBs and ducts. Genes expressed in the epithelium of TEBs and ducts 
were  subtracted  from  the  Post-LN  and  Pre-LN  gene  data  sets  to  remove  the 
epithelium associated genes.  Then the list of genes remaining in  the Post-LN 
data set was compared with the Pre-LN data set (See 2.2.5.6.2). The Post-LN 
strip consists of the epithelium and stroma of TEBs and ducts while the Pre-LN 
strip predominantly consists of ductal epithelium and stroma. In addition both 
tissue  strips  contain  stroma  distant  from  the  epithelial  structures,  i.e.  distal 
stroma.  The  comparison  of  epithelium-free  Post-LN  and  Pre-LN  gene  sets 
therefore permits the identification of stromal genes associated with TEBs in the 
Post-LN tissue strip and ducts in the Pre-LN strip after exclusion of stromal genes 
common  to  both  environments  (stromal  genes  expressed  around  both  the 
epithelium of TEBs as well as ducts and genes of the distal stroma).  
Both, Post-LN and Pre-LN gene lists initially consisted of 23,239 genes, which 
was  reduced  to  16,661  genes  after  exclusion  of  6,577  transcript  IDs 
corresponding to non-annotated internal Affymetrix controls. Further elimination 
of 14,071 TEB and 537 duct epithelium expressed genes from the Post-LN data 
set and 14,219 duct and 756 TEBs epithelium expressed genes from the Pre-LN 
data set led to the identification of the 2,053 Post-LN expressed and 1,687 Pre-
LN expressed stromal genes. A Venn diagram based comparison of these stromal 
transcript  IDs  revealed  the  presence  of  579  TEB-  and  213  duct  stroma-only 
associated genes (Figure 3-8). The full list of above identified stromal genes is 
shown in Appendix 6.  
3.2.6.3  Identification and classification of new, potential regulators of 
pubertal mouse mammary gland morphogenesis – candidate gene 
approach 
The  main  search  for  new  genes,  potentially  involved  in  the  orchestration  of 
ductal tree outgrowth during puberty, was carried out using the list of genes 
identified to be over-expressed in the epithelium of TEBs. TEBs were chosen as a 
focus of the study due to the key role they play in governing directional ductal      174 
 
 
Figure 3-8 Identification of TEB- and duct-associated stromal genes. 
The Venn diagram shows identification of 579 and 213 genes  expressed only in the stroma of 
TEBs or ducts respectively. Common non-specific stromal genes (1,474) are represented by the 
eclipse. The list of stromal genes was created by subtracting the epithelium expressed genes of 
TEBs  and  ducts  from  the  Post-LN  and  Pre-LN  gene  data  sets  and  comparing  lists  of  genes 
remaining in the Post-LN data set with Pre-LN data set. Full list of identified genes is deposited in 
Appendix 6. 
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outgrowth  during  puberty.  The  list  of  new  genes  that  could  potentially  be 
involved  in  regulation  of  pubertal  mammary  morphogenesis  was  obtained  by 
comparing the list of genes up-regulated in isolated TEBs (TEBs vs ducts) with 
genes  up-regulated  in  Post-LN  strips  (Post-LN  vs  Pre-LN)  and  identifying  the 
common gene set. The common gene set therefore contained transcripts whose 
expression was significantly up-regulated in both the epithelium of isolated TEBs 
and epithelium or stroma of TEBs placed within their natural environment, i.e. 
surrounded by stroma. This type of analysis also ensured that the up-regulated 
genes included in the final epithelial gene set were not influenced by any of the 
technical issues that could arise during the enzymatic isolation,  collection or 
storage of the isolated TEBs. 
The Venn diagram comparison of 425 and 565 genes over-expressed in TEBs and 
Post-LN strips respectively revealed the presence of 65 common genes (Figure 3-
9). The molecular function of each gene and its involvement in other biological 
processes that share similarities with pubertal mammary gland development was 
researched  using  information  deposited  in  publicly  available  databases  and 
published scientific papers, and the potential significance in pubertal mammary 
gland  morphogenesis  was  evaluated.  Classification  of  the  genes  according  to 
their main molecular functions identified 11 functional categories. The majority 
of genes (58.5%) encoded proteins that exhibited molecular functions connected 
with cell cycle and cellular proliferation, 15.3% were functionally implicated in 
cellular adhesion, 13.8% in cell death, 9.2% in intracellular transport and 7.7% in 
DNA  repair.  The  remaining  genes  encoded  proteins  involved  in  signal 
transduction (6.1%), metabolism (6.1%), regulation of transcription (6.1%) and 
immune  response  (4.6%).  A  further  6.1%  and  1.5%  of  the  genes  encoded 
structural proteins and growth factors respectively. The remaining 2 genes (3%) 
were left uncategorised due to unknown function (Figure 3-10 A). 
Furthermore, of particular interest was also each gene‟s involvement in other 
biological  processes  that  share  similarities  with  mammary  gland  development 
(See  2.2.5.9.3).  The  biological  processes  of  interest  included:  cellular 
migration, lung and kidney morphogenesis or cancer, embryonic and branching 
morphogenesis,  axonal  guidance.  Their  association  with  pubertal  mouse 
mammary gland will be discussed in 3.3.2.1. Literature available on each gene 
was also searched for previously documented evidence of a role in mammary      176 
 
 
Figure 3-9 Identification of TEB epithelial gene set. 
The Venn diagram shows the identification of 65 genes common to gene lists of 425 up-regulated 
genes in isolated TEBs (TEBs vs ducts) and 565 up-regulated genes in Post-LN strip. Full list of 
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Figure 3-10 Literature search based analysis of the 65 TEB epithelial gene set. 
Prevalence of all (A) molecular and (B) biological functions represented in the epithelial gene set 
assigned to genes using information obtained during literature search. TEBs epithelial gene set 
consists of the common genes identified to be up-regulated in both isolated TEBs (TEBs vs ducts) 
and Post-LN tissue strip (Post-LN vs Pre-LN). List of genes in each molecular, biological functional 
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gland development or breast cancer. Furthermore, since E2 is one of the main 
hormonal  cues  regulating  pubertal  morphogenesis  potential  oestrogen 
responsiveness  based  on  ERGDB,  a  database  which  includes  genes  whose 
expression has been experimentally shown to be up-regulated or down-regulated 
by  E2  (See  2.2.5.9.4),  was  noted  for  each  gene.  Literature  searches  for  all 
genes  except  Lama1  and  Ect2  oncogene  (Ect2)  were  focused  on  information 
obtained from M. musculus and H. sapiens. Functional information on Ect2 was 
based on D. melanogaster and C. elegans while the functional information on 
Lama1 was obtained from G. gallus. As a result, it was revealed that 52% of 
identified  genes  were  previously  recognized  to  be  associated  with  mammary 
gland morphogenesis and breast cancer. A further 30.7% and 16.9% were known 
to be involved in lung and kidney morphogenesis and cancer respectively while 
15.3%, 29.2%, 13.8% and 24.6% were known to be implicated in embryogenesis, 
cellular migration, branching morphogenesis and axonal guidance respectively. 
Finally, 35.4% of examined genes were identified to be oestrogen responsive as 
defined by ERGDB (Figure 3-10 B).  
The list of genes included in each molecular function and the type of biological 
functions they comply with are shown in Table 3-5. 
3.2.6.4  Comparison analysis of biological functions over-represented in the 
epithelial and stromal transcriptomes of TEBs and ducts. (Pathway 
analysis) 
IPA was used to perform a global  characterisation of the biological functions 
over-represented within the following gene sets. See Figure 3-1 (p.151) for the 
overview. 
  the TEB and duct epithelium „up-regulated gene sets‟  
  the TEB-only and duct-only epithelium „expressed gene sets‟ 
  the TEB-only and duct-only stroma „expressed gene sets‟  
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Table  3-5  Categorisation  of  65  TEB  epithelial  genes  based  on  molecular  and  biological 
function. 
TEB  epithelial  gene  set  comprised  genes  identified  as  commonly  up-regulated  in  both  isolated 
TEBs (TEB vs duct) and Post-LN tissue strips (Post-LN vs Pre-LN). All genes except Ect2 were 
assigned a molecular and biological function using information obtained from a literature search 
based on M. musculus and H. sapiens. Some biological functions of Ect2 were studied using C. 
elegans (*). 





























































Molecular Function: Cell Cycle (mitosis, meiosis, replication) and Cellular Proliferation 
Anln  Anilin  x  x    x  x    x  x  [281] [282] 
[283] 
Asf1B  Asf1 anti-silencing function 1 
homolog B 
                 
AurkB  Aurora kinase B    x    x        x  [284] [285] 
Birc5  Baculoviral IAP repeat-
containing 5 
x  x    x        x  [286] [287] 
[288] 
Bub1  Budding uninhibited by 
benzimidazoles 1 homolog 
  x 
 
  x 
 
        [289] [290] 
[291] 
Bub1B  Budding unihibited by 
benzimidazoles 1 homolog 
beta 
      x 
 
      x 
 
[292] 
Ccna2  Cyclin A2    x              [293] 
Ccnb2  Cyclin B2                   
Cenpa  Centromere protein A    x            x  [294] 
Dlg7  Disk large homolog 7    x      x  x      [295] [296] 
[297] 
Dna2L  DNA2 DNA replication 
helicase 2-like 
  x            x  [298] 
Ect2  Ect 2 oncogene  x(*)      x      x    [299] [300] 
[301] [302] 
Fbxo5  F-box protein 5        x              [303] 
Fignl1  Fidgetin-like 1      x  x          [304] [305] 
[306] 
H2afx  H2A Histone family member X    x            x  [307] 
Hells  Helicase,  lymphoid specific                   
Hist1H2ab  Histone cluster, H2ab                x   
Incep  Inner centromere protein    x    x          [308] [284] 
[285] 
Kif11  Kinesin family member 11  x  x    x      x  x  [309] [310] 
[311] [312] 
Kif23  Kinesin family member 23                   
Kif2C  Kinesin family member 2C  x 
 
            x  [313] 
Mcm3  Minichromosome 
maintenance deficient 3 
  x    x  x      x  [314] [315] 
[316] 
Mcm5  Minichromosome 
maintenance deficient 5 
              x   
Ncaph  Non-SMC condensing I 
complex, subunit H 
                 
Nusap1  Nuclear and spindle 
associated protein 1 
              x   
Pbk  PDZ binding kinase    x    x  x      x  [317] [318] 
[319] 
Plk1  Polo-like kinase 1  x  x            x  [320]     180 
 
Prc1  Protein regulator of 
cytokinesis 1 
  x            x  [321] 
Racgap1  Rac CTPase-activating 
protein 1 
x  x  x    x    x    [322] [323] 
[324] [325] 
[326] 
Sgol2  Shugoshin-like 2 (S. Pombe)                   
Skp2  S-phase kinase-associated 
protein 2 
x  x    x      x    [327] [328] 
[329] [330] 
Smc4  Structural maintenance of 
chromosomes 4 
                 
Stil  Scl/Tal1 interrupting locus      x        x    [331] 
Tk1  Thymidine kinase 1    x            x  [332] 
Top2a  Topoisomerase (DNA)II alpha    x          x  x  [333] [334] 
Tpx2  Microtubule-associated 
protein homolog (X. Laevis)  
                x 
 
x  [335] 
Uhrf1  Ubiquitin-like, containing 
PHD and RING finger domains 
   
x 




    x  [336] [337] 
[338] 
Zwilch  Kinetochore associated, 
homolog (D. Melanogaster) 
                 
Molecular Function: Cell Adhesion 
Dlg7  Disk large homolog    x      x  x      [295] [296] 
[297] 
Emb  Embigin  x  x  x    x  x      [339] [340] 
[341] 
Fbln2  Fibulin 2   x  x  x    x        [342] [343] 
[344] 
Fbn2  Fibrillin 2  x    x  x  x  x      [345] [346] 
[347] 
Fgb  Fibrinogen  x  x    x  x    x    [348] [349] 
[350] 
Lama1  Laminin  x  x   x        x     [351] [227] 
Ppp2r2b  Protein phosphatase 2 
regulatory subunit 
  x              [352] 
Reln  Reelin  x  x        x  x    [353] [354] 
Vcan  Versican  x  x    x  x  x  x    [355] [356] 
[357] 
Wnt5a  Wingless-related MMTV 













x  [358] [261] 
[359] 
Molecular Function: Cell Death (apoptosis, ubiquitin proteosome pathway) 
Atad2  ATPase family, AAA domain 
containing 2 
  x    x        x  [360] 
Birc5  Baculoviral IAP repeat-
containing 5 
x  x    x        x  [287] [286] 
[288] 
Bub1  Budding uninhibited by 
benzimidazoles 1 homolog 
   
x 
   
x 
        [292] 
Ccna2  Cyclin A2    x              [293] 
Fbxo5  F-box protein 5    x              [303] 
Fignl1  Fidgetin-like 1      x  x          [304] [305] 
[306] 
Ppp2r2b  Protein phosphatase 2 
regulatory subunit 
  x              [352] 
Skp2  S-phase kinase-associated 
protein 2 
x  x    x      x    [327] [328] 
[329] [330] 
Tk1  Thymidine kinase 1    x            x  [332] 
Molecular Function: Intracellular Transport 
Kif11  Kinesin family member 11  x  x    x      x  x  [309] [310] 
[311] [312] 
Kif23  Kinesin family member 23                   
Kif2C  Kinesin family member 2C  x 
 
            x  [313] 
Racgap1  Rac CTPase-activating 
protein 1 
x  x  x    x    x    [322] [323] 
[325] [324]     181 
 
[326] 
Slc7a5  Solute carrier family 7    x    x        x  [361] [362] 
Smc4  Structural maintenance of 
chromosomes 4 
                 
Molecular Function: DNA Repair 
H2aFx  H2A Histone family member X    x            x  [307] 
Hist1h2ab  Histone cluster, H2ab                x   
Neil3  Nei like 3 (E. Coli)                   
Top2a  Topoisomerase (DNA)II alpha    x          x  x  [333] [334] 
Uhrf1  Ubiquitin-like, containing 
PHD and RING finger domains 
  x 
 




    x  [336] [337] 
[338] 
Molecular Function: Signal Transduction 
Arhgap11a  Rho GTPase activating 
protein 11a 
                 
Pcp4  Purkinje cell protein 4      x        x    [363] [364] 
Ppp2r2b  Protein phosphatase 2 
regulatory subunit 
  x              [352] 
Wnt5a  Wingless-related MMTV 













x  [358] [261] 
[359] 
Molecular Function: Metabolism 
Gfpt2  Glutamine fructose-6-
phosphate transaminase 2 
                 
Ltb4dh  Leukotriene B4 12-
hydroxydehydrogenase 
                 
Nt5dc2  5‟-nucleotidase domain 
containing 2  
                 
Tk1  Thymidine kinase 1    x            x  [332] 
Molecular Function: Transcription Regulation 
Il33  Interleukin 33  x  x              [365] [366] 
Mcm3  Minichromosome 
maintenance deficient 3 
  x    x  x      x  [314] [315] 
[316] 
Myef2  Myelin gene expression factor                   
Uhrf1  Ubiquitin-like, containing 
PHD and RING finger domains 
  x 
 




    x  [336] [337] 
[338] 
Molecular Function: Structural Protein 
H2afx  H2A Histone family member X    x            x  [307] 
Hist1h2ab  Histone cluster, H2ab                x   
Tubb6  Tubulin beta 6  x                [367] 
Upk3a  Uroplakin 3a                   
Molecular Function: Immune Response 
Fgb  Fibrinogen  x  x    x  x    x    [350] [348] 
[349] 
Il33  Interleukin 33  x  x              [365] [366] 
Itih2  Inter-alpha trypsin inhibitor, 
heavy chain 2 
                 
Molecular Function: Growth Factor 
Nrg1  Neuregulin-1 type 1 beta 1a  x  x  x  x    x  x    [368] [369] 
[370] [371] 
Molecular Function: Unknown 
Mlkl  Mixed lineage kinase 
domain-like 
  x              [372] 
Serpinb11  Serine (or cysteine) 
peptidase inhibitor clade B, 
member 11 
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Thus, epithelial transcriptomes of TEBs and ducts were represented by two gene 
sets each, i.e. an „up-regulated gene set‟ and „expressed gene set‟ while their 
stroma associated signatures were represented by the „expressed gene set‟ only. 
„Pathway analysis‟ of these gene sets was performed to depict and compare the 
functional characteristics between epithelial and stromal transcriptomes of TEBs 
and ducts. 
Each data set was screened for the presence of mapped, function eligible genes, 
which were then assigned to different functional categories depending on their 
molecular and  cellular  function  or  their  role  in  development  and  function  of 
physiological  systems.  The  over-represented  biological  functions  were  ranked 
according to the calculated p-values (See 2.2.5.9.1). 
The  following  numbers  of  genes  were  shown  to  be  mapped  and  allocated  a 
function according to IKD: within the „up-regulated gene sets‟ of the TEB and 
duct epithelium respectively, 422 and 186 were mapped and 355 (83%) and 148 
(79%) were allocated a function. With the „expressed gene sets‟ of TEB and duct 
epithelium respectively, 1374 and 3470 genes were mapped and 1198 (72%) and 
2810 (70%) genes were allocated a function. Finally the stroma „expressed gene 
sets‟ of TEB and duct consisted of 568 and 211 mapped genes respectively, of 
which 443 (76.5%) and 149 (70%) were allocated a function.  
„Pathway analysis‟ revealed clear differences between biological functions over- 
represented in the data sets of the TEBs and ducts environments. Differences in 
the  biological  functions  were  prominent  in  both  of  the  studied  functional 
categories,  i.e.  molecular  and  cellular  function  and  physiological  systems 
development and function. The top 5 molecular and cellular functions and the 
top 5 functions associated with physiological systems development and function 
that were over-represented in the data sets along with the number of genes 
complying  with  each  category  are  shown  in  Table  3-6  and  Table  3-7 
respectively.   
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3.2.6.4.1  Molecular and Cellular Functions: Identification of the top 
5 over-represented categories  
 
Genes up-regulated in TEB and duct epithelium („up-regulated gene sets‟) 
Briefly, as seen in Table 3-6, the set of genes up-regulated in TEB epithelium 
was functionally mostly associated with cell cycle and cell proliferation („Cell 
Cycle‟,  „Cellular  Assembly  and  Organisation‟,  „Cellular  Growth  and 
Proliferation‟)  and  „DNA  Replication,  Recombination  and  Repair‟.  The  duct 
epithelium up-regulated gene set was rather associated with cellular signalling 
(„Cell-to-Cell Signalling and Interaction‟, „Cell Signalling‟), „Molecular Transport‟ 
or „Cell Death‟ than „Cell Proliferation‟. Both of the above mentioned gene sets 
also contained genes functionally associated with „Cellular Movement‟ which was 
interestingly ranked higher in the ductal data set (#2) with 24.3% of genes than 
in the TEB data set (#4) with 6% of genes.  
Genes expressed in the TEB- and duct-only epithelium („expressed gene sets‟) 
More prominent differences between the epithelial transcriptomes of TEBs and 
ducts  were  revealed  when  the  IPA  results  for  the  entire  expressed 
transcriptomes  of  TEB-  or  duct-only  epithelium  were  compared.  The  most 
apparent difference was seen in terms of „Cellular Movement‟ which was the 
most over-represented function in the TEBs data set (27.8% of genes) but was 
absent  from  the  top  5  functions  associated  with  the  ductal  data  set.  The 
remaining four top functional categories of the TEB data set were associated 
with  cellular  proliferation  and  signalling  („Cellular  Growth  and  Proliferation‟, 
„Cell-to-Cell  Signalling  and  Interaction‟,  „Cellular  Signalling‟)  and  „Molecular 
Transport‟ which made it comparable to the functional profile of the TEB „up-
regulated gene set‟. In contrast, the duct-only „expressed gene set‟ was shown 
to  share  fewer  similarities  with  the  duct  „up-regulated  gene  set‟  and 
represented  a  more  regulatory  profile  („DNA  Replication,  Recombination  and 
Repair‟,  „RNA  Post-Transcriptional  Modification‟,  „Cellular  Assembly  and 
Organisation‟)  than  the  TEB-only  „expressed  gene  set‟.  „Cell  Cycle‟  and 
„Molecular  Transport‟  were  the  two  remaining  biological  functions  over- 
represented in the duct-only „expressed gene set‟.      184 
 
TEBs  DUCTS 
 













GENES UP-REGUATED IN THE ISOLATED EPITHELIUM ‘UP-REGULATED GENE SETS’ 
Cell Cycle   137 
(38.6%) 




Cellular Assembly and Organisation  82  
(23%) 
Cellular Movement  36 
(24.3%) 




Cell Death  55 
(37.1%) 
Cellular Movement  22  
 (6%) 
Cell Signalling  39 
(26.3%) 
Cellular Growth and Proliferation  126 
(35.5%) 
Molecular Transport  52  
(35%) 
GENES EXPRESSED IN THE ISOLATED EPITHELIUM ‘EXPRESSED GENE SETS’ 
Cellular Movement  333 
(27.8%) 








Cell Cycle  416 
(14.8%) 






Cell Signalling  232 
(19.3%) 




Molecular Transport  209 
(17.4%) 
Molecular Transport  103 
(3.6%) 
GENES EXPRESSED IN THE STROMA ‘EXPRESSED GENE SETS’ 
Cell Death  148 
(33.4%) 
Lipid Metabolism  22 
(14.7%) 
Cell Morphology  76 
(17.1%) 
Small Molecule Biochemistry  42 
(28.9%) 
Cellular Growth and Proliferation  141 
(31.8%) 
Carbohydrate Metabolism  15 
(10%) 
Cellular Movement  96 
(20.5%) 
Cellular Compromise  7 
(4.7%) 




Cell Morphology  11 
(7.4%) 
Table 3-6 Comparison of the top 5 cellular and molecular functions over-represented in the 
epithelial and stromal data sets of TEBs and ducts. 
The top 5 functions were identified using IPA. The over-representation of each functional category 
within  the  data  set  was  shown  to  be  statistically  significant  (p≤0.05).  Functional  analysis  was 
performed on the three gene sets: genes up-regulated in the isolated epithelium of TEBs and ducts 
(3.2.6.1.1), genes expressed in the isolated epithelium of TEBs and ducts (3.2.6.2.1) and genes 
expressed in the stroma of TEBs and ducts (3.2.6.2.2). Only genes mapped and function eligible 
according  to  the  IKD  were  used  for  the  analysis.  Number  of  genes  and  the  calculation  of  the 
percentage of genes were based on the number of genes associated with the given function and 
the number of function eligible genes within the studied data set. The list of genes belonging to 
each functional category and the calculated p-values are shown in Appendix 7. 
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Genes expressed in TEB- and duct-only stroma („expressed gene sets‟) 
The  biggest  differences  between  the  TEB  and  duct  transcriptomes  were 
identified in the stromal compartments. The stroma of the TEB-only, similarly to 
the epithelium, was characterised as a very dynamic and motile environment 
(„Cell Morphology‟, „Cellular Growth and Proliferation‟, „Cell Death‟, „Cell-to-
Cell Signalling and Interaction‟, „Cellular Movement‟). On the other hand, the 
stromal transcriptome of the ducts was mostly involved in sustaining the ductal 
epithelium by being involved in metabolic processes („Lipid Metabolism‟, „Small 
Molecule  Biochemistry‟  or  „Carbohydrate  Metabolism‟),  „Cellular  Compromise‟ 
and „Cell Morphology‟.  
3.2.6.4.2  Physiological System Development and Function – 
Identification of the top 5 over- represented categories 
 
Functional differences between TEB and duct epithelial and stromal data sets 
were also noticeable with regards to their involvement in physiological system 
development  and  function.  Only  1.1%-6.5%,  1.8%-2.9%  and  0.7%-8.7%  genes, 
however,  were  assigned  to  the  top  5  functions  in  the  TEB  epithelium  „up-
regulated genes set‟, duct-only epithelium „expressed gene set‟ and duct-only 
stroma „expressed gene set‟ respectively. 
Genes up-regulated in TEB and duct epithelium („up-regulated gene sets‟) 
As seen in the Table 3-7 most of the genes identified to be up-regulated in the 
TEB  epithelium  were  involved  in  maintenance  of  tissue  morphology  and 
embryonic  development.  Furthermore,  they  were  also  found  to  play  roles  in 
regulating  the  function  and  development  of  connective  tissue  and 
cardiovascular,  skeletal  and  muscle  systems.  Genes  up-regulated  in  the  duct 
epithelium were also shown to play roles in the „Development and Function of 
the  Cardiovascular  System‟  and  to  be  functionally  associated  with  „Tissue 
Morphology  and  Development‟.  In  addition,  genes  over-expressed  in  the  duct 
epithelium were involved in „Haematological System Development and Function‟ 
and „Immune Cell Trafficking‟.      186 
 
TEBs  DUCTS 
Physiological System 













GENES UP-REGULATED IN THE ISOLATED EPITHELIUM ‘UP-REGULATED GENE SETS’ 
Tissue Morphology  12 
(3.4%) 
Haematological System 
Development and Function 
51 
(34.4%) 
Embryonic Development  23 
(6.5%) 
Tissue Morphology  34 
(23%) 
Cardiovascular System 
Development and Function  
4  
(1.1 %) 
Immune Cell Trafficking  35 
(23.6%) 





Development and Function 
21 
(14.2%) 
Skeletal and Muscular System 
Development and Function 
4  
(1.1%) 
Tissue Development  23 
(15.5%) 
GENES EXPRESSED IN THE ISOLATED EPITHELIUM ‘EXPRESSED GENE SETS’ 
Immune Response  339 
(28.3%) 




Immune and Lymphatic System 
Development and Function 
301 
(25.1%) 
Embryonic Development  65 
(2.3%) 
Tissue Morphology  245 
(20.4%) 
Tumour Morphology  53 
(1.8%) 
Haematological System 




Development and Function 
57 
(2%) 
Tissue Development  309 
(25.8%) 
Organ Development  57 
(2%) 
GENES EXPRESSED IN THE STROMA ‘EXPRESSED GENE SETS’ 
Organismal Survival  74 
(16.7%) 
Skeletal and Muscular System 




Development  and Function 
102 
(23%) 
Tissue Development  10 
(6.7%) 
Cardiovascular System 
Development and Function 
51 
(11.5%) 
Organismal Development  9 
(6%) 
Tissue Morphology  75 
(16.9%) 
Auditory and Vestibular System 
Development and Function 
1 
(0.7%) 
Tissue Development  88 
(19.8%) 
Cardiovascular System 
Development and Function 
6 
(4%) 
Table  3-7  Comparison  of  the  top  5  categories  associated  with  the  physiological  system 
development and function shown to be over-represented in the epithelial and stromal data 
sets of TEBs and ducts. 
For the legend see Table 3-5. The list of genes belonging to each functional category and the 
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Genes expressed in the TEB- and duct-only epithelium („expressed gene sets‟) 
The top functional categories over-represented in the epithelium of TEB- and 
duct-only „expressed gene sets‟ were different to these seen in the TEB and duct 
epithelium „up-regulated gene sets‟. Although, „Tissue Morphology‟ and „Tissue 
Development‟ were still within the functional categories over-represented in the 
TEB-only  epithelium  „expressed  gene  set‟,  here  the  highest  ranked  functions 
were  „Immune  Response‟  (28.3%  of  genes)  and  „Immune  System  Development 
and  Function‟  (25.1%  of  genes).  In contrast  to  the  analysis  based  on  the up-
regulated  epithelial  genes,  this  analysis  indicated  that  the  „Haematological 
System Development and Function‟ was associated with the TEBs. Furthermore, 
functional  categories,  such as  „Embryonic Development‟,  „Cardiovascular-  and 
Connective Tissue Development and Function‟ were also shown to be associated 
with  ducts  instead  of  TEBs,  contradicting the  results  of  the  above  presented 
analysis. The two remaining functional categories for the duct-only epithelium 
expressed gene data set were „Tumour Morphology‟ and „Organ Development‟.   
Genes expressed in the TEB- and duct-only stroma („expressed gene sets‟) 
Finally, functional analysis of genes expressed in the stroma failed to reveal any 
new functional characteristics of the TEB-only stroma, apart from implicating it 
in „Organism survival‟. It confirmed, however, the contribution of TEB associated 
genes (epithelial as well as stromal) to the regulation of tissue morphology and 
development  and  their  involvement  in  the  development  and  function  of 
haematological  and  cardiovascular  systems.  Analysis  of  the  duct-only  stroma 
„expressed  gene  set‟,  however,  implicated  this  transcriptome  in  both  -  the 
previously  mentioned  functional  categories  („Skeletal-  and  Cardiovascular 
System Development and Function‟, „Tissue Development‟) and new ones, such 
as – „Organism Development‟, „Auditory and Vestibular System Development and 
Function‟. 
All  functional  categories  found  to  be  over-represented  in  this  analysis  were 
statistically significant. The list of genes implicated in each cellular/molecular 
process-based  category  and  physiological  system  development  and  function 
based categories, alongside with the p-values calculated for each category are 
shown in Appendix 7 and Appendix 8 respectively.           188 
 
 
3.2.6.5  ‘Cellular Movement’ during pubertal mouse mammary gland 
morphogenesis – Comparison of transcriptomes from TEBs and 
ducts 
The association of TEB and duct transcriptomes with the three key biological 
functions: „Cellular Movement‟, „Nervous System Development and Function‟ and 
„Embryonic  Development‟  were  chosen  to  be  discussed  in  more  detail  (See 
3.2.6.5, 3.2.6.6 and 3.2.6.7) (Figure 3-11). 
One  of  the  main  events  which  characterises  pubertal  mouse  mammary  gland 
development  is  the  expansion  of  the  ductal  tree.  This  ductal  morphogenesis 
consists  of  ductal  elongation  mediated  by  TEBs  outgrowth,  branching  and 
directional turning, and secondary ductal branching. None of these processes are 
yet fully characterised but based on their motile character they are likely to be 
associated  with  the  expression  of  genes  functionally  involved  in  migratory 
processes, cellular movement or cellular invasion.  
Hence,  to  explore  this  hypothesis,  the  information  obtained  from  IPA  (See 
3.2.6.4)  was  used  to  examine  the  level  and  expression  pattern  of  genes 
associated  with  „Cellular  Movement‟  during  pubertal  mouse  mammary  gland 
development.  Genes  identified  as  associated  with  the  „Cellular  Movement‟ 
according to the IKD, were compared throughout all six gene sets (TEB or duct 
epithelium  „up-regulated  gene  sets‟,  TEB-  or  duct-only  epithelium  „expressed 
gene sets‟, TEB- or duct-only stroma „expressed gene sets‟). Furthermore, based 
on the emerging evidence which shows the association of EMT, which is a process 
in  which  the  adherent  epithelial  cells  shed  their  epithelial  characteristics  in 
favour of acquiring mesenchymal properties, with promoting cellular migration 
during  embryonic  development  or  cellular  invasion  during  tumour  metastasis 
formation  (reviewed  in  [373]),  the  gene  sets  shown  to  be  differentially 
expressed in TEB environment were manually screened for the presence of EMT 
signature genes. The EMT signature consists of EMT core signature genes plus 10 
additional key mesenchymal markers (See 2.2.5.9.2). The EMT core signature      189 
 
 
Figure  3-11  Selective,  Ingenuity  Pathway  Analysis  (IPA)-based  functional  comparison 
analysis of the identified pubertal gene sets. 
IPA analysis was performed as described in 3.2.1.5 and the following functional categories were 
selected for the comparison analysis: (A) Cellular Movement (B) Nervous System Development 
and Function (C) Embryonic Development. The association of each functional category within the 
data set was shown to be statistically significantly (p≤0.05). Comparison analysis was performed 
using three gene sets: genes up- regulated in the isolated epithelium of TEBs and ducts (3.2.6.1.1), 
genes expressed in the isolated epithelium of TEBs and ducts (3.2.6.2.1) and genes expressed in 
the stroma of TEBs and ducts (3.2.6.2.2). Only genes mapped and ‘function eligible’ according to 
the IKD were used for the analysis. The calculation of the percentages of genes associated with 
each category  was  based on the  number of genes  associated  with the  given  function  and the 
overall number of function eligible genes within the studied data set. The full list of subcategories 
identified within each functional category, genes belonging to each subcategory and the calculated 
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was developed by Taube at al. (2010) and it consists of 87 and 159 genes that 
were  found  up-regulated  and  down-regulated  respectively  as  a  response  to 
inducing EMT in breast cancer cells in vitro [270] (See Table 2-8). Based on the 
fact  that  a  mesenchymal  genotype  can  be  characterised  by  both  the  up-
regulation of mesenchymal and down-regulation of epithelial markers both the 
TEB up- and down-regulated (i.e. duct up-regulated) gene lists were screened.  
The  presence  of  mesenchymal  markers  (up-regulated  in  response  to  EMT) 
amongst the TEB down-regulated genes and the presence of epithelial markers 
(down-regulated in response to EMT) in the TEB up-regulated genes was also 
assessed. This served as a negative control.  
Terminal end buds 
In  general,  most  genes  associated  with  „Cellular  Movement‟  were  identified 
within  the  TEB  gene sets.  27.8%,  21.7%  and  6.2%  of  epithelium  „expressed-‟, 
stroma „expressed-‟ and epithelium „up-regulated gene sets‟ respectively were 
shown  to  be  functionally  implicated  in  „Cellular  Movement‟  (Figure  3-11  A). 
Some of the functional sub categories represented in the gene set expressed in 
the  TEB-only  epithelium  were  „cellular  movement  or  migration  of  eukaryotic 
cells,  -immune  response  cells,  -cell  lines  (normal,  embryonic,  tumour)‟; 
„infiltration  or  chemotaxis  of  eukaryotic  cells,  „-immune  response  cells‟  and 
„invasion of eukaryotic cells, -cell lines (normal and tumour)‟. Some of the genes 
expressed in the TEB-only stroma were shown to be involved in the „movement 
of eukaryotic cells, -cell lines (normal and tumour)‟; „migration of normal cells, 
-cell  lines  (normal  and  tumour),  -immune  response  cells‟;  „cell  movement  of 
central  nervous  system  cells,  -immune  response  cells,  -tumour  cell  lines‟; 
„invasion of normal cells and neuroglia‟ and „chemotaxis of eukaryotic cells, -
bone and nervous tissue cell lines‟‟. Genes up-regulated in the TEBs epithelium, 
on the other hand, were shown to be mostly implicated in the „chemorepulsion 
of neuritis‟ and „chemotaxis of bone marrow-derived macrophages‟. 
The  screening  of  TEB  environment  up-and  down-regulated  genes  lists  for  the 
presence  of  EMT  signature  genes  revealed  presence  of  3  and  11  EMT  up-
regulated markers within TEB epithelium (TEBs vs ducts) and TEB epithelium-
stroma (Post-LN vs Pre-LN) up-regulated genes respectively which accounted for     191 
 
3 % and 11% of EMT signature genes respectively. As for the EMT down-regulated 
markers, 8 (5%) and 16 (10%) of them could be seen in TEB epithelium (ducts vs 
TEBs)  and  TEB  epithelium-stroma  (Pre-LN  vs  Post-LN)  down-regulated  genes 
respectively.  Furthermore,  17  out  of  the  31  EMT  marker  genes  found  to  be 
differentially  expressed  in  TEB  environment,  have  not  yet  been  described  or 
studied  in  mouse  mammary  gland  before.  These  genes  are:  Col1a2,  Col5a2, 
Extracellular  matrix  protein  1(Ecm1),  Fibroblast  activation  protein  (Fap), 
Fibulin  1  (Fbln1),  Fibrillin  1  (Fbn1),  Cytochrome  b  reductase  1  (Cybrd1), 
Adaptor  protein  complex  AP1,  mu  2  subunit  (Ap1m2),  Coxsackie  virus  and 
adenovirus receptor (Cxadr), Potassium channel, subfamily K, member 1(Kcnk1), 
Kallikrein-related  peptidase  8  (Klk8),  Ladinin  (Lad1),  Tripartite  motif-
containing  29  (Trim29),  Aldehyde  dehydrogenase  family  1,  subfamily  A3 
(Aldh1a3), N-myc downstream regulated gene 1 ( Ndrg1) and Synaptotagmin-like 
1 (Slp1).  
The negative experimental control, however, revealed that 4 (4%) and 3 (3%) of 
EMT  up-regulated  genes  (mesenchymal  markers)  were  down-regulated  in  TEB 
epithelium  (ducts  vs  TEBs)  and  TEB  epithelium-stroma  (Pre-LN  vs  Post-LN) 
respectively and 6 (3.7%) and 5 (3%) of EMT down-regulated genes (epithelial 
markers)  were  up-regulated  in  TEB  epithelium  (TEBs  vs  ducts)  and  TEB 
epithelium-stroma (Post-LN vs Pre-LN) respectively.  
Full list of identified genes can be seen in Table 3-7. 
Ducts 
Looking  at  the  gene  expression  for  ducts,  24.3%,  5.3%  and  0.9%  of  genes 
belonging  to  the  epithelium  „up-regulated-„,  stroma  „expressed-„,  epithelium 
„expressed  gene  sets‟  respectively  were  shown  to  be  functionally  involved  in 
processes  associated  with  „Cellular  Movement‟  (Figure  3-11  A).  Genes  up-
regulated in duct epithelium were shown to be associated with the following 
subcategories: „cell movement of immune response cells‟, „-cell lines (normal 
and  tumour)‟;  „cell  rolling‟  or  „infiltration  of  immune  response  cells‟; 
„chemotaxis of immune response cells and fibroblasts‟; „migration of immune 
response  cells,  -cell  lines  (normal  and  tumour),  -astrocytes‟  and  „invasion  of 
normal cells, -cell lines (normal and tumour)‟. Subcategories for the stroma      192 
 
EMT up-regulated markers up-regulated in 
Isolated TEB epithelium  TEB epithelium and stroma 
Cytochrome b reductase 1 (Cybrd1) 
Hyaluronan synthase 1 (Has2) 
Wingless-related MMTV integration site 5a 
(Wnt5a) 
Collagen type1, alpha 2 (Col1a2) 
Collagen type 5, alpha 2(Col5a2) 
Discorin domain receptor family member 2 
(Ddr2) 
Extracellular matrix protein 1 (ECM1) 
Fibroblast activation protein (FAP) 
Fibulin 1 (Fbln1) 
Fibrillin 1 (Fbn1) 
Olfactomedin-like 3 (Olfml3) 
Procollagen C-endopeptidase enhancer 
protein (Pcolce) 
Paired related homeobox 1 (Prrx1) 
Wingless-related MMTV integration site 5a 
(Wnt5a) 
EMT down-regulated markers down-regulated in 
Isolated TEB epithelium  TEB epithelium and stroma 
Annexin A8 (Anxa8) 
Aldehyde dehydrogenase family 1 subfamily 3a 
(Aldh1a3) 
Interleukin 1 beta (Il1b) 
Keratin 14 (Krt14) 
Keratin 15 (Krt 15) 
Keratin 17 (Krt17) 
N-myc downstream regulated gene 1 (Ndrg1) 
Stomatin-like 1 (Slp1) 
Annexin A8 (Anxa8) 
Adaptor protein complex AP-1, mu 2 subunit 
(Ap1m2) 
BCL-2 interacting killer (BIK) 
Coxsackie virus and adenovirus receptor 
(Cxadr) 
Interferon regulatory factor 6 (Irf6) 
Potassium channel, subfamily K, member 1 
(Kcnk1) 
Kallikrein related-peptidase 8 (Klk8) 
Keratin 17 (Krt17) 
Keratin 18 (Krt18) 
Keratin 5 (Krt5) 
Ladinin (Lad1) 
Prostasin (Prss8) 
Tripartite motif-containing 29 (Trim29) 
Stomatin-like 1 (Slp1) 
EMT up-regulated markers down-regulated in (negative control) 
Isolated TEB epithelium  TEB epithelium and stroma 
Latent transforming growth factor beta binding 
protein 1 (Ltbp1) 
Latent transforming growth factor beta binding 
protein 2 (Ltbp2) 
Membrane metallo endopeptidase (Mme) 
Pentraxin related gene (Ptx3) 
Coiled-coil domain containing 92 (Ccdc92) 
Latent transforming growth factor beta 
binding protein 2 (Ltbp2) 
Melanophilin (Mlph) 
EMT down-regulated markers up-regulated in (negative control) 
Isolated TEBs  TEB epithelium and stroma 
Cyclin D2 (Ccnd2) 
Desmocollin 2 (Dsc2) 
Insulin-like growth factor binding protein 2 
(Igfbp2) 
Keratin 5b (Krt6b) 
Rnf128 
S100 calcium binding protein A14 (S110a14) 
Annexin A3 (Anxa3) 
Gho GTPase activating protein 25 (Arhgap25) 
Coronin, actin binding protein 1A (Coro1a) 
Interferon gamma inducible protein 30 
(Ifi30) 
Interleukin 80 (Il80) 
Table 3-8 List of EMT core signature genes also identified as differentially expressed in TEB 
environment. 
EMT signature consists of the EMT core signature genes plus the 10 additional key mesenchymal 
markers (See Table 2-8). EMT signature consists of the up-regulated as well as down-regulated in 
response to EMT genes thus both the TEB up-regulated (TEBs vs ducts) (Post-LN vs Pre-LN) and 
down-regulated (ducts vs TEBs) (Pre-LN vs Post-LN) gene lists were screened. Genes that have 
not been studied in mouse mammary gland before are highlighted in grey. Screening for EMT up-
regulated markers identified as down-regulated in TEB environment and the EMT down-regulated 
markers identified as up-regulated in TEB environment was used as a negative control.      193 
 
expressed genes around ducts only included: „cell movement of microtubules, -
epithelial cells‟; „migration of muscle cells, -gonadal cell lines, -hepatic stellate 
cells, -proepicardial cells‟; „invasion of hybrid cells, -smooth muscle cells‟ and 
„chemotaxis of keratinocytes‟. Finally, all of the „Cellular Movement‟ associated 
genes expressed in the duct-only epithelium were functionally connected with 
„cytokinesis‟.  
In  summary,  the  following  gene  sets  were  identified  as  exhibiting  the  most 
motile  character:  TEB-only  epithelium  „expressed  gene  set‟,  duct  epithelium 
„up-regulated  gene  set‟,  TEB-only  stroma  „expressed  gene  set‟  and  duct-only 
stroma „expressed gene set‟.  
The  full  list  of  detailed  functional  categories,  calculated  p-values  and  genes 
complying with each category are shown in Appendix 9 A.       
3.2.6.6   ‘Nervous System Development and Function’ during mouse 
mammary gland morphogenesis – Comparison of transcriptomes 
from TEBs and ducts 
Several  genes  previously  recorded  to  be  associated  with  nervous  system 
development  or  function,  i.e.  axonal  guidance  or  axonal  growth  cones 
development, were recently suggested to be involved in a ductal morphogenesis 
of the mouse mammary gland [113] [259]. 
Based on those observations, we performed a detailed functional analysis of the 
„Nervous  System  Development  and  Function‟  associated  genes  in  the 
transcriptomes of TEBs and ducts.  
The  study  was  based  on  the  information  obtained  from  the  IPA  and  the 
comparison  analysis  was  performed  as  described  in  3.2.6.4.  As  presented  in 
Figure 3-11 B, the majority of nervous system associated genes were expressed 
within the stroma of TEBs (9.7%), duct epithelium up-regulated genes (5.4%) and 
the duct-only stroma (4%). In contrast, very few nervous system associated genes 
were expressed within the TEB epithelium „up-regulated gene set‟ (0.9%) and 
duct epithelium „expressed gene set‟ (0.1%).      194 
 
Terminal end buds 
Thus, the clearest reference in pubertal mouse mammary gland gene expression 
to  the  pattern  of  gene  expression  characteristic  for  the  nervous  system 
development and function was seen in the stroma of the TEBs. In contrast, the 
epithelium of TEBs expressed only a single gene, implicated in chemorepulsion 
of  sympathetic  neurites  (Sema3B).  Some  of  the  TEB-only  stroma  associated 
functional  subcategories  included:  „outgrowth  of  neurites‟,  „-sensory  axons‟; 
„myelination‟; „activation, chemorepulsion or stimulation of neurons‟; „migration 
or survival of astrocytes‟ and „chemotaxis of neuronal tissue cell lines‟.  
Ducts 
Although fewer „Nervous System Development and Function‟ associated genes, 
were  found  in  the  ductal  genes  sets,  they  were  expressed  almost  equally 
between epithelium and stroma. Some of the functional subcategories were as 
follows:  „survival,  migration  of  astrocytes‟;  „activation  and  stimulation  of 
neurons‟ (duct epithelium up-regulated genes), „maturation of synaptic vesicles‟ 
(duct-only  epithelium  expressed  genes)  and  „axogenesis  of  neurons‟  and 
„communication of nervous tissue cell lines‟ (duct-only stroma expressed genes).  
The  full  list  of  detailed  functional  categories,  calculated  p-values  and  genes 
complying with each category are shown in Appendix 9 B.  
3.2.6.7  ‘Embryonic Development’ during pubertal mouse mammary gland 
morphogenesis – Comparison of transcriptomes from TEBs and 
ducts 
Embryonic  development  is  known  to  be  fully  dependent  on  the  presence  of 
reciprocal  signalling  between  the  epithelial  and  mesenchymal  environments 
[374].  Furthermore,  stromal-epithelial  interactions  are  vital  for  normal  post 
natal ductal outgrowth and branching of the mouse mammary gland [126] and 
play an important role in creating a permissive environment for initiation and 
promotion of carcinogenesis (reviewed in [375]).      195 
 
Given the great importance of stromal-epithelial cross-talk during both mouse 
mammary morphogenesis and embryonic development, the TEB and ductal gene 
sets  were  also  screened  for  the  presence  of  genes,  identified  in  the  IKD  as 
implicated  in  „Embryonic  Development‟  (as  described  in  3.2.6.4).  IPA  based, 
comparison analysis identified „Embryonic Development‟ associated genes in all 
of the examined genes sets, i.e. both epithelial and stromal compartments of 
TEBs and ducts. The direct comparison of TEB and duct environments showed a 
slightly stronger association of TEB data sets with „Embryonic Development‟ than 
duct data sets. Furthermore, both epithelial and stromal compartments of TEBs 
or  ducts  contained  a  similar  percentage  of  genes  known  to  be  involved  in 
embryonic development.  
Terminal end buds 
Amongst TEB gene sets, 4.2%, 6.5% and 5.9% of epithelium expressed, epithelium 
up-regulated  and  stroma  expressed  genes  respectively  were  shown  to  be 
functionally associated with the embryonic development (Figure 3-11 C). Some 
of the functional subcategories identified to be associated with the TEBs gene 
sets  were  as  follows:  „remodelling  or  patterning  of  the  tissue  (epithelium 
expressed  genes)‟,  „formation  of  embryoblast  and  mesenchyme‟;  „survival  of 
embryonic cells‟; „patterning of nervous tissue‟ (epithelium up-regulated genes) 
and „development of embryo‟.  
Ducts 
As for ducts gene sets, 2.3%, 4% and 4.7% of epithelium expressed, epithelium 
up-regulated  and  stroma  expressed  genes  respectively  were  previously 
implicated in „Embryonic Development‟ (Figure 3-11 C). The following examples 
of functional subcategories were associated with identified genes: „survival or 
cell death of embryonic cells‟; „growth of embryo and blastocyst‟; „folding of 
embryonic  tissue‟;  „proliferation  of  morula‟  (epithelium  expressed  genes); 
„formation of forelimb bud‟, „‟morphology of branchial arch‟ (stroma expressed 
genes) while all of the „Embryonic Development‟ associated genes identified in 
the  ductal  epithelium  „up-regulated  gene  set‟  were  shown  to  be  functionally 
implicated  in  „branching  morphogenesis  of  carcinoma,  -thyroid  tumour,  and 
kidney cell lines‟.      196 
 
The  full  list  of  detailed  functional  categories,  calculated  p-values  and  genes 
complying with each category are shown in Appendix 9 C. 
3.2.7  Summary 
This study was performed to carry out detailed microarray analysis of the mouse 
mammary  gland  pubertal  transcriptome.  As  a  result,  6  individual  gene  sets, 
containing genes expressed or up-regulated in the epithelium or stroma of the 
TEBs or ducts were identified. Furthermore, 65 genes were selected as potential 
new  regulators  of  pubertal  mouse  mammary  gland  morphogenesis,  based  on 
their  association  with  the  epithelium  of  TEBs.  A  literature  search  allowed 
classification  of  these  genes  according  to  their  main  biological  function  and 
involvement  in  other  biological  processes  known  to  share  similarities  with 
mammary  gland  morphogenesis,  i.e.  lung,  kidney  morphogenesis  and  cancer, 
cellular  migration,  embryonic  and  branching  morphogenesis  and  axonal 
guidance.  Further  „functional‟  analysis  was  performed  on  the  epithelial  and 
stromal  gene  sets  using  IPA  to  identify  the  top  biological  functions  over-
represented  in  each  gene  set.  Epithelial  and  stromal  gene  sets  were  also 
screened  and  compared  for  the  presence  of  „Cellular  Movement‟,  „Nervous 
System  Development  and  Function‟  and  „Embryonic  Development‟  associated 
genes  and  the  main associated  functional  categories  were  identified.  Finally, 
TEB environment up-regulated and down-regulated genes were screened for the 
presence of EMT-associated genes.     197 
 
3.3 Discussion 
Gene expression profiling using DNA microarrays is one of the most successful 
tool  for  the  analysis  of  global  gene  expression.  Although  it  does  have  its 
drawbacks,  such  as  decreased  sensitivity  of  signal  detection  if  the  gene 
expressing cells comprise a small subset of cells within the tested tissue, and 
requirement for good quality RNA, it is the only method that allows simultaneous 
analysis  of  the  expression  levels  for  large  numbers  of  genes.  Since  the 
completion  of  the  human  genome  project  and  sequencing  projects  in  other 
species, DNA microarrays aid quick and comprehensive analysis and comparison 
of multiple transcriptomes. This high throughput overview of the transcriptome 
can then be used to either identify the differentially expressed genes or over-
represented trends in cellular functions, regulatory mechanisms and pathways 
which taken together provide clues about the studied system and can serve as a 
scaffold for further investigations.  
The  principal  aim  of  this  part  of  the  project  was  to  use  oligonucleotide 
microarrays to study gene expression during ductal outgrowth of pubertal mouse 
mammary  gland  to  investigate  its  underlying  mechanisms.  The  main 
morphological characteristic of the mouse mammary gland at this stage is the 
presence of TEBs at the tips of the growing ducts. TEBs are only seen at puberty 
and generally regress upon adulthood when ductal epithelium reaches the edge 
of the fat pad. They are highly motile, and based on their localisation, they are 
thought  to  drive  forward  ductal  outgrowth,  promote  primary  branching  by 
undergoing dichotomous bifurcation and turning and regulate spatial patterning 
of  the  ductal  tree  (reviewed  in  1.2.2.1).  Thus,  it  seems  that  a  good 
understanding of TEB biology is fundamental to understanding the mechanisms 
that underlie and regulate the phenomenon of ductal morphogenesis. Despite 
that the function of individual genes in TEB formation and ductal outgrowth have 
been studied using several mouse models (for example: over-expression of FGF4 
or ErbB2 deficiency was shown to cause disorganisation of TEB morphology and 
structure [158] [118]) (Table 1-1) or in vitro experiments, such as 3D Matrigel 
gel cultures of mammary epithelial organoids [105], our current knowledge of 
TEB associated gene expression is limited to two microarray studies, carried out 
by Morris et al. (2006) [259] and Kouros-Mehr et al. (2006) [256]. Although, to     198 
 
date, there are six microarray analyses that have been carried out to provide 
insights  into  the  pubertal  transcriptome,  these  are  the  only  two  that  used 
isolated epithelium of TEBs and ducts, with the former using enzymatic digestion 
and the latter microdissection to isolate the epithelium. McBryan et al. (2007) 
[194]; Deroo et al. (2009) [257]; Howlin et al. (2006) [193] and Master et al. 
(2002)  [258]  used  whole  mouse  mammary  glands  which  although  useful  for 
comparing  general  gene  expression  patterns  between  samples,  are  limited  in 
their  detection  of  genes  that  are  weakly  expressed  or  present  only  within  a 
minor population of cells, as for TEBs in the whole mammary gland.    
Given the importance of TEBs in pubertal mouse mammary gland morphogenesis 
and the currently limited understanding of the biology behind the TEB driven 
ductal  patterning  at  puberty,  this  project  was  devised  to  present  a 
comprehensive study of the TEB transcriptome. The experimental methodology 
that  we  used  was  based  on  that  previously  developed  in  our  laboratory  and 
published by Morris et al. (2006) using an enzyme-based technique for TEB and 
duct isolation. It uses collagenase II to digest collagen and mechanical force to 
further separate the epithelium from the stroma and as demonstrated in that 
early  study  is  an  efficient  way  to  isolate  the  individual  epithelial  structures 
without compromising the quality of their RNA content [113]. Collagen fibres are 
major components of the fibrous ECM in the mouse mammary gland. They anchor 
the  epithelial  cells  and  provide  them  with  physical  support  and  thus,  when 
digested, the epithelium can be easily separated from its surrounding stroma. It 
is worth noting, however, that the composition of the fibrous connective ECM 
and  thus  the  amount  of  deposited  collagen  varies  depending  on  its  spatial 
location. It is denser at the neck region of TEBs or around the ducts and looser 
at the tips and flanks of TEBs [53]. Therefore, while it is fairly easy to isolate a 
clear TEB, it is often seen that the ductal epithelium requires longer exposure to 
enzyme to be successfully isolated from the stroma. The Morris  et al. (2006) 
study,  however,  had  limitations  in  terms  of  the  restricted  transcriptome 
represented on these early microarray chips - MG-U74Av2 chips from Affymetrix 
(10, 043 annotated transcripts) and the methods available for data analyses at 
the time.  
In  our  study,  we  used  Affymetrix  exon  in  situ  synthesised  oligonucleotide 
microarrays, which provide 17,500 well annotated transcript IDs and enable the     199 
 
differential examination of gene expression at the exon level. Along with manual 
analysis,  we  used  several  types  of  bioinformatic  software  to  facilitate  a 
comprehensive analysis of the obtained microarray data. Although, similarly to 
Morris  et  al.  (2006),  we  used  WT  mice  to  collect  isolated  TEB  and  duct 
epithelium, we employed TG mice instead of their WT counterparts to collect 
mammary  tissue  strips.  TG  mice  express  EGFP  under  the  control  of  a  CAG 
promoter (combination of -actin promoter and hCMV enhancer) [265]. Due to 
differences  in cell  density,  EGFP  expression  is  stronger in epithelium  than  in 
stroma, which facilitates the visualisation of the ductal tree under UV and thus 
enables more accurate assessment of tissue strip boundaries and hence more 
reliable  comparison  of  microarray  data.  We  used  the  RNA  extracted  from 
mammary tissue strips, Pre-LN (ductal epithelium and stroma) and Post-LN (TEB 
and duct epithelium and stroma) to validate gene expression patterns obtained 
from  the  isolated  epithelium  [113].  Both  TEB  and  ducts  are  embedded  in 
mammary stroma which not only provides physical support, but also serves as a 
signalling source which is a prerequisite for normal TEB formation and ductal 
outgrowth. It is, therefore, important to ensure that the removal of epithelium 
from its natural environment does not alter gene expression. In addition, Post- 
and  Pre-LN  tissue  strips  were  used  to  identify  the  stroma  associated  genes 
around TEBs and ducts respectively.    
3.3.1 Identification of pubertal signature of mouse mammary 
gland - Main concept behind the analysis  
We  compared  gene  expression  levels  between  TEBs  and  ducts  and  identified 
genome  wide  epithelium-  (See  3.2.6.1.1  and  3.2.6.2.1),  epithelium-stroma- 
(See 3.2.6.1.2) and stroma associated (See 3.2.6.2.2) signatures of TEBs and 
ducts and thus presented the most comprehensive study of these structures to 
date. Reciprocal cross-talk between epithelial and stromal compartments is one 
of the prerequisites for normal ductal morphogenesis at puberty; however, most 
studies trying to decipher epithelial or stromal gene expression have mostly used 
IHC, IF or in situ hybridisation on mouse mammary gland tissue sections [152] 
[256] which is time consuming and can only investigate a restricted number of 
pre-chosen  genes.  More  recently  microarray  analysis  has  been  utilised  to 
investigate TEB and duct associated gene expression. While both Kouros-Mehr et     200 
 
al. (2006) and Morris et al. (2006) successfully isolated and studied epithelial-
stromal  environments  of  TEBs  and  ducts,  and  Morris  et  al.  (2006)  further 
succeeded in the isolation and comparison of their epithelial transcriptomes, the 
characterisation of stromal transcriptomes has proven a bigger challenge and has 
not  been  previously  reported.  Our  study  therefore  not  only  adds  to  the 
understanding of epithelial transcriptomes, but also identifies and characterises 
stromal  signatures  of  TEB  and  ducts  so  providing  detailed  gene  expression 
analysis of both epithelium and stroma of TEBs and ducts.  
We used various microarray analysis tools to identify different types of gene sets 
(either  the  „up-regulated  gene  sets‟  or  the  „expressed  gene  sets‟)  and  thus 
produced  an  extensive  array  of  gene  expression  data  that  could  be  used  to 
unravel and study the characteristics of each signature.  
Given the large amount of collected data, this project was mainly focused on:  
  Identification  of  new  potential  regulators  of  mouse  mammary  gland 
morphogenesis at puberty. 
  Identification  and  comparison  of  functional  characteristics  of  the 
epithelial and stromal transcriptomes of TEBs and ducts.  
The overview of the experimental design of microarray analyses carried out in 
this project can be seen in Figure 3-1 (p.151). The entire expression database 
(.CEL and .CHP files) however, is made available in a Supplementary DVD.   
3.3.2 Identification and classification of new potential regulators 
of mouse mammary gland morphogenesis at puberty 
Numerous  studies  have  identified  stromal  and  epithelial  genes  that  could 
orchestrate ductal morphogenesis to date (reviewed in 1.2.3). Some of the most 
recent findings include: the essential role of Reelin (Reln) signalling in normal 
extension and expansion of the ductal tree [353] and the requirement for CrkII 
expression  in  normal  ductal  elongation  at  puberty  [246].  Here,  we  further 
contribute to this research by utilizing microarray gene expression analysis to 
search for new pubertal regulators of ductal outgrowth. Since this produced a     201 
 
vast amount of gene expression data we focused our search solely on TEBs. It is 
important to note, however, that although when compared to TEBs, ducts are 
considered growth quiescent, they do give rise to secondary branching and thus 
play an important role in pubertal patterning of the ductal tree [114]. It may 
therefore be of benefit to repeat these analyses using the duct „up-regulated 
gene set‟. 
3.3.2.1  Comments on the methodology used 
We looked at two sets of TEB „up-regulated gene sets‟: the TEB epithelium- and 
TEB  epithelial-stromal  „up-regulated  gene  sets‟.  These  were  identified  using 
isolated  epithelium  and  whole  mammary  tissue  strips  respectively  (For  the 
summary of experimental concept see Figure 3-1). We used the whole mammary 
tissue strips to ensure that the observed changes in gene expression were real 
and did not arise as a result of the isolation procedure or errors in data analysis. 
Although an original study by Morris et al. (2006) [113] had indicated this was 
not  the  case,  it  is  possible  that  any  potential  difference  in  the  handling  or 
preparation of biological material might affect gene expression which in turn 
might influence the results. Although enzymatic digestion proved an excellent 
tool for the isolation of stroma-free TEBs and ducts, its efficiency posed a major 
limitation. Based on personal observations, only 2 TEB and 2 ducts on average, 
that were not contaminated by the remains of stroma, could be retrieved from 
each mouse mammary gland. The limited number, along with the small size of 
these structures (the size of TEBs ranges from 0.1 to 0.5 mm [52] and is thought 
to be affected by the phase of oestrus cycle [47]) mean that a large number of 
mice  (~150)  would  be  needed  to  collect the  minimal  amount of  RNA  (1.5µg) 
required for each GeneChip
® Mouse Exon 1.0 ST microarray chip. In this project, 
therefore, to limit the use of animals we collected fewer epithelial structures 
and  therefore  attained  only  enough  RNA  to  carry  out  the  gene  expression 
analysis of isolated epithelium in duplicate instead of triplicate.  
Since conventional statistical significance can only be assessed with a minimum 
of  three  replicates,  in  this  project  we  employed  an  alternative  method  for 
microarray analysis - a 5% LFC Model (See 2.2.5.5.1). Briefly, FC for each gene 
is evaluated across the entire range of absolute expression levels for any number 
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across the entire range of expression values and the top 5% of genes with HFC in 
each bin are considered as significantly differentially expressed. The selected 
genes  are  then  ranked  by  a  calculation  that  combines  the  FC  and  absolute 
expression and the degree of importance for each gene is assigned. Compared to 
standard bioinformatical approaches, which select differentially expressed genes 
by setting a FC cut off and using p-value as a measure of statistical significance, 
the 5% LFC Model selects the differentially expressed genes on the basis of their 
FC and expression levels.  
In conventional analysis most of the inherent error in calculated gene expression 
results  from  two  issues:  at  low  expression  intensities,  genes  tend  to  show  a 
greater error in their measured expression levels and thus may falsely reach any 
given  FC  cut-off,  while  at  higher  intensities  where  fewer  errors  in  measured 
gene  expression  levels  are  observed,  genes  whose  expression  is  significantly 
changed might be missed [269]. By selecting differentially expressed genes on 
the  basis  of  both  their  FC  and  expression  levels  to  minimise  their  inherent 
errors,  the  5%  LFC  Model  enables  confident  analysis  of  microarray  data, 
particularly where no standard measurement of inherent error can be used due 
to insufficient replicates.  
Despite its potential, however, there has only been one documented use of the 
5%  LFC  Model  in  microarray  analysis  since  2002,  when  it  was  first  developed 
[376].  To  ensure  its  experimental  reliability  we  used  whole  mammary  tissue 
strips and conventional microarray analysis to validate the data analysed using 
LFC Model. When collected from six animals, tissue strips provided enough RNA 
for the microarray analysis to be carried out in triplicate; hence gene expression 
profiling could be performed using standard parameters, such as FC and p-value 
and  standard  software,  such  as  Partek
®  Genomics™  Suite  software  (See 
2.2.5.5.2). This served as good control to assess the performance and validate 
the reliability of the generated data.  It is important to note, however, that both 
the  FC  cut-off  (Partek
®  Genomics™  Suite  software)  and  X%  (LFC  Model)  use 
arbitrary parameters and thus although set within their common range in this 
project (1.5 and 3.0 for FC and 5%-10% for LFC) the parameters may sometimes 
be  inappropriate.  Additional  measures  of  data  quality  control  are  therefore 
necessary to validate the results of microarray analysis. Here, we performed a 
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microarray analysis and successfully confirmed the quality of our data (Figure 3-
6) (Figure 3-7) (Table 3-2).     
We identified a list of 65 genes with enriched expression in the epithelium of 
TEBs (See 3.2.6.3) (Table 3-5). These genes were chosen as initial gene targets 
due to their association with both the epithelium of isolated TEBs and Post-LN 
strip, which ensured a high level of stringency in our analysis. The remaining 360 
TEB epithelium up-regulated genes, however, can be seen in Appendix 2.  It is 
tempting  to  speculate  that  most  of  these  TEB  associated  genes  may  be 
functionally involved in the regulation of TEB motility and ductal patterning. 
However, the term „TEB motility‟ still needs to be clearly defined and is quite 
complex in reality. Despite being at the centre of mammary gland associated 
research  since  the  early  1970‟s,  only  a  few  suggestions  have  been  made  to 
explain the enigma of TEB movement (See 1.2.3) to date. For example: motile 
activities  of  TEBs  may  be  explained  by  three  actions:  forward  movement, 
bifurcation and turning; forward movement may be driven by the increased cell 
mass that results from intensive mitosis (as demonstrated by high mitotic rate 
and  thymidine-labelling  index  [377]  [126]  [102]  in  the  cells  of  TEB);  guiding 
molecules  (CFS-1  or  eotaxin)  [87]  and  growth  factors  (TGF-ß)  [110]  may  be 
implicated in TEB turning; and BM and ECM composition may be important for 
TEB  bifurcation  [50]  [56]  [109].  More  recently,  microarray  technology  has 
provided data on gene expression function in TEBs that confirmed that most of 
the genes up-regulated in TEB environment associate with DNA replication, cell 
division or cell-cycle regulation as well as axonal guidance, actin remodelling, 
ECM interaction, nucleotide synthesis, protease activity, apoptosis and cellular 
adhesion  [113]  [256].  Here,  we  performed  a  literature  search on  the  65  TEB 
epithelium-associated genes to further characterise their functional groups and 
thus contribute to the scientific understanding of the enigma of TEB motility.  
Since  no  clear  criteria  could  be  used  to  select  potential  regulators  of  TEB 
motility,  we  took  each  gene  in  turn  and  searched  the  literature  for  an 
association with other biological processes that are known to share similarities 
with  pubertal  mouse  mammary  development,  and  could  therefore  serve  as 
candidate  regulators  of  ductal  outgrowth.  The  processes  that  we  focused  on 
were: embryogenesis, branching morphogenesis, lung- kidney- development or 
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Embryogenesis and pubertal mouse mammary gland development both depend 
on uninterrupted cross-talk between endodermal or ectodermal/epithelial and 
mesenchymal/stromal  cells  [11]  [12].  For  example,  during  mammary  gland 
embryogenesis, at day E16 mammary buds elongate to form mammary sprouts 
which invade primary mesenchyme to grow into the embryonic fat pad where 
they undergo branching to create a primary ductal tree. At puberty (~3 to ~10 
weeks)  the  ductal  tree  elongates  and  branches  by  epithelial  invasion  of 
surrounding  stroma  with  forward  movement,  primary  branching  and  turning 
being driven by TEBs. This forward movement of TEBs most likely occurs due to 
cell rearrangement and collective migration [105] (See 1.2.2.1.1) as recently 
also  demonstrated  for  nephron  formation  during  kidney  morphogenesis  of 
zebrafish  (Danio  rerio)  using  in  vivo  cell  imaging  [378].  It  is  worth  noting, 
however,  that in nephron formation,  full epithelial polarisation of pronephric 
cells is preserved [378] whereas TEB-like organoids are multilayered and only 
partially polarised [105]. Branching morphogenesis in kidneys and lungs shares 
further  similarities  with  mammary  glands,  including  the  dependence  on 
epithelial-stromal cross talk in which MMPs are thought to be crucial, (reviewed 
in [379]) and the regulatory role of FGF family members (reviewed in [379]). As 
is the case for primary branch formation of mouse mammary gland, most of the 
renal tubular branches (~75%) that form during murine kidney development in 
vitro  also  result  from  bifurcation  [380].  Not  only  are  the  fundamentals  of 
branching morphogenesis hypothesised to be similar for different organs but they 
are also similar across a range of organisms.  For example,  Sprouty is a gene 
involved  in  both  mammalian  kidney  branching  [381]  and  tracheal  branching 
morphogenesis in Drosophila m. [382]. Similar extrapolations can be applied to 
the  basic  aspects  of  migration.  Cellular  migration  is  essential  for  organism 
development and although fundamental to a diverse spectrum of processes such 
as organogenesis, wound healing or immune response it is conducted in different 
ways  with  some  cells  migrating  as  individuals  (germ  [383]  and  immune  [384] 
cells) and others collectively as tightly or loosely associated groups (neural crest 
formation,  wound  healing  [385],  epithelial  organogenesis  [105]  [378]  [386]). 
Regardless of the process, some common features of migration include: a degree 
of  polarity,  active  use  of  the  cytoskeleton  (actin,  myosin)  and  dynamic 
interactions  between  migratory  cells  and  their  surrounding  environment 
(reviewed  in  [387]).  As  is  the  case  for  single  cell  migration,  collective  cell     205 
 
migration  may  also  be  involved  in  tissue  invasion  during  tumorigenesis  [388] 
[389]. Other processes that drive cancer progression in mammary gland, kidney 
or lung and which can assist our understanding of normal organogenesis of these 
organs include epithelial-mesenchymal interactions and ECM remodelling. In a 
comparison of genetic similarities  between embryonic lung development and 
lung carcinoma MYC, Hedgehog, Rb and Wnt pathways were highlighted in both 
the normal lung development and tumorigenesis [390]. Finally, axonal guidance 
molecules  (Sprr1A,  Sema3B,  BASP1)  which  act  on  axonal  growth  cones  and 
govern neuronal migration during nervous system development have also been 
detected in the TEB environment during mammary gland outgrowth at puberty 
[113]  and  thus  may  be  important  in  directing  its  epithelial  outgrowth,  as 
recently shown for Reln - originally identified as crucial for neuronal migration 
[353].   
The  similarities  between  these  biological  processes  and  pubertal  mouse 
mammary  gland  development  highlighted  above,  suggest  that  molecular 
regulators may also be conserved across different organs/biological processes. A 
few  of  such  proteins  have  indeed  been  identified.  For  example,  Fgf2br  is 
essential both for the development of mammary buds during embryogenesis and 
maintenance of TEBs at puberty [20] [159]; p190B-RhoGAP is necessary for the 
development  of  embryonic  mammary  bud  and  TEB  migration  at  puberty  [24] 
[391];  both  Ntn1  and  Neo1  although  initially  identified  as  axonal  growth 
guidance cues are also essential for the maintenance of TEB integrity and normal 
ductal  morphogenesis  at  puberty  [120]  [117];  TGF-ß  is  a  potent  inhibitor  is 
branching morphogenesis in mammary gland, kidney and lung (reviewed in [379]) 
while the increased levels of MMP2 and MMP14 are seen at the tips of both the 
uteric and mammary branches in vivo [235] [392].  
3.3.2.2  Comments on the results 
Firstly, we found that the majority (58.5%) of the 65 TEB epithelium enriched 
genes were associated with proliferation or cell-cycle activity which is consistent 
with the previous observations of Morris et al. (2006) [113]; Kouros-Mehr et al. 
(2006) [256] and McBryan et al. [194] . Also in agreement with the two latter 
studies, we showed that 15.3%, 13.8%, 9.2%, 6.1%, 6.1% and 6.1% of these genes 
encoded  proteins  that  are  implicated  in  cellular  adhesion,  cell  death,     206 
 
intracellular  transport,  regulation  of  transcription,  structural  proteins  and 
metabolism  respectively.  A  previously  unreported  finding,  however,  was  that 
DNA repair (7.7%), signal transduction (6.1%) and immune response (4.6%) were 
significantly  over-represented  within  the  TEB  epithelium  associated  genes 
(Figure 3-10 A) (Table 3-5). Secondly, we identified genes that have previously 
been associated with normal lung (19)  and kidney (10)  morphogenesis/cancer 
and others that are known to be implicated in cellular migration (19), nervous 
system development (16), embryogenesis (10) and branching morphogenesis (9) 
providing a wide array of candidate genes with potential as regulators of ductal 
pubertal  development  (Figure  3-10  B)  (Table  3-5).  Together,  the  strong 
association  of  TEB  transcriptome  with  proliferation  and  cell  cycle  associated 
genes supports the hypothesis that the forward movement of TEBs may result 
from the increased cell mass, caused by intensive mitosis in both cap and body 
cells [102]. While the identification of immune response- and cellular adhesion-
linked  genes  as  associated  with  TEB  transcriptome  may  further  highlight  the 
importance of immune response for ductal outgrowth (Reviewed in 1.2.3.2.4) 
and  the  possibility  of  collective  cell  migration  to  serve  as  a  mode  for  TEB 
elongation [105]. Finally, the strong link between the TEB transcriptome and the 
lung-,  kidney-,  nervous  system-,  branching  morphogenesis,  embryonic 
development or cellular migration associated genes supports the idea that the 
degree  of  conservation  can  be  noted  during  the  morphogenesis  of  different 
organs  and  for  different  developmental  processes  and  further  highlights  the 
potential of these systems/processes to provide information on the TEB driven 
mammary morphogenesis at puberty.    
Finally, based on these findings, we identified Fbln2 as a candidate regulator of 
ductal morphogenesis at puberty and investigated its expression and function in 
mammary gland as discussed in detail in Chapter 4.  
3.3.2.3  Further analyses 
Other genes that share this potential and could be investigated in the future 
include Emb or Fbn2. Emb is a cell adhesion molecule that is expressed in the 
uteric  bud  of  the  developing  kidney  [341],  mammary  gland  cancer-  and 
embryonic cell lines [339] [340] and involuting mouse mammary gland [340] and 
is  thought  to  be  implicated  in  regulating  cell-ECM  interactions  during     207 
 
development [340], branching morphogenesis during kidney development [341] 
and migration of adipose tissue macrophages [393]. Fbn2 which also belongs to 
the family of cell adhesion molecules, is associated with epithelial-mesenchymal 
interactions during lung and kidney embryogenesis [346] [347]. It may also be 
involved  in  branching  morphogenesis  in  lungs,  since  treatment  with  Fbn2 
antisense oligodeoxynucleotide leads to smaller lungs with only a rudimentary 
epithelial tree [346]. Its heparin- and integrin-binding sites also suggested a role 
in cellular migration [394].        
When  screening  for  other  potential  regulators  of  mouse  mammary  gland 
development  at  puberty,  in  future  it  may  be  beneficial  to  include  branching 
morphogenesis  of  salivary  gland  (reviewed  in  [379]  [395])  or  embryonic 
development  of  other  skin  appendages  such  as  hair  follicles  and  teeth 
respectively  (reviewed  in  [396])  since  there  is  considerable  molecular 
conservation  of  branching  morphogenesis  between  epithelial  organs  and 
similarities  between  embryonic  development  and  pubertal  morphogenesis  of 
mouse mammary gland. Despite this, however, it must be noted, that several 
organ-specific  cues  can  be  distinguished  for  each  biological  process.  For 
example,  i)  embryonic  branching  in  lung  and  kidney  is  accompanied  by  an 
outgrowth of the whole organ whereas the dimensions of the mammary gland 
stroma  in  which  epithelial  branching  occurs  do  not  change  or  ii)  epithelial 
branching in mammalian lungs and kidney takes place prenatally and adopts a 
rather conventional pattern in lungs (almost identical between the individuals) 
while  most  of  the  mammary  gland  development  takes  place  after  birth  and 
appears  non-stereotyped  as  its  epithelial  patterning  depends  on  the  milieu. 
Hence, using our comparative approach, any new genes identified as likely to 
serve an important role in pubertal mouse mammary gland development would 
be  those  conserved  in  various  systems  rather  than  specific  to  mammary 
morphogenesis. Furthermore, although genes up-regulated in TEB are an obvious 
primary  target  when  studying  the  genomics  behind  TEB  driven  mammary 
morphogenesis, the TEB down-regulated (i.e. ducts up-regulated) genes may be 
equally important. Although no down-regulated genes have been described as 
essential for ductal morphogenesis as yet, this phenomenon has been reported in 
other systems. Down-regulation of Hox-A7, a gene involved in ECM regulation 
and  cell  migration  during  lineage  commitment  or  maturation  seems  to  be     208 
 
essential  for  early  HL-60  monocytic  differentiation.  As  demonstrated  in  vitro 
using bone marrow stromal-like matrix sustained expression of Hox-A7 impaired 
cellular  migration  and  adhesion  to  fibronectin  and  thus  impaired  monocytic 
differentiation [397]. Finally, it is also important to mention that not only the 
differentially expressed (i.e. up- or down-regulated) genes but also the genes 
that are globally expressed in the pubertal mammary epithelium may play a role 
in  its  morphogenesis.  In  fact,  an  example  of  such  gene  has  previously  been 
reported by Howlin et al. who showed that CITED1, which expression level is 
similar  for  the  TEB  and  duct  epithelium,  is  essential  for  pubertal  outgrowth 
[193]. A comparison analysis of the pubertal and adult (V12) mouse mammary 
gland  transcriptomes  would  therefore  be  needed  in  the  future  to  further 
decipher this phenomenon.   
Other ways to search for candidate genes rather than looking for those showing 
similar cellular/biological functions are: i) by selecting on their level of over-
expression (we used this approach to identify Upk3a as a second target gene as 
discussed  in  detail  in  Chapter  4);  ii)  by  chromosomal  location  or  iii)  by 
association with canonical pathways which are already known to be involved in 
the studied system.    
3.3.3 Identification and comparison of functional characteristics 
of the epithelial and stromal transcriptomes of TEBs and 
ducts 
Since little is known about differences in gene expression between the TEB and 
duct  environments,  especially  between  their  epithelial  and  stromal 
compartments,  as  a  third  part  of  this  project,  we  identified  an  array  of 
biological functions that characterise each compartment. 
3.3.3.1  Comments on methodology used 
We identified four „expressed gene sets‟, namely: TEB-only stroma-, duct-only 
stroma- and TEB-only epithelium-, duct- only epithelium- in addition to two „up-
regulated gene sets‟, namely: TEB epithelium- and duct epithelium-. The „up-
regulated gene sets‟ were used to compare the epithelial gene expression only,     209 
 
as discussed above. „The expressed gene sets‟, on the other hand, were used to 
find  differences  in  gene  expression  between  stroma  and  epithelium.  This  is 
because  the  analysis  used  to  select  the  stroma  associated  genes  (manual 
screening  of  the  raw  gene  expression  data  from  the  isolated  epithelium  and 
tissue strips (See 3.2.6.2.2)) did not allow calculation of FCs but only enabled 
presence or absence of gene expression to be determined. To provide a suitable 
comparison we also identified epithelium expressed gene sets (See 3.2.6.2.1). 
For summary of experimental concept see Table 2-5. 
When using gene lists to elucidate the general trends in biological processes or 
pathways there are different sets of criteria that can be used. Firstly, rather 
than using the most highly expressed genes, it may be argued that a gene set 
consisting of the widest range of representative genes may be of more relevance 
to understand the biological system  in question. Genes with large changes in 
expression  values  may  not  necessarily  make  the  strongest  contribution  to 
biological processes and thus should not be prioritised over those that show less 
pronounced  expression  levels.  Furthermore,  it  is  not  necessary  for  all  genes 
within a given pathway or biological process to be highly differentially expressed 
in  order  for  the  pathway  to  be  important.  Thus,  the  „expressed  gene  sets‟, 
although initially used in this study because of the limitation of the methodology 
used for data analysis, actually provided a comprehensive and unbiased analysis 
since they include genes with a range of expression levels from the most highly 
expressed to those with expression only slightly altered.  
In contrast, the „up-regulated gene sets‟ used in „pathway analysis‟ helped to 
focus the analysis. By incorporating genes expressed over a certain level and 
thus excluding genes whose expression oscillated around the baseline level (of 
FC 1.1) and thus may have been associated with the specific environment just 
due to chance,  the risk of non specificity in identified profiles was reduced. 
Moreover,  since  some  biological  processes,  e.g.  EMT  require  both  the  up-
regulation of mesenchymal genes (Twist [272], Snail 3 [273], Slug [274])  and 
down-regulation of the epithelial markers (E-cad [280], Sprr1a [270]), only the 
use  of  the  „up-regulated  gene  sets‟  together  with  the  corresponding  „down-
regulated gene set‟ will fully unravel such mechanisms. This analysis could not 
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Therefore  in  this  study,  we  used  both  the  „expressed  gene  sets‟  and  „up-
regulated gene sets‟ to provide a comprehensive novel analysis of the general 
trends  and  differences  in  the  functional  characteristics  of  TEB  and  duct 
epithelium and stroma („expressed gene sets‟). We also compared the biological 
processes associated with the genes identified as significantly up-regulated in 
TEB and duct epithelium („up-regulated gene sets‟). In addition to that, since we 
used both gene sets to functionally characterise the TEB and duct epithelium we 
enabled  the  comparison  of  the  potential  differences  in  generated  data  when 
using different gene list.  
3.3.3.2  Comments on results 
Since the motility of TEBs and ducts at puberty is very different we originally 
hypothesised  that  their  gene  expression  would  reflect  different  patterns  of 
biological behaviour and indeed this was the case, as outlined below. 
„Pathway analysis‟ on the basis on microarray data is a valuable tool to establish 
the  biological  changes  that  occur in biological  systems  and  has  as  such  been 
widely  used.  However,  it  is  also  important  to  bear  in  mind  its  limitations.  
Firstly, it is based on mRNA expression only. Secondly, the association of genes 
with given processes is established depending on the information deposited in 
the manually created knowledge data base  (See 3.3.3.5). Some of the genes 
selected by IPA as indicative of the given functional category are non specific 
and can often be found to associate with a range of different cellular functions 
and systems. It is therefore, important to note that this type of analysis may be 
biased and not fully representative of functional processes activated in vivo and 
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3.3.3.2.1  Characterisation of the TEB and duct transcriptomes using 
‘expressed gene sets’  
 
Terminal end bud epithelium 
Comparison of the „expressed gene sets‟ showed both the epithelium and stroma 
of TEBs to be strongly associated with „Cellular Movement‟ (27.8% and 20.5% of 
genes respectively) and „Cell-Cell Signalling and Interaction‟ (27.9% and 23.7% of 
genes  respectively)  (Table  3-5).  Thus,  suggesting  not  only  a  high  but  also  a 
comparable level of the motility associated genes in both milieus. In general, 
this finding would not be surprising as it is in agreement with the emerging idea 
of  both  the  epithelial  and  stromal  compartments  of  TEB  being  necessary  for 
ductal  outgrowth  but  playing  different  role  in  its  regulation  (reviewed  in 
1.2.3.2).  Here,  however,  the  link  between  TEB  transcriptome  and  „Cellular 
Migration‟ was mostly attributed to the presence of genes associated with the 
regulation of immune cell motility. 
As shown by IPA results, the sub-groups within the „Cellular Movement‟ category 
that were common for the epithelium and stroma of TEB included both positive 
and  negative  regulation  of  e.g.  „the  movement  or  migration  of  the  immune 
system  components‟  (eosinophils,  mononuclear  lymphocytes,  phagocytes, 
leukocytes and monocytes) or „-nervous system components‟ (dendric cells). This 
association with immune cell motility was further seen in the TEB epithelium 
exclusive  sub-categories,  which  consisted  of  both  positive  and  negative 
regulation  of  the  „movement/migration  of  neutrophils,  -macrophages,  -T 
lymphocytes,  -antigen  presenting  cells,  -bone  marrow  cells‟;  „chemotaxis  of 
blood  cells,  -dendric  cells,  -leukocytes‟  and  „homing  of  phagocytes,  -
lymphocytes, -blood cells‟ and „migration and chemotaxis of tumour cell lines‟ 
(Appendix 9 A).  
This  striking  association  of  TEB  epithelium  with  the  immune  response  gene 
signature  was  further  supported  in  our  analysis  by  an  association  of  the 
epithelium expressed gene set with „Immune Response‟ (28.3%), „Immune and 
Lymphatic  System  Development  and  Function‟  (25.1%)  and  „Haematological 
System  Development  and  Function‟  (29%).  Together,  these  results  are  in     212 
 
agreement  with  the  emerging  importance  of  innate  immune  response  for 
pubertal mammary morphogenesis.  
As  reviewed  in  Chapter  1  (1.2.1.2.3  and  1.2.3.2.4),  the  formation  and 
outgrowth of TEBs during puberty is closely paralleled and dependent on the 
accumulation of macrophages, eosinophils and mast cells in the stroma around 
TEBs (macrophages, eosinophils) and ducts (mast cells) [85] [89]. Furthermore, 
inflammatory cells (neutrophils, eosinophils, macrophages and plasma cells) and 
acute-phase response genes, such as  CD14, lipopolysaccharide-binding protein 
(Lbp)  and  STAT3  associate  with  early  involution  of  mouse  mammary  gland 
suggesting a wound healing-like process to be a part of the early response to 
weaning [38]. The recruitment of haemopoietic cells may be regulated by the 
signalling  cues  expressed  in  mammary  epithelium  (reviewed  in  [87]).  As 
demonstrated for macrophages, the growth factor which regulates their motility 
(CSF-1) [398] is expressed in mammary epithelial cells [87] and when ablated 
(null mutation in CSF-1 - Csf1
op/Csf1
op mice [220]) or dysfunctional (loss of CSF-1 
receptor - CSF-1R KO
-/- mice [399]) a reduced macrophage density in mammary 
gland can be seen. Furthermore, a high expression of the cytokines IL-6, IL-8 and 
High in normal 1 (HIN-1) have been reported in human breast epithelial cells 
[400] [401].    
Here, we report that, as suggested by the results of IPA, epithelial transcriptome 
of  TEBs  may  also  encode  proteins  involved  in  positive  regulation  of 
„proliferation/activation/accumulation of mononuclear leukocytes  (Cd 2 antigen 
-Cd2,  Cd  22  antigen  -  Cd22),  -T  lymphocytes  (Cd  4  antigen  -  Cd4)  and  -B 
lymphocytes‟  (Bone  marrow  stromal  cell  antigen  1  -  Bst1,  Brutton 
agammaglabulinemia  tyrosine  kinase  -  Btk)  and  „adhesion  of  neutrophils‟              
(Chemokine (C-C motif) ligand 3 - Ccl3). It is important to note, however, that 
not all of these genes are specific to the identified process. While Cd4 and Bst1 
serve  as  markers  of  T  and  B  cells  respectively,  Btk  expression  have  been 
associated with both the B cell maturation and mast cell activation.  Ccl3 has 
been associated with neutrophils and T-lymphocytes. Thus, although these data 
are in agreement with our „Cellular Migration‟ results which also suggested the 
high abundance of genes associated with the immune system components and 
their motility within the epithelium of TEBs (which in fact is higher than that 
seen for the stroma) it is important to note that some of these genes may not be     213 
 
specific to the immune response. The other possibility is that because of the 
direct proximity of haemapoietic cells and mammary epithelium and as seen for 
macrophages, potential association of immune cells with ColI fibres which are 
deposited around the flanks of TEBs  [83], some immune cells may have been 
isolated with mammary epithelium.    
Nevertheless,  if  confirmed,  these  data  may  not  only  further  highlight  the 
importance of the immune response in pubertal mammary morphogenesis but 
also support and add to the understanding of the emerging role of mammary 
epithelium  in  controlling  the  homing  of  migrating  hematopoietic  cells  into 
adjacent  stroma.  Furthermore,  since  macrophages  have  also  been  shown  to 
localise to the inside of the body of TEBs [87], it may be that the immune system 
components other than macrophages also associate with mammary epithelium 
but additional research should be carried out to validate these possibilities. T 
and B lymphocyte markers and neutrophil associated genes have been suggested 
as  TEB  epithelium  expressed  by  both  the  results  of  „Immune  Response‟  and 
„Cellular migration‟ groupings. Furthermore, these immune system components 
have  previously  been  reported  as  involved  in  wound  healing  and  shown  to 
infiltrate  the  mammary  gland  during  pregnancy  (B  lymphocytes)  [402]  and 
involution  (neutrophils)  [38]  but  have  not  yet  been  reported  in  the  pubertal 
mouse  mammary  gland.  In  fact,  a  previous  study,  using  leukocyte  lineage 
markers (B220, CD3 and Gr1) demonstrated that while present in the mammary 
lymph node, no T-, B lymphocytes or neutrophils could be seen in the vicinity of 
its pubertal epithelium  [87]. Despite this, since wound healing has previously 
been linked to mammary involution and several traits characteristic of  wound 
repair are seen in pubertal mammary morphogenesis (epithelial growth, stromal 
reorganisation and immune cell infiltration) the repeated identification of T-, B 
lymphocyte or neutrophil associated genes in pubertal mouse mammary gland 
should be investigated further. 
Terminal end bud stroma 
A similar association with the immune system was detected by IPA, in the TEB-
only stroma „expressed gene set‟, where „Haematological System Development 
and Function‟ ranked to the top 5 over-represented processes and encompassed 
the  23%  of  TEB  stroma  and  IPA  eligible  genes  (Table  3-7).  This  was  also     214 
 
consistent  with  the  results  of  the  analysis,  discussed  above,  that  showed  an 
association  of  TEB  stroma  with  the  migratory  signature  of  immune  system 
components. Most of the sub-categories associated with the stroma expressed 
genes were similar to these identified for the TEB epithelium gene set. Some of 
the  stroma-exclusive  categories,  however,  included  positive  regulation  of 
„proliferation of natural killer T lymphocytes (NKTL)‟ (E74-like factor 4 - Elf4, 
Interleukin 18 - Il18), „recruitment/quantity of phagocytes (Glypican 3 - Gpc3) 
and -Langerhans cells‟ (Signal regulatory protein α - Sirpa, Interferon regulatory 
factor - Irf). The Langerhans cells are dendritic cells of the epidermis which are 
similar in morphology and function to macrophages. They capture, uptake and 
process antigens while the NTKL and phagocytes mark cells for destruction by 
apoptosis and ingest antigens respectively. As mentioned before, it is important 
to note, however, that neither Elf4 nor Il18 are exclusive to NKTL cells but can 
also  be  associated  with  T-lymphocytes  while  Gpc3  is  a  membrane  associated 
proteoglycan which has also been suggested to play role in cell division in many 
cell types. Sirpa, furthermore, may also be involved in phagocytosis, mast- and 
dendritic  cells  activation.  Thus,  the  association  of  TEB  stroma  with  these 
immune cells should be taken with caution.  Nonetheless,  if confirmed,  these 
results may add to the understanding of the role of phagocytosis (as suggested 
for macrophages [84] [87]) in contributing to stroma remodelling at the tip of 
the advancing TEB at puberty.  
As  previously  mentioned,  the  stromal  transcriptome  of  TEBs  has  also  been 
suggested  to  associate  with  „Cellular  Movement‟  (Table  3-6).  While  it  was 
partially  suggested  as  being  involved  in  regulating  the  „motility  of  immune 
system-  and  nervous  system  components‟  (See  the  first  paragraph  of  this 
section)  some  of  the  other  genes  within  the  stroma  of  TEBs  additionally 
appeared to be associated with „movement/chemotaxis of cancer cell lines‟ and 
„invasion of neuroglia‟ (provides support and protection for growing neurons). 
Given  the  emerging  similarities  between  TEB  outgrowth  and  breast  cancer 
progression and neuronal development further investigation of these genes in 
ductal morphogenesis may prove beneficial.  
Finally,  as  proposed  by  IPA,  association  of  TEB  stroma  with  „Cardiovascular 
System Development and Function‟ (11.5%) (Table 3-7) may be suggestive of the 
presence of dynamic cardiovascular morphogenesis at puberty. To date, there     215 
 
has only been one published study that looked into vessel development during 
mouse mammary gland development at puberty. It has reported, however, that 
no morphological evidence for active vascular development in pubertal mouse 
mammary  gland  can  be  seen,  identifying  embryogenesis,  pregnancy  and 
lactation as the highly angiogenic time points [403]. Our data further suggested 
that  the  epithelial  transcriptome  of  ducts  may  also  contain  the  angiogenesis 
associated genes (Table 3-7) and that TEB epithelium expresses high levels of 
Vascular  endothelial  growth  factor  (VEGF),  which  is  a  known  stimulator  of 
angiogenesis. Thus, if confirmed, these results could shine a new light on the 
area of vascular development during mammary gland morphogenesis and the role 
of TEBs in angiogenesis.  Further research will be necessary to validate these 
possibilities.   
Some  of  the  other  processes  identified  in  TEB  stroma  included  „Cell  Death‟ 
(33.4%), „Tissue Morphology‟ (16.9%) and „Tissue Development‟ (19.8%). These 
are in agreement with TEB stroma being an actively remodelling milieu (Table 3-
6) (Table 3-7).  
Duct epithelium 
In  contrast  to  the  TEB  environment,  neither  the  migratory  nor  the  immune 
system  associated  gene  signatures  could  be  identified  in  the  duct  „expressed 
gene sets‟. Furthermore, as compared to TEBs, where both the epithelial and 
stromal  compartments  shared  fairly  similar  functional  characteristics, 
substantial differences were detected in the functional roles of ductal epithelial 
and stromal transcriptomes. Our analysis suggested that the processes that are 
highest  in  the  ductal  epithelial  transcriptome  are  „Embryonic  Development‟ 
(2.3%) (See 3.3.3.3) and „Connective Tissue Development and Function‟ (2.9%) 
(Table 3-7).  It is important to note,  however, that the association of ductal 
transcriptome with these categories is based on a very low percentage of genes 
and thus may not be fully reliable. Furthermore, all sub-categories within the 
„Connective  Tissue  Development  and  Function‟  group  were  associated  with 
fibroblasts which may also indicate the contamination of ductal epithelium with 
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The  rest  of  the  duct-only  epithelium  „expressed  gene  set‟  was  suggested  to 
associate  mostly  with  non-specialised  mechanisms  essential  for  cell  survival, 
replication  and  regulation  of  gene  expression.  Namely,  „Cell  Cycle‟  (14.8%), 
DNA- or RNA-processing associated applications (11.8% and 4% respectively) or 
organogenesis - „Cellular Assembly and Organisation‟ (Table 3-6). These suggest 
that, although lower than in TEBs, considerable levels of cellular proliferation 
are sustained in ductal epithelium. 
Duct stroma 
The  transcriptome  associated  with  ductal  stroma  was  mainly  linked  to  „Lipid 
Metabolism  (14.7%),  „Carbohydrate  Metabolism‟  (15%)  and  „Small  Molecule 
Biochemistry‟  (28.9%)  (Table  3-6)  and  thus  indicated  an  intense  metabolic 
activity.  Lipid  and  carbohydrate  metabolism  has  been  reported  in  lactating 
mouse  mammary  glands  in  experiments  dating  back  to  1950  [404]  while  the 
metabolism of brown adipose tissue (fatty acid metabolism) has been studied in 
2002 by Master et al. using the pre-pubertal mouse mammary glands [258]. More 
recently  the  expression  of  genes  associated  with  „Lipid  Metabolism‟  and 
„Carbohydrate  Metabolism‟  was  demonstrated  to  decrease  during  puberty  in 
normal mice [258] or in response to estradiol in ovariectomised mice [257]. To 
our  knowledge,  however,  a  detailed  biochemical  study  of  metabolic  changes 
accompanying pubertal mouse mammary gland morphogenesis has not yet been 
performed.  Here,  we  identified  the  ductal  stroma  as  the  place  of  highest 
metabolic activity in pubertal mouse mammary gland and identified the list of 
associated  genes  (Appendix  7)  which  may  provide  a  foundation  for  further 
investigations.  
3.3.3.2.2  Characterisation of TEB and duct transcriptomes based on 
the ‘up-regulated gene sets’  
 
Terminal end bud epithelium 
The suggested differences between TEBs and ducts were further highlighted by 
comparing  the  epithelium  „up-regulated  gene  sets‟.  As  was  the  case  for  TEB 
epithelium-only „expressed gene set‟ the mRNAs up-regulated in the epithelium     217 
 
of TEBs were mainly associated with cell survival and proliferation („Cell cycle‟ 
(38.6%), DNA Replication, Recombination and Repair (34%) and Cellular Growth 
and Proliferation‟ (35.5%)), which is consistent with the results of Morris et al. 
(2006) and Kouros-Mehr et al. (2006) [256], as well as „Cellular Movement‟ (6%) 
(Table 3-6). As opposed to the „expressed gene set‟, which was suggested to be 
closely associated with movement of immune- and nervous system components, 
the  up-regulated  genes  of  TEB  epithelium  were  mainly  associated  with 
„promoting the cytokinesis‟ and „chemorepulsion of neurites‟ (Sema3A, Sema3B). 
„Embryonic Development‟ (See 3.3.3.3) which was not seen in the „expressed 
gene  set‟,  „Connective  Tissue  Development  and  Function‟  and  „Skeletal  and 
Muscular Development and Function‟ were also over-represented (Table 3-7). 
The sub-groups in „Skeletal and Muscular Development and Function‟ category 
were  mostly  associated  with  fibroblasts  (which  again  may  indicate  stromal 
contamination) and promoting the „cell cycle progression in muscle cells‟.  
Duct epithelium 
Whereas the top functional characteristics of TEB epithelium „expressed-‟ and 
TEB epithelium „up-regulated gene sets‟ were reasonably comparable this was 
not the case for the ductal gene sets, where only one category, the „Molecular 
Transport‟ was common to both analyses (Table 3-6). The most striking result 
from  this  analysis  was  that  „Cellular  Movement‟  associated  genes  were  the 
second highest functional group within the duct epithelium „up-regulated gene 
set‟  (Table  3-6).  Furthermore,  a  wide  array  of  functional  sub-categories 
associated  with  cellular  motility  (immune  cell,  nervous  system  component, 
smooth  muscle  cell,  cancer  cell  line,  kidney  morphogenesis)  were  over-
represented  within  the  ductal  epithelial  transcriptome  while  the  TEBs  were 
suggested  to  associate  mostly  with  immune  cell  migration  (expressed  genes), 
axonal guidance and cytokinesis (up-regulated genes). This was further surprising 
as the „Cellular Movement‟ signature appeared to be stronger in duct- rather 
than TEB up-regulated transcriptomes. Over all, these results suggest that ductal 
epithelium  may  play  a  bigger  role  in  regulating  pubertal  morphogenesis  in 
mammary gland than previously anticipated. Another possibility is that the duct 
epithelium  „up-regulated  genes‟  that  were  functionally  classified  under  the 
„Cellular Migration‟ category rather than being the makers of motile behaviour 
they are common regulators of various processes and thus in vivo they may not     218 
 
function to drive cellular migration in ductal epithelium. Further examination of 
individual genes involved in each category should be performed to validate these 
possibilities (Appendix 9 A).    
The  suggested  presence  of  immune  system-associated  genes  in  the  duct 
epithelium „up-regulated gene set‟, as demonstrated by the contribution of the 
34.4% of genes to the „Haematological System Development and Function‟ and 
26.3%  to  „Immune  Cell  Trafficking‟  (Table  3-7)  is  in  agreement  with  the 
previously discussed association of duct-only expressed genes with the immune 
response  components  (See  above).  While  many  of  the  functional  sub-groups 
within  the  immune  system  category  were  similar  to  those  identified  for  TEB 
environment  (e.g.  positive  regulation  of  the  „recruitment/activation  of 
neutrophils, -phagocytes, -lymphocytes, -mast cells‟) the „change of shape of 
basophils‟ (Ccl3, Chemokine (C-C motif) receptor 2 - Ccr2) was specific to this 
gene  set.  Ccl3  is  a  chemokine.    Although,  as  seen  for  many  other  genes, 
mentioned  in  analysis,  it  is  not  entirely  basophile  specific  (eosinophils, 
neutrophils),  it  has  been  shown  to  promote  the  chemotaxis  of  granulocytes. 
Thus,  its  expression  by  ductal  epithelium  may  support  the  role  of  mammary 
epithelium in the recruitment of haemopoietic cells to the proximal mammary 
stroma. The expression of Ccr2 in ductal epithelium, however, is less clear (it 
has  been  previously  shown  to  be  expressed  by  mammary  epithelium  during 
inflammation [405]).  
Granulocytes may either act to induce an inflammatory reaction (mostly allergy) 
or ingest foreign particles. If confirmed, the association of mammary epithelium 
with phagocytes may suggest a possible role of phagocytosis in lumen formation. 
Pubertal  epithelium  and  especially  TEBs  show  very  substantial  apoptotic  rate 
(11.3  %)  which  is  higher  than  that  calculated  for  any  other  stage  of  mouse 
mammary development (apoptosis detected for involution is 4.5%) [61]. It must 
be noted, however, that the association of immune cells with lumen formation 
has only been suggested by one study. Gouon-Evans et al. (2002) reported that 
macrophages which engulf apoptotic epithelial cells can be seen in the proximal 
area of lumen within the TEBs [87]. To date, it has been further proposed that 
lumen  formation  in  pubertal  epithelium  is  dependent  on  caspase-mediated 
apoptosis and Bcl2-like 11 (BIM) expression, which may induce the detachment 
of cells from its matrix, termed anoikis (as previously seen during involution) and     219 
 
thus mark cells for degradation [244] [406]. This can be further supported by the 
recent finding showing that the body cells of TEBs lack matrix attachment [244]. 
The  down-regulation  or  loss  of  BIM  in  vitro  or  in  BIM  KO
-/-  mice,  however, 
although  prevented  apoptotic  clearance  of  cells  did  not  abrogate  but  only 
delayed  lumen  formation  in  both  systems,  thus  suggesting  presence  of 
alternative mechanisms for lumen formation and clearing [244]. Hence, further 
research into its possible mechanisms should be warranted.    
In  summary,  the  functional  characteristics  of  TEBs  and  ducts  appeared  quite 
different depending on the type of gene sets used for the analysis. This suggests 
that both types of analysis ought to be completed for a comprehensive picture of 
gene  expression  patterns  and the use  of „pathway  analysis‟  to  aid  functional 
characterisation of transcriptomes should be taken with a lot of caution.  
3.3.3.3  Association of pubertal development with embryogenesis 
Similarities  between  embryonic  development  and  pubertal  mouse  mammary 
gland  development  have  already  been  discussed  in  3.3.2  with  some  of  the 
embryogenesis associated genes suggested as potential regulators of mammary 
gland morphogenesis at puberty. For that analysis, however, we hypothesised 
that it is the TEB transcriptome that would contain the embryonic development 
associated genes. The identification of the duct-only epithelium „expressed gene 
set‟  as  that  most  associated  with  this  process  suggested,  however,  that  the 
morphogenic  potential  of  embryogenesis  associated  genes  should  perhaps  be 
assessed with respect to the ductal transcriptome rather than the TEB one. The 
embryonic signature identified within the duct-only epithelium „expressed gene 
set‟, however, associated with embryonic cell lines, which is general and did not 
hint  towards  any  specific  assumptions.  What  stands  out,  however,  and  may 
provide  the  foundation  for  further  research  is  the  association  of  ductal 
epithelium  „up-regulated  gene  set‟  with  the  positive  regulation  of  „branching 
morphogenesis‟  (kidney,  carcinoma,  thyroid  and  kidney  cell  lines)  and  the 
association  of  duct-only  stroma  „expressed  gene  set‟  with  promoting  the 
„morphogenesis  of  forelimb  bud,  branchial  arch  and  cardiovascular  system‟. 
Some,  although  fewer,  „Embryonic  development‟  related  genes,  and  thus  not 
complying with top 5 categories, could be also seen in the TEB transcriptome. As 
for the duct-only epithelium expressed genes, however, the link of TEB gene sets     220 
 
with the „Embryonic Development‟ is fairly general (Appendix 9 C). In summary, 
these  suggest  that  both  TEB  and  duct  transcriptomes  associate  with  the 
„Embryonic  Development‟  gene  signature  and  as  mammary  gland  is  the  only 
organ  where  the  majority  of  development  occurs  postnatally  these  results 
reflect the highly morphogenic character of its development at puberty. 
3.3.3.4  Association of pubertal development with EMT          
Although,  initially  reported  as  fundamental  for  cellular  migration  during 
embryonic  development,  recent  evidence,  although  highly  controversial,  has 
linked  EMT  with  cellular  invasion  during  tumour  progression  and  metastasis 
formation (reviewed in [373] [407]). Not only do epithelial breast cancer cell 
lines  express  mesenchymal  markers  in  vitro  [270],  but  using  different  mouse 
models of breast cancer with genetically marked epithelial and mesenchymal 
cells,  the  presence  of  some  EMT  markers  has  been  demonstrated  in  breast 
cancer cells in vivo [408] [409]. Since there are parallels between embryonic 
development, cancer progression and mammary gland outgrowth, i.e. epithelial 
invasion of surrounding stroma and poor polarity seen in the cap cells of TEBs 
(further discussed in 5.2.2) [56], it is tempting to speculate that EMT may serve 
as a mechanism underlying ductal outgrowth and that cap cells may serve as 
sites  of  this  transition  (they  lack  cell-cell  junctions,  show  poor  apical  basal 
polarity and localise to the outer layer of TEBs). 
In fact, this possibility has already been addressed by two studies. Kouros-Mehr 
et al. (2006) found that Snail-1 and Twist-1, mesenchymal markers of EMT, were 
enriched in the TEB microenvironment when compared to its ductal counterpart 
[256] while Nelson et al. (2006), using epithelial tubules formed by EpH4 cells in 
3D culture, demonstrated that an EMT-like transition event is required at the 
branch points for branching to occur [110].  
Since the mesenchymal genotype can be characterised by both the up-regulation 
of mesenchymal- and the down-regulation of epithelial markers (The list of EMT 
markers can be seen in Table 2-8) in this project we further examined this issue 
by  screening  the  TEB  environment  up-  and  down-regulated  (i.e.  duct 
environment up-regulated) gene sets for the presence of EMT signature genes. 
We  looked  at  256  EMT  markers  and  thus  performed  the  most  comprehensive     221 
 
analysis of the EMT response in pubertal mouse mammary gland development to 
date.  We  found  that  13%  of  mesenchymal  markers  were  up-regulated  in  TEB 
while 12% of epithelial markers were down-regulated in TEB environment (up-
regulated in ducts) highlighting the potential for TEB outgrowth to be promoted 
by  EMT.  However,  our  negative  control  showed  that  a  further  6.25%  of  the 
epithelial makers were up-regulated in TEB compartment while a 6.8% of the 
mesenchymal markers were seen in the TEB down-regulated milieu (Table 3-7). 
Moreover, as further revealed by literature search, performed on the individual 
EMT associated genes differentially expressed in TEB transcriptome but not yet 
described or studied in mammary, i.e. 17 out of 31 EMT marker genes (Col1a2, 
Col5a2,  Ecm1,  Fap,  Fbln1,  Fbn1,  Cybrd1,  Ap1m2,  Cxadr,  Kcnk1,  Klk8,  Lad1, 
Trim29, Aldh1a3, Ndrg1 and Slp1) some of these markers were non specific. 
In summary, these results may suggest the individual EMT associated genes with 
the potential to be important for pubertal morphogenesis. For example, Prrx1, a 
member of homeobox gene family that is one of the mesenchymal markers found 
to be over-expressed in TEBs, has previously been shown to be critical for tooth 
morphogenesis  [410].  Furthermore,  homeobox  genes  in  general  have  been 
associated  with  normal  embryonic  and  postnatal  mouse  mammary  gland 
development and carcinogenesis [411]. However, due to the lack of specificity of 
some genes in the EMT signature and a relatively high number of the negative 
control genes within the TEB transcriptome these results do not allow to make 
final  conclusions  about  the  involvement  of  EMT  in  pubertal  mammary 
morphogenesis, but also they do not rule it out.   
3.3.3.5  Association of pubertal transcriptome with nervous system  
The „Nervous System Development and Function‟ was not identified amongst the 
top functions over-expressed in pubertal transcriptome. The known association 
of  axonal  guidance  proteins  with  ductal  outgrowth at  puberty  (See  3.3.2.1), 
however,  prompted  us  to  further  screen  the  TEB  and  duct  gene  sets  for  the 
presence of the nervous system associated genes. In contrast to previous findings 
(3.3.2.1) which associated axonal guidance molecules with the epithelium of 
TEBs, our results suggested that, in fact, it is primarily the stroma of TEBs that 
shows this association. The stroma contained 43 genes involved in processes such 
as „outgrowth of neurites (projections from the cell body of a neuron), -sensory     222 
 
axons‟;  „survival/quantity  of  astrocytes  (glial  cells  in  brain  or  spinal  cord),  -
neurites‟ or „myelination‟ (formation of myelin sheath around axon or neuron). 
Fewer, but still a significant number of nervous system associated genes could 
be identified in both the epithelium and stroma of ducts and these appeared to 
be  involved  in  „migration/survival  of  astrocytes‟;  „stimulation/activation  of 
neurons‟ (epithelium) and „axogenesis and branching of axons‟ (stroma). The TEB 
epithelium in comparison, had a transcriptome least associated with the nervous 
system,  with  only  one  gene  -  Sema3B,  linked  to  chemorepulsion  of  neurites 
(Appendix 9 B). To fully appreciate the strength of these results, however, it is 
important  to  note  that,  to  date,  several  genes  identified  as  associated  with 
neuronal development have been also implicated in angiogenesis. Neuropilin 1 
and  2  have  been  characterised  as  receptors  for  both  semaphorins  in  axonal 
guidance and VEGF for angiogenesis (reviewed in [412]). Thus, it is possible that 
this  neuronal  signature  may  be  indicative  of  vascular-  rather  than  neuronal 
development.  Further  examination  of  individual  genes  identified  within  these 
subcategories should be warranted. Nonetheless, if confirmed, these results may 
provide  further  positive  evidence  that  the  axonal  guidance/nervous  system 
development  gene  signature  is  associated  with  pubertal  mouse  mammary 
development, highlight mammary stroma as its source and potentially provide 
new gene targets which could be studied in the future to help to further unravel 
the link between mammary and axonal development.  
3.3.3.6  Further analyses 
In general IPA is a powerful and desirable tool for post-analysis of microarray 
data and frequently appears as software of choice in published gene expression 
studies [413] [414] [415]. It is, however, based on a manually created database 
which although curated by PhD trained scientists, updated quarterly and based 
on information mined from 32 top peer-reviewed journals, is man-made and may 
therefore be prone to bias and not always up to date with the literature. In 
addition,  genes  can  only  be  assigned  a  specific  function  based  on  the 
information  deposited  in  the  database.  Thus,  since  IPA  depends  on  its  own 
comprehensive but biased knowledge database, the results may be limited and 
influenced by its content. Furthermore, it is important to note that some of the 
genes used by IPA as indicative of the given functional category are non specific 
and  can  often  be  found  to  associate  with  a  range  of  different  cells  and     223 
 
processes. Some of the other non specific genes not mentioned in this discussion 
include Endothelial-specific receptor tyrosine kinase (Tek) or Cyclin D1 (Ccdn1). 
Tek is normally associated with endothelial cells, but in our analysis defined a 
positive regulator of the „quantity of antigen presenting cells‟ while  Ccdn1 is 
generally abundant throughout cell cycle but defined here as a maker of the 
„chemotaxis  of  bone  marrow  derived  macrophages‟.  This  may  introduce 
additional bias into the analysis. Having said that, it is also important to note 
that  many  genes,  such  as  Cd4,  Bst1,  Elf4  which  are  specific  markers  of  T 
lymphocytes, B lymphocytes and NKTLs respectively have also been found in our 
analysis. It must be stressed, therefore, that the results of IPA analysis and any 
other „pathway analysis‟, may be used to sketch the general picture that could 
highlight and suggest the potential avenues for further investigation, but has the 
potential to be biased and thus should be interpreted with caution. 
Furthermore, since this study was based entirely on RNA data and not all RNA 
undergoes translation or protein products from RNA may at times locate to sites 
different  from  their  RNA  matrices  (as  seen  for  extracellular  proteins)  it  is 
important  to  note  that  the  proteins  transcribed  from  epithelial  mRNA  might 
localise to the stroma rather than the epithelium. The converse is also true as 
seen  for  some  of  the  BM  components,  such  as  Lama1,  which,  although 
synthesised  in  stromal  fibroblasts  is  detectable  as  protein  in  BM  [82].  Thus, 
although  transcriptomics  might  be  used  for  initial  studies,  protein  analysis  is 
needed to fully decipher the characteristics of organ morphogenesis.  
In addition, it is important to note that all the results presented in this chapter 
were  based  on  the  up-regulated  or  expressed  genes  only.  Hence,  it  may  be 
beneficial  to  repeat  the  „pathway  analysis‟  for  TEB  and  duct  epithelium  up-
regulated  genes  using  both  the  up-  and  down-regulated  gene  sets 
simultaneously.  
3.3.4 Summary 
In summary, our work has shown that microarray analysis can be used both to 
identify potential new regulators (e.g. Fbln2, Upk3a) and provide clues that may 
help to characterise complex processes and their drivers associated with mouse 
mammary  gland  development  at  puberty.  We  identified  the  genome  wide     224 
 
epithelium-,  epithelial-stromal-  and  stroma-associated  signatures  of  TEBs  and 
ducts and compared the biological functions and processes associated with each 
transcriptome.  As  a  result,  not only  did  we  add to  the  understanding  of  the 
epithelial transcriptomes of TEBs and ducts but also provided insights into the 
characteristics  of their  stromal  gene  expression  and thus  presented  the  most 
comprehensive gene expression analysis of TEBs and ducts to date.  
We  highlighted  the  association  of  TEB  transcriptome  with  kidney  and  lung 
morphogenesis/cancer,  cellular  migration,  nervous  system,  embryonic 
development  and  branching  morphogenesis  associated  gene  signatures  and 
suggested that these genes could provide new pubertal regulators of mammary 
morphogenesis.  
We suggested that the stroma and epithelium of TEBs associates with similar 
processes  and  these  are  mainly  „Cellular  Migration‟,  „Immune  System 
Development and Function‟ and „Embryonic Development‟ whereas the epithelial 
and stromal signatures of ducts may differ considerably. We suggested that the 
ductal epithelial transcriptome associates with „Embryonic Development‟- and 
immune system (especially the migration of immune system components) gene 
signatures while ductal stroma appears as a place of high metabolic activity. 
Thus, suggesting that mammary epithelium may express cues that promote the 
infiltration of haemapoietic cells into epithelium adjacent stroma and proposed 
that an active angiogenesis may occur in mammary gland at puberty. In addition, 
we presented the most comprehensive analysis of the EMT response associated 
genes in pubertal mouse mammary gland development, to date, but were not 
able to draw final conclusions from our data on its involvement in controlling 
TEB  outgrowth.  We  addressed  the  potential  association  of  the  pubertal 
mammary  transcriptome  with  neuronal  development  gene  signature  and 
suggested that the TEB stroma and duct epithelium may comprise the highest 
number of axonal guidance genes.  
Finally,  we  identified  the  potential  presence  of  many  cell  types,  including 
neutrophils, T-, B-lymphocytes and NTKLs; and genes, such as: Emb, Fbn2, Fap 
or Slt1 that have not previously been linked to pubertal mouse mammary gland 
but  may  be  potentially  important  for  its  morphogenesis.  These  pose  many     225 
 
questions  that  still  need  to  be  answered  and  may  suggest  many  potential 
avenues of investigation that could guide future work.        226 
 
4  Identification of new potential regulators of 
pubertal mouse mammary gland 
morphogenesis: Uroplakin 3a and Fibulin 2 
4.1 Introduction 
One of the main focuses of the microarray analysis performed in this study was 
the  identification  of  new  genes  with  potential  to  regulate  pubertal  mouse 
mammary gland development (See 3.2.6.3). These were selected from the list 
of 65 TEB epithelium up-regulated genes based on two criteria such as: i) FC 
level ii) association with  biological processes known to share similarities with 
pubertal mouse mammary gland morphogenesis (See 3.2.6.3) (Table 3-5). Two 
genes Uroplakin 3a (Upk3a) and Fibulin 2 (Fbln2) were identified and selected 
for further investigation.  
4.2 Results 
4.2.1 UROPLAKIN 3A 
4.2.1.1  Introduction 
Upk3a was selected as a candidate regulator of pubertal mouse mammary gland 
development because it was identified as the most over-expressed gene within 
the 65-gene list. In fact, as shown by 5% LFC Model-based microarray analysis, 
Upk3a was identified as the most up-regulated gene (10.74 fold up-regulated) in 
the epithelium of isolated TEBs (TEBs vs ducts) (Table 3-4). 
To date, Upk3a has only been detected and functionally associated with normal 
or impaired bladder development. It encodes a membrane protein consisting of 
287 amino acids (aa) and is characterised by a molecular mass of 47 kDa from 
which  ~  29  kDa  and  ~  18  kDa  account  for  apoprotein  and  complex  glycans 
respectively.  The  mature  Upk3a  protein  consists  of  a  189  aa  long  N-terminal 
domain  that  encloses  all  potential  N-glycosylation  sites  and  a  52  aa  long  C-    227 
 
terminal,  cytoplasmic domain within which multiple phosphorylation sites are 
contained. The remaining ~ 46 aa make up a single transmembrane domain.  
Upk3a  belongs  to  the  uroplakin  family,  which  consists  of  four  additional 
proteins: Upk1a (27 kDa), Upk1b (28 kDa), Upk2 (15 kDa) and Upk3b (35 kDa) 
[416] [417]. The cytoplasmic domain is exclusive to Upk3a and was postulated to 
enable  the  interaction  of  Upk3a  with  the  cell  cytoskeleton  [418].  N-  and  C-
terminal domains of Upk3a are joined by a single transmembrane domain [418] 
[419]. All five uroplakins are known to be integral, structural components of a 
differentiated  bladder  urothelium.  The  two  dimensional  (2D)  crystals  of 
hexagonally packed 16 nm uroplakin particles have been shown to assemble as 
plaques  and  are  called  asymmetric  membrane  units  (AMU).  Plaques  line  the 
apical  side  of  terminally  differentiated  mammalian  urothelial  umbrella  cells, 
called superficial cells [420] [421]. Urothelial plaques are postulated to function 
as a permeability barrier and serve as a means for stabilizing the luminal bladder 
surface during contractions and expansion [422]. In the urothelium, uroplakins 
exist  and  function  as  heterodimers  (1a/2  and  1b/3)  [423]  [424].  This 
conformation  enables  them  to  exit  from  the  endoplasmic  reticulum  and  is  a 
prerequisite  to  reach  the  cell  surface  [425].  Formation  of  Upk3a/Upk1b 
heterodimer triggers a conformational change in Upk3a and protein maturation. 
The 43 kDa immature, endoplasmic reticulum form of Upk3a gets converted to 
the 47 kDa glycosylated, mature and stable protein (Golgi form).  
Gene targeted ablation of Upk3a confirmed its functional association and vital 
role  in  normal  plaque  formation  [422].  Examination  of  bladder  structure  and 
function  in  Upk3a  deficient  mice  revealed  a  reduced  size  of  the  urothelial 
plaques  causing  increased  urothelial  permeability,  increased  proliferation  of 
umbrella cells, presence of retrograde flow of urine from the bladder into the 
ureters  (vesicoureteral  reflux),  accumulation  of  urine  in  the  renal  pelvis 
(hydronephrosis),  abnormal  voiding  patterns  and  an  increase  in  spontaneous 
contractions and pressure in the bladder [422] [420] [426] [427]. Furthermore, 
Matsumoto et al. (2008) showed that loss of Upk3a expression is associated with 
the  occurrence  of  transitional  cell  carcinoma,  a  highly  aggressive,  invasive 
bladder cancer [428]. In contrast, Lai et al. (2010),  however, identified Upk3a 
as a novel promising marker for the detection of bladder carcinoma from urine 
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Given the lack of an established, precise biological function and its exclusivity in 
association with the urothelium derived structures, such as renal pelvis, urethra, 
urinary bladder and prostate urethra [430] when all other human tissues with an 
exception  for  ovarian  Brenner  tumour,  which  however,  is  thought  to  be  of 
urothelial  origin,  have  to  date  been  demonstrated  as  negative  for  Upk3a 
expression [431], Upk3a emerged as an interesting target for mouse mammary 
gland associated research. Our aim was to confirm the up-regulation of Upk3a 
expression in the mouse mammary gland during puberty, determine its precise 
localisation  in  TEBs  and  identify  its  role  in  normal  mouse  mammary  gland 
development at puberty.       
4.2.1.2  Validation of Upk3a expression in pubertal mouse mammary gland. 
The association of Upk3a with the TEB transcriptome was further supported by 
microarray  comparison  analysis  of  Post-LN  and  Pre-LN  data  sets  (Partek
® 
Genomics™ Suite software) (See 2.2.5.5.2) where Upk3a was shown to be 3.01 
fold over-expressed in the Post-LN strip – ranking (#) to position 21 (p-value< 
0.001) (Figure 4-1 A). 
The TEB associated increase of Upk3a expression was also seen very clearly when 
the  level  of  absolute  gene  expression  was  compared  across  all  microarray 
replicates. The expression level was shown to be uniform across the replicates of 
each biological sample except for one 12 week old virgin replicate. The highest 
expression  level of  Upk3a  was  noted in  the  isolated  epithelium  of  TEBs.  The 
isolated ductal epithelium and Post-LN strips showed the second highest Upk3a 
expression  level  (10.74-  and  11.1-  fold  lower  than  isolated  TEB  epithelium 
respectively). Upk3a expression in Pre-LN strips was 3.01 and 3.1 fold lower than 
that seen in Post-LN strips and isolated ducts respectively. The lowest  Upk3a 
expression, however, was noted in the Fat pad with the Upk3a gene expression 
level similar to the one detected in the negative control - adult (V12) mammary 
glands (Figure 4-1 B).  
Further validation of TEBs-associated pattern of Upk3a expression in the mouse 
mammary gland was performed using Q RT PCR. As seen in Figure 4-2 A, Upk3a 
mRNA levels displayed a 4-fold increase in expression levels in the Post-LN strips      229 
 
 
Figure 4-1 Upk3a expression profiling in the pubertal mouse mammary gland by microarray 
analysis. 
(A) Level of Upk3a up-regulation in the TEBs (TEBs vs ducts) and Post-LN strips (Post-LN vs Pre-
LN). Microarray analysis of TEB and duct data sets were performed using 5% LFC Model (See 
2.2.5.5.1), while the Post-LN and Pre-LN data sets were compared using Partek® ® Genomics™ 
Suite software (See 2.2.5.5.2). Rank number was assigned based on the FC level. Calculated FCs 
were statistically significant i.e. p-value≤0.05 for genes over-expressed in Post-LN and within 5% 
LFC  Model  for  genes  over-expressed  in  the  TEBs  isolated  epithelium.  (B)  Absolute  Upk3a 
expression  levels  for  all  microarray  replicates.  Absolute  gene  expression  in  each  microarray 
replicate  was  calculated  using  Expression  Console™.  RMA  was  performed  prior  to  gene 
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Figure 4-2 Validation of Upk3a mRNA expression in the pubertal mouse mammary gland by 
Q RT PCR. 
(A) Mean expression level of Upk3a, Sema3B and Ltf mRNA in the Post-LN strips relative to Pre-
LN tissue strips. Sema3B and Ltf served as controls. Krt18 expression was used as an internal 
control for normalisation. Error bars are S.E.M. (*) denotes statistical significance, (*) p-value≤0.05 
(**) p-value≤0.01 (***) p-value≤0.001, n=3 
(B) Representative illustration of the mean expression level of Upk3a in Post-LN strip and bladder 
relative  to  Pre-LN  strip.  The  cDNA  produced  from  bladder  RNA  without  addition  of  Reverse 
Transcriptase (RT) served as a negative expression control.  Krt18 expression was used as an 
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in  comparison  to  the  Pre-LN  mouse  mammary  gland  tissue  strips.  Expression 
levels of Sema3B and Ltf that are known to be expressed in the TEB and duct 
epithelium  respectively  were  used  as  experimental  controls.  Due  to  the 
prevalent association of Upk3a expression with the TEB epithelium, the Upk3a 
expression was measured by normalising the calculated gene expression level 
against that of Krt18. In addition mouse bladder was used as a positive control. 
Krt18  is  a  marker  of  both  epithelial  cells  and  urothelial  umbrella  cells  [432] 
[433]. The calculated expression of Upk3a in the Post-LN mouse mammary gland 
tissue strip, although higher than that in the Pre-LN strip, was 17-fold lower than 
in the mouse bladder (Figure 4-2 B).  
Despite the presence of Upk3a mRNA in pubertal mouse mammary gland and its 
TEB-associated  expression  pattern,  its expression  in  the  mammary  epithelium 
could not be confirmed at the protein level. Western blot analysis of protein 
extracts from Post-LN and Pre-LN mouse mammary gland tissue strips showed a 
lack  of  Upk3a  expression  in  the  mammary  gland  although  the  protein  was 
present in murine bladder (positive control) (Figure 4-3 A). The antibody used in 
this  study  (AU1)  is  an  Upk3a  specific  mouse  IgG1  monoclonal  antibody  that 
recognizes an unspecified epitope residing within the extracellular domain [419]. 
Upk3a in the bladder protein extract was detected on the western blot as bands 
of  between  43-47  kDa  which  corresponded  to  the  size  of  the  immature 
(Endoplasmic reticulum) or mature (Golgi) forms of Upk3a. These bands were 
absent from the Post-LN and Pre-LN blots. The lack of Upk3a protein expression 
in  the  pubertal  mouse  mammary  glands  was  further  confirmed  using  IHC. 
Paraffin wax embedded tissue sections of mammary gland and bladder, collected 
from 6 week old mouse were stained with AU1. In the bladder the umbrella cell 
region stained very strongly and uniformly for Upk3a (Figure 4-3 D). Although 
faint staining was also visible in the apical side of the mammary gland luminal 
epithelium (Figure 4-3 B) the same staining pattern was present in the negative 
control section (no primary antibody) and it was therefore considered as non 
specific secondary antibody reactivity (Figure 4-3 C).  
In order to ensure that the discrepancy between the mRNA and protein levels of 
Upk3a  in  the  mouse  mammary  gland  was  not  attributed  to  a  tissue  specific 
alteration in the gene sequence affecting the epitope recognised by the AU1 
antibody, full length Upk3a cDNA was synthesised from pubertal mammary gland      232 
 
 
Figure 4-3 Validation of Upk3a protein expression in the pubertal mouse mammary gland. 
(A) Western Blotting. Representative analysis of Upk3a expression in the bladder (positive control), 
Post-LN strip and Pre-LN strip. Upk3a protein (47kDa) was identified using mouse monoclonal AU1 
antibody. ß-actin was used as loading control. n=2 
(B)  (C)  (D)  IHC.  (B)  (C)  Longitudinal  sections  through  a  6  week  old  mouse  mammary  gland, 
showing fragment of representative epithelium and (D) mouse bladder showing part of urothelium. 
(B) (D) were stained using AU1 antibody. (C) serves as negative control (no primary antibody). (D) 
serves as positive control. Upk3a staining was prominent in urothelial umbrella cell region. Staining 
seen on the apical border of luminal epithelial cells in the mouse mammary gland was unspecific as 
it  is  also  visible  in  the  negative  control.  Secondary  antibody  was  horseradish  peroxidase 
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Pre-LN and Post-LN tissue strips and urinary bladder and sequenced. The length 
of  cDNA  obtained  from  all  three  sites  was  equal  and  there  were  no  major 
differences in the nucleotide sequence or nucleotide rearrangements between 
the sequences. 
In  summary,  although  Upk3a  had  potential  to  be  a  pubertal,  TEB-associated 
regulator  of  mammary  gland  morphogenesis  its  expression  could  only  be 
detected at the mRNA level.  
4.2.2 FIBULIN 2  
4.2.2.1  Introduction 
Fbln2 was selected as a candidate regulator of pubertal mouse mammary gland 
development  because  it  was  identified  within  the  65  TEB  epithelium  up-
regulated  genes  and  has  previously  been  reported  to  associate  with  other 
biological processes known to share similarities with ductal morphogenesis, such 
as  cell  adhesion  and  migration,  embryonic  development  and  kidney 
morphogenesis (Table 3-5).  
Fbln2 belongs to the highly conserved, ancient family of ECM glycoproteins.  The 
family name originates from the word  fibula which in Latin means „clasp‟ or 
„buckle‟ and refers to their ability to act as a linker for other proteins.  The 
Fibulin family incorporates six known members (Fbln1-Fbln6), all of which are 
characterised by the presence of a series of EGF-like motifs, followed by the 
carboxy-terminal  fibulin-type  module.  The  closest  relative  to  Fbln2  is  Fbln1C 
which shares 43 % aa sequence identity (Figure 4-4 A). 
Fbln2 cDNA was originally cloned from mouse fibroblasts in 1993 [434] and the 
gene was located to the mouse chromosome 6 band D-E [435]. Fbln2 was shown 
to exist as two alternatively spliced variants: V1 and V2, consisting of 18 and 17 
exons  respectively.  Based  on  the  cDNA  sequence,  Fbln2  V1  was  predicted  to 
comprise a 3633 bp-long open reading frame as well as a 50bp and 664bp long 5‟ 
and 3‟ untranslated regions respectively. At the protein level, Fbln2 translated 
into a 26-residue long signal peptide and a 1195-residues long mature protein.      234 
 
 
Figure  4-4  The  overview  of  domain  models  for  Fbln2  (M.  musculus  and  H.  sapiens  and 
Fbln1C (M. musculus). 
Names of domains are indicated on the top of each diagram. Blue boxes at the left hand side 
denote the N-terminus domain (N-term). The N-term domain consists of Na and Nb subdomains. 
Pink  diamonds  in  domain  I  indicated  three  motifs  related  to  anaphylatoxins.  Yellow  circles  in 
domain  II  denote  EGF-like  repeats  and  those  with  asterisk  in  the  middle  posses  Ca
2+  binding 
consensus sequence. The first EGF-like repeat  is linked to domain I  and the second  EGF-like 
repeat with aa linkers (arrow head). The yellow circle with red outline represents exon 9. The gray 
box at the right hand site denotes the C-terminal domain (III) Annotation seen at the bottom of each 
diagram  indicate  positions  of  the  potential  N-glycosylation  sites  (N1,  N2,  N3  and  N4)  and  the 
position of RGD consensus (RGD).      
(A) Murine Fbln1C. Fbln1 C is the closest relative to Fbln2 with 43% aa identity. It lacks the N-
terminal domain, has 9 EGF-like repeats and its C-terminal domain is shorter (B) Murine Fbln2 V1 
(top model) and (C) Fbln2 V2 (bottom model). Fbln2 V2 lacks EGF-like domain 3 which is encoded 
by exon 9. Potential glycosylation site 2 (N2) is also absent (D) The human Fbln2 lacks exon 9 and 
thus  does  not  encode  EGF-like  repeat  3.  Potential  glycosylation  site  2  (N2)  and  the  RGD 
consensus sequence are absent. 
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Fbln2 V1 (195 kDa) consists of four domains (N, I, II and III). The N-terminus (N-
domain) is unique to Fbln2. It incorporates two sub domains spanning over 408 
aa residues. The first sub domain is cysteine rich (Na) and the second is cysteine 
free (Nb). Domain I consists of three anaphylatoxin-like motifs (each ~ 40 aa long 
and containing six cysteines) and is connected to the domain II via a 50 aa long 
link. Domain II consists of 11 EGF-like repeats, 10 of which contain consensus 
motifs  for  Ca
2+  binding  that  are  hypothesized  to  regulate  protein-protein 
interactions  [434]  [436].  In  general  EGF-like  repeats  are  postulated  to 
participate in the interactions of ECM proteins with cellular receptors [437] as 
well as play a role in the stabilization of protein structure due to the presence of 
multiple  disulfide  bridges  which  in  conjunction  with  other  copies  of  Fbln2 
protein facilitate the formation of rod-like structures [438]. Recombinant Fbln2 
incorporates three disulfide bridges and is produced and secreted by human cell 
clones as a disulfide-bonded trimer. The final, domain III (C-terminal) of Fbln2 
V1 is composed of a single globular module. Furthermore, as indicated by the aa 
sequence prediction study, there are four potential N-linked glycosylation sites 
at  the  aa  positions  179,  497,  737  and  1072  and  a  single  Arg-Gly-Asp  (RGD) 
attachment site, indicative of adhesive properties, at position 395-397 (Figure 
4-4 B).  
Fbln2 V2 shares all of the above sequence characteristics but for the presence of 
exon 9 which encodes the EGF-like domain 3 (709-755 aa) and contains a single 
potential N-linked glycosylation site (aa 737) (Figure 4-4 C).        
Fbln2 shows a high degree of interspecies conservation as the human protein 
shares around 90% aa identity with the domains Na, I, II and III and 62% with the 
domain Nb of the murine counterpart. The human gene thus far characterised 
lacks the EGF-like repeat on exon 9, hence encodes only the shorter (V2) Fbln2 
isoform  and  fails  to  contain  the  predicted  RGD  domain,  which  results  in  a 
substantial  difference  in  cell  adhesion  activity  and  RGD-dependent  integrin 
receptor binding between the two species [435] (Figure 4-4 D).      
The  promoter  region  of  Fbln2  has  been  shown  to  contain  the  trans-acting 
transcription factor 1 (Sp1)-, activator protein 2 (AP-2)- and CCAAT enhancer 
binding  protein  (C/EBP)  binding  sites  [439].  The  Sp1  consensus  sequence  is 
involved  in  gene  expression  in  early  development  and  confers  high  promoter     236 
 
activity while the AP-2 and C/EBP transcription factors are known to regulate 
gene expression during embryogenesis and differentiation respectively. 
Expression of Fbln2 is detected mostly at the BMs and stroma of many mouse 
embryonic and adult tissues. During embryogenesis it is prominently expressed 
at  embryonic  sites  of  EMT  during  cardiac  valvuloseptal  formation  [343]  or 
precartilage formation [440]. In adulthood it is still associated with the valves 
and septa of heart [343], endothelial cells (EC) of the aortic arch and coronary 
blood  vessels  [441]  and  it  can  further  be  seen  in  skin  (epidermal  cell  layer, 
dermis and adipose tissue), keratinocytes of hair follicles, epithelial cell layer 
and  Bowman‟s  and  Descemet‟s  membranes  and  stroma  of  cornea  and 
surrounding the extracellular spaces around the muscle fibres in the skeletal and 
heart muscles. A lower level of Fbln2 mRNA expression has also been detected in 
the lung, liver, kidney, brain, spleen and testis [434]. 
Based on in vitro studies the function of Fbln2 may be in forming intramolecular 
bridges  which  link  and  stabilize  the  organisation  of  supramolecular  ECM 
structures, i.e. basement membranes, elastic fibres and fibronectin matrix [442] 
[443]  [444].  Furthermore,  Fbln2  co-localises  and  interacts  with  Fbn1  in  the 
bundles  of  microfibrils  that  appear  to  intersect  the  lamina  densa  of  kidney 
glomeruli and perichondrium [344]. The timing of expression, tissue localisation 
and spatial localisation within the tissues also suggest that it may promote either 
proliferation  or  differentiation  or  migration  of  mesenchymal  cells  during 
organogenesis and endorse structural stability during adulthood. The detection 
of  Fbln2  expression  in  testis  [445]  and  ovaries  [435]  in  connection  with  the 
recently discovered involvement of Fbln2 in the sequestering of sex hormone 
binding  globulin  (SHBG)  within  the  stroma  of  uterus  and  thus  regulating  the 
access of SHBG to target cells [446], suggest functional association of Fbln2 with 
the female and male reproduction systems. Finally, since it is over-expressed 
during wound repair processes, Fbln2 may also be involved in tissue remodelling 
[447] [448]. In contrast to the in vitro studies, however, an in vivo Fbln2 KO
-/- 
based study did not confirm the need for Fbln2 in elastogenesis, development 
and fertility as the Fbln2-null mice were shown to be viable, fertile and lacking 
any gross anatomical abnormalities or dysfunction in assembly of elastic fibres 
[266]. Very recently, however, the generation of double KO mice for Fbln2 and 
Fbln5 shone a new light onto Fbln2 function, demonstrating that both of the     237 
 
proteins function cooperatively to redirect the assembly of elastic fibres to form 
the internal elastic lamina in blood vessels during postnatal development [449].   
Finally,  the  dysfunction  of  Fbln2  has  been  associated  with  some  pathological 
conditions.  Deposition  of  Fbln2  in  elastic  fibres  was  demonstrated  in  solar 
elastosis, a skin condition caused by sun damage [450]. In tumourigenesis, Fbln2 
has been identified to have opposing functions. On the one hand, it was found 
amongst the metastasis-associated genes in adenocarcinomas  [451], was over-
expressed in a HER2/Neu –driven mouse model of breast cancer [452] and was 
associated with poor prognosis and metastatic potential of primary solid tumours 
of  different  types  [451].  On  the  other  hand,  however  it  was  identified  as 
frequently  methylated  in  breast  tumors  [453]  and  down-regulated  in  breast 
cancer cell lines and primary breast tumours [342].   
Given  the  association  of  Fbln2  with  organogenesis,  tissue  remodelling  and 
tumourigenesis  and  its  documented  involvement  in  the  regulation  of  cell 
adhesion and migration in different biological systems, together with the up to 
date lack of reported Fbln2 expression and association with mouse mammary 
gland  development,  Fbln2  arose  as  a  promising  novel  target  in  the  study  of 
pubertal regulators of mouse mammary gland morphogenesis. Thus, we aimed to 
confirm  and  examine  the  Fbln2  expression  pattern  during  normal  mouse 
mammary gland development, with a focus on puberty. Furthermore, we set out 
to  study  the  role  of  Fbln2  in  pubertal  morphogenesis  by  examining  the 
morphology  of  the  ductal  tree  in  Fbln2  KO
-/-  mice,  exploring  the  expression 
patterns of its binding partners, estimating the influence of systemic hormones 
on  its  expression  in  vivo  and  investigating  its  role  in  the  regulation  of  cell 
migration and adhesion in vitro. Finally, we set out to establish a TEB explant 
culture model to facilitate the study Fbln2 expression in vitro.  
4.2.2.2  Validation of Fbln2 expression during pubertal mouse mammary 
gland development.  
Fbln2 was amongst the 65 genes commonly up-regulated in the epithelium of 
TEBs (TEBs vs ducts) (5% LFC Model) (See 3.2.6.1.1) and Post-LN strip (Post-LN 
vs Pre-LN) (Partek
® Genomics™ Suite software) (See 3.2.6.1.2) by 2.16 fold (# 
182) and 1.75 fold (# 285) (p-value<0.001) respectively (Figure 4-5 A). The      238 
 
 
Figure 4-5 Fbln2 expression profiling in the pubertal mouse mammary gland by microarray 
analysis. 
(A) Level of Fbln2 up-regulation in the TEBs (TEBs vs ducts) and Post-LN strips (Post-LN vs Pre-
LN). Microarray analysis of TEB and duct data sets were performed using 5% LFC Model (See 
2.2.5.5.1), while the Post-LN and Pre-LN data sets were compared using Partek® ® Genomics™ 
Suite software (See 2.2.5.5.2). Rank number was assigned based on the FC level. Calculated FCs 
were statistically significant i.e. p-value≤0.05 for genes over-expressed in Post-LN and within 5% 
LFC  Model  for  genes  over-expressed  in  isolated  epithelium  of  TEBs.  (B)  Absolute  Fbln2 
expression  levels  throughout  all  microarray  replicates.  Absolute  gene  expression  in  each 
microarray  replicate  was  calculated  using  Expression  Console™.  RMA  was  performed  prior  to 
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increase of Fbln2 expression in association with TEBs was confirmed when the 
level of absolute gene expression was compared across all replicates used in the 
microarray  experiment.  The  comparison  of  absolute  gene  expression  also 
revealed the expression of Fbln2 within the empty Fat pad. The Fat pad was 
excised  at  a  significant  distance  from  the  epithelium  to  prevent  its 
contamination with epithelium and its associated stroma. The absolute level of 
Fbln2 expression was highest in isolated TEBs, Fat pad and Post-LN strips with 
Fat pad showing similar and Post-LN -1.2 fold lower gene expression levels than 
isolated TEBs. Some variability between the replicates could be seen for the Fat 
pad strips. The absolute level of Fbln2 expression was lower in the remaining 
samples, with isolated duct epithelium, Pre-LN strip and V12 showing 2.16, 1.9 
and 1.6 fold lower expression than that calculated in the isolated TEB epithelium 
respectively (Figure 4-5 B).     
Expression of Fbln2 within the epithelium of TEBs was further confirmed by Q RT 
PCR analysis of total RNA extracts collected from isolated TEBs and ducts and 
Post-LN  and  Pre-LN  mammary  gland  tissue  strips.  The  Fat  pad  associated 
expression of Fbln2 was not taken into consideration in these as well as most of 
the subsequent experiments since at the time of the study Fbln2 was thought to 
be mostly expressed in the epithelium and only low expression was thought to be 
associated  with  stroma  (absolute  gene  expression  profiling  and  some  of  the 
protein localisation studies were performed as one of the last analyses). As seen 
in Figure 4-6 A and B Fbln2 expression was 3.4 fold higher in both, isolated TEBs 
compared to ducts, and Post-LN strip compared to Pre-LN. Expression levels of 
Sprr1A  and  Ltf,  genes  previously  associated  with  TEB  and  duct  epithelium 
respectively  were  used  as  experimental  controls.  As  only  the  epithelium 
associated expression of Fbln2 was taken into consideration in this experiment, 
Krt18 (an epithelial marker) instead of ß-actin (expressed ubiquitously in the 
tissue)  was  used  for  normalisation.  Krt18  aids  the  normalisation  of  the 
calculated gene levels to the amount of epithelium. It is worth noting, however, 
that  Post-LN  and  Pre-LN  strips  consist  of  both  epithelium  and  its  associated 
stroma, which as suggested by the high absolute expression of Fbln2 in Fat pad 
(Figure 4-5 B) and further demonstrated in succeeding experiments (Figure 4-
7), also expresses Fbln2. Therefore despite using Krt18 normalisation to examine  
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Figure 4-6 Validation of Fbln2 expression in pubertal mouse mammary gland. 
(A) (B) Q RT PCR. (A) Mean expression level of Fbln2 and Sprr1a mRNA in isolated TEBs relative 
to isolated ducts and (B) Fbln2, Sprr1a and Ltf mRNA in the Post-LN strips relative to Pre-LN 
tissue strips. Sprr1a and Ltf served as controls for TEBs and ducts respectively. Krt18 expression 
was used as an internal control for normalisation. In (A) n=pooled from 300 mice and error bars 
denote technical variability. In (B) error bars are S.E.M. and (*) denotes statistical significance, (*) 
p-value≤0.05 (**) p-value≤0.01 (***) p-value≤0.001, n=3 
(C) Western Blotting. Representative analysis of Fbln2 expression in the Pre-LN strips, Post-LN 
strips and skin (positive control). Fbln2 protein (195 kDa) was identified using rabbit polyclonal anti- 
Fbln2 antibody. Asterisks (*) denote two additional, uncharacterised bands of a lower molecular 
weight (150 kDa, 135 kDa). ß-actin was used as loading control. n=3. Densitometry was carried out 
to calculate relative expression of Fbln2 protein normalised to ß-actin protein levels for the same 
set of samples. 
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epithelial gene expression, some of the detected signal might be attributed to 
the stromal compartment.  
Pubertal  expression  of  Fbln2  (195  kDa)  was  further  confirmed  at  the  protein 
level by Western Blotting using protein lysates, extracted with RIPA buffer from 
murine  skin  and  Post-,  Pre-LN  tissue  strips  and  blotted  under  denaturing 
conditions (Figure 4-6 C). The level of Fbln2 expression was 1.6 and 6.2 fold 
higher in the Post-LN strip than the Pre-LN strip and skin respectively (positive 
expression control)  as  revealed  in  densitometry  analysis.  Previously  reported, 
uncharacterised bands of the mobility below the predicted protein (150 kDa and 
135 kDa) (denoted by asterisks in Figure 4-6 C) were also present. 
4.2.2.3  Localisation of Fbln2 in the pubertal mouse mammary gland 
To assess the localisation of Fbln2 within the pubertal mouse mammary gland, 6 
week  old  mammary  glands  were  fixed  in  10  %  Neutral  Buffered  Formalin, 
paraffin  wax  embedded  and  sectioned.  Chosen  sections  were  H&E  stained  to 
assess tissue morphology and ensure the presence of TEB and duct epithelium. 
Positively  evaluated  tissue  sections  were  stained  with  routine  anti-Fbln2 
antibody  using  IHC  and  IF.  Haematoxylin  and  DAPI  were  used  as  nuclear 
counterstains for IHC and IF respectively. The obtained results were consistent 
with the Fbln2 expression profile determined by microarray analysis. 
As seen in Figure 4-7, Fbln2 expression was localised to both the epithelium and 
the  stroma  of  pubertal  mouse  mammary  gland.  Stromal  expression  was 
restricted to the proximal zone surrounding the TEB and duct epithelium, with 
the former appearing stronger; and the distal capsule located at the very edge 
of the Fat pad. While Fbln2 was present in the stroma surrounding both TEBs and 
ducts its epithelial expression was almost exclusively associated with TEBs. As 
seen  by  IHC  on  transverse  sections  through  the  isolated  TEBs  and  TEBs 
surrounded by the stroma (Post-LN strip) most Fbln2 expression was localised to 
the cap cells (the outermost cell layer in TEBs) (Figure 4-8 A). The additional 
expression of Fbln2 in the TEBs was present in the body cells (Figure 4-8 A). In 
comparison  to  the  TEBs,  ductal  epithelial expression  of  Fbln2  was  very  weak 
(Figure 4-8 B).      242 
 
 
Figure 4-7 Localisation of Fbln2 expression in pubertal mouse mammary gland by IHC. 
(A) Longitudinal section through 6 week old mouse mammary gland stained with rabbit polyclonal 
anti-Fbln2  antibody  and  horse  radish  peroxidase  conjugated  secondary  antibody  (brown). 
Haematoxylin (blue) was used to stain nuclei. Fbln2 expression was associated with epithelium of 
TEBs (arrow), stroma around TEBs and ducts (dotted arrow), stromal capsule around the edge of 
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Figure 4-8 Localisation of Fbln2 expression in the pubertal TEBs and ducts by IHC. 
(A) Longitudinal (left) and transverse (top right) sections through a TEB and its surrounding stroma 
(left) and transverse section through an enzymatically isolated TEB (bottom right) (B) Longitudinal 
section  through  a duct and its surrounding stroma.  (C) Negative (no primary  antibody) control. 
Staining in (A) (B) was performed using anti-Fbln2 antibody (brown). Haematoxylin was used to 
stain nuclei (blue). In (A) most Fbln2 expression was associated with the outer cell layer of TEBs 
(cap cells) (arrow). Some expression was also detectable within body cells (dotted arrow) and the 
stroma  around  TEB  (asterisk).  Fbln2  expression  seemed  to  localise  to  the  cell  membranes, 
cytoplasm  and  extracellular  spaces.  (B)  In  the  duct,  Fbln2  expression  was  weak  and  mostly 
associated with the stroma around ductal epithelium (asterisk). Scale bars are 50 µm. 
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A similar pattern of expression was observed when longitudinal sections through 
the  TEBs  and  ducts  were  stained  for  Fbln2  using  IF  (Figure  4-9).  Fbln2 
expression was almost absent from ductal epithelium (Figure 4-9 C), but was 
present abundantly in the cap cell- and at a lower level in body cell-region of 
TEBs (transverse and longitudinal sections) (Figure 4-9 A-B). In the cap cells, 
Fbln2 staining appeared membrane bound, cytoplasmic and extracellular (Figure 
4-10 A) while within the body cells it was present in cytoplasm or between the 
cells  and  was  not  uniformly  expressed  across  all  body  cells  (Figure  4-10  B). 
Some Fbln2 positive staining could also be seen in the BM region (Figure 4-10 
A).  The  expression  of  Fbln2  in  cap  cell  membranes  and  low  cytoplasmic 
expression  in  ductal  epithelium  were  further  demonstrated  when  3D 
reconstruction  was  performed  on  the  series  of  transverse  sections  through 
pubertal mouse mammary gland (Figure 4-11). 
The  observed  staining  pattern  was  specific  to  Fbln2-antibody  binding  as 
demonstrated by the absence of staining in the epithelium of the negative (no 
primary  antibody)  controls  (Figure  4-8  C)  (Figure  4-9  D).  Positive  Fbln2 
expression was also noted in the blood vessels throughout mammary gland tissue 
(in all IHC and IF sections) (data not shown). 
IHC  and  IF  of  pubertal  mouse  mammary  glands  demonstrated  that  Fbln2 
expression was stronger in the TEBs and their surrounding stroma than in the 
ducts, thus confirming our microarray, Q RT-PCR and Western blot results. 
4.2.2.4  Fbln2 expression across the different stages of mouse mammary 
gland development. 
Post-natal  mouse  mammary  gland  morphogenesis  can  be  divided  into  the 
following  six  distinct  developmental  stages:  pre-puberty,  puberty,  adulthood, 
pregnancy,  lactation and  involution.  Each of  these  stages  is  characterised  by 
diverse events and regulated in a different manner. Therefore, the expression of 
Fbln2 at the RNA level and its tissue localisation was investigated throughout the 
various  developmental  stages  using  whole  tissue  strips  and  whole  mouse 
mammary glands (Figure 4-12 A). The experiments were performed using Q RT 
PCR and IHC. Relative to the Post-LN strip, the level of Fbln2 expression was 3.6 
fold up-regulated in whole mammary glands during pre-puberty but similar     245 
 
 
Figure 4-9 Localisation of Fbln2 expression in the pubertal epithelium of TEBs and ducts by 
IF. 
(A) Transverse and (B) longitudinal sections through TEB and (C) longitudinal sections through 
duct  of  6  week  old  mouse  mammary  glands  are  shown.  (D)  is  a  negative  control  (no  primary 
antibody). Staining was performed using Alexa Fluor 488 conjugated anti-Fbln2 antibody (green) 
and nuclear DAPI (blue). Fbln2 expression was associated with cap cells (arrow) (A) (B). Weak 
staining could be seen in body cells (arrow head). Very weak Fbln2 staining could be detected in 
the duct (C) Images were captured by confocal microscopy. Scale bars are 50 µm.     246 
 
 
Figure 4-10 Localisation of Fbln2 expression in the pubertal TEB by IF. 
Images show representative areas of the pubertal TEBs stained with anti-Fbln2 antibody that are 
shown in Figure 4-9. (A) Cap cells showing membrane (arrow) and cytoplasmic (dashed arrow) 
staining pattern (B) Body cells showing Fbln2 staining in the cytoplasm or extracellular spaces 
(arrow head). Images were acquired by confocal microscopy. Scale bars are 10 µm.     247 
 
 
Figure 4-11 3D reconstruction of pubertal TEBs and ducts stained with anti-Fbln2 antibody. 
3D reconstruction of the series of (A) transverse sections through the TEB and (B) longitudinal 
sections through the duct of a 6 week mouse mammary gland. 3D reconstruction was performed 
using Velocity software. Images were acquired every 0.7-0.8 µm. (A) Fbln2 staining in the TEB was 
restricted  to  cap  cells  and  BM  region  (white  arrow).  Duct  epithelium  was  negative  for  Fbln2 
expression. Weak staining visible in B was nonspecific (See Figure 4-9 D). Images were captured 
by confocal microscopy. Scale bars are 20 µm.        248 
 
 
Figure 4-12 Fbln2 mRNA expression throughout different stages of mouse mammary gland 
development by Q RT PCR. 
(A) Mean expression levels of Fbln2 in whole glands collected at pre-puberty, puberty, adulthood, 
pregnancy, lactation and involution. Post-LN strip served as a positive control. Expression levels 
were normalised against Krt18. Error bars denote technical variability, n=1, as only 1 animal was 
used per time point but experiments were repeated 3 times.  
(B) (C) Mean expression levels of Fbln2 in whole glands collected at pre-puberty (2 and 3 weeks) 
relative to puberty 6 weeks. Expression levels were normalised against Krt 18 (B) and ß-actin (C). 
Error bars are S.E.M, (*) denotes statistical significance (**) p≤0.01, n=3. Experiments were done in 
triplicates for each sample. 
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during  puberty,  which  served  as  a  good  experimental  control.  Furthermore, 
moderate  Fbln2  expression  (although  significantly  lower  than  in  the  Post-LN 
strip) was also noted in the following samples: pregnancy day 3, lactation days 1 
and 7. However, this experiment was performed on samples collected from a 
single  set  of  animals,  hence  detected  expression  levels  might  not  be  fully 
representative.  Since  Fbln2  was  expressed  at  the  protein  level  in  both 
epithelium  and  stroma  of  the  pubertal  mouse  mammary  gland,  Fbln2  RNA 
expression profiling was repeated at chosen time points (pre-puberty, puberty) 
to compare the levels of Fbln2 expression relative to the amount of epithelium 
or to the total number of cells. This was calculated by normalising the gene 
expression  to  Krt18  and  ß-actin  expression  levels  respectively.  Initially  only 
Krt18 was used for normalisation, but with the expression of Fbln2 in stroma 
noted on IHC, IF and absolute gene expression profiling, data was re-normalised 
against ß-actin since its expression is ubiquitous. This showed that the level of 
Fbln2 expression varied depending on whether its expression was normalised to 
the amount of epithelium or to the total number of cells. When normalised to 
Krt18, pre-pubertal Fbln2 expression at 2 and 3 weeks was on average 25 and 16 
fold higher than its pubertal (6 weeks) expression respectively (Figure 4-12 B) 
and all of these FCs were statistically significant. In contrast when normalised to 
ß-actin,  Fbln2  expression  levels  were  similar  between  all  of  the  three  time 
points,  with  only  the  pre-puberty  week  3  sample  showing    slightly  lower 
expression  (Figure  4-12  C).  None  of  these  FCs,  however,  reached  statistical 
significance. 
A  similar  pattern  of  Fbln2  expression  was  observed  at  the  protein  level.  In 
concordance  with  the  mRNA  expression  profile,  IHC  stained  sections  of  the 
mouse  mammary  gland  developmental  stages  demonstrated  positive  Fbln2 
expression during pre-puberty, puberty, adulthood and early pregnancy (Figure 
4-13, 4-14). In discrepancy with the mRNA data, however, no Fbln2 expression 
was detected during lactation (Figure 4-15 A). In the pre-pubertal and pubertal 
mammary gland Fbln2 localised to the epithelium (cap cells and body cells) and 
stroma  around  TEB-like  structure  and  TEBs  respectively  (Figure  4-13  A-C). 
During puberty, protein expression was also detectable in the duct epithelium 
and  stroma,  as  discussed  in  4.1.2.3  (Figure  4-13  C).  This  ductal  expression 
pattern, although very diminished, was further detectable in the 12 week old      250 
 
 
Figure 4-13 Fbln2 protein expression and localisation during virgin mouse mammary gland 
development by IHC. 
Longitudinal and transverse sections through (A) (B) 3, (C) 6 and (D) (E) 12 weeks old mouse 
mammary glands showing representative fragments of epithelium stained with anti-Fbln2 antibody 
(brown). Nuclei were stained with haematoxylin (blue). (B) and (E) are higher magnification images 
of the areas highlighted by asterisks in images A and D respectively. (F) shows a negative (no 
primary antibody) control. Fbln2 expression was localised to the TEBs (black arrows) (A) (C) and in 
much lesser extend to the pubertal ducts (black arrow heads) (C). In the adult mammary gland 
some weak Fbln2 expression was associated with the stroma around ducts (arrow head) (D). Scale 
bars are 200 µm. At least 3 animals (6 glands) were examined per developmental stage. 
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Figure 4-14 Fbln2 protein expression and localisation in the mouse mammary gland during 
pregnancy time points by IHC. 
Longitudinal sections through mammary glands collected from pregnant mice (left) and magnified 
fragments of representative epithelium (right) (highlighted by asterisk on the left) stained with anti-
Fbln2 antibody (brown). Nuclei were stained with Haematoxylin (blue). Fbln2 expression switched 
on 48h after conception, increased by 72h and disappeared by pregnancy day 4.5. Some Fbln2 
positive staining could be seen at 14.5 days. Scale bars are 200 µm. At least 3 animals (6 glands) 
were examined per developmental stage. 
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Figure 4-15 Fbln2 protein expression and localisation in the mouse mammary gland during 
lactation and involution by IHC. 
Longitudinal sections through (A) lactating and (B) involuting mouse mammary glands showing 
representative  fragments  of  epithelium  stained  with  anti-Fbln2  antibody  (brown).  Nuclei  were 
stained with Haematoxylin (blue). No Fbln2 expression could be detected. Scale bars are 200 µm. 
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adult  mammary  glands  (Figure  4-13  D  and  E).  Prominent  Fbln2  expression, 
comparable to that in the pre-pubertal or pubertal TEBs was detectable during 
early pregnancy, with the onset at 48h, a peak at 72h and disappearance by day 
4.5 (Figure 4-14). At these time points, Fbln2 appeared localised exclusively to 
the cell membranes and cytoplasm of the outer most, presumably myoepithelial 
layer of the ductal epithelium and the stroma around it (as seen at puberty). 
The expression of Fbln2 in the distal stromal capsule was very prominent at pre-
puberty (3 weeks), puberty (6 weeks) and pregnancy 72h; largely reduced by the 
onset of adulthood and pregnancy day 14.5 and absent from involution day 7 and 
lactation day 3 (Figure 4-16 A-G).  
All  of  the  observed  staining  was  specific  to  Fbln2-antibody  binding  as 
demonstrated  by  the  lack  of  staining  in  the  negative  (no  primary  antibody) 
controls (Figure 4-13 F) (Figure 4-16 H). 
4.2.2.5  Localisation of Fbln2 expression using a preliminary in vitro model 
of TEB explant culture 
The confocal images and light microscopy suggested that the Fbln2 was present 
in the cytoplasm, on the membrane and possibly in the extracellular spaces in 
TEBs at puberty. In order to analyse the localisation more precisely we decided 
to attempt to culture TEBs as explants, with the assumption that the cap cells 
and  the  body  cells  would  migrate  out  from  the  explant  as  a  monolayer  or 
multilayer  and  thus  be  more  amenable  to  study.  Consideration  was  given  to 
using  TEBs  embedded  in  Matrigel,  but  this  would  have  involved  histological 
sectioning.  The methodology was based on that used previously for keratinocyte 
explant  cultures  [454]  with  modifications  which  were  thought  might  help  to 
maintain the cells. Briefly, TEBs were isolated as previously described (2.2.1.5) 
and plated out on fibronectin (10ug/ml) coated chamber slides, with a thin film 
of culture medium (Dulbecco‟s Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F12)  supplemented  with  2mM  L-glutamine  and  Leukaemia  Inhibitory 
Factor (LIF) (1000U/ml). LIF was used in an attempt to prevent differentiation. 
Fibronectin was used to improve attachment. Explants were cultures in Galaxy S 
tissue culture incubator at 37°C in a humidified atmosphere with 5% CO2.      254 
 
 
Figure 4-16 Fbln2 protein expression in the stromal capsule throughout the developmental 
time points of mouse mammary gland morphogenesis by IHC. 
Sections  through  mouse  mammary  glands  collected  at  different  time  points  during  mammary 
morphogenesis showing representative fragments of stromal capsule (arrow head) stained  with 
anti-Fbln2 antibody (brown). Nuclei are stained with Haematoxylin (blue). Strong Fbln2 expression 
could be seen at pre-puberty (3 weeks) (A), puberty (6 weeks) (B) and pregnancy 72h (D). Weaker 
Fbln2 expression could be noted in adulthood (12 weeks) (C) and pregnancy 14.5d (E). No Fbln2 
staining  could  be  seen  in  lactation  day  7  (F),  involution  day  3  (G)  and  negative  (no  primary 
antibody) control (H). Scale bars are 100 µm. At least 3 animals were examined for each time 
point.     255 
 
After 24h, explants attached and further medium was added to a level of 2mm, 
with care not to disturb the explants. Cells spread out from the periphery of the 
explant over the next 4 days and the cultures were then terminated by fixation 
in absolute alcohol. A pavement of epithelial cells formed around the explant 
(Figure 4-17). Cell division was seen in the outgrowths, but the majority of the 
outgrowth  was  through  migration  and  cell  spreading.  The  preliminary  IHC 
analysis of outgrowths demonstrated: i) positive Ktr18 staining in all of the cells 
within  the  outgrowth,  suggesting  their  epithelial  origin  (Figure  4-17  A);  ii) 
positive Krt14 staining in some of the cells,  confirming their epithelial origin 
(Figure 4-17 B); iii) positive SMA staining seen in the cells at the periphery of 
the outgrowths, suggesting their myoepithelial/cap cell character (Figure 4-17 
C). On the basis of this preliminary characterisation of the epithelial nature of 
the  outgrowths  we  stained  the  cultures  with  routine  anti-Fbln2  antibody. 
Explants showed positive Fbln2 expression which localised to the cytoplasm, cell 
membranes and cellular processes that protruded from some cells and resembled 
cob-web-like structure which seems to run around, above and between cells like 
intracellular glue (Figure 4-18). The cytoplasmic and cell-membrane associated 
expression of Fbln2 is consistent with the sites of its expression in the epithelium 
of TEB in vivo (Figure 4-10). No double labelling was performed, but there was 
no correlation between the distribution of the CK14 and SMA positive cells and 
the  Fbln2  expression.  This  was  a  very  preliminary  study,  but  enabled  us  to 
localise the Fbln2 in vitro and to confirm the localisation of the protein and its 
apparent  secretion  into  the  extracellular  compartment.  Clearly  this  explant 
system  also  has  limitations,  with  lack  of  stroma,  the  all  important  immune 
system and loss of the in vivo 3D cellular organisation, but may have some role 
in studies of body and cap cells if further characterised. 
4.2.2.6  Fbln2 splice variants and their pubertal expression pattern.  
As mentioned previously, there are two alternative splice variants of Fbln2 gene, 
known as Fbln2 V1 and Fbln2 V2. The former includes 18 exons while the latter 
lacks the sequence for exon 9 and hence consists of 17 exons (Figure 4-19 A). 
The distribution pattern of the two splice variants appears tissue specific. As 
shown by Grässel et al. (1990), using PCR and exon 9 flanking primers to amplify 
the cDNA of Fbln2, Fbln2 V1 is predominantly expressed in the heart while Fbln2     256 
 
 
Figure  4-17  Preliminary  analysis  of  the  morphological  characteristics  of  explant  culture 
outgrowths by ICH. 
TEB explant outgrowths stained with (A) anti-Ktr18, (B) anti-Krt14 and (C) anti-SMA antibodies. (A) 
(B) Positive Krt18 (uniform) and Krt14 (some cells) staining suggests the epithelial character of 
outgrowths.  (C)  Positive  SMA  staining,  seen  at  the  periphery  of  the  outgrowths,  suggests  a 
myoepithelial/cap cell character of these cells. At least 3 TEB outgrowths were stained with each 
antibody and examined. Scale bars are 100µm.     257 
 
 
Figure 4-18 Preliminary investigation of Fbln2 expression in the outgrowths of TEB explants 
by ICH. 
(A) Image of TEB explant outgrowth (B) (C) (D) Representative fragments of TEB explant shown in 
A.  Fbln2  expression  appeared  to  be  associated  with  the  cytoplasm  (arrow),  cell  membranes 
(asterisk) and cellular processes of some cells within the outgrowths. At least 3 TEB outgrowths 
were stained with anti-Fbln2 antibody and examined. Scale bars are 100µm (right) and 25µm (left).           258 
 
V2  is  more  abundant  in  the  kidney.  The  NIH3T3  cell  line  expresses  only  full 
length Fbln2, i.e. Fbln2 V1 [439]. 
In this project, two distinct methods of splice variant detection were used to 
analyse  the  mammary  gland  specific  pattern  of  Fbln2  V1  and  Fbln2  V2 
expression.  Firstly,  the  expression  of  each  exon  was  analysed  and  compared 
between  the  isolated  TEBs  and  ducts  using  the  XRAY  Excel®  Array  based 
microarray analysis (See 2.2.5.7). Secondly, the cDNA produced from the RNA 
extracted from the Post-LN, Pre-LN tissue strips and isolated TEBs and ducts was 
PCR amplified as described by Grässel et al. [439] and resolved by using agarose 
gel electrophoresis. Primer location is demonstrated in Figure 4-19 A. 
Fbln2 exon expression analysis showed a comparable exon expression pattern 
between the isolated TEBs and ducts. As demonstrated in Figure 4-19 B, the two 
lines indicating mean expression of Fbln2 in TEBs (blue line) and ducts (red line) 
were roughly parallel and where present, the divergence from this parallel co-
localisation  (exons  that  are  contained  within  the  two  vertical  lines)  was  too 
small  to  be  significant.  Thus,  a  lack  of  variation  in  alternative  RNA  splicing 
between TEBs and ducts was demonstrated. A more detailed, probe set based 
gene expression analysis of the probe set number 9 which is complimentary to 
the  DNA  fragment  between  nucleotide  positions  91209637-91209763,  thus 
corresponding to exon 9 of Fbln2 gene (91209624-91209764) confirmed the above 
mentioned finding (Figure 4-19 C). No significant difference in the expression 
pattern was seen either when the 9
th probe set was compared to other probe 
sets  which  suggested  that  exon  9  was  expressed  at  a  similar  level  to  the 
remaining exons or when the 9
th probe set was compared between TEB and duct 
samples, suggesting a similar level of exon 9 expression in both samples (Figure 
4-19 C). Given that exon 9 is only present in  Fbln2 V1 it would suggest this 
isoform is prevalent in both the TEB and duct samples.  
PCR based analysis further revealed the presence of both V1 and V2 Fbln2 splice 
variants in the Post-LN and Pre-LN mammary tissue strips and isolated TEBs and 
ducts.  As  seen  in  Figure  4-19  D,  the  corresponding  electrophoresis  gels 
presented two amplification bands of 394 and 254 bp consistent with the size 
predicted for V1 and V2 Fbln2 variants respectively. The V1 splice isoform of 
Fbln2 appeared stronger in the Post-LN strips and isolated TEBs and ducts which      259 
 
 
Figure 4-19 The expression of Fbln2 splice variants in the pubertal mouse mammary gland. 
(A)  Graphical  comparison  of  Fbln2  V1  and  Fbln2  V2  genomic  DNA  organisation.  Red  boxes 
indicate  common  exons.  Blue  box  denotes  exon  9  (exclusive  for  Fbln2  V1).  The  approximate 
locations of primer annealing sites are denoted with arrows. Green arrows show primers used for 
PCR experiments. Blue arrows show primers used in Q RT PCR experiments. (B) (C) Comparison 
of Fbln2 expression in isolated TEBs (blue) and duct (red). Analysis shown at (B) the exon level 
and (C) probe set level. Each probe set represents a different exon cluster and there is one exon 
cluster per exon. Comparison was carried out using XRAY Excel® Array Analysis v.2.5 Microsoft® 
Excel® add-in. Probe set number 9 was designed against a fragment of DNA located in exon 9 
(absent from Fbln2 V2). Although 12 exons showed non parallel expression level between TEB and 
duct samples (denoted by two vertical black lines) the differences in expression were not significant 
enough  to  indicate  differences  in  alternative  splicing  between  the  samples.  Error  bars  indicate 
standard  deviation  at  each  (B)  probe  set  or  (C)  probe.  (D)  PCR.  Electropherogram  illustrating 
presence of Fbln2 V1 (394 bp) and V2 (254 bp) splice variants expression in Post-LN and Pre-LN 
strips and isolated TEBs and ducts. +ve contains cDNA from mouse kidney (positive control). -ve 
are PCR quality controls (-RT). Tissue strips were collected from two individual mice. Fbln2 V1 
seems to be prevalent in Post-LN strip and isolated TEBs or ducts samples. V1:V2 ratio in Pre-LN 
strip is inconclusive, n=pooled from 300 mice for the isolated TEBs and ducts for tissue strips 1 
animal was used for each Pre-LN and Post-LN strips. Experiment was repeated 4 times with similar 
results. 
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was consistent with the exon expression data. No difference in band strength, 
however,  was  seen  for  the  V1/V2  ratio  in  the  Pre-LN  strips.  The  observed 
expression pattern of Fbln2 splice variants was representative of mammary gland 
tissue strips collected from 4 individual mice and isolated TEBs and ducts pooled 
from 300 mice. cDNA synthesized from kidney RNA served as a positive control. 
4.2.2.7  Characterisation of the additional, 150 kDa and 135 kDa proteins, 
detected by the routine anti-Fbln2 antibody. 
Although the molecular weight of the mature, monomeric Fbln2 protein is 195 
kDa, two major, additional bands of a molecular weight of 150 kDa and 135 kDa 
were detectable using the anti-Fbln2 antibody throughout most of the Western 
blotting experiments. Bands of similar molecular weight have also been reported 
by other research groups (using the same antibody) and speculated to arise as a 
result of proteolytic cleavage, but their true nature has not yet been elucidated 
[434] [455].  
To investigate the identity of the two bands further and check for differences in 
their expression in different components of mouse mammary gland, experiments 
were designed to test the following hypotheses:  (1)  195  kDa  band stands for 
Fbln2 V1 while 150 kDa or 135 kDa denotes Fbln2 V2; (2) both bands (135 kDa 
and 150 kDa) arise due to the N- or C-terminus targeted proteolytic cleavage; (3) 
the  proteolytic  cleavage  pattern  could  vary  depending  on  the  stromal 
environment of proteases present.  
HYPOTHESIS  1:  The  first  hypothesis  resulted  from  molecular  mass  prediction 
studies  carried  out  for  Fbln2  V1  and  V2.  The  mass  of  the  V1  isoform  was 
predicted as 131 kDa, revealing that the remaining 64 kDa of the mature protein 
is attributed to post-translational modifications, such as N-glycosylation. Fbln2 
V2 was predicted to weigh 126 kDa. However, since there are 4 potential N-
glycosylation sites in the Fbln2 V1 sequence and one of them is located within 
exon 9 which is absent from its V2 counterpart, it is likely that the actual size 
difference between the V1 and V2 isoforms is much greater than 5 kDa, and thus 
the V2 isoform of Fbln2 could in fact weigh 150 kDa. To test this hypothesis, we 
used protein extracts from NIH3T3 (mouse fibroblasts), EpH4 and HC11 (mouse 
mammary  epithelial)  cell  lines.  These  cell  lines  were  chosen  on  the  basis  of     261 
 
cDNA profiling by PCR as described in 4.2.2.6 which showed that NIH3T3 express 
both Fbln2 V1 and Fbln2 V2 isoforms, EpH4 express only the Fbln2 V2 isoform 
while HC11 show no Fbln2 at all and thus when studied collectively they serve a 
good  system  to  investigate  the  identity  of  Fbln2  bands.  As  seen  on  the 
representative gels in Figure 4-20 A, the amplification bands of 394 (V1) and 
254 (V2) bp were seen in the NIH3T3 cell line while only the lower weight one of 
254 bp (V2) was detectable in the EpH4 amplicon. No amplicons were produced 
from HC11 cDNA. Q RT PCR further confirmed these results (Figure 4-20 B). By 
using two sets of primers, designed to amplify the common region of V1 and V2 
isoforms or Fbln2 V2 exclusively (designed against cDNA fragment spanning exon 
8  and  10)  the  exact  same  pattern  of  Fbln2  splice  variant  expression,  as 
demonstrated  by  cDNA  profiling  by  PCR,  was  seen.  Primer  location  is 
demonstrated in Figure 4-19 A. On the basis of these findings, Fbln2 protein 
expression was compared between EpH4, NIH3T3 and HC11 cells. The Western 
blot,  however,  showed  no  major  differences  in  the  Fbln2  banding  pattern 
between the protein extracts from the EpH4 and NIH3T3 cells, as all three main 
bands (195 kDa, 150 kDa, and 135 kDa) were visible. There was no loss of 195 
kDa (putative V1) either (Figure 4-20 C). The only slight difference was visible 
when the mobility of the top two bands was compared between lanes. In the 
EpH4 cells protein extracts the top band, corresponding to the mature Fbln2 
protein showed a slightly lower molecular weight than that seen in NIH3T3 cells 
at 195 kDa. The middle band, on the other hand, appeared to migrate slower, 
corresponding to a higher molecular weight than its NIH3T3 counterpart. All of 
the  bands  detected  were  specific  for  Fbln2-anti-Fbln2  antibody  binding  as 
demonstrated  by  the  lack  of  bands  in  the  negative  control  (HC11  cells). 
Collectively, it was demonstrated that it is unlikely for either the 150 kDa band 
or the 135 kDa band to correspond to Fbln2 V2.  
HYPOTHESIS 2: To test the second hypothesis, that both of the lower molecular 
weight bands arise due to N- or C-terminus targeted proteolytic cleavage, we 
initially aimed to use two additional, commercial antibodies, raised against N- or 
C-terminus of Fbln2 (See Figure 4-4 B and C). It was, however, not possible to 
test this hypothesis as the anti-C-terminus antibody could not be used due to 
problems with its optimisation (data not shown). As a result, we used the anti-N-
terminus antibody only and thus tested for the presence of the potential      262 
 
 
Figure 4-20 Fbln2 expression profiling in the mouse cell lines and identification of Fbln2 V2 
expression in EpH4 cells. 
(A) PCR. Electrophoretogram illustrating Fbln2 V2 (254 bp) expression in EpH4 cells. HC11 cells 
were used as a negative Fbln2 expression control. –RT was used as PCR quality control, n=1 (B) 
Q RT PCR. Fbln2 and Fbln2 V2 expression profiling in NIH3T3, EpH4 and HC11 cells. Total Fbln2 
expression was estimated using primers designed against the common region of Fbln2 V1 and V2 
splice variants. Expression of Fbln2 V2 was identified using PCR primers designed to span exon 8 
and  10  (Fbln2  V2  lacks  exon  9).  ß-actin  expression  was  used  as  an  internal  control  for 
normalisation. Graph shows exclusive  Fbln2 V2 expression in EpH4 cells and lack of  Fbln2 or 
Fbln2 V1 expression in HC11 cells. NIH3T3 cells were used as positive control (express both splice 
variants. Error bars denote technical variability (S.E.M.), n=1 (C) Western blotting. Fbln2 (195 kDa) 
expression in the protein  extracts collected from two different EpH4 cell cultures, NIH3T3 cells 
(positive control) and HC11 cells (negative control). Protein extracts were collected using RIPA 
buffer. Expression analysis was performed using anti-Fbln2 antibody. ß-actin was used as loading 
control. 
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variation in proteolytic cleavage solely within the N-terminus of Fbln2. The N-
terminus anti-Fbln2 antibody was used to detect Fbln2 expression in the NIH3T3 
protein  extracts  (RIPA  lysis  buffer)  and  the  resulting  expression  pattern  was 
compared with that detected with the anti-Fbln2 antibody routinely used in this 
project  (raised  against  the  whole  protein)  [434].  As  demonstrated  in  Figure       
4-21, the largest two bands (195 kDa and 150 kDa) were detectable with both 
the full-length and N-terminus anti-Fbln2 antibodies. The discrepancies in the 
signal  intensities  seen  between  the  two  antibodies  were  most  probably 
attributed to the difference in the protein-antibody binding affinities. The 135 
kDa  band,  however,  was  absent  from  the  blot  incubated  with  the  anti-N-
terminus antibody indicating either the absence of protein‟s N-terminus within 
the sequence denoted by this band or the lack of cross-reactivity between the 
antibody and protein sequence in this instance. Nonetheless, this suggested that 
proteolytic cleavage could be responsible for the banding pattern.  HC11 protein 
extract was used as negative control to ensure the antibody specificity. 
HYPOTHESIS  3:  This  experiment  was  designed  to  test  whether  the  banding 
pattern detected by the anti-Fbln2 antibody (full length) was dependent on the 
origin of mammary stroma, i.e. if it was TEB- or duct-associated, and at the 
same  time to test  whether the  lysis  buffer  used  for  Fbln2  extraction  had an 
effect. Protein extracts from Post-LN and Pre-LN strips were prepared using four 
lysis buffers to investigate the varied efficiency in Fbln2 solubilisation and were 
compared  by  Western  blotting.  The  lysis  buffers  used  in  this  experiment 
included: RIPA, NP-40, EDTA and Urea. Both RIPA and NP-40 belong to the group 
of detergent lysis buffers. EDTA and Urea buffers, on the other hand, do not 
contain  detergents.  EDTA  buffer  binds  Ca
2+  which  is  essential  for  the 
maintenance of the trimeric structure of Fbln2 while the Urea buffer causes the 
denaturation of proteins. Both the EDTA and Urea buffers were previously shown 
to solubilise 80% of Fbln2 [444]. Post- and Pre-LN tissue strips were selected as 
they  contain  the  epithelium  and  stroma  of  both  TEBs  and  ducts  or  only  the 
ductal  compartment  respectively,  hence  enabling  the  comparison  of  TEB  and 
duct  environments.  As  seen  in  Figure  4-22  there  was  no  obvious  difference 
between  the  banding  patterns  detected  in  the  Post-LN  and  Pre-LN  protein 
extracts. However, although the three main bands were detectable in NP-40, 
EDTA and Urea protein lysates there was some difference between the signal      264 
 
 
Figure 4-21 Comparison of Fbln2 expression pattern detected using different antibodies. 
Western blotting showing Fbln2 expression in two mouse cell lines; HC11 (negative control) (lane 
1) and NIH3T3 (lane 2). Expression analysis was performed with two antibodies raised against N-
terminus of Fbln2 (left) and the whole protein (right). Protein extracts were collected using RIPA 
lysis buffer. Blot was cut in two to allow different antibody probing on the same blot. Experiment 
was performed using protein lysates extracted upon three different cell passages. Bands of interest 
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Figure 4-22 Comparison of Fbln2 expression pattern detected using different lysis buffers. 
Western blotting. Analysis of Fbln2 expression pattern in Post-LN (lanes 1-4 on the left) and Pre-
LN strips (lanes 1-4 on the right) protein extracts prepared using following lysis buffers: RIPA (lane 
1), NP-40 (lane 2), EDTA (lane 3) and Urea (lane 4). Protein extract collected from NIH3T3 (RIPA 
buffer) was used as a positive control (lane 5). Expression analysis was performed using anti-Fbln2 
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intensities of the 150 kDa and 135 kDa bands. The 195 kDa was prominent in all 
the protein lysates. The 150 kDa band was the least visible in NP-40 and EDTA 
protein lysates while the 135 kDa band was the least detectable one in the Urea 
protein lysate. Although, the expression of all three bands that correspond to 
Fbln2 has previously been shown to be detectable in Post-LN and Pre-LN RIPA 
buffer protein extracts (See Figure 4-6 C), no evident expression of the 150 kDa 
and 135 kDa bands could be demonstrated in RIPA protein lysate used in this 
experiment.  This  could  be  due  to  the  degradation  of  this  protein  extract. 
Furthermore,  an  additional  ~220  kDa  band  was  present  in  all  of  the  lysates 
except for the Urea lysate. It is unclear what the ~220 kDa band corresponds to. 
NIH3T3 cells protein lysate extracted in RIPA buffer served as a positive control. 
The direct comparison of protein lysates was valid as demonstrated by uniform 
ß-actin expression levels throughout the samples. Taken together, these results 
show that the observed cleavage pattern is uniform across the TEB and duct 
microenvironments which suggests that the processing of Fbln2 does not rely on 
any  of  the  proteases  that  are  exclusive  to  the  either  TEB  or  duct  stroma. 
Secondly, as seen in Figure 4-22, different lysis buffers extract the 150 kDa and 
135 kDa Fbln2 bands with different efficiencies and thus it may be beneficial to 
employ  the  identified  optimal  extraction  conditions  to  further  study  each  of 
these bands. 
4.2.2.8  The impact of systemic hormones on the regulation of Fbln2 
expression in mouse mammary gland.   
Hormonal  regulation  of  Fbln2  has  already  been  documented  by  Okada  et  al. 
(2003) and Gu et al. (2007) who demonstrated its stimulation by P in human 
endometrial stromal cells in vitro [456] and down-regulation by hydrocortisone 
in  the  bone  marrow  stroma  in  vitro  respectively  [457].  Taking  this  into 
consideration along with knowledge of the importance of systemic hormones in 
pubertal  mouse  mammary  development,  the  impact  of  E2  and  P  on  mouse 
mammary gland Fbln2 expression was examined. Hormone induced changes in 
Fbln2 expression and tissue localisation were assessed using mouse mammary 
glands collected from 4.5 week old mice primed for a week with E2, E2+P or 
placebo hormone pellets prior to gland excision.      267 
 
As shown by the Q RT PCR, expression of Fbln2 was highly up-regulated by both 
the E2 and E2+P hormonal treatments (Figure 4-23). The mean expression of 
Fbln2  in  the  E2+P  and  E2  primed  glands  was  40.4  fold  and  36.2  fold  higher 
respectively than that calculated in the Pre-LN strip (negative control). Glands 
primed with placebo pellets showed a 7.1 fold up-regulation in Fbln2 expression 
when  compared  with  Pre-LN  strip.  Furthermore,  a  3.5  fold  up-regulation  of 
Fbln2 was calculated in the Post-LN strip when compared to Pre-LN strip and it 
was  used  as  a  positive  control.  When  gene  expression  was  compared  only 
between the treated mammary glands, using the placebo as a reference, Fbln2 
was  4  fold  and  3.6  fold  up-regulated  in  the  E2+P  and  E2  treated  glands 
respectively.  The  difference  in  Fbln2  expression  was  statistically  significantly 
only when comparing placebo and E2+P  treatments.  The level of  Fbln2  over-
expression in the E2 treated glands compared to placebo ones failed to reach 
statistical significance probably due to considerable biological variation and a 
low number of replicates (4 mice). It is possible, however, that the calculated 
FC(s) may differ slightly as at the time of commencing these experiments, prior 
to localisation studies, Fbln2 was thought to be associated only with mammary 
epithelium and so levels of Fbln2 were normalised using Krt18 expression, i.e. 
the amount of epithelium instead of the total number of cells.  
Thus,  to confirm the Q RT PCR results,  the impact of E2 and E2+P  on Fbln2 
expression  and  spatial  localisation  was  analysed  at  the  protein  level  by  IHC, 
using  the  routine  anti-Fbln2  antibody  (Figure  4-24).  The  obtained  results 
provided further insights into hormone induced changes in Fbln2 expression and 
localisation in mouse mammary gland. In the placebo primed mice (control), the 
mammary gland associated expression of Fbln2 was similar to that seen in pre-
pubertal/pubertal  mice  (Figure  4-24  A).  Fbln2  was  mostly  localised  to  the 
epithelium and stroma of TEBs. Some Fbln2 expression was also detectable in 
the ductal stroma and stromal capsule at the edge of Fat pad. The pattern of 
Fbln2 expression in the mammary TEBs and ducts of the E2+P primed mice was 
similar  to  that  seen  in  placebo.  Fbln2  was  consistently  localised  to  the 
epithelium and stroma of TEBs and on a much lower level to the stroma of ducts 
(Figure 4-24 B). What was different between the two treatments, however, was 
the significant increase in Fbln2 expression at the stromal capsule at the edge of 
Fat pad (Figure 4-24 A and B). This stromal capsule-specific increase in Fbln2     268 
 
 
Figure 4-23 Hormonal regulation of Fbln2 expression at the mRNA level by Q RT PCR. 
Mean expression level of Fbln2 in Post-LN tissue strip (6 weeks old) and hormone primed glands 
(4.5 weeks old) – placebo, oestrogen-progesterone (E2+P) and oestrogen (E2), relative to Pre-LN 
tissue strip (6 weeks old). Post-LN and placebo were used as positive controls. Pre-LN was used 
as negative control. Krt18 expression was used as an internal control for normalisation. Error bars 
are S.E.M. (***) denotes statistical significance of p-value≤0.001, n=1 (Pre-LN and Post-LN) n=3 
(placebo and E+P) n=4 (E). N stands for number of animals. Both glands were used from each 
animal.     269 
 
 
Figure 4-24 Hormonal regulation of Fbln2 expression on protein level by IHC. 
(A) (B) (C) Sections through 4.5 week old mouse mammary glands obtained from mouse primed 
with  (A)  placebo,  (B)  E+P  and  (C)  E  hormone  pellets  for  1  week  prior  to  tissue  collection. 
Mammary  glands  were  stained  with  anti-Fbln2  antibody  (brown)  and  Haematoxylin  (blue)  to 
visualise nuclei. (D) Negative (no primary) antibody control. Images on the left show mammary 
epithelium. Images on the right show stromal capsule around the edge of Fat pad. (A) Placebo 
treated glands showed normal Fbln2 staining pattern – prevalent in TEB epithelium, weaker in duct 
epithelium and present in the stroma around epithelium and in the capsule around the edges. (B) 
E+P treated glands showed similar epithelial staining pattern to placebo treated glands. Higher 
Fbln2 staining, however, could be noted in the stromal capsule around the edge of the Fat pad. (C) 
E primed glands showed lack of Fbln2 expression in the ductal epithelium and its high abundance 
in the stromal capsule. Arrows denote TEBs and dotted arrows indicate ducts. At least 3 mice (6 
mammary glands) were studied for each treatment. Scale bars are 100 µm. 
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expression was even more pronounced when the mammary glands obtained from 
the E2 treated animals  were examined while the ductal localisation of Fbln2 
seemed  completely  absent  from  these  glands  (Figure  4-24  C).  All  of  the 
observed  staining  patterns  were  specific  to  Fbln2-antibody  binding  as 
demonstrated by the lack of the staining in the negative (no primary antibody) 
control (Figure 4-24 D). 
4.2.2.9  Investigation of Fbln2 functions in non malignant mouse mammary 
epithelial cells in vitro by the over-expression of Fbln2 in HC11 cells. 
As  shown  in  this  project,  pubertal  mammary  expression  of  Fbln2  is  mainly 
localised to the BM, outer membranes, cytoplasm of cap cells and most probably 
the  cytoplasm  and  extracellular  spaces  between  the  body  cells  of  mouse 
mammary TEBs. Given this specific epithelial localisation of Fbln2 and widely 
recognised importance of TEBs for promoting the directional outgrowth of the 
ductal tree, we examined the involvement of Fbln2 in cellular migration and 
adhesion in vitro using HC11 cells. The HC11 cell line originates from normal 
mammary  epithelial  cells  [458]  and,  as  demonstrated  previously,  lacks  Fbln2 
expression  (both  at  the  RNA  and  protein  level)  (Figure  4-20).  It  therefore 
provides  a  good  system  for  studying  the  impact  of  Fbln2  over-expression  on 
normal mouse mammary epithelium. Over-expression of Fbln2 was performed by 
transfecting  the  HC11  cells  with  a  Fbln2  expressing  plasmid  (pRc/CMV-Fbln2) 
(See 2.2.2.3).  
4.2.2.9.1  Optimisation of transfection 
 
Optimal experimental conditions were established by transfecting equal amounts 
of HC11 cells with pEGFP reporter plasmid, using varied volumes of two different 
transfection  reagents  (Lipofectamine
™  and  DharmaFECT
®)  and  DNA  (in  a 
transfection  reagent  to  DNA  ratio  of  1:1)  and  examining  the  number  and 
appearance of cells 24h after transfection, using a fluorescent microscope (See 
2.2.2.4.1). As demonstrated in Figure 4-25 A, maximal transfection efficiency 
and minimal cell toxicity were achieved using 4 µl of Lipofectamine
™ and 4µg of 
DNA, thus making it standard for all further experiments. A representative image      271 
 
 
Figure 4-25 In vitro over-expression of Fbln2 in HC11 cells. 
(A)  Optimisation  of  transfection  efficiency.  Different  volumes  of  transfection  reagents,  either 
Lipofectamine™(left) or DharmaFECT
® Duo (right) Transfection Reagents were used to transfect 
equal amount of HC11 cells with pEGFP (transfection reagent to DNA ratio 1:1). Green fluorescent 
cells (living and dead) were counted. Error bars are S.E.M. Experiments were repeated 3 times (B) 
Representative image of HC11 cells transfected with pEGFP using optimal transfection conditions - 
4µl of Lipofectamine™ Transfection Reagent and 4µg DNA – used for all subsequent transfections. 
Living cell is denoted with white arrow. Dead cell is highlighted with white dotted arrow. Scale bar is 
500 µm (C) Western blot. Fbln2 (195 kDa) expression in HC11 cells transfected with pRc/CMV-
Fbln2 (lanes 2-4) and pcDNA3 (negative control) (lanes 5-7). Fbln2 expression was analysed 24h 
after the transfections. Protein extract obtained from NIH3T3 cells (lane 1) was used as positive 
control. ß-actin was used as a loading control. Experiments were repeated 3 times. 
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of cells transfected using the identified optimal conditions is shown in Figure 4-
25 B. Once the optimal conditions were found, transient transfections were used 
to  over-express  Fbln2  V1  in  HC11  cells.  Western  blotting  confirmed  the 
introduction  of  Fbln2  V1  into  HC11  cells  (Figure  4-25  C).  All  three  bands 
corresponding to various Fbln2 fragments were seen on the blot (lane 2, 3 and 
4). The largest, 195 kDa band, however, appeared much stronger than the two 
smaller ones (150 kDa, 135 kDa). The appearance of these bands was specific to 
Fbln2 V1-antibody binding detected by the anti-Fbln2 antibody as none of these 
bands were detected in the negative control (HC11 cells transfected with the 
empty vector, pcDNA3) (lane 5, 6 and 7). NIH3T3 cells (lane 1) were used as a 
positive  control.  No  morphological  changes  could  be  seen  in  the  transfected 
cells.    
4.2.2.9.2  The effect of Fbln2 on the migratory properties of HC11 
cells 
 
Fbln2 over-expressing HC11 cells were used to assess the impact of Fbln2 on cell 
migration. Empty vector transfected HC11 cells were used as a negative control 
(Figure 4-26 A). The migratory properties of pRc/CMV-Fbln2 transfected HC11 
cells were studied on confluent cells using a wound healing assay (scratch assay) 
(See 2.2.2.5). The percentage of wound closure was compared at  each time 
point  (4h,  7h,  11h,  24h  and  36h)  after  creating  the  scratch  for  Fbln2  over-
expressing- and control cells. There was no difference in the speed of wound 
closure between the two types of HC11 cells, suggesting that Fbln2 does not 
have an impact on the speed of cellular migration in HC11 cells under the given 
conditions (Figure 4-26 B).  
4.2.2.9.3  The effect of Fbln2 on the adhesiveness of HC11 cells    
 
The  pRc/CMV-Fbln2  and  empty  vector  transfected  (control)  HC11  cells  were 
further used to investigate the impact of Fbln2 on regulating the adhesiveness of 
cells to plastic or ECM proteins coated surfaces (See 2.2.2.6). ECM molecules 
used in this assay included: ColI, ColII, ColIV, Fn, Lama1, Tn and Vtn. Blank wells 
were coated with BSA and served as a negative control for the ECM substrates      273 
 
 
Figure 4-26 The effect of Fbln2 on the regulation of HC11 cells migration using a wound 
healing assay. 
(A) Western blot showing the levels of Fbln2 expression in HC11 cells,  used in wound healing 
assays. Protein extracts were prepared using RIPA buffer, at the conclusion of each assay. Fbln2 
(195  kDa)  expression  in  HC11  cells  transfected  with  pRc/CMV-Fbln2  (lanes  1-3)  and  pcDNA3 
(negative control) (lanes 4-6). Protein extract obtained from NIH3T3 cells (lane 7) was used as 
positive control. The same amount of protein (50µg) was loaded to each well. (B) Representative 
graph illustrates the speed of wound closure in HC11 cells transfected with pRC/CMV-Fbln2 (to 
express Fbln2 V1) or pcDNA3 (negative control). The assay was performed on confluent cells (48h 
after transfections). No difference in the speed of cell migration could be noted in Fbln2 expressing 
HC11  cells  in  comparison  to  empty  vector  transfected  HC11  cells.  Error  bars  are  S.E.M. 
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(experimental noise) while the HC11 cells transfected with empty vector served 
as a negative control for Fbln2 expression. The adhesion assay was performed 
using HC11 cells plated at a density of 1.5x10
6 cells/well which was chosen to 
give optical density (OD) values within the optimal OD detection range (0.5-1), 
after optimisation of experimental conditions (Figure 4-27 A).  
Fbln2  over-expression  increased  the  adhesiveness  of  HC11  cells  to  four  ECM 
proteins, i.e. increased OD significantly - Vtn (0.369), Tn (0.307), Fn (0.289) and 
Lama1 (0.239). Furthermore, these four ECM molecules appeared successful in 
stimulating the adhesion of HC11 cells as the ODs for both Fbln2 transfected- 
and control cells were distinguishably higher than these seen for the remaining 
three ECM molecules (ColI, ColII and ColIV) where in general a much lower level 
of adhesiveness of HC11 cells, with no major  difference between Fbln2 over-
expressing- or control cells,  was noted  (Figure 4-27 B). Similarly, as seen in 
Figure 4-27 C, Fbln2 over-expression appeared to have no significant effect on 
the adhesion of HC11 cells to plastic surfaces. Dry wells (no cells added) were 
used as a negative control. 
4.2.2.10  Fbln2 binding partners and their expression during pubertal 
mouse mammary gland development.  
Based on the finding that Fbln2 interaction with some ECM proteins  increases 
their adhesiveness to HC11 cells (See 4.2.2.9.3) and published evidence for the 
presence  of an extensive  array  of  protein-protein  interactions  between  Fbln2 
and  some  ECM  proteins  or  cell  membrane  receptors,  the  pubertal  mammary 
gland associated expression of Fbln2 binding partners was investigated.  
Depending  on  the  type  of  the  biological  or  experimental  system  or  studied 
protein function, different proteins have been reported to bind to Fbln2. None 
of these molecules, however, have yet been studied in association with Fbln2 in 
the  mouse  mammary  gland.    An  up  to  date  literature  search  identified  13 
proteins  as  Fbln2  binding  partners  (Figure  4-28).  11  of  these  proteins  were 
located to ECM, i.e. versican (Vcan),  Lama1,  Fbn1,  collagen VIαIII (ColVIαIII), 
collagen  IVαI  (ColIVαI),  collagen  XVIIIαI  (ColXVIIIαI),  Eln,  Fn,  perlacan  (Per), 
aggrecan (Acan), Nid. The remaining two, the integrin ß3 (Itgb3) and integrin α5 
(Itga5) were previously shown to function as membrane receptors for Fbln2.     275 
 
 
Figure 4-27 Effect of Fbln2 on the regulation of adhesive properties of HC11 cells using 
adhesion assays. 
(A) (B) Cell adhesion to ECM proteins (A) Optimisation of assay sensitivity. Untransfected HC11 
cells at 3 different cell/ml concentrations (0.5X10
6, 1X10
6 and 2X10
6) were used. A concentration of 
1.5X10
6 cells/ml was regarded as optimal and used in all subsequent adhesion assays. Data was 
calculated based on one transfection experiment. One well per condition was seeded (B) HC11 
cells either transfected with pRC/CMV-Fbln2 (to express Fbln2 V1) or pcDNA3 (negative control) 
vectors for 24h – comparison of adhesiveness to ECM proteins. Blank wells were coated with BSA.  
Error bars denote technical variability (S.E.M), (**) denotes statistical significance p-value≤0.01, 
(***) p-value≤0.001. Data is based on one transfection experiment. Cells were seeded in triplicates 
for  each  condition.  (C)  Cell  adhesion  to  plastic  surfaces.  HC11  cells  either  transfected  with 
pRC/CMV-Fbln2 (to express Fbln2 V1) or pcDNA3 (negative control) vectors for 24h. Blank lacks 
any  cells.  Data  is  based  on  single  experiment.  Cells  were  seeded  in  triplicates  for  each 
experimental condition. Error bars are S.E.M. and denote technical variability.     276 
 
 
Figure 4-28 Potential binding partners for Fbln2 in the mouse mammary  gland and their 
pubertal gene expression level. 
Selection  of  Fbln2  binding  partners  and  their  cellular  compartmentalization  was  based  on  a 
literature  search.  All  13  proteins  were  shown  to  interact  with  Fbln2  in  different  experimental 
systems. Pubertal gene expression was examined using Post-LN up-regulated gene set (Post-LN 
vs Pre-LN) (See 3.2.6.1.2) and TEB up-regulated gene set (TEBs vs ducts) (See 3.2.6.1.1.). Genes 
identified  as  up-regulated  in  Post-LN  strips  and  TEBs  are  marked  as  yellow  and  blue  circles 
respectively. White circles denote genes showing unaltered expression in the Post-LN and Pre-LN 
strips. A circle denotes an ECM protein while a T-like shape represents a transmembrane receptor. 
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In  order  to  identify  which  of  these  proteins  could  potentially  serve  as  Fbln2 
binding partners in pubertal mouse mammary gland, expression of each of these 
factors  was  assessed  in  our  microarray  data  set.  Since  Fbln2  appeared to  be 
over-expressed in the epithelium and stroma of TEBs and the stromal capsule 
around  the  edge  of  the  Fat  pad,  these  tissue  compartments  were  used  to 
examine the level of pubertal expression for the known Fbln2 binding partners. 
The  Post-LN  up-regulated  gene  set  (Post-LN  vs  Pre-LN)  (See  3.2.6.1.2)  and 
isolated TEBs up-regulated gene set (TEBs vs ducts) (See 3.2.6.1.1) were used 
to identify genes up-regulated in TEB stroma and epithelium and TEB epithelium 
respectively, while the empty Fat pad up-regulated gene set (See 3.2.6.1.3) 
was  used  to  determine  genes  over-expressed  in  the  distal  Fat  pad  (stromal 
capsule).  Nearly  half  of  the  examined  genes  (6/13)  were  shown  to  be  up-
regulated in the Post-LN strip, i.e. TEB epithelium and surrounding stroma. The 
highest up-regulation (2.64 fold) was noted for  Vcan. A further two potential 
binding partners (ColIVaI, ColXVIIIaI)  were identified as over-expressed in the 
isolated epithelium of TEB.  None of the molecules of interest,  however, was 
shown to be significantly over-expressed in the empty Fat pad. The names of the 
classified genes and the levels of their up-regulation (FC values) are summarized 
in Table 4-1. The remaining 5 genes, that is Fn, Per, Acan, Nid2 and Itga5 did 
not differ in their expression level between the Post-LN and Pre-LN tissue strips 
(Table 4-2). Fn,  Per and  Itga5 were expressed at a high level in both tissue 
compartments.  Acan  and  Nid2,  in  contrast  were  minimally  expressed  during 
pubertal  morphogenesis.  A  summary  of  the  Fbln2  binding  partners‟  pubertal 
expression pattern is shown in Figure 4-28.      
4.2.2.10.1  Fibronectin and Fbln2 co localisation study.   
 
The best documented binding partner for Fbln2 is Fn. It is associated with Fbln2 
in the bone marrow stroma in vivo [459] and during skin regeneration [460] and 
shows binding in protein interaction studies in vitro [442]. Based on the existing 
documentation  of  Fbln2-Fn  interaction  in  vivo  and  the  evidence  that  of  all 
binding partners, Fbln2 shows the strongest binding affinity to Fn (equal for both 
mouse and human proteins) [442], a potential interaction between Fbln2 and Fn 
during  pubertal  mouse  mammary  morphogenesis  was  investigated  further. 
Although, Fn was not shown to be significantly over-expressed in the TEB      278 
 
Gene name  Gene symbol  FC  Original Reference 
GENES UP-REGULATED IN THE POST-LN STRIP 
Versican  Vcan  2.64  [461] [448] 
Laminin  Lama1  1.88  [462] 
Integrin beta 3  Itgb3  1.59  [463] 
Fibrillin 1  Fbn1  1.54  [344] 
Collagen 6a3  Col6a3  1.61  [442] 
Elastin  Eln  1.75  [464] [443] 
GENES UP-REGULATED IN THE ISOLATED TEBS 
Collagen 4a1  Col4a1  1.73  [442] 
Collagen 18a1  Col18a1  1.87  [443] 
Table  4-1  List  of  Fbln2  binding  partners  up-regulated  during  pubertal  mouse  mammary 
gland development. 
Selection  of  Fbln2  binding  partners  was  based  on  a  literature  search  with  reference  given  in 
column 4. Pubertal gene expression was examined using Post-LN up-regulated gene set (Post-LN 
vs Pre-LN) (See 3.2.6.1.2) and TEB up-regulated gene set (TEBs vs ducts) (See 3.2.6.1.1). All FCs 
were statistically significant. 
Gene name  Gene symbol  Level of expression  Original Reference 
Fibronectin  Fn1  High  [444] [442] [460] [459] 
Perlecan  Per  High  [442] 
Aggrecan  Acan  Low  [461] 
Nidogen 2   Nid2  Low  [442] 
Integrin alpha 5  Itga5  High  [463] 
Table  4-2  List  of  Fbln2  binding  partners  shown  to  exhibit  an  unaltered  expression  level 
during pubertal mouse mammary gland development. 
Selection  of  Fbln2  binding  partners  was  based  on  a  literature  search.  Firstly,  pubertal  gene 
expression  was  examined  using  Post-LN  up-regulated  gene  set  (Post-LN  vs  Pre-LN)  (See 
3.2.6.1.2) and TEB up-regulated gene set (TEBs vs ducts) (See 3.2.6.1.1). Secondly, each gene’s 
expression  level  in  the  Post-LN  and  Pre-LN  strip  was  compared  using  RMA  normalised  gene 
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epithelium or stroma (Post-LN) its expression was high in the Post-LN strip where 
Fbln2 was shown to be over-expressed. To examine the possibility of the two 
proteins interacting during the outgrowth of TEBs, IF was used to examine the 
co-localisation of the two proteins in the 6 week old mouse mammary gland. The 
co-localisation was performed using serial tissue sections since both antibodies 
used  in  this  experiment  were  raised  in  the  same  host.  As  seen  in  the 
representative confocal images of mammary epithelium, shown in Figure 4-29, 
Fbln2  failed  to  co-localise  with  Fn.  As  previously  demonstrated,  Fbln2  was 
expressed in the epithelium and stroma of TEBs and to a much lower extent in 
the ductal epithelium  (Figure 4-29 A-B) while Fn appeared to be exclusively 
localised to the stroma around ducts (Figure 4-29 B). The trace of Fn expression 
visible in the TEBs epithelium (Figure 4-29 A) is nonspecific, as it also appears 
to be present in the negative (no primary antibody) control (Figure 4-29 C).   
4.2.2.10.2  Elastin and Fbln2 co-localisation study 
 
Eln, after Fn is the second most investigated binding partner of Fbln2. In vivo, it 
is mostly present in blood vessels, lung and skin tissue where it interacts with 
Fbn1 to form elastic fibres which are critical for tissue elasticity [465]. Based on 
the recently suggested role of Fbln2 in elastic fibre assembly in internal elastic 
lamina of blood vessels [449] and significant up-regulation of Eln expression in 
TEB environment (See Table 4-1), preliminary experiments were carried out to 
assess  the  potential  of  Fbln2  and  Eln  interaction  during  pubertal  mouse 
mammary morphogenesis. The localisation of Eln expression in 6 week old mouse 
mammary  glands  was  carried  out  using  EVG  staining  (See  2.2.6.7)  and  the 
obtained  expression  pattern  was  compared  to  that  determined  for  Fbln2.  As 
shown in representative light microscopy images, although mostly absent from 
the epithelium and stroma of TEB (a single Eln fibre can be seen in TEB stroma) 
(Figure 4-30 A), a positive Eln expression, as shown in positive staining control 
(Figure 4-30 C), could be seen in the distal stromal capsule (Figure 4-30 B) of 
pubertal mouse mammary gland. Since Fbln2 is seen to localise to this region it 
may be that the two proteins interact during pubertal mammary morphogenesis 
but further investigation is needed to assess this possibility.          280 
 
 
Figure 4-29 Co-localisation of Fbln2 and Fn expression in the pubertal mouse mammary 
gland using IF. 
Transverse sections through a  6  week mouse mammary  gland showing  (A) TEB  and (B) duct 
stained  with  anti-Fbln2  (green)  or  anti-Fn  (red)  antibodies  and  nuclear  DAPI  (blue).  (C)  shows 
negative (no primary antibody) controls. Fbln2 and Fn did not co-localise in the epithelium or its 
surrounding  stroma  in  pubertal  mouse  mammary  gland.  Images  were  acquired  using  confocal 
microscopy. Scale bars are 50 µm.     281 
 
 
Figure 4-30 Localisation of Eln expression in pubertal mouse mammary gland using Elastica 
van Gieson staining. 
Sections through a 6 week mammary gland showing (A) TEB (B) distal stromal capsule and (C) 
vein. (C) is a positive staining control. Elastin (blue) localised to the distal stromal capsule but was 
mostly absent from TEB epithelium and stroma. A single Eln fibre could be seen in TEB stroma 
(arrow head). Black arrows denote elastin fibres. Scale bars are 50 um. Mammary glands from at 
least 3 mice were used.      282 
 
4.2.2.11  Fbln2 is not essential for pre-pubertal and pubertal mouse 
mammary gland development.  
Since Fbln2 is highly expressed in virgin mice during pre-pubertal and pubertal 
mouse mammary gland development and is associated and localised to TEB it has 
potential to serve as a regulator of TEB structure, organisation or migration or to 
play a role in ductal tree morphogenesis. Thus, in order to evaluate whether the 
presence  of  Fbln2  is  essential  for  normal  ductal  morphogenesis  and  TEB 
morphology, mammary wholemounts, collected from Fbln2 KO
-/- and WT mice, 
were examined to assess the impact of Fbln2 deficiency on pre-pubertal and 
pubertal mammary development. Both transgenic and WT mice were of the same 
genetic background (C57BL/6). 
Total loss of Fbln2 expression in these glands was confirmed by IHC. 6 week old 
mouse mammary glands collected from Fbln2 KO
-/- and WT mice were processed, 
embedded in molten wax, sectioned and stained with the routinely used anti-
Fbln2  antibody.  No  Fbln2  expression  could  be  seen  in  the  epithelium,  its 
surrounding stroma or the distal stromal capsule of Fbln2 KO
-/- mouse mammary 
glands (Figure 4-31 A). The appearance of the section closely resembled that 
seen in the negative (no primary antibody) control (Figure 4-31 B). WT mouse 
mammary glands were used as a positive staining control. When stained with 
anti-Fbln2 antibody, a normal mouse mammary gland associated Fbln2 staining 
pattern  was  detected  in  the  WT  control.  As  seen  in  Figure  4-31  C,  Fbln2 
expression was localised to both the epithelial (cap and body cells) and stromal 
microenvironment  of  TEBs  and  the  distal  stromal  capsule,  thus  verifying  the 
antibody reactivity.  
Wholemounts of Fbln2 KO
-/- and WT controls were then examined in triplicates 
for  each  time  point.  Analysis  of  the  wholemounts  revealed  no  major 
morphological differences between Fbln2 KO
-/- and WT mice. Both the length 
and degree of branching of the ductal tree appeared similar for Fbln2 KO
-/- and 
WT mice both at pre-puberty (3 weeks) and puberty (6 weeks) (Figure 4-32). 
Although TEBs appeared slightly smaller and more elongated in Fbln2 KO
-/- when 
compared to WT (Figure 4-32 inserts) further histological examination of these 
structures by H&E staining failed to demonstrate any significant differences      283 
 
 
Figure 4-31 Comparison of Fbln2 expression in Fbln2 WT and Fbln2 KO-/- pubertal mouse 
mammary glands by IHC. 
Sections through a 6 week mammary glands collected from (A) Fbln2 KO
-/- and (B) (C) WT mice 
showing representative fragment of epithelium – TEB (left hand side) and stromal capsule (right 
hand side) stained with anti-Fbln2 antibody (brown). Nuclei were stained with haematoxylin (blue) 
(A) (B) No Fbln2 expression could be noted (B) is a negative (no primary antibody control) (C) 
Prominent Fbln2 staining could be seen in both the epithelium of TEB and its surrounding stroma 
and the stromal capsule. Scale bars are 50 µm. 3 Fbln2 KO
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Figure 4-32 Wholemount analysis of pre-pubertal and pubertal Fbln2 KO-/- mouse mammary 
gland. 
Representative wholemounts of 3 week (A) WT (+/+) and (B) Fbln2 KO (-/-) and 6 week (C) WT 
(+/+) and (D) Fbln2 KO (-/-) mammary glands stained with carmine alum. Inserts (on the right) 
show  representative  parts  of  the  ductal  tree  and  TEBs.  No  significant  difference  in  the  ductal 
outgrowth could be seen in Fbln2 KO
-/- mammary glands in comparison to WT mammary glands. 
TEBs in the KO
-/- mammary glands, however, appeared smaller and more elongated than those 
seen in their WT counterparts. Scale bars are 1mm (wholemounts) and 200 µm (inserts). 
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between the TEB from the pubertal Fbln2 KO
-/- and WT mammary glands (Figure 
4-33).    
Finally,  based  on  previous  reports  of  compensatory  up-regulation  of  Fbln1 
expression in Fbln2 KO
-/- aorta [266], tissue sections through the pubertal Fbln2 
KO
-/-  and  WT  mouse  mammary  glands  were  further  stained  with  anti-Fbln1 
antibody. The level and pattern of mammary gland associated Fbln1 expression 
was compared between the Fbln2 deficient and WT mouse mammary glands and 
it was revealed that when compared to WT mammary glands, the expression of 
Fbln1 in the epithelium of Fbln2 KO
-/- glands was significantly increased (Figure 
4-34 A and B). Furthermore, the epithelial localisation of Fbln1 in both types of 
mammary glands was also different. In WT mammary glands, the expression of 
Fbln1 in TEBs was diffused throughout their epithelium and surrounding stroma 
rather  than  localised  to  specific  cell  types  (Figure  4-34  A).  In  Fbln2  KO
-/- 
mammary glands, on the other hand, the expression of Fbln1 appeared closely 
associated with the epithelium of TEBs: body cells (cytoplasm and extracellular 
spaces), membranes, cytoplasm, extracellular spaces of cap cells and BM and 
their surrounding stroma (Figure 4-34 B), where Fbln2 preferentially localises 
(Figure 4-34 C). The observed Fbln1 staining was specific as demonstrated by 
the  presence  of  minimal  background  staining  in  the  negative  (no  primary 
antibody)  control  (Figure  4-34  D).  The  expression  of  Fbln1  in  distal  stromal 
capsules of Fbln2 KO
-/- and WT pubertal mouse mammary glands did not seem to 
differ (data not shown).  
Collectively, these results demonstrate that in the presence of Fbln1, Fbln2 is 
not  essential  for  virgin  mammary  gland  development  and  suggest  potential 
functional  redundancy  and  compensation  between  Fbln1  and  Fbln2  during 
pubertal mouse mammary gland development. 
4.2.2.12  Summary 
In summary, this study was carried out to examine the potential of Upk3a and 
Fbln2  to  serve  as  novel  regulators  of  pubertal  mouse  mammary  gland 
morphogenesis. Due to the absence of Upk3a protein detection in the pubertal 
mouse mammary gland all further research was focused exclusively on Fbln2 and      286 
 
 
Figure 4-33 Comparison of TEB histology in WT and Fbln2 KO-/- pubertal mouse mammary 
glands by H&E staining. 
Longitudinal sections through 6 week mammary glands collected from (A) WT and (B) Fbln2 KO
-/- 
mice. Representative TEBs are shown. Nuclei were stained with haematoxylin while the cytoplasm 
was stained with eosin. No major morphological differences could be seen between the two TEBs. 
Cap cells are denoted by arrow. Body cells are denoted by dotted arrow. Scale bars are 50 µm.     287 
 
 
Figure 4-34 The up-regulation and spatial localisation of Fbln1 in the epithelium of Fbln2  
KO
-/- pubertal mouse mammary glands. 
Longitudinal and transverse sections through 6 week (A) (C) (D) WT and (B) Fbln2 KO
-/- mouse 
mammary glands showing representative fragments of epithelium (TEB) stained with anti-Fbln1 
antibody (A) (B) or anti-Fbln2 (C) antibody. (D) is  a negative (no primary antibody) control for 
Fbln1. Fbln1 in WT gland was contained in the stroma around TEB (arrow)  (A). In Fbln2 KO
-/- 
glands, however Fbln1 was over-expressed and localised to BM (arrow head) cap cells (dotted 
arrow) and cytoplasm and extracellular spaces between body cells (asterisk) (B). This expression 
pattern was similar to that seen for Fbln2 in WT pubertal mouse mammary glands (C). Scale bars 
are 50 µm. Three animals were examined for each experiment.         288 
 
its mammary gland associated expression, localisation and function. Fbln2 was 
shown  to  be  expressed  in  the  mouse  mammary  glands  during  pre-puberty, 
puberty,  adulthood  (very  low  level)  and  early  pregnancy  (24-72h).  During 
puberty its localisation was mostly confined to the stroma and epithelium of 
TEBs (cap cells and some body cells) and the stromal capsule located at the edge 
of fat pad with only residual expression seen in the stroma and epithelium of the 
ducts. Preliminary experiments that aimed to develop a TEB explant culture, 
showed a similar pattern of Fbln2 expression in TEB outgrowths in vitro, with 
Fbln2 associating with cell membranes, cytoplasm and cellular processes. At the 
mRNA level, Fbln2 was expressed in the form of two splice variants (Fbln2 V1 
and Fbln2 V2) with the former predominant in the TEB environment and ductal 
epithelium. Furthermore, the expression and localisation of Fbln2 in the mouse 
mammary gland appeared to be positively regulated by systemic hormones (E2 
and  P).  The  in  vitro  functional  studies  revealed  Fbln2-mediated  increase  in 
adhesiveness of the HC11 cells to Vtn, Tn, Lama1 and Fn coated surfaces, and 
hence suggested the possibility of these proteins interacting with Fbln2 in the 
mammary gland in vivo. However, Fbln2 failed to co-localise with Fn in vivo. In 
silico  analysis  further  revealed  the  over-expression  of  8  out  of  13  binding 
partners of Fbln2 in the TEB compartment (as seen for Fbln2) while 3 out of the 
remaining  5,  even  though  expressed  at  a  similar  level  in  TEB  and  duct 
compartments, were still expressed in TEBs at a very high level. One of these 
binding partners was Eln which, as previously seen for Fbln2, was demonstrated 
to localise to distal stromal capsule of pubertal mouse mammary gland. Finally, 
despite the given expression pattern, Fbln2 was shown not to be necessary for 
ductal  morphogenesis  and  TEB  formation  in  pre-puberty  and  puberty.  As 
suggested  by  the  over-expression  of  Fbln1  in  the  epithelium  of  Fbln2  KO
-/- 
mammary glands,  however, the lack of a mammary phenotype in these mice 
might  be  attributed  to  the  possible  functional  redundancy  and  compensation 
between Fbln1 and Fbln2. 
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4.3 Disscussion 
Genome-wide gene expression screening, such as microarray analysis of pubertal 
mammary gland discussed in Chapter 3, is useful not only for global comparison 
and functional characterisation of different transcriptomes, but it can also be 
used  to  identify  new  genes  with  potential  to  regulate  pubertal  outgrowth. 
Several strategies, already discussed in Chapter 3 (3.3), can be used to select 
candidate genes. The two that were used in this project include i) ranking of 
genes  according  to  the  highest  up-regulation  level  and  ii)  candidate  gene 
approach. It was through these two screening methods that Upk3a and Fbln2 
first came to the attention of our research group.  
Based on the microarray analysis, the expression of both genes was associated 
with migrating TEBs. They were both up-regulated in the isolated epithelium of 
TEBs (TEB vs ducts) (See 3.2.6.1.1) and TEB microenvironment (Post-LN vs Pre-
LN) (See 3.2.6.1.2). Upk3a was the most differentially expressed RNA in the 
epithelium  of  TEBs  compared  to  epithelium  of  ducts  and  although  the  most 
abundant  gene  in  TEB  epithelium  is  not  necessarily  the  most  important  in 
orchestrating its motility, as most of the TEB up-regulated genes are cell cycle 
regulators ([256] and our observations) (See Table 3-5), the function of Upk3a 
was  unknown  and  it  therefore  seemed  an  obvious  target  for  further 
investigation. Fbln2, on the other hand, despite being ranked only to position 
182 and 285 within the list of genes up-regulated in the epithelial and stromal-
epithelial  compartment  of  TEB  respectively,  was  demonstrated  by  literature 
search  to  be  associated  with  biological  processes  known  to  share  similarities 
with ductal morphogenesis. As discussed in Chapter 3 (3.3.2.1), there are many 
molecules  known  to  be  pivotal  in  developmental  processes  such  as 
embryogenesis  (e.g.  Fgf2br  [159]  [20]),  branching  morphogenesis  of  lung  or 
kidney (e.g. TGF-ß [379]) or axonal guidance (e.g. Ntn1 and Neo1 [120] [117]) 
that  have  recently  also  been  described  as  crucial  for  mammary  pubertal 
morphogenesis.                 290 
 
4.3.1 Uroplakin 3a 
At the time of study (2008) fairly little was known about Upk3a. The majority of 
its associated research was focused on urinary bladder where Upk3a was shown 
to be strongly expressed and assembled as plaques (AMU) on the apical side of 
urothelial umbrella cells [420] [421]. The only other organs where Upk3a was 
localised included renal pelvis, urethra and prostatic urethra, all of which also 
derive  from  urothelium  [430].  In  mammary  gland  research,  only  one  study 
mentioned  Upk3a.  It  was  a  microarray  study,  conducted  on  microdissected 
microenvironments of TEBs and ducts to find new regulators of mouse mammary 
branching  morphogenesis  that  identified  Upk3a  as  one  of  the  most  highly 
enriched RNAs of TEB transcriptome [256] therefore confirming our results. No 
further investigation into its role in pubertal mammary morphogenesis, however, 
was carried out.  
To date, the only suggested function of Upk3a is the structural stabilisation of 
the  luminal  side  of  terminally  differentiated  umbrella  cells  during  bladder 
contraction  and  expansion  [422].  Although  the  mechanism  by  which  AMU 
stabilises the urothelial lining has not yet been elucidated it has been proposed 
that AMU might interact with the actin cytoskeleton of umbrella cells to regulate 
its dynamics [425]. Actin filaments are present and essential for the survival of 
most cells types. Polymerised actin filaments, in conjunction with several actin-
binding/severing proteins, are critical components of the cytoskeletal scaffold 
which  provides  an  internal  mechanical  support  and  maintains  and  regulates 
cellular shape. There are over 100 proteins that have been shown to regulate 
either the polymerisation, length, assembly, turnover or cross-linking of actin 
filaments.  Furthermore,  when  interacting  with  myosin  motor  proteins,  actin 
filaments  have  also  been  shown  to  provide  the  force  for  cell  movement  by 
pulling  up  the  rear  of  moving  cells  or  providing  tracks  for  short  distance 
movement of intracellular materials (reviewed in [466]).  
Motile behaviour (migration, bifurcation and spatial positioning) and change of 
shape in response to systemic hormones at estrus cycle are characteristic of TEB 
at puberty (See 1.2.3.2.1). Furthermore, there is evidence demonstrating the 
importance of actin-binding proteins for sustaining the motile character of TEB     291 
 
and thus promoting ductal outgrowth at puberty. Crowley et al. (2000) showed 
that  lack  of  Gsn  (Gsn  KO  mice),  a  major  regulator  of  actin  cytoskeleton 
formation and function, severely delays the migration and bifurcation of TEB at 
puberty [243]. TEB formation and ductal outgrowth is inhibited until week 9 with 
the  epithelial  tree  remaining  rudimentary  and  even  when  the  epithelium 
eventually fills the fat pad, no side branching can be seen  [243]. Taking into 
account  the  possible  role  of  Upk3a  in  stabilising  the  actin  cytoskeleton  of 
urothelial umbrella cells, the high Upk3a mRNA expression in the epithelium of 
TEBs  at  puberty  and  the  importance  of  proper  regulation  of  actin  dynamics 
during TEB outgrowth at puberty, it is tempting to speculate that Upk3a may 
stabilize the cellular actin cytoskeleton during migration and shape remodelling 
of TEBs at puberty.  
Despite its promising potential as a new regulator of pubertal morphogenesis, 
Upk3a expression in the mammary gland could not be confirmed at the protein 
level (Western blot and IHC) thus preventing further investigations into its role. 
Such discrepancies between the mRNA and protein levels are not unusual. It has 
been long observed and described by many different studies that differential 
expression of mRNA can capture 40-50% of the variation in protein expression 
[467]  [468]  [469].  This  incongruent  expression  between  mRNA  and  protein  is 
most commonly attributed to post-transcriptional regulatory mechanisms which 
control the stability and distribution of mRNA transcripts. The main players in 
this process are RNA binding proteins (RBPs) which interact with mRNA through 
their RNA binding motif to regulate events such as alternative splicing, mRNA 
processing, export, surveillance, degradation, turnover or microRNAs (miRNAs) 
which  facilitate  gene  silencing.  Since  prominent  expression  of  Upk3a  was 
detected in protein extracts and tissue sections collected from bladder but none 
found  in  mouse  mammary  gland  (See  Figure  4-3)  it  is  possible  that  post-
transcriptional regulation of Upk3a expression differs between the two tissues. 
Another possibility is that Upk3a does undergo translation in the mammary gland 
but,  due  to  the  presence  of  different  post-translational  modifications  (N-
glycosylation or possibly phosphorylation) than those seen in the bladder, it is 
non-immunoreactive. In the bladder, Upk3a exists in two forms, as an immature 
(43 kDa) and mature (47 kDa) protein. The immature protein is synthesised in 
the endoplasmic reticulum of umbrella cells. It has three N-linked high mannose     292 
 
oligosaccharides that are attached to an extracellular domain [418]. In order to 
mature, Upk3a is required to form a heterodimer with Upk1b [425]. Formation of 
the Upk3a/Upk1b heterodimer stabilises the Upk3a subunit and enables its exit 
from the endoplasmic reticulum and transit to the plasma membrane where the 
mature  47  kDa  Upk3a  protein  can  be  seen.  The  molecular  weight  of  mature 
protein  increases  which  is  indicative  of  additional  post-translational 
modifications that occur on the way [418]. Hence, both the presence of post-
translational modifications and the formation of the Upk3a/Upk1b heterodimer 
are  prerequisites  for  Upk3a  maturation.  Since  the  AU1  antibody  used  in  this 
project (specific mouse IgG1 monoclonal antibody that recognizes an unspecified 
epitope residing within the extracellular domain) stains only the apical side of 
umbrella cells  [419],  it  recognises  the  mature  form of  Upk3a.  It  is  therefore 
possible that either the mature form of Upk3a does not exist in mammary gland 
due to the failure to form a heterodimer with Upk1b or the epitope on Upk3a, 
which is recognised by AU1 antibody in the bladder, is masked by different post-
translational modifications in the mammary gland. It is worth noting, however, 
that  data  obtained  from  the  microarray  analysis  indicated  that  Upk1b  is 
expressed in the isolated TEBs (data not shown). This suggests that unless it does 
not get translated, the failure to form a Upk3a/Upk1b heterodimer can not be 
attributed to the lack of Upk1b expression. As only a single anti-Upk3a antibody 
(AU1) was available when this study was carried out it would be of benefit, to 
stain  mammary  gland-  and  bladder  (positive  control)  tissue  sections  with 
different antibodies raised against Upk3a and compare the immunoreactivity of 
its different epitopes and thus assess the possibility for the post-translationally 
modified version of Upk3a being expressed in mammary gland. However, it was 
decided not to pursue this line of investigation and to focus on Fbln2.  
4.3.2 Fibulin 2 
As for Upk3a at the time of study, little was known about the function of Fbln2 
and most research concentrated on its localisation and role in the embryonic and 
adult  cardiovascular  development.  Further  investigation  of  Fbln2  expression 
showed its localisation in skin, hair follicles, skeletal and heart muscles and at a 
lower  level  in  lung,  liver,  kidney,  brain,  spleen,  testis,  uterus  and  ovaries, 
suggesting it is ubiquitously expressed during adulthood [434] [435] [445] [446].     293 
 
Despite being this widely expressed, however, the significance of its expression 
has  only  recently  been  addressed  in  the  cardiovascular  system  (See  below). 
Furthermore, although Fbln2 has been studied in breast cancer [452] [453] [342], 
its role in normal mouse mammary gland has not been investigated. Currently, in 
vitro  protein  interaction  studies  and  in  vivo  cardiac  system  investigations 
suggest that Fbln2 is likely to stabilise the organisation of ECM [442] [443] [444] 
and  promote  migration  of  mesenchymal  cells  during  organogenesis  and  tissue 
remodelling in response to injury [343] [342] [447] [448]. Since ECM structure, 
assembly and signalling are vital to tissue remodelling during ductal outgrowth 
at puberty and TEBs are migratory at this time point, Fbln2 arose as a promising 
new potential regulator of pubertal mouse mammary gland development. The 
following  aspects  of  Fbln2  expression  in  the  mammary  gland  were  therefore 
addressed in this project: 
  the localisation of Fbln2 within pubertal mammary gland and other stages   
of morphogenesis (See 4.3.2.1) 
  characterisation of Fbln2 expression at puberty (See 4.3.2.2) 
  hormonal regulation of Fbln2 expression (See 4.3.2.3) 
  potential functions of Fbln2 in pubertal mouse mammary gland (See 
4.3.2.4) 
As a result, we demonstrated that Fbln2 is expressed in and localised to the 
mouse  mammary  gland  at  pre-puberty,  puberty  and  early  pregnancy  where 
although possibly playing a role in TEB outgrowth (puberty) and perhaps tertiary 
branching  morphogenesis  (pregnancy)  it  may  also  have  a  structural  function. 
Furthermore, the functions of Fbln2 are probably exerted by interaction with 
some  of  its  known  binding  partners  and  its  expression  may  be  hormone 
regulated,  but  its  loss  does  not  produce  an  obvious  mammary  pubertal 
phenotype in vivo.  
4.3.2.1  Localisation of Fbln2 in pubertal mouse mammary gland 
Our  initial  microarray  analysis  identified  Fbln2  as  highly  expressed  in  the 
epithelium and stroma of the TEBs and also the distal stromal capsule of the 
pubertal  mouse  mammary  gland  (Figure  4-7).  The  accompanying  protein     294 
 
localisation study further confirmed that Fbln2 expression is indeed not confined 
to a single tissue compartment.   
Within mammary stroma, Fbln2 protein was strongly localised to the region of 
the BM and fibrous connective tissue of the ECM surrounding TEBs and the distal 
stromal capsule of the mammary gland (Figure 4-7 A) (Figure 4-35). When the 
longitudinal sections of TEB were examined it was clear that the deposition of 
Fbln2 in the fibrous ECM was not uniform. Fbln2 staining was more condensed 
around the flank and neck of TEBs rather than at their tip (Figure 4-35). This 
pattern is consistent with the general spatial localisation of interstitial fibrous 
connective ECM in pubertal mouse mammary gland which is denser at the neck 
region  of  TEB  or  around  the  ducts  and  looser  at  the  TEB‟s  tip  [53].  The 
localisation of Fbln2 in the region of BM was not continuous either (Figure 4-35). 
This could be explained by the plane of sectioning or Fbln2 not being uniform 
throughout the whole BM of TEBs. The latter justification can be supported by 
the fact that the composition of BM of TEBs varies, for example the BM at their 
tip is composed of hyaluronate whereas the neck of TEBs contains S-GAGs [50]. 
Fbln2 was also found, at a very high level within the distal stromal capsule – a 
thin tissue layer that envelopes the edges of the mammary gland and facilitates 
the attachment of the excised gland to the glass slide during wholemounting 
(personal  observation).  To  the  best  of  our  knowledge,  the  presence  of  this 
capsule in the mouse mammary gland has not been described in the literature 
before.  In  rat  mammary  glands,  a  similar  structure  has  been  described  as  a 
highly  vascularised  capsule  of  fibrillar  connective  tissue  that  determines  the 
margins of the mammary gland and serves as a boundary for epithelial expansion 
[470]. Some weak Fbln2 expression was also localised to the fibrous connective 
tissue around ducts (Figure 4-8 B). The level of this expression, however, was 
very  low  and  not  uniform  throughout  the  whole  mammary  gland.  Generally, 
Fbln2 localisation to ductal stroma was stronger in Post-LN strips and weaker in 
Pre-LN  strips.  Since  ducts  form  and  elongate  by  incorporating  cells  that 
previously belonged to TEBs, the stroma around ducts which are close to TEB, is 
likely  to  share  more  similarities  with  TEB  associated  stroma  than  that  seen 
around distal ducts, hence the level of Fbln2 expression in ductal stroma may 
depend  on  its  proximity  to  TEBs.  Although  the  association  of  Fbln2  with  the 
stromal compartment of the mammary gland may not have been surprising, since      295 
 
 
Figure 4-35 Localisation of Fbln2 expression in pubertal TEB by IHC. 
Longitudinal sections through a TEB and its surrounding stroma stained with anti-Fbln2 antibody 
(brown). Haematoxylin was used to stain nuclei (blue). Fbln2 expression was not uniform. It could 
be seen in some parts of BM – black arrow while black dotted arrow denotes the area where BM is 
absent. Fbln2 could be also seen in fibrous ECM around the flanks (red arrows) and neck of TEB 
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Fbln2 has previously been localised to the ECM of other organs (BM of kidney 
glomeruli, internal elastic lamina of blood vessels and the stroma surrounding 
cornea and skeletal or heart muscles [344] [449] [434]) its localisation to the 
epithelium was unexpected as this has not been detected before.  
Fbln2 could be detected in both cap- and body cells of TEBs, but as shown by 
confocal  microscopy,  the  pattern  of  abundance  in  these  cell  types  was  not 
uniform.  In  cap  cells,  most  protein  appeared  to  be  associated  with  cell 
membranes while a slightly weaker and more diffuse signal could be detected in 
what appeared to be the cytoplasm and extracellular spaces (Figure 4-10 A). A 
similarly  diffuse,  although  more  punctated  pattern,  was  seen  in  body  cells. 
Here,  Fbln2  appeared  to  localise  to  extracellular  spaces  or  cytoplasm  rather 
than cell membranes and was not uniformly present throughout the entire mass 
of body cells (Figure 4-10 B). In the ducts, on the other hand, the pattern of 
Fbln2  was  heterogeneous.  Although  predominantly  negative  (especially  in  the 
Pre-LN  region)  there were  some  ducts  and  ductules  that  showed  a  weak  but 
similar staining pattern to that seen in TEBs. Here, however, the staining was 
stronger in the region of BM and ECM than the epithelium. Although confocal 
microscopy  allowed  us  to  localise  Fbln2  to  some  extent,  immunoelectron 
microscopy  is  needed  to  clarify  its  intracellular  localisation  and  potential 
association with ECM proteins.  
In pubertal mouse mammary gland, the components of BM are synthesised by 
both cap cells and stromal fibroblasts while the fibrous ECM is mostly secreted 
by fibroblasts [50] [93]. Fibroblasts may also act as a source of Fbln2 across a 
range  of  biological  systems.  Mouse  embryonic  fibroblasts  (NIH3T3),  human 
embryonic,  dermal  or  corneal  fibroblast  have  all  been  shown  to  express  and 
secrete  Fbln2  in  vitro  [444]  [471].  Together,  these  results  suggest  that  the 
expression of Fbln2 in the epithelium, demonstrated by microarray analysis, is 
mainly associated with cap cells, while the stromal Fbln2 may be synthesised by 
fibroblasts.  Fbln2  is  an  extracellular  protein  and  therefore  after  being 
synthesised it is probably secreted. It is most likely that fibroblasts secrete Fbln2 
to BM and fibrous ECM or just fibrous ECM, while Fbln2 expressed by cap cells 
gets incorporated into BM. As for the epithelium localised Fbln2, while it is most 
probable  that  the  Fbln2  found  in  the  cap  cell  membrane,  cytoplasm  and 
extracellular  spaces  is  synthesised  in  the  cap  cells  themselves  the  source  of     297 
 
Fbln2 expression in body cells is less clear. It is possible that body cells either 
synthesise and secrete Fbln2 themselves or perhaps derive it from cap cells. To 
validate these hypotheses however it would be necessary to carry out  in situ 
hybridisation. The secretion of Fbln2 by cap cells towards the body cells of TEBs 
may result from the poor apical-basal polarity of cap cells. This may lead to 
Fbln2 being non directionally secreted to the inner epithelial layers of the TEB 
instead of the BM, as is sometimes seen for hyaluronate and laminin [56] which 
could also explain the non-uniform abundance of Fbln2.  
Our preliminary primary culture experiments on TEB clearly demonstrated that 
the epithelial cells in culture secrete Fbln2. The cytoplasmic and cell membrane 
associations of Fbln2 in these cultures (Figure 4-18) was consistent with that 
seen in TEBs in vivo (Figure 4-10) while the association of Fbln2 with cellular 
processes may resemble the pattern seen in TEB stroma in vivo (Figure 4-8 A). It 
would  be  beneficial,  therefore,  to  develop  this  model  to  study  regulation  of 
Fbln2 in vitro.   
In  addition  to  its  pubertal  expression,  we  also  detected  Fbln2  in  mouse 
mammary  glands  during  pre-puberty  and  early  pregnancy.  Pre-puberty  is 
regarded as a period of around 3-4 weeks which starts at birth and lasts till the 
onset of puberty which is defined by three events: the vaginal opening, first 
oestrus  and  the  following  increase  in  the  production  and  secretion  of 
gonadotrophins and E2 [45]. Here, we reported the expression of Fbln2 in the 2 
and 3 week old mouse mammary glands by Q RT PCR (Figure 4-12 B and C) and 
showed  that  its  spatial  localisation  in  these  glands  resembled  that  seen  at 
puberty, with Fbln2 expressed in: i) the epithelial (cap cells and body cells) and 
stromal milieu of TEB-like structures (Figure 4-13 A and B) and ii) throughout 
the distal stromal capsule (Figure 4-16 A). This suggests that the expression of 
Fbln2 in the pubertal mouse mammary gland instead of being novel serves a 
continuation of that present at pre-puberty. While given that the pre-pubertal 
mammary gland consists of a rudimentary ductal tree that resembles that seen 
at the E18.5 (reviewed in  [3]) and Fbln2 has previously been associated with 
cardiac- [343] and cartilage embryogenesis [440] it is further plausible that the 
presence  of  Fbln2  at  pre-puberty  originates  and  is  a  continuation  of  that 
commenced  during  the  embryonic  development  of  mammary  gland.  The 
association  of  Fbln2  with  mammary  embryogenesis,  however,  has  not  been     298 
 
studied  to  date  and  thus  IHC  or  in  situ  hybridisation  on  embryonic  tissue 
sections, neonatal and pre-pubertal mouse mammary gland tissue sections would 
be needed to test this hypothesis.  
While the association of Fbln2 with pre-pubertal and pubertal mouse mammary 
glands appeared fairly steady (until it distinctly fades away with the onset of 
adulthood) the recurrence of Fbln2 at early pregnancy was sudden and restricted 
to only a short time frame of around 60h, between day 2 and 4.5 of pregnancy. 
It is first visible at day 2, peaks at day 3 and disappears by day 4.5. In these 
glands Fbln2 localised to ductal myoepithelium and stroma  (Figure 4-14) and 
the  distal  stromal  capsule  (Figure  4-16  D).  The  presence  of  Fbln2  in 
myoepithelium is consistent with myoepithelium being derived from cap cells 
and thus might share some of its characteristics. Stromal Fbln2, on the other 
hand, is most probably expressed by stromal fibroblasts or myoepithelial cells 
both  of  which  can  synthesise  BM  components.  Although  very  obvious  at  the 
protein level using IHC, these changes were not apparent by Q RT PCR on the 
RNA level. As demonstrated in Figure 4-12 A the level of Fbln2 expression at 
pregnancy day 3 was almost baseline. It is worth noting, however, that the RNA 
used for each time point was obtained from a single animal and normalised only 
to the amount of epithelium (Krt18) instead of the entire number of cells and 
thus might not be fully representative. Nonetheless, the expression of Fbln2 at 
early  pregnancy  is  intriguing  and  might  provide  some  further  clues  into  its 
function in the future.  
The current knowledge of systemic and morphological events in early pregnancy 
is limited and only few conclusions can be made. All that is known is that early 
pregnancy  is  characterised  by  increased  proliferation  of  epithelial  cells  [36], 
ducts become dilated between day 2 and 3 and epithelium starts to bud at the 
tips and along ducts to form either alveolar buds or tertiary side branches [48]. 
This  could  suggest  a  potential  role  of  Fbln2  during  the  initiation  of  ductal 
budding  and  perhaps  that  the  expression  of  Fbln2  is  initiated  in  response  to 
other  genes  or  hormones.  Some  of  the  genes  known  to  be  active  at  early 
pregnancy include BMP2, Msx2 and Msx1 [218] but their association with Fbln2 
has not been reported to date. Furthermore, although many hormones, such as 
P,  E2,  PRL,  placental  lactogen,  oxytocin,  GH,  PTH,  insulin,  corticosteroids, 
PTHrP  and  leptin  are  thought  to  regulate  proliferation  and  differentiation  of     299 
 
mammary  epithelium  at  pregnancy  (reviewed  in  [36]),  to  the  best  of  our 
knowledge the exact timing of their expression has not yet been elucidated. The 
two most likely candidates to stimulate Fbln2 expression, however, are P and 
PRL. Prl promotes P expression and the levels of both hormones rise with the 
onset of pregnancy [472]. Furthermore, when primed in vivo with E2+P pellets, 
mouse mammary glands show higher Fbln2 expression than that seen in placebo 
controls (Figure 4-23) (See 4.2.2.8). E2 is known to be particularly elevated 
during  the  second  rather  than the  first  half  of  gestation  when  the  extensive 
lobuloalveolar growth takes place [473].  
Together, the temporal and spatial expression of Fbln2 during mouse mammary 
gland development suggests its association with the active stages (puberty, early 
pregnancy and possibly embryogenesis) and sites (TEBs at puberty and ducts at 
early pregnancy) of its morphogenesis. 
4.3.2.2  The characteristics of Fbln2 expression in mammary gland 
Fbln2 RNA exists as one of two splice variants:  Fbln2 V1 or Fbln2 V2, and as 
shown by Grässel et al. (1990) the distribution of these splice variants is tissue 
specific [439]. It has been reported that Fbln2 V1 is predominantly expressed in 
heart and NIH3T3 cells while Fbln2 V2 is more abundant in the kidney [439]. In 
this study, we demonstrated that both Fbln2 V1 and Fbln2 V2 are expressed in 
mouse  mammary  gland  at  puberty  (Figure  4-19 B-D).  However,  we  failed  to 
replicate the NIH3T3 Fbln2 expression data observed by Grässel et al. (1990) as 
in our experiments, even when repeated using a number of different low passage 
aliquots of NIH3T3,  the cells expressed both splice variants (RNA  level). This 
discrepancy could be due to potential transformation of either of the NIH3T3 
cell  lines.  Although  neither  the  XRAY  Excel®  Array  based  microarray  splicing 
analysis  nor  the  PCR  are  fully  quantitative,  the  results  they  generated  were 
consistent. Fbln2 V1 appeared to be prevalent in Post-LN strips and isolated TEBs 
and ducts, but no clear difference between the V1/V2 ratio could be seen in 
Pre-LN strips (Figure 4-19 B-D). These preliminary data suggest differences in 
Fbln2 splice variant expression between the stroma around TEBs and that around 
ducts  which  in  turn  could  suggest  different  functions  of  Fbln2  in  the  two 
environments. However, this possibility still needs to be verified by repeating 
the experiments with a bigger array of samples or using Q RT PCR or northern     300 
 
blotting  for  quantitative  measurement  of  gene  expression.  Furthermore,  it  is 
also questionable whether the two isoforms exhibit different functions. Fbln2 V1 
and Fbln2 V2 differ only by the RNA sequence which encodes a single EGF-like 
repeat which although postulated to participate in the interactions between ECM 
proteins [437] and stabilization of protein structure [438], when absent (human 
Fbln2 expresses only the V2 isoform) does not affect protein-protein interactions 
[435].     
Since Fbln2 V1 and Fbln2 V2 proteins differ only by a single EGF-like repeat their 
molecular weight is predicted to differ by only 5 kDa. However, the presence of 
a potential N-glycosylation site within the alternatively spliced  domain raised 
the possibility that the difference in molecular weights of the two proteins was 
greater.  Using  protein  extracts  from  NIH3T3,  EpH4  and  HC11  cells,  which 
expressed  Fbln2  V1  and  Fbln2  V2,  just  Fbln2  V2  and  no  Fbln2  respectively 
(Figure 4-20 C), and comparing the obtained banding pattern to that seen in 
protein  extracts  from  mammary  tissue  strips  (Figure  4-6  C)  we  showed  that 
Fbln2 V1 and Fbln2 V2 can not be separated using either Bis-Tris or Tris-Acetate 
(better resolution for larger proteins) 1D electrophoresis and Western blotting. 
This suggests a small difference between their sizes which could be attributed to 
either  the  presence  of  small  polysaccharide  chain  on  Fbln2  V1  or  complete 
absence of a potential N-glycosylation at that site.         
Fbln2 is known to be sensitive to proteolysis. In vitro, soluble Fbln2 is cleaved by 
matrix  metalloproteinases  (stromelysin,  matrilysin),  circulating  proteases 
(thrombin,  plasmin  and  kallikrein)  and  granule  stored  proteases  (leucocyte 
elastase, mast cell chymase), and, when immunoblotted with the routine full 
length  anti-Fbln2  antibody,  gives  rise  to  fragments  ranging  from  15-150  kDa 
[455]. The two bands of 150 kDa and 135 kDa that are additional to the main 195 
kDa  band  have  also  been  detected  in  protein  extracts  from  cultured  murine 
fibroblasts that were immunoblotted using the same anti-Fbln2 antibody. They 
were  suggested  to  result  from  proteolytic  cleavage  of  the  mature  195  kDa 
protein but no research was carried out to unravel their true nature [455]. Here, 
we report for the first time, that the 135 kDa and 150 kDa Fbln2 exist in vivo 
(Figure 4-6 C) and add to their understanding by demonstrating that in pubertal 
mouse mammary gland the 135 kDa Fbln2 peptide lacks the N-terminus (Figure 
4-21). This finding, along with the fact that none of these bands correspond to     301 
 
Fbln2 V2, and the known sensitivity of Fbln2 to proteolytic cleavage agree with 
the proposal of Sasaki et al. (1996) [455], that both of these additional peptides 
are  products  of  proteolytic  cleavage  of  mature  Fbln2.  Furthermore,  by 
demonstrating  that  no  significant  differences  in  Fbln2  banding  pattern  exist 
between Pre- and Post-LN strip protein extracts (Figure 4-22) we suggest that 
the protease(s) responsible for Fbln2 cleavage are generic to pubertal mouse 
mammary gland stroma rather than specific to the migratory environment of TEB 
or the more static ductal milieu.  
Since  a  similar  Fbln2  binding  pattern  can  be  detected  in  cultured  mouse 
fibroblasts and the fibroblasts in mammary gland are likely to synthesise stromal 
Fbln2, it is tempting to speculate that the proteases in question are associated 
with  fibroblasts.  Furthermore,  based  on  the  similarities  between the  sizes  of 
Fbln2 fragments identified from pubertal mouse mammary gland protein extract 
and  those  generated  by  proteases  in  vitro  [455],  kallikrein  and  stromelysin 
(MMP-3) are the most likely candidates to facilitate some of Fbln2 cleavage in 
mammary gland. When treated with kallikrein, two types of Fbln2 products can 
be  detected:  mature  undigested  195  kD  protein  and  the  150  kDa  cleavage 
product.  In  addition  Klkb1,  the  gene  which  encodes  the  inactivated  form  of 
kallikrein  (prekallikrein),  is  ubiquitously  expressed  throughout  the  body  with 
particularly  high  expression  in  mammary  gland  during  stromal  remodelling 
periods,  i.e.  puberty  and  involution,  where  it  localises  to  mast  cells,  and  is 
critical for stromal ECM remodelling during involution [474]. Stromelysin, on the 
other hand, cleaves Fbln2 more effectively and only the 150 kDa band can be 
noted [455]. Again, the expression of stromelysin, although ubiquitous, is highly 
associated  with  pubertal  mouse  mammary  gland  where  it  is  important  for 
pubertal  outgrowth.  Mammary  glands  of  MMP3  deficient  mice  (MMP3  KO
-/-) 
display a ductal tree that is thinner and characterised by a lower number of side 
branches than that seen in the WT controls [235]. Since Fbln2 is one of the ECM 
components  in  pubertal  mouse  mammary  gland  and  since  normal  ECM 
composition and remodelling are important for ductal morphogenesis at puberty, 
it would be beneficial to further characterise the 135 kDa and 150 kDa Fbln2 
peptides  by  mass  spectrometry  to  establish  their  sequence.  It  would  also  be 
helpful to screen for other ECM remodelling proteases that are expressed in the 
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of the advancing TEB and examine their potential to facilitate the cleavage of 
Fbln2. Some of these potential candidates could include MMP2, MMP9, MMP11 or 
MMP14 [235].     
4.3.2.3  Hormonal regulation of Fbln2 expression 
Our data also highlighted the possibility that Fbln2 expression in the mammary 
gland is regulated by systemic hormones. We demonstrated a significant increase 
of Fbln2 expression in mouse mammary glands collected from 4.5 week old mice 
that were primed with E2 or E2+P pellets for a week (Figure 4-23). Although the 
Fbln2 expression level was normalised to the amount of epithelium rather than 
the total number of cells which, as shown in Figure 4-12 B and C, could have 
impacted upon the level of calculated gene expression, the Q RT PCR results 
were  consistent  with  the  IHC  data  (Figure  4.24).  Interestingly,  while  Fbln2 
localised to the TEB and duct environments and the distal stromal capsule in 
both the placebo and E2+P treated glands, in E2 primed mammary glands Fbln2 
expression  was  switched  off  in  ductal  epithelium  and  stroma  (Figure  4-24). 
Since  Fbln2  expression  was  seen  within  the  ductal  environment  at  puberty, 
which are regulated by E2 and P, it suggests that the observed effect of E2 on 
ducts might be unnatural and caused by an excessive level of E2 and thus may 
not reflect the Fbln2 regulation by E2 in vivo. This can be further substantiated 
by the unnatural appearance, thickness and decreased mechanical elasticity of 
the fat pad in these glands (Figure 4-36 B). The E2+P pellets used in this study 
consisted  mostly  of  P  and  when  used  for  the  week-long  priming,  evoked  a 
pregnancy-like  state  in  the  pubertal  mouse  mammary  gland  (Figure  4-36  C), 
mimicking the hormonal milieu of pregnancy where P is high and E2 levels are 
much  less  pronounced.  The  previously  described  up-regulation  of  Fbln2 
expression during early pregnancy where P is present implies that P may play a 
role in promoting Fbln2 expression. This hypothesis is complicated, however, by 
the fact that no difference in Fbln2 expression can be seen between pre-puberty 
and puberty (Figure 4-12 C) suggesting that the levels of pubertal E2 and P do 
not affect Fbln2 expression in vivo. Collectively, it appears that while expression 
of Fbln2 in virgin glands is not regulated by systemic hormones (E2 and P), high 
levels  of  P  characteristic  of  pregnancy  and  seen  in  our  in  vivo  experiments, 
might mediate the expression of Fbln2. This hypothesis can further be supported 
by the identification of Fbln2 amongst the genes over-expressed in human      303 
 
 
Figure 4-36 Wholemounts collected from hormone primed TG mice. 
3.5 week old mice primed with (A) placebo, (B) E2 and (C) E2+P pellets for 7 days. Images were 
acquired using a fluorescence dissecting microscope (Stemi SV6). Scale bar is 50µm.          
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endometrial stromal short-term cell culture in response to P treatment [456]. To 
explore  the  potential  role  of  P  in  mediating  the  expression  of  Fbln2  during 
mammary morphogenesis in the future it would be beneficial to use the PR KO
-/- 
mice  and  examine  the  expression  of  Fbln2  during  different  stages  of  mouse 
mammary gland development in the absence of P signalling. The in vitro model 
for  TEB  explant  culture  (See  4.2.2.5)  may  also  facilitate  the  study  of  Fbln2 
expression in response to hormones. 
4.3.2.4  Potential functions of Fbln2 in pubertal mouse mammary gland   
At puberty, Fbln2 is mostly associated with the epithelium and stroma around 
TEBs which are known to be a driving force of ductal development. Thus, based 
on  its  mammary  location  and  its  to  date  suggested  functions  in  different 
biological systems, we propose two potential functions that Fbln2 may have in 
pubertal mouse mammary gland:  
  Stabilising the structure of TEB 
  Facilitating the motility of TEBs  
4.3.2.4.1  Structural function 
 
Numerous in vitro protein interaction studies and analyses of recently generated 
double KO
-/- (Fbln2 and Fbln5), mice as well as the presence of multiple EGF-like 
repeats with Ca
2+ binding sites, which are postulated to facilitate and regulate 
protein-protein  and  protein-cellular  receptor  interactions  [436]  [437],  suggest 
that Fbln2 is involved in stabilising the organisation of ECM structures, especially 
BM, elastic fibres and fibronectin matrix [442] [443] [444] [449]. Thus, given the 
partly stromal localisation of Fbln2 in mouse mammary gland it is possible that 
Fbln2 may function in a similar way in pubertal mouse mammary gland.  
As demonstrated in this study, Fbln2 localised to the BM region of TEBs where it 
is likely to exert its function by interacting with Lama1. Lama1 is one of the 
molecules that have previously been identified, by protein binding studies, to 
interact with Fbln2 in vitro [462] [442]. It is one of the main components of BM 
in the mammary gland (reviewed in [91]) and, as highlighted by our microarray     305 
 
study, it was highly expressed in the Post-LN strip (Table 4-1 and 4-2). When 
used to study the effect of Fbln2 over-expression on the adhesiveness of HC11 to 
ECM  matrices,  the  increased  adhesion  of HC11  cells  to  Lama1  could  be  seen 
(Figure  4-27  B).  In  the  mammary  gland,  Lama1  is  crucial  for  normal  TEB 
development at puberty as its deficiency results in the formation of fewer TEBs 
and  consequently  reduced  ductal  outgrowth  when  compared  to  WT  controls 
[227].  Together  these  results  suggest  that  Fbln2  may  stabilise  the 
supramolecular  network  of  Lama1  in  BM  and  therefore  contribute  to  the 
machinery  that  maintains  TEB  structure  and  function  during  pubertal 
morphogenesis. Further co-localisation and protein binding studies, however, are 
required to validate this hypothesis. 
The presence of Fbln2 expression in the stroma of TEBs and the distal stromal 
capsule of mammary gland suggest that this structural role of Fbln2 may also 
extend to the fibrous connective tissue of the ECM in pubertal mammary gland. 
The fibrous connective ECM in mammary gland consists of an extended network 
of cross-linked ECM components which include Fn, Col, Tn, Eln, SLRP or SPARC 
(reviewed  in  [91]).  Previous  evidence  indicating  presence  of  protein-protein 
interactions  between  Fn,  ColVIaIII  and  Eln  and  Fbln2  in  other  experimental 
systems [442] [443] [444] [459] [460] [464] together with the identification of  
Fn, ColIVa and Eln as highly expressed in the TEB environment by our microarray 
analysis (Table 4-1, 4-2) suggests that Fbln2 may be functionally associated with 
any of these molecules in mouse mammary gland at puberty.  
As for Fn, an interaction between Fbln2 and Fn has been demonstrated both in 
vitro and in vivo. Fbln2 strongly binds to Fn in protein binding assays [442], co-
localises with Fn in murine dermal and human embryonic fibroblasts cultures [460] 
and in Fn fibrils as shown by IF, and localises to Fn fibrils in human fibroblasts as 
shown by EM [444]. In the mammary gland, lack of Fn delays ductal outgrowth and 
decreases ductal branching at puberty [232] and, as demonstrated in this study, 
the HC11 cells over-expressing recombinant Fbln2 adhered more strongly to Fn 
than the controls (Figure 4-27 B). Although all these findings suggest Fbln2 may 
interact with the Fn matrix in mammary gland at puberty, no co-localisation of 
the two proteins in the mammary stroma could be noted (Figure 4-29) making it 
unlikely for Fbln2 and Fn to act as binding partners during TEB outgrowth in vivo.      306 
 
In  contrast  potential  co-localisation of  Fbln2  with  Eln  in  the  mammary  gland 
could  be  seen  in  preliminary  localisation  studies.  Eln  was  demonstrated  to 
localise mostly to the stromal capsule of pubertal mouse mammary glands. A 
single Eln fibre could also be seen in the stroma around TEBs (Figure 4-30 A-B). 
Eln is the second most investigated binding partner of Fbln2 after Fn. In vivo, it 
is mostly present in blood vessels, lung and skin tissue where it interacts with 
Fbn1  to  form  elastic fibres  which  are critical  for  tissue  elasticity  [465].  This 
process  of  elastic  fibre  assembly  is  dependent  on  specific  protein-protein 
interactions  between  Eln  and/or  Fbn1  and  their  associated  proteins.  As 
demonstrated  by  Chapman  et  al.  (2010)  when  functioning  cooperatively  with 
Fbln5, Fbln2 is likely to be one of the key players required for normal assembly 
of elastic fibres in internal elastic lamina of blood vessels [449]. Together these 
findings  not  only  present  the  potential  for  Fbln2  and  Eln  interactions  in  the 
mammary gland but also provide further insights into the structure of the as yet 
uncharacterised stromal capsule.  
Another potential Fbln2  binding partner in mouse mammary gland at puberty 
might be Vcan as it interacts with Fbln2 in other systems [461] [448] [344] and is 
up-regulated in the TEB stroma (Table 4-1 and 4-2), however, to date it has not 
been studied in mammary gland.  
Taken together, the characteristic multistructural and cross linked composition 
of ECM in the mammary gland, the presence of Fbln2 in mammary ECM and its 
multifunctional  binding  properties,  suggest  that  Fbln2  may  serve  as  a  global 
“glue” forming an intramolecular bridge which integrates into ECM using several 
routes to link and stabilise the structure of the mammary stroma and that in 
turn provides the scaffold for the associated stromal and epithelial cells. The 
proposed stabilising property of Fbln2 is consistent with the absence of Fbln2 
expression at the tip of TEB but its deposition at its flank and neck and can 
further be exerted onto cap- and body cells of TEBs where the Fbln2 expression 
appears to be associated with cellular membranes, cytoplasm and extracellular 
spaces and thus may be involved in the maintenance of TEB integrity, as seen for 
Ntn1 and Neo1 [117].  
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4.3.2.4.2  Migratory function 
 
The high expression of Fbln2 in both the stroma and epithelium of TEBs, which 
are very motile structures and serve as key drivers of ductal morphogenesis at 
puberty,  could  suggest  a  potential  role  for  Fbln2  in  the  regulation  of  TEB 
migration and hence ductal outgrowth. To date, the role of Fbln2 in migration 
has only been studied in terms of single cell migration and was shown to differ 
depending on the experimental system. Down-regulation of Fbln2 occurred in 
both the breast cancer cell lines (MDA-MB-231 and BT-20) and breast tumours 
and, when over-expressed in vitro, it reduced cell motility and invasiveness of 
breast  cancer  cells  [342].  It  was  present  in  murine  non-neoplastic  vascular 
lesions in vivo and when up-regulated it increased smooth muscle cell migration 
in response to injury in vitro [448]. Furthermore, in embryonic cardiovascular 
development  Fbln2  has  been  identified  as  up-regulated  during  EMT  where  it 
selectively  localised  to  mesenchymal  cells,  i.e.  migrating  cells  of  developing 
cardiac  valves  and  aortic  arch  vessels  [441].  Our  data,  however,  does  not 
support these findings as it demonstrates that the over-expression of Fbln2 in 
non-malignant mouse mammary epithelial cells (HC11) did not alter the ability 
of these cells to migrate (Figure 4-26 B). It is worth noting, however, that the 
wound healing assay, which was used to study cell migration in this project, was 
carried out on a plastic surface. Based on the fact that Fbln2 belongs to ECM 
molecules  and  closely  interacts  with  other  ECM  components  it  would  be 
beneficial  to  validate  these  primary  findings  using  additional  methods  which 
incorporate substances that mimic extracellular environment such as surfaces 
coated with synthetic ECM molecules or fibroblasts (2D assays). On the account 
of the structural complexity and varied composition of ECM in vivo it may further 
be of use to study the impact of Fbln2 expression on mammary epithelial cell 
migration using the 3D matrix based techniques. An example of such assay is a 
Matrigel  coated  Boyden  migration  chamber  which  uses  chemoattraction  to 
promote cell migration and heterogenic composition of Matrigel (ColIV, Lama1, 
proteoglycans, EMC degrading proteins and their inhibitors, growth factors and 
many others) to reconstitute stromal environment of mammary gland and thus 
can  be,  and  in  fact  already  has  been  [475],  used  to  study  the  HC11  cell 
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Although the exact mechanism is yet unknown, the migration of TEB does not 
appear to be based on single cells but most likely is characterised by collective 
cell migration – a coherent movement of a group of cells whose leading edge, in 
the in vitro cultured TEB-like organoids, is agglomerated as demonstrated by the 
positive  E-cadherin  and  P-cadherin  staining,  and  appears  to  migrate  despite 
lacking  cellular  extensions  or  protrusions  [105].  Although  the  underlying 
mechanism for this activity is yet to be elucidated there are several potential 
ways in which Fbln2 could positively regulate this mechanism of migration.  
Firstly,  its  localisation  to  BM  and  cellular  membranes  of  cap  cells  and 
extracellular  spaces  of  body  cells  means  Fbln2  may  facilitate  collective  cell 
migration by maintaining the tissue integrity of TEB. It may physically strengthen 
the architecture of BM by binding and cross-linking it with other ECM molecules 
and by assisting in maintaining the adhesion between cap cells and body cells. 
The presence of a single RGD site within its structure supports this theory since 
it is indicative of adhesive properties [434] and, as shown in this study and by 
Sasaki et al. (1990), Fbln2 was able to promote adhesiveness of mammary cell 
lines to ECM coated surfaces (Figure 4-27 B) [463].  
Secondly,  the  stroma  expressed  Fbln2  may  not  only  have  the  structural  role 
discussed above but, since ECM is critical for epithelial-stromal cross talk and 
ECM remodelling is essential for TEB migration at puberty, stromal Fbln2 may 
also  take  part  in  regulating  pubertal  outgrowth.  In  vitro,  Fbln2  shows  strong 
binding affinity to Itgb3 and Itga5, the BM associated receptors which connect 
the ECM with the epithelial cell cytoskeleton [463] and as demonstrated by our 
microarray study, were highly expressed in TEBs (Table 4-1 and 4-2). Fbln2 may 
therefore mediate signal transmission between the stroma and epithelium and 
hence influence the phenotype and behaviour of TEBs.  
A  third  possibility,  however,  is  that  Fbln2  may  influence  TEB  migration  by 
remodelling  of  ECM.  This  property  of  fibulins  has  been  long  observed  in 
Caenorhabditis elegans where fibulin-1 (FBL-1) which corresponds to mammalian 
Fbln1C is involved in directing the cellular migration of gonadal distal tip cells 
during gonad organogenesis in vivo [476] [477]. FBL-1 is expressed in the stroma 
around  migrating  cells  where  it  appears  to  interact  with  „Abnormal  GONad 
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with thrombospondin type 1 motif (ADAMTS). It was concluded that FBL-1 drives 
gonadal migration by antagonising the action of GON-1 by interacting with other 
ECM  molecules,  which  are  substrates  for  ADAMTS  directed  cleavage.  One  of 
these ECM molecules could be Acan which both binds Fbln1C and is known to be 
cleaved by ADAMTS [478]. Since Fbln1C is the closest relative to Fbln2 [434] its 
involvement in directing gonadal distal tip cell migration might provide insights 
into its potential regulatory function in mammary morphogenesis at puberty.  
Finally, as the expression of Fbln2 was concentrated around the neck and flanks 
of TEBs, in a similar expression pattern to that described for ColI, it may play a 
similar role to that proposed for ColI in acting as a girdle to contain and direct 
the pressure generated during reshaping of TEB into ductal dimensions and thus 
create the force to promote their forward movement [53].  
Thus, there are several ways in which the formation of the Fbln2 network in ECM 
or epithelium of TEBs might provide a structural backbone for mammary ductal 
tree development or facilitate ductal elongation in pubertal mouse mammary 
gland. Furthermore, it is worth adding that Fbln2 expression in the mammary 
myoepithelium  and  its  surrounding  stroma  at  early  pregnancy  indicates  its 
potential in priming the ducts for tertiary branching, a process characteristic for 
this developmental stage, and as discussed for puberty this may be achieved by 
Fbln2 either i) providing a structural scaffold that  maintains tissue integrity or 
ii) priming ductal epithelium and stroma for cellular migration via preparing the 
cells  for  collective  migration,  mediating  epithelial-stromal  cross  talk  or 
promoting/regulating  ECM  remodelling  (See  paragraphs  above).  Further 
experiments, however, are required to test these hypotheses.  
Despite its specific localisation and rich array of potential functions loss of Fbln2 
did  not  result  in  a  mammary  phenotype,  but  showed  comparable  TEB 
morphology (slight differences in TEB size and shape could be seen in the Fbln2 
KO
-/-  mammary  glands  which  appeared  smaller  and  more  oval  than  their  WT 
counterparts but a larger number of mouse mammary glands should be studied 
to substantiate this observation), length and degree of branching of the ductal 
tree to that seen in WT controls (Figure 4-32) (Figure 4-33). This is consistent 
with  the  results  of  earlier  study  by  Sicot  et  al.  (2007)  which  showed  the 
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of a phenotype in response to Fbln2 deficiency is probably due to compensation 
by Fbln1 expression, which in fact was not only up-regulated in TEB environment 
in Fbln2 KO
-/- mouse mammary glands when compared to WT controls (Figure 4-
34 A and B) but also localised to cap cells and BM, places associated with Fbln2 
but not Fbln1 expression in WT controls (Figure 4-35 A, B and C). This indicates 
that loss of Fbln2 triggers an increase in expression and an alteration in the 
localisation of Fbln1 in mammary gland. Since IHC is not quantitative, further 
studies should be carried out to quantify the level of Fbln1 in Fbln2 KO
-/- and WT 
mice. Fbln1 binds to most of the molecules that interact with Fbln2, such as Fn, 
Lama1, Nid, Col18a1, Vcan and Acan [443] [442] and therefore it is possible that 
the  compensatory  expression  of  Fbln1  is  sufficient  to  rescue  the  Fbln2  KO
-/- 
phenotype. Further studies should be carried out to evaluate this hypothesis. It 
would be necessary to generate a mouse model lacking the expression of both 
Fbln1  and  Fbln2.  Since  Fbln1  KO
-/-  mice  are  prenatally  lethal  mainly  due  to 
haemorrhage (defective BM of small blood vessels) [479], however, it would be 
necessary to generate Fbln2 KO
-/- mice expressing loxP flanked Fbln1 gene and a 
transgene construct consisting of full-length Cre recombinase cDNA under the 
control of MMTV promoter. The mammary gland expressed Cre would bind to 
loxP sequences and splice the loxP flanked DNA and thus KO Fbln1 expression in 
a  selective,  tissue  specific  manner.  Given  the  presence  of  the  potential 
mechanism by which Fbln2 deficiency is immediately compensated by the Fbln1 
expression it is tempting to speculate that rather than being indispensable for 
the  pubertal  mammary  morphogenesis  or  general  mouse  development,  as 
suggested  before  [266],  it  is  perhaps  that  Fbln2  is  so  essential  for  these 
processes  that  just  in  case  it  is  lost  an  alternative  mechanism,  such  as 
compensation with Fbln1 expression, are in place. This can further be supported 
by the results of recently generated and studied double knockout mice for Fbln2 
and  Fbln5 genes which present a severe phenotype within the cardiovascular 
system (severe disorganisation of the elastic lamina in blood vessels which can 
not be seen in single Fbln2 or Fbln5 KO
-/- mouse models) suggesting that when 
interacting with Fbln5,  Fbln2 is essential for elastic fibre formation [449]. At 
the time of this study the double KO mouse model was not available to us but an 
examination of mammary glands collected from these mice would be essential to 
further  study  the  role  of  Fbln2  during  in  vivo  mouse  mammary  gland 
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4.3.2.5  Summary  
In summary, this study is the first to demonstrate and research the expression of 
Fbln2  in  pubertal  mouse  mammary  gland.  We  propose  that  Fbln2  might  be 
expressed  in  response  to  P  and  although  its  deficiency  does  not  result  in  an 
obvious  pubertal  mammary  phenotype,  its  diverse  localisation  throughout  the 
mammary stroma and epithelium suggests it is likely to interact with different 
ECM structures at different places and thus contribute to an array of different 
structural and migratory functions during pubertal mammary morphogenesis and 
possibly pre-puberty and early pregnancy.              312 
 
5  Final conclusions and future work 
5.1 Final Conclusions 
This  thesis  demonstrates  the  benefit  of  DNA  microarray  analysis  in  studying 
pubertal  development  of  mouse  mammary  gland  to  either  identify  putative 
regulators  („candidate  gene  approach‟)  or  unravel  global  trends  in  gene 
expression („pathway analysis‟) and thus add to the understanding of biological 
mechanisms that underlie the TEB driven morphogenesis and ductal branching at 
puberty and reveal many potential avenues for further investigations.  
Using RNA obtained from isolated epithelium of TEBs, ducts and whole mouse 
mammary tissue strips not only did we identify gene sets associated with each of 
the pubertal compartments (the epithelium or stroma of TEBs,  epithelium or 
stroma of ducts or the epithelium free distal Fat pad) but we also characterised 
each milieu. We are the first to identify and characterise stromal transcriptomes 
of TEBs and ducts and together with the detailed analysis of pubertal epithelium 
this  thesis  provides  the  most  comprehensive  comparison  analysis  of  the 
functional characteristics of TEBs and ducts to date.  
We  focused  our  analysis  on  an  individual  gene  level  and  selected  Upk3a  and 
Fbln2 as potential regulators of pubertal mouse mammary morphogenesis. While 
our studies on Upk3a were limited since it could not be detected at the protein 
level we demonstrated strong expression of Fbln2 in both the epithelium and 
stroma  of  TEBs  and  the  distal  stromal  capsule  of  mouse  mammary  gland  at 
puberty. In addition, we showed that Fbln2 was expressed in TEB-like structures 
and distal stromal capsule in pre-pubertal mammary glands and myoepithelium, 
its  surrounding  stroma  and  distal  stromal  capsule  in  mammary  glands  during 
early pregnancy (day 2 - day 4.5). This suggested that Fbln2 expression switches 
on  at  embryogenesis  (embryonic  expression  of  Fbln2  has  been  demonstrated 
during the cardiovascular development) and continues during pre-puberty and 
puberty. We postulated that Fbln2 may be expressed in response to P during 
puberty  and  early-pregnancy  and  that  the  lack  of  an  obvious  mammary 
phenotype  in  Fbln2  KO
-/-  mice  at  puberty  might  be  attributed  to  the  over-
compensation  of  Fbln2  loss  by  Fbln1.  The  diverse  localisation  of  Fbln2     313 
 
throughout  the  mammary  stroma  and  epithelium  suggested  its  potential  to 
interact with various ECM structures at different places and thus contribute to 
an  array  of  different  structural  and  migratory  functions  during  mammary 
morphogenesis.          
5.2 Future directions 
5.2.1 Further analysis of TEB and duct transcriptomes to study 
mouse mammary gland development at puberty 
In  this  study  we  hypothesised  that  the  TEB  associated  genes  are  involved  in 
promoting  and  regulating  the  development  of  mouse  mammary  gland.  We 
suggested many candidates with a potential to serve as these regulators from 
which  we  further  researched  association  of  two  with  pubertal  morphogenesis 
(Upk3a and Fbln2). In the future, it would be beneficial, therefore,  to study 
some of the other identified genes in more detail, to asses their role in pubertal 
morphogenesis  (e.g.  adhesion  associated  genes  -  Emb,  Fbn2;  EMT  associated 
genes - Lad1, Slp1, migration associated genes or others as suggested in Chapter 
3.3). The signals from the stroma are as important for mammary morphogenesis 
as these originating from the epithelium (reviewed in 1.2.3.2) and although not 
yet  demonstrated  for  pubertal  morphogenesis  of  mouse  mammary  gland,  the 
down-regulation of genes has been proven essential in morphogenesis of other 
systems  (HL-60  monocytic  differentiation  or  EMT).  Thus,  in  the  future,  the 
search for the potential regulators of pubertal mammary morphogenesis should 
be  broadened  to  include  the  identified  in  this  project,  579  TEB-only  stroma 
associated genes (See 3.2.6.2.2) and the 186 TEB epithelium down-regulated 
(duct up-regulated) genes (See 3.2.6.1.1). 
Moreover, although the „pathway analysis‟ carried out in this study suggested 
the  associations  of  TEB  and  duct  transcriptomes  with  a  range  of  different 
biological processes/functions, and highlighted the candidate genes associated 
with each one of them, this type of analysis may not be fully representative of 
functional processes activated in vivo and should only be used as a start point 
for further investigation (See 3.3.3.5). To take this analysis forward, therefore, 
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mammary  gland  morphogenesis  should  be  examined  at  functional  level.  The 
„Cardiovascular System Development‟ and „Immune Response‟ are the examples 
of  such  processes.  To  date,  only  three  types  of  innate  immune  system 
components – macrophages, eosinophils and mast cells have been documented to 
associate with TEBs and ducts at puberty. The „pathway analysis‟ presented in 
this thesis, however, suggested possible association of pubertal epithelium with 
other  immune  system  components  (e.g.  neutrophils,  T  lymphocytes,  B 
lymphocytes,  NKTL,  phagocytes  or  Langerhans  cells)  (on  the  basis  of  their 
marker gene expression) (See 3.3.3.2).  In the future, therefore it would be of 
benefit to use Q RT PCR to confirm the up-regulation of these marker genes in 
mouse  mammary  gland  at  puberty  and  IHC  or  IF  to  investigate  their  spatial 
expression.  Moreover,  since  no  active  blood  vessel  development  has  been 
associated with mammary gland at puberty, to date, it may be of interest to 
follow up the link between angiogenesis and TEBs, suggested by the „pathway 
analysis‟ and gene expression analysis. Our microarray analysis showed VEGF to 
be up-regulated in TEB epithelium, and the epithelial expression of VEGF during 
pregnancy  and  lactation  has  previously  been  shown  to  promote  angiogenesis 
[480]. It may be that migrating TEBs express genes which take part in promoting 
vascular  outgrowth  or  vascular  outgrowth  promotes  directional  migration  of 
TEBs. It would be necessary to validate the expression VEGF and VEGF receptors 
(FMS-like tyrosine kinase 1 - Flt-1 and Kinase insert domain protein receptor - 
Flk-1) at the protein level and examine the effects of their deficiency on ductal 
outgrowth. Since, the VEGF KO
-/- mice are embryonically lethal [481] it would be 
essential  to  generate  a  mouse  model  that  would  knock  out  VEGF  under  the 
control of MMTV promoter in a cre-lox system, to enable its selective silencing at 
the different stages of mammary gland development. The other possibility would 
be to implant mouse mammary glands with the slow release VEGF pellets (e.g. 
Elvax  40P  implants  [52])  and  examine  the  indirect  effect  of  VEGF  on  local 
angiogenesis and TEB outgrowth.  
The data generated by IPA could further be analysed to gain information about 
the processes already known to be associated with pubertal morphogenesis, but 
which underlying mechanisms are still to be elucidated, such as lumen formation 
in  TEBs.  This  could  be  commenced  by  researching  the  association  of  TEB 
epithelium with the apoptosis/cell death-linked genes.     315 
 
Finally, during the course of this project, we also compared the exon expression 
levels between the isolated TEBs and ducts and mouse mammary gland tissue 
strips  to  study  the  alternative  splicing.  This  analysis,  however,  has  not  been 
addressed in this thesis due to time constraints. Since the alternative splicing of 
mRNA is one of the mechanisms regulating gene expression in higher Eukaryotes 
the  comparison  of  splicing  changes  between  the  transcriptomes  of  TEBs  and 
ducts might provide valuable information on their transcriptomics.  
5.2.2 Further analysis of TEB and duct transcriptomes to study 
breast cancer 
It has recently emerged that TEB migration might share similarities with breast 
cancer cell invasion. These are reflected in the rapid growth, epithelial invasion 
of surrounding stroma and its dependence on stromal-epithelial interactions seen 
in  both  tissues  (reviewed  in  [100])  and  the  similarities  in  systemic  and  local 
regulation of the outgrowths. E2 and its receptor ERα are both crucial for TEB 
development, ductal outgrowth at puberty [126] [127] [133] (See 1.2.3.2.1) and 
breast cancer progression, as demonstrated by the sensitivity of some cancers to 
E2 and the positive impact of Tamoxifen (a synthetic molecule which binds to ER 
and modulates its transcriptional capabilities) on the treatment of ER+ tumours 
(reviewed in [482]). Both TEBs and breast cancer cells have been also suggested 
to  migrate  in  similar  manner  and  the  collective  cell  migration  (previously 
discussed in 4.1.3.3 and demonstrated in fully dedifferentiated breast cancers, 
such as lobular breast cancer) (reviewed in [388]) and EMT (previously discussed 
in  4.1.2.1)  have  been  suggested  as  the  candidate  drivers.  Finally,  individual 
genes such as ErbB2 (Her2), an EGF-like receptor which localises to TEBs during 
pubertal  development  and  is  critical  for  their  normal  morphology  and  ductal 
elongation [118] have been shown to serve as an important therapeutic target in 
breast cancer (reviewed in [483]).  
In  further  studies  the  TEB  transcriptome  associated  genes,  identified  in  this 
thesis  (425  TEB  epithelium  up-regulated  genes  (3.4.1.1.1)  and  565  TEB 
epithelium-stroma up-regulated genes (3.4.1.1.2)), could be used to assess their 
expression levels in breast cancer microarray data sets,  e.g. the Netherlands 
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(NIK  295)  [484],  and  correlate  the  results  with  outcome  and  metastatic 
potential. Preliminary work from our laboratory showed that human orthologues 
of mouse genes that were identified as up-regulated in isolated TEBs compared 
to ducts by Morris et al. (2006) [113] may distinguish breast cancers with good 
prognosis in the NKI 295 breast cancer data set [484] (unpublished data). Thus, it 
would  be  interesting  to  carry  out  further  in  silico  analysis  (hierarchical 
clustering)  using  our  more  comprehensive  TEB  signature  to  validate  these 
results. This and other breast cancer data sets, such as a 99 breast cancer data 
set by Sotiriou et al. [485], could be used to test whether the TEB signature 
clusters with any of the clinical variables (e.g. presence of metastasis, cancer 
grade,  LN  status,  Her2,  ER,  PR  status).  As  the  mitosis-associated  genes 
constitute a large part of TEB transcriptome it would be essential that these are 
subtracted prior to analysis. If any associations were found, the individual genes 
may be identified and further studied. In addition, if carried out the „pathway 
analysis‟ of these signatures might provide further information on the signalling 
pathways associated with breast cancer and its progression.  
5.2.3 The use of microRNA profiling to study pubertal 
development of mouse mammary gland 
Finally,  it  may  be  beneficial  to  carry  out  the  microRNA  (miRNA)  expression 
profiling  on  isolated  TEB  and  ducts  and  mammary  gland  tissue  strips  and 
compare the TEB signature with breast cancer data sets, as described above.  
MiRNAs  are  non-coding  negative  regulators  of  gene  expression  (reviewed  in 
[486]). Their expression pattern is unique to different organs and processes. It 
can distinguish between normal and tumour tissues [487] [488] or even aid the 
classification of cancers based on their lineage and differentiation state. miRNA 
signature is more stable, reproducible and conserved between the species (~20%) 
than that associated with mRNA profiling [489]. Thus, when used for pubertal 
gene expression analysis, miRNA profiling would not only complement the mRNA 
results but it may also provide new insights into the mechanisms of the TEB 
driven ductal morphogenesis at puberty, identify new regulators or define novel 
signalling pathways involved. This could further define possible links between 
the TEB signature and breast cancer, and thus reveal new avenues for further     317 
 
research on both the normal mammary gland morphogenesis and its malignant 
counterparts. 
5.2.4 Further investigation into the role of Upk3a and Fbln2 in 
pubertal morphogenesis of mouse mammary gland 
Since only a single anti-Upk3a antibody has been tested during the course of this 
project, further evaluation of the expression of Upk3a in mouse mammary gland 
should be carried out using antibodies raised against different epitopes of the 
protein.   
The  first  line  for  future  investigation  into  the  role  of  Fbln2  in  pubertal 
morphogenesis of mouse mammary gland, on the other hand, would be to use 
the mouse models to study the effect of its loss on the pubertal mouse mammary 
gland in vivo. Although, the initial morphological comparison of pre-pubertal and 
pubertal  mouse  mammary  glands  from  Fbln2  KO
-/-  mice  and  their  WT 
counterparts has already been performed during the course of this project, that 
study was based on a limited number of animals only (See 4.2.2.11). Although it 
did not demonstrate any major morphological differences in the length or the 
degree of branching of the ductal tree between the mammary glands, some of 
the  TEBs  in  the  mammary  glands  from  pubertal  Fbln2  KO
-/-  mice  appeared 
slightly smaller and more elongated than those seen in their WT counterparts. A 
more comprehensive analysis based on higher number of replicates, therefore, 
ought to be performed in the future to validate these results. Moreover, as we 
have  shown  that  the  loss  of  Fbln2  in  Fbln2  KO
-/-  mouse  mammary  glands 
appeared to be over-compensated by the expression of Fbln1 (also seen in Fbln2 
KO
-/- aorta [266]) and this phenomenon may rescue the pubertal phenotype, it 
would be further essential to generate a double (Fbln2 and Fbln1) KO. Since 
Fbln1 KO
-/- mice are prenatally lethal [479] it would be necessary, however, to 
generate Fbln2 KO
-/- mice expressing loxP flanked Fbln1 gene and a transgene 
construct consisting of full-length Cre recombinase cDNA under the control of 
MMTV  promoter.  The  mammary  gland  expressed  Cre  would  bind  to  loxP 
sequences and splice the loxP flanked DNA and thus KO Fbln1 expression in a 
selective tissue specific manner. Furthermore, during the write up of this thesis, 
the  double  KO
-/-  (Fbln2  and  Fbln5)  mouse  model  was  generated.  It  showed     318 
 
vascular phenotype (disorganised internal elastic lamina in blood vessels) that 
could not be seen in either of the single KO(s) (Fbln2 KO
-/- or Fbln5 KO
-/-) [449], 
but  due  to  the  time  constraints  of  this  project  we  could  not  carry  out  its 
examination. The assessment of Fbln5 expression in mouse mammary gland and 
its  co-localisation  with  the  mammary  Fbln2,  alongside  with  morphological 
examination of mammary glands, collected from these mice, therefore, would 
be essential to progress with studying the role of Fbln2 during in vivo mouse 
mammary gland development in the future. If present, the potential phenotype 
would  provide  further  suggestions on  role of  Fbln2  in  mouse  mammary  gland 
morphogenesis. 
Most of the functional studies for Fbln2 in pubertal mammary gland development 
were based on the in vitro 2D cell adhesion- or wound healing assays and in vivo 
mouse models. Both systems, however, have clear disadvantages. Mouse models 
are expensive to produce, subject to potential over-compensation/redundancy 
effects  and  stringent  regulation  which  often  results  in  studies  utilising  low 
replicate  numbers  while  the  2D  in  vitro  assays  fail  to  mimic  the  complex 
structure and composition of ECM in vivo. Furthermore, no cell line to date, has 
been  generated  from  the  pubertal  mammary  epithelium  (mammary  epithelial 
cell lines available to date derive from pregnant mice – HC11, EpH4 cells). Thus, 
no epithelial structures, with morphological similarity to TEBs in vivo, have been 
reported to form from epithelial cells in culture.  Future research, therefore, 
should  focus  on  the  development  of  TEB  explant  culture  model.  Preliminary 
analyses showing its potential to act as a good in vitro model for pubertal mouse 
mammary gland research have been described in 4.2.2.5. Future work should 
address further characterisation of cells within the outgrowths to further ensure 
that their characteristics resemble those of TEB epithelium in vivo and can be 
maintained  in  culture.  Moreover,  given  the  importance  of  epithelial-stromal 
interactions during pubertal mammary morphogenesis it would be of benefit to 
identify the most suitable matrix for mimicking stromal environment of TEBs in 
vivo.  
When successfully developed and validated this explant culture model may be 
used  in  studying  the  regulation  of  Fbln2  expression.  For  example,  upon  the 
positive ER and PR expression in explant cultures, this system could be used to 
further  study  the  regulation  of  Fbln2  expression  by  systemic  hormones.     319 
 
Furthermore,  the  developed  experimental  conditions  could  be  also  used  to 
culture the pre-pubertal TEB-like structures and mammary epithelium extracted 
from mammary glands at early pregnancy, both of which have been also shown 
to  express  Fbln2.  These  cultures  could  be  then  utilised  to  compare  the 
histological characteristics of TEBs and TEB-like outgrowths (it is not yet clear if 
TEB-like  structures  are  equivalent  of  TEBs  at  puberty).  Furthermore,  when 
compared,  these  three  models  might  provide  insights  into  the  regulation  of 
Fbln2 expression at different stages of mouse mammary gland morphogenesis. 
Similarly, the explant culture model might also be used to further characterise 
and  compare  the  histology  of  TEBs  collected  from  WT  and  Fbln2  KO  mouse 
models.  Finally,  as  Fbln2  may  play  the  structural  role  in  mammary  gland  by 
stabilising the organisation of ECM and, as shown in our study, Fbln2 enhanced 
the adhesiveness of HC11 cells to Lama1, Vtn and Tn it may be of benefit to 
further validate these findings and test the level of adhesiveness of TEB explants 
to each one of these matrices.  
Finally,  when  fully  developed  and  optimised,  in  the  future,  the  TEB  explant 
culture  model  may  provide  a  relevant  and  accessible  tool  for  studying  the 
expression and regulation of any of the chosen, TEB associated genes, in vitro. 
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6  Appendices 
 
 
Appendix 1 Fbln2 V1 expression vector. 
 
 
Appendix 2 List of genes over-expressed in TEB and duct epithelium. 
Appendix 3 List of genes over-expressed in Post- and Pre-LN mouse mammary gland tissue 
strips. 
Appendix 4 List of genes over-expressed in the epithelium free mammary Fat pad. 
Appendix 5 List of genes expressed in TEB-only and duct-only epithelium. 
Appendix 6 List of genes expressed in TEB-only and duct-only stroma. 
Appendix 7 List of genes associated with the identified ‘Molecular and Cellular Function’ 
categories. 
Appendix 8 List of genes associated with the identified ‘Physiological System Development 
and Function’ categories. 
Appendix  9  List  of  functional  sub-group  associated  with  'Cellular  Movement'',  'Nervous 
System  Development  and  Function'  and  'Embryonic  Development'  and  their  associated 
genes. 
 
Appendices 2-9 are provided in the Supplementary DVD. 
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Appendix 10 List of presentations prepared on the data from this thesis. 
 
  „Stromal-epithelial  interactions  during  ductal  morphogenesis  of  mouse 
mammary gland‟ – Oral presentation at the departmental seminar, University 
of Glasgow (Glasgow, UK; 2007) 
  „Pubertal development of mouse mammary gland‟ – Oral presentation at the 
departmental seminar, University of Glasgow (Glasgow, UK; 2008) 
  „Epithelial and stromal transcriptome analysis of pubertal mouse mammary 
gland‟ – Poster presentation at Breast Cancer Breakthrough Annual Meeting 
(Oxford, UK; 2008) 
  „Epithelial  and  stromal  transcriptome  analysis  of  the  pubertal  mouse 
mammary gland and identification of Fbln2 as a novel pubertal regulator of 
mouse  mammary  gland  morphogenesis‟  –  Poster  presentation  at  Gordon 
Research Conference on Mammary Gland Biology (New Port, USA; 2009)    
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